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Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are, combined, the 
second most common type of dementia in the elderly but remain both poorly understood and 
researched. Diagnosis is based upon clinical symptoms yet there is considerable overlap between 
DLB, PDD and Alzheimer’s disease (AD), in terms of clinical presentation and pathology. Synapses are 
critical for neuronal communication and form the basis of memory and behaviour. The loss of zinc 
transporter 3 (ZnT3) has been implicated in age-related cognitive decline (based upon work in ZnT3-
knockout mice), an observation corroborated by reports of reduced cortical zinc and ZnT3 in the 
brains of individuals with AD.  
This project utilised a cohort of AD, PDD, DLB and control brains with cognitive data and semi-
quantitative scores for key behavioural symptoms (depression, agitation, hallucinations, 
persecution) and the principal pathologies (amyloid-beta, tau and alpha-synuclein). Semi-
quantitative Western blotting was used to investigate key synaptic proteins; zinc transporter 3, 
PSD95, beta-III-tubulin and synaptophysin in three cortical regions.  
The major findings of this project were the occurrence of a loss of regulation of synaptic zinc, which 
predicted cognitive decline, depression and severity of amyloid-beta, tau and alpha-synuclein 
pathology in different cortical areas. Differences were also demonstrated in synaptic biochemistry 
between DLB and PDD cases, with PDD cases having a greater synaptic dysfunction. 
Important outcomes of this study include the potential for zinc modulation as a new target for the 
treatment of depression and cognitive decline in LBD, possibly through a modification of pathology, 
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1.1 Neurodegeneration and Dementia 
1.1.1  Background 
Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), collectively described as 
Lewy body dementias (LBD), have very similar pathology yet a subtly different clinical presentation. 
There is debate about the prevalence of DLB, ranging from  7% of all dementia cases (Kester and 
Scheltens, 2009) to the higher estimate of around 15%  (Aarsland et al., 2008); however most studies 
agree DLB is the second most common type of dementia. Again, there are differing estimates of PDD 
prevalence, between 40-60% of Parkinson’s disease (PD) patients at age 70 ultimately develop PDD, 
this increases to 80-90% at age 90 (Buter et al., 2008; Kester and Scheltens, 2009); in another study 
over a 20 year period around 80% of PD patients developed dementia  (Hely et al., 2008). However a 
more conservative estimate provided by a comprehensive review of PDD prevalence studies 
estimates 24% of PD patients to have dementia (Aarsland et al., 2005c). Furthermore it is highly 
probable that most – if not all- PD patients would eventually develop PDD based upon an 8 year 
prospective study in which over 75% of PD patients developed PDD (Aarsland et al., 2003). 
Both DLB and PDD are characterised by pathological deposition of aggregated protein into 
intracellular inclusions called Lewy bodies (LB) and dystrophic neuritis also called Lewy neurites. 
Clinically DLB and PDD share the core symptoms of fluctuating cognition (referring to considerable 
variances over a short time in abilities such as attention and language), visual hallucinations and 
parkinsonism yet can be thought of as existing on a spectrum. Other common symptoms such as 
psychosis, aggression/agitation, depression and sleep disturbances are responsible for a great 






1.1.2.1 DLB, PDD and AD overview 
The central clinical feature required for a diagnosis of probable or possible DLB, as defined by the 
third report of the DLB consortium is ‘Dementia defined as progressive cognitive decline of sufficient 
magnitude to interfere with normal social or occupational function’; this can be accompanied by an 
increasing degree of memory loss and worsening attention, executive function and visuospatial 
function (McKeith et al., 2005). McKeith and colleagues outline a number of other clinical features to 
assist in diagnosis DLB. Symptoms that are termed ‘core features’, two of which are required for a 
diagnosis of probable DLB and one for possible DLB, are ‘fluctuating cognition with pronounced 
variations in attention and alertness, recurrent visual hallucinations that are typically well formed 
and detailed, and spontaneous features of parkinsonism’ (McKeith et al., 2005). Additionally there 
are a number of ‘suggestive’ features (REM sleep behaviour disorder, neuroleptic sensitivity and low 
dopamine transporter uptake in the basal ganglia) and ‘supportive’ features (see subsequent section 
on other symptoms) that contribute towards diagnosis. 
Whilst cognitive and functional decline remain the core features of dementia a wide variety of 
behavioural symptoms can present in many dementia cases before or after the onset of the 
aforementioned core symptoms. Such behavioural symptoms can represent a more significant 
problem to carers and patients than the typical decline in activities of daily living and in cognition 
that occurs in dementia (McKeith et al., 2005). Generally behavioural symptoms follow the same 
pattern of a gradually increasing severity as the disease progresses however there is variation in this; 
some behaviours such as hallucinations and REM sleep behaviour disorder do not consistently obey 
this trend – but rather decline or disappear as the disease progresses (Ballard et al., 1997; Boeve et 
al., 2004; Gauthier et al., 2010).  
Cognitive symptoms in PDD and DLB are predominantly confined to attention, constructional, 
memory, visuospatial and executive domains (Emre et al., 2007). Behavioural and neuropsychiatric 
symptoms include hallucinations, which are common in PDD (around 45%) and even more so in DLB 
(up to 80%), and tend to coexist with delusions. Mood disturbances are another frequent symptom 
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in all three dementias, these include depression anxiety and apathy. Apathy in particular has been 
reported to be present in up to 80% of DLB patients and around 50% of AD. In general, behavioural 
and neuropsychiatric symptoms are less frequent and/or severe in PDD. PDD is also characterised by 
motor symptoms, as is DLB following the onset of dementia. The severity tends to be similar but not 
all DLB cases present with motor symptoms (McKeith et al., 2004). These typically present as 
progressive bradykinesia, rigidity, postural instability and tremor (Dickson, 2012).  
Alzheimer’s disease is defined by a gradual onset of the following symptoms; worsening cognition (in 
particular learning and recall, word finding, spatial cognition and executive dysfunction) (McKhann 
et al., 2011). 
See subsequent sections for further details on the symptoms of particular interest to this project. 
1.1.2.2 Fluctuating Cognition 
Fluctuating cognition, although a core feature of DLB, is by no means exclusive to DLB but is a 
reported in other dementias – notably in Alzheimer’s disease (AD) (Bradshaw et al., 2004). Bradshaw 
and colleagues undertook a small study comparing fluctuations between DLB and AD patients in 
which they described several qualitative differences in fluctuations between the two dementias 
based upon interviews with caregivers and patients (Bradshaw et al., 2004). Fluctuations in DLB were 
typically characterised by a greater variation in the abilities of the individual than in AD and this 
variation tends to occur over a shorter time interval - within the course of a single day whereas the 
AD patients in the study generally had fluctuations lasting for an entire day (Bradshaw et al., 2004). 
This is consistent with the consensus that fluctuating cognition is more frequent and of greater 
severity in DLB than AD (McKeith et al., 2005). 
Additionally Bradshaw and colleagues observed that fluctuations in AD appeared to be triggered by 
context and environment – and that this tended to result in increased repetitiveness and 
forgetfulness; whereas in DLB no trigger to fluctuations was evident – suggesting an internal 
mechanism behind this feature. The resulting decline in cognitive ability was typified by reduced 
attention and awareness (Bradshaw et al., 2004). 
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However reliable and accurate assessment of fluctuations in dementia remains challenging with 
poor inter-rater reliability between scorers, despite the prevalence of fluctuating cognition, this is in 
part due to its inherent variability (Cummings, 2004; McKeith et al., 2005). 
 
1.1.2.3 Visual Hallucinations 
Visual hallucinations in Lewy body dementias are usually complex and well formed (often featuring 
animals) and as a key symptom of DLB and PDD they represent an important tool for diagnosis and 
discrimination from other dementias (McKeith et al., 2005; Tröster, 2008). Deficits in functions 
related to the visual system may predispose individuals to visual hallucinations, Cagnin and 
colleagues recently demonstrated poor visual attention to be an independent predictor of visual 
hallucinations (Cagnin et al., 2012; Tröster, 2008). Cagnin and co-authors highlight the concord 
between this finding (Cagnin et al., 2012) and a recent model for the genesis of visual hallucinations 
proposed by Collerton et al. in which it was suggested that deteriorations in attention and visual 
perception generate hallucinations (Collerton et al., 2005). Visual hallucinations are unique amongst 
DLB and PDD symptoms in that a clear link to pathology in a specific brain region has been 
demonstrated. Harding et al. showed a strong positive relationship between Lewy bodies in the 
temporal cortex and the presence of visual hallucinations – with early onset of hallucinations being 
predicted by a density of Lewy pathology in the parahippocampal and inferior temporal cortices 
(Harding et al., 2002). 
In terms of the neurochemistry of hallucinations; deficits in cholinergic neurotransmission in the 
temporal cortex may be partially responsible for hallucinations in LBD – two studies examining 
choline acetyltransferase (ChAT) levels found a significant relationship between reduced levels of 
ChAT and visual hallucinations in part of the visual association area (the perirhinal cortex - BA36) 




Parkinsonism in DLB broadly resembles that found in PD (and therefore by extension PDD) (McKeith 
et al., 2005). One difference between parkinsonism in DLB and PDD is a difference in the 
predominance of the two forms – postural-instability gait difficulty (PIGD) and tremor dominant 
(TD); in a study of around 100 patients the former was the more common in DLB and PDD whereas 
there was an equal distribution of the two forms of parkinsonism in non-demented PD patients 
(Burn et al., 2003). PIGD and TD were formalised as the primary subtypes of clinical presentation of 
parkinsonism in 1990 in a cohort study by Jankovic and colleagues (Jankovic et al., 1990). The PIGD 
subtype - in addition to the instability of posture and difficulties with gait implicit in the name - is 
characterised by a greater severity of bradykinesia and impairment of motor function, intellectual 
faculty and daily activities of living than TD; furthermore PIGD is associated with a more accelerated 
progression and earlier onset of disease (Jankovic et al., 1990). 
1.1.2.5 Other Symptoms 
REM sleep behaviour disorder is a termed a ‘suggestive feature of DLB’ according to the 3rd report of 
the DLB consortium (McKeith et al., 2005) due to its rarity in non-synucleinopathy dementias and 
prevalence of 50% in LBD (Boeve et al., 2004). Typically presentation consists of aggressive, and 
sometimes complex, movement and vocalisation accompanied by vivid and distressing dreams 
during sleep (McKeith et al., 2005). It has been suggested REM sleep behaviour disorder is a 
precursor to LBD as in a study of 27 non-demented individuals with REM sleep behaviour disorder 
around 63% subsequently developed DLB or PDD (Claassen et al., 2010).  
Of the LBD symptoms termed ‘supportive’ only those that feature in the data for this study will be 
dealt with in detail here; these are depression, delusions and agitation.  
1.1.2.6 Depression 
Depression is common in PD, DLB and PDD and may be up to twice as common as it is in AD; as 
demonstrated by a comprehensive study based upon Geriatric Depression Scale scores from a 
cohort of 192 patients – half with AD and half with DLB (Yamane et al., 2011). This is supported by a 
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similar finding in another study – in which 50% of participants with dementia showed signs of 
depression and that depression was significantly more frequent in DLB than AD (Fritze et al., 2011b). 
However there remains some debate as to the relative frequencies of depression across the 
dementias, a notably large study involving 921 patients by Caputo et al. found no difference in the 
rates of depression between AD and DLB (Caputo et al., 2008). 
Persistence of depression is another factor contributing to the clinical picture in DLB and is likewise 
more pronounced than it is in AD (Fritze et al., 2011a).  
The question of the origin of geriatric depression is a complex one. There may be several factors 
independently linked to depression found in dementia. Depression alone is – according to the World 
Health Organisation – the leading cause of disability in the world (Reddy, 2010) and is an established 
risk factor for dementia. Depression has been shown to worsen cognition, an effect which is likely to 
contribute to the development of dementia (Rapp et al., 2011); although the authors remark upon 
the limitation imposed by the poor diagnostic reliability of depression. Additional evidence for 
depression having a causative link to dementia is provided by a study showing a high ratio of plasma 
Aβ 40 to Aβ 42 to be associated with depression and reduced cognition in a subset of depressed 
individuals participating in the study which the authors speculate to represent a prodromal stage of 
AD (Sun et al., 2008). 
Other factors such as excessive cortisol (hypercortisolemia) as a result of depression and stress 
activating the have been implicated in the genesis dementia. Hippocampal neurons appear to be 
particularly vulnerable to hypercortisolemia, which can result in decreased hippocampal volume and 
a consequent cognitive deficit (Byers and Yaffe, 2011).  
An investigation comparing amyloid brain imaging (Pittsburgh compound B (PiB) retention – see 
brain imaging section for discussion) in individuals with mild cognitive impairment (MCI) with and 
without depression further supports the notion that depression is a prodromal marker for dementia. 
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Butters et al. observed normal PiB binding when cognition was unperturbed regardless of the 
depressive state of the individual, yet 50% of participants with MCI and depression showed PiB 
retention consistent with that found in AD (Butters et al., 2008). Furthermore, it has been 
demonstrated that increased tau and Aβ pathology in the hippocampus was associated with a 
history of depression in AD patients, although this did not hold true for other cortical regions, this 
probably contributed to the accelerated cognitive decline reported in these individuals (Rapp et al., 
2006). This link to the pathology and biochemistry of AD is crucial in confirming that the high 
incidence of depression in dementia is not simply an artefact of the prevalence of the two conditions 
in the elderly. 
Structural changes occur in brain regions associated with cognition (prefrontal cortex and 
hippocampus) in chronic and late-onset depression (Ballmaier et al., 2008; Xekardaki et al., 2012). 
Once these imaging methods become more established they could prove invaluable as a screening 
and diagnostic tool for the early stages of dementia. 
However, there is a counter argument that it is dementia that generates and drives depression; 
individuals at an early stage of dementia are aware of their condition and prognosis. This can have a 
profound psychological impact including a highly negative self-perception leading to depression 
(Lahr et al., 2007). Finally other factors may obscure the picture such as sleep disturbance and ‘sub-
optimal effort’ as a consequence of depression artificially reducing the score on cognitive tests 
(Weisenbach et al., 2012). 
1.1.2.7 Agitation and Aggression 
Agitation and aggression are two intrinsically interwoven symptoms that can present in LBD and AD. 
They are associated with an increased risk of adverse events (such as injury) to the patient and 
increased distress to both carer and patient, and as a direct consequence are linked to earlier 
institutionalisation (Ballard et al., 2009).  
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Aggression can manifest as verbal and/or physical assault, frequently whilst personal care is being 
administered; whereas agitation typically presents as restlessness and anxiety-related behaviours 
such as hand-wringing and pacing. Both agitation and aggression have been linked to more rapid 
progression of dementia, as are many of the physical issues associated with the later stages of 
dementia such as dehydration, infections and pain, which are in turn established triggers of agitation 
and aggression (Hall and O'Connor, 2004). Estimates of the prevalence of agitation and aggression in 
dementia vary immensely from 10% to 100%, probably due to bias introduced by the setting of the 
study and care-giver interviews (a common source of information on psychiatric symptoms) (Sachs, 
2006). Other factors that can initiate or compound agitation and aggression include environment 
related stress (eg. noise) and sensory impairment (eg. hearing loss) (Hall and O'Connor, 2004). Thus, 
by addressing elements such as these, successful management of agitation and aggression can be 
achieved though non-pharmacological means (Ballard et al., 2009).  
The majority of studies examining the relationship between cognitive status and 
agitation/aggression have demonstrated an inverse relationship (negative correlation) (Hall and 
O'Connor, 2004). When Welsh and colleagues dissected the cognitive impairment they  reported 
that – based upon CAMCOG scores - language impairment was the greatest predictor of aggression 
(Welsh et al., 1996), something that has also been observed in younger psychiatric patients; the 
proposed explanation was linked to the resultant frustration from an inability to communicate (Hall 
and O'Connor, 2004).  
Imaging brain metabolism (FDG-PET – see imaging section) in AD patients suggests frontal and 
temporal lobe hypofunction (in the guise of reduced metabolic activity) to be significant contributors 
to agitation and aggression (Sultzer et al., 1995). This is supported by two studies, one – Norton et 
al. - using a behavioural test specifically designed to assess frontal dysfunction – the Frontal Lobe 
Personality Scale – which found a similar link between frontal lobe dysfunction and agitation and 
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aggression; whereas Tekin and colleagues demonstrated this link through the Neuropsychiatric 
inventory (Norton et al., 2001; Tekin et al., 2001). 
Whilst anatomical correlates have been established for agitation and correlation, knowledge of the 
neurochemistry of agitation and aggression in dementia remains muddled but likely involves the 
prefrontal cortex. Indeed it has been shown that a reduction in alpha 1 adrenoceptors in the 
prefrontal cortex is associated with increased aggression in AD patients (Sharp et al., 2007). Other 
studies have shown increases in noradrenaline levels and heightened sensitivity to noradrenaline in 
AD patients – perhaps representing a compensatory mechanism in response to the decrease in 
adrenoceptors (Lindenmayer, 2000). Decreases in GABA and reductions in dopamine may also be 
involved in mediating agitative and aggressive behaviour in dementia (Sachs, 2006). 
Investigation and assessment of agitation and aggression remains challenging due to a host of issues 
such as poor representation in clinical trials and studies (because of non-compliance of individuals 
with agitation and aggression as a direct result of this symptom), multiple criteria for defining 
agitation and aggression and coincidence with other psychiatric symptoms (complicating 
distinguishing cause and effect of individual symptoms)  (Sachs, 2006). Two established tools for 
assessing agitation are the Neuropsychiatric Inventory (see cognitive and behavioural tests section) 
and the Cohen-Mansfield Agitation Inventory (Cohen-Mansfield et al., 1989). In a comparison of the 
inter-rater and test-retest reliability of these two scales the Cohen-Mansfield Agitation Inventory 
was shown to be superior (Zuidema et al., 2011). 
1.1.2.8 Persecution/Delusions 
Up to 45% of AD patients have been reported to experience delusions which often centre around 
suspicions of theft, infidelity and persecution (Gauthier et al., 2010) and this is also a commonly 
reported symptom ‘supportive’ of a diagnosis of DLB and PDD (McKeith et al., 2005). Studies have 
reported prevalence rates of delusions in DLB as high as 78% - and even the more conservative 
estimates of 57% are considerably higher than both AD and PDD – delusions in the latter have been 
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reported to occur in around 25 to 30% (Emre et al., 2007). Furthermore delusions tend to be 
persistent – Steinberg et al. found 65% of demented individuals suffered delusions for more than 1 
year at follow-up (Steinberg et al., 2004). 
Ballard and colleagues found delusions to be linked to an increase in M1 muscarinic receptor binding 
in BA36, the same region implicated in visual hallucinations. This provides a mechanistic basis for the 
coincidence of visual hallucinations and delusions in many patients (Ballard et al., 2000). 
Comparisons of SPECT imaging in dementia patients with and without delusions of theft and 
persecutions have highlighted another brain region – the frontal cortex – as involved in these 




1.1.3 Cognitive and Behavioural Tests 
1.1.3.1 NPI 
The Neuropsychiatric Inventory (NPI) is one of the most commonly used assessments of behavioural 
symptoms and disturbances in dementia. It takes the form of screening questions and in-depth ‘sub-
questions’ asked of a carer familiar with the patient ideally on a monthly basis. Twelve symptoms are 
covered; hallucinations, delusions, agitation/aggression, dysphoria/depression, anxiety, irritability, 
disinhibition, euphoria, apathy, aberrant motor behaviour, sleep and night-time behaviour changes 
and appetite and eating changes (Cummings, 1997; Cummings et al., 1994). The score is a 
multiplication of the intensity of the symptom by the frequency. Carers represent a superior source 
of information on these symptoms to patients as patients are prone to forgetting symptoms; an 
issue that can be compounded by patients with severe dementia having difficulty in understanding 
relevant questions. Thus it is the carer who is asked to rate the severity and frequency of any of the 
listed behaviours which has occurred in the given time-frame, in addition to the degree of distress 
caused to the carer by the behaviour in question (Cummings, 1997). 
The NPI has been shown to perform at least as well as two other behavioural tests (BEHAVE-AD and 
the Hamilton rating scale for depression) in scoring symptoms in a group of patients and carers, half 
of which had AD and half other dementias (Cummings, 1997). Notable advantages of the NPI include 
the wide range of behaviours assessed, its relative ease of scoring (due to the observable nature of 
each behavioural domain) and speed of administration (a consequence of the screening questions 
allowing the avoidance of the documentation of behaviours not present) (de Medeiros et al., 2010). 
Furthermore, the behaviours featured in the test are specific to dementia, some - such as euphoria 
and disinhibition – being uncommon in AD assist in distinguishing AD from other dementias. The NPI 
resolves a similar issue with regards to determining if depression is a symptom of dementia or has 
occurred independently (Cummings, 1997). 
Drawbacks of the NPI include the dependence on the caregiver for information as there clearly is a 
possibility for bias or distortion of the scoring depending on the caregiver’s background and 
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relationship to the patient.  Another is a lack of sensitivity in distinguishing mild and severe 
dementia (de Medeiros et al., 2010). 
1.1.3.2 MMSE 
The Mini Mental State Examination (MMSE) is a questionnaire designed in 1975 by Folstein and 
colleagues (Folstein et al., 1975) for the purpose of providing a rapid and easily delivered numerical 
assessment of cognitive function. A testament to the success of the MMSE is the fact that it is now 
the most widely used tool for evaluating cognition across multiple languages and psychiatric 
disorders, in particular dementia (Bak and Mioshi, 2007). Despite this utility the MMSE is not 
recommended by Mckeith et al. as being sufficient to diagnose DLB as it was unable to detect crucial 
features such as fluctuating cognition and visual hallucinations (McKeith et al., 2005). However, 
despite development of more complex and sensitive tests, the MMSE is still appropriate and 
accurate for screening MCI and AD from healthy cognition, as shown in a comparative study with 
two such cognitive tests (CAMCOG and Montreal Cognitive Assessment) conducted on over 300 AD 
patients and 140 individuals with MCI (Roalf et al., 2012). 
It is sometimes of assistance to research to use MMSE scores (which can total 30 provided the 
subject’s faculties such as vision and hearing enable an attempt at all questions) as a basis for 
categorising patients into ‘cognitively normal’, ‘moderately impaired’ or ‘severely impaired’ based 







1.1.4.1 PET and SPECT 
Functional brain imaging techniques, primarily positron emission tomography (PET) and single-
photon emission computed tomography (SPECT), are increasingly being used to assist with 
antemortem diagnosis in suspected dementia patients. Both PET and SPECT measure gamma 
radiation produced from radioactive tracer compounds introduced into the brain. PET imaging is 
used to provide a 3D image of cerebral glucose metabolism. PET compounds in routine use are 
typically radioactively labelled sugars, such as fluorodeoxyglucose (FDG), that emit positrons which 
interact with electrons to produce two photons travelling in opposite directions; this is instrumental 
in achieving the higher resolution of PET when compared to SPECT. Thus the gamma radiation from 
a region of brain tissue corresponds to the degree of sugar uptake and hence metabolism, from 
which a measure of brain activity can be gained (Bear et al., 2006; Broderick, 2005).  
    The uptake of SPECT compounds (eg hexamethylpropylene amine oxime – Tc-HMPAO) into brain 
tissue is proportional to the blood flow, which in turn is tightly linked to metabolism and brain 
activity; providing a 3D image of cerebral blood perfusion. However the gamma radiation recorded 
from a SPECT image is directly emitted by the compound causing a loss in resolution compared to 
PET imaging (Broderick, 2005). 
Another important difference between PET and SPECT is the tracer compounds themselves; PET 
compounds have a shorter half life than typical SPECT compounds and so must be synthesized on 
site prior to a scan, escalating the cost of a PET scan. SPECT compounds, having a considerably 
longer half-life, do not suffer this drawback and consequent expense (Broderick, 2005). 
  PET studies in patients with DLB, PDD and PD have revealed much about the pattern of metabolic 
deficit across brain regions and can assist with the separation of these diseases, which remains a 




    All three neurodegenerative conditions tend to have reduced metabolic activity in parietal, frontal, 
anterior cingulate and occipital regions with the greatest deficit occurring in DLB (Yong et al., 2007). 
A relative preservation of metabolic levels in medial temporal cortices coupled with a reduction in 
the occipital cortices in DLB and PDD can distinguish these dementias from AD (Ishii et al., 1999). 
Furthermore DLB and PDD may be differentiated from PD by the greater deficit in parietal and 
frontal metabolism (Yong et al., 2007). Indeed Yong et al. suggest that the progression of metabolic 
deficit in the frontal and parietal regions may be a substrate for the progression of PD into PDD. 
    It is likely that clinical aspects of dementia can be attributed to decreases in metabolic activity in a 
specific brain region. Firbank et al. propose that metabolic deficits in the lateral parietal cortex in 
PDD may have some responsibility for visual hallucinations in PDD patients (Firbank et al., 2003). 
Likewise Yong et al. argue that decreased frontal activity may correspond to executive and 
visuospatial dysfunction, this is supported by the matching increased hypometabolism and executive 
dysfunction generally reported in DLB over PDD.  
   When assessing the current knowledge of metabolic profiles across brain regions in the Lewy body 
dementias evidence can be found for the theory of DLB and PDD existing on a spectrum rather than 
as discrete disease states (McKeith, 2009). These alterations in brain consumption of glucose and 
rates of regional blood perfusion have provided a considerable improvement to the differentiation 
and diagnosis of dementias. 
  PET imaging can be used to assess regional alterations in neurotransmitter receptors. When 
administered to a subject, radio-labeled fluorodopa is taken up into dopaminergic neurons at a rate 
proportional to l-amino decarboxylase activity, itself dependent on the number of dopaminergic 
synapses in that brain region (Broderick, 2005).  
Differentiating PDD from PD is relatively easy compared to the far harder task of separating DLB 
from AD especially at an early stage if parkinsonism symptoms have not manifested and the 
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fluctuating cognition is subtle (Walker and Walker, 2009). Some loss of nigrostriatal dopaminergic 
neurons occurs prior to expression of a parkinsonism phenotype, this was corroborated by ex vivo 
ligand binding studies of the dopamine system which showed DLB cases to have around a 57% loss 
of dopamine nerve terminals whilst AD and control cases were not different to one another (Piggott 
et al., 1999). FP-CIT SPECT (a cocaine analogue marketed commercially as DaTSCAN by GE 
Healthcare) is increasingly used  for in vivo imaging of the mid brain dopamine system and typically 
shows a similar profile of binding to that reported ex-vivo (Piggott et al., 1999), reduced ligand 
uptake in DLB, with and AD and controls not significantly different in uptake (Walker and Walker, 
2009). 
   Clinical diagnosis of DLB following the consensus guidelines set out by McKeith and colleagues 
(McKeith et al., 2005) has less than perfect sensitivity and specificity hence a follow up confirmation 
of FP-CIT scan results with post-mortem diagnosis is the gold standard. The validity of this approach 
was supported by a study where all bar one case with abnormal FP-CIT were pathologically 
confirmed as DLB and none with normal FP-CIT were determined to be DLB, thus elegantly 
demonstrating the clinical utility of FP-CIT in diagnosing DLB (Walker et al., 2007). This is of great 
advantage in PD patients but less so in dementia patients where imaging of other neurotransmitter 
systems such as the cholinergic would be of greater interest yet there are no suitable radiolabelled 
ligands for any other neurotransmitter system.  
 
     Development of Pittsburgh compound B (PIB), a thioflavin analogue that binds selectively to Aβ, 
allowed in vivo imaging of Aβ for the first time (Klunk et al., 2004). It remains the most widely used 
experimental method of visualizing AD pathology in patients after it was first demonstrated that PIB 
uptake in AD was significantly higher than controls in a number of regions, notably in the prefrontal 
cortex (PFC), anterior cingulated gyrus, parietal and temporal cortices (Klunk et al., 2004; Quigley et 
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al., 2011). Imaging Aβ in this way offers the potential of a window to early disease events and 
progression of the disease, something that is generally denied to post-mortem studies.  
     PIB PET studies on AD cases corroborated the amyloid cascade hypothesis after follow up studies 
on patients showed PIB binding to plateau during disease progression in accord with the amyloid 
hypothesis proposition that amyloid accumulation is an early event and reaches a peak well in 
advance of the terminal stages of the disease (Quigley et al., 2011). PIB PET investigations have also 
demonstrated a lack of correlation between Aβ levels and cognitive performance and some studies 
have shown elevated PIB levels in control patients (Jack et al., 2008; Klunk et al., 2004; Quigley et al., 
2011) which may indicate Aβ to be less dominant in driving cognitive deterioration than sometimes 
argued.          
    Investigations of PIB uptake in DLB and PDD cases have shown some DLB cases to resemble AD in 
that it is characterised by a higher Aβ burden than control and PDD – both of which were similar in 
their PIB uptake (Edison et al., 2008; Gomperts et al., 2008). This contrast between DLB and PDD was 
not accounted for by dementia severity; indeed Gomperts et al. propose that Aβ deposition in PD 
advances onset of cognitive decline resulting in the reduced interval between motor and cognitive 
symptoms necessary for diagnosis of DLB.  
    PIB does not bind to α-syn or tau; this allows identification of so called pure AD from dementias 
with little or no Aβ such as fronto-temporal dementia (FTD) and even PDD, but makes distinguishing 
AD from DLB harder. However the reported differences between DLB and PDD allow more 
confidence in separating these dementias than the 1 year rule established by the DLB consortium 
(McKeith et al., 2005). Regardless, there is a clear need for PET tracers that can selectively bind α-syn 





The third major form of functional brain imaging employed in the diagnosis, management and 
research of dementia is functional magnetic resonance imaging (fMRI) – a development of magnetic 
resonance imaging (MRI). MRI takes advantage of the jump between different energy states that 
hydrogen atoms undergo when exposed to a magnetic field, this allows differences in the amount of 
hydrogen present to be visualised. Because white matter, grey matter, blood vessels and other 
anatomical features of the brain have differing compositions (fatty myelin sheaths, lipid membranes, 
water, plasma, etc), their respective hydrogen atom contents also differ and can be distinguished on 
this basis with the aim of computer software (Bear et al., 2006; Broderick, 2005).  
Demyelination and lesions are particularly evident on MRI scans due to the loss of fat and increase in 
water these events cause (Bear et al., 2006). Before the advent of functional MRI, conventional MRI 
was used to provide basic anatomical images of the brain. These had their use in providing insights 
into atrophy of certain brain regions in dementia, indeed hippocampal atrophy remains a good 
predictor for AD (Murray, 2011). 
fMRI takes advantage of the difference magnetic resonances of oxyhaemoglobin and 
deoxyhaemoglobin and utilises this to image metabolism via the demand and use of oxygen by 
neurons in different brain regions revealed by the type of haemoglobin found there (Bear et al., 
2006).   
Diffusion tensor imaging (DTI) is a new form of fMRI put to use in DLB and PDD studies which utilises 
the increase in mean diffusivity of water when neurodegeneration has damaged neuronal structure 
and brain tissue, in particular white matter tracts. This is referred to as fractional anisotropy (FA). A 
decrease in the directionally orientated diffusion of water corresponds to a decrease in FA (Medina 
and Gaviria, 2008; Watson et al., 2012). 
32 
 
As with many imaging studies there are conflicting reports from DTI investigations into LBD (due to 
low numbers of cases, patient variability and inconsistencies in diagnosis), but most of the evidence 
is for a reduction in FA in the inferior longitudinal fasciculus (involved in recognition of written 
language (Shinoura et al., 2013)), posterior cingulate gyrus (see brain regions section) and precuneal 
areas (instrumental in the retrieval of contextual episodic memory (Lundstrom et al., 2005)) (Watson 
et al., 2012). DLB is generally characterised by a more posterior reduction in FA, in particular the 
parieto-occipital regions, which could in part explain the visual disturbances common in DLB. AD 
tends towards a more generalised reduction in FA across the brain(Watson et al., 2012). 
DTI corroborates evidence from SPECT and PET investigations showing precuneal and occipital hypo 
perfusion and metabolism (Colloby et al., 2002; Imamura et al., 1997). These regions are not 
associated with any great degree of grey matter loss (Middelkoop et al., 2001) leading Watson et al. 
to suggest that DLB is characterised by white matter loss and therefore synaptic dysfunction as 





1.1.5.1 Treatment of motor symptoms 
 
Treatment of Lewy body diseases has the three aims of optimising motor and cognitive function 
whilst minimising unwanted symptoms of depression, hallucinations, delusions, anxiety, daytime 
hypersomnolence and orthostatic hypotension (Boeve, 2005). Dopaminergic drugs (L-dopa, its 
analogues and dopamine receptor agonists), are the predominant treatment for PD and can be 
referred to as dopamine replacement therapy (Rang et al., 2003). They are administered to alleviate 
the parkinsonism motor symptoms in PDD and sometimes DLB but come with side effects, especially 
in instances of prolonged or high dosage. Dyskinesia, troubling involuntary movements which 
typically present in patients who have been on dopamine replacement therapy such as levodopa for 
two or more years (Rang et al., 2003), is amongst the most troublesome but other side effects 
include delusions, hallucinations, hypersomnolence and orthostatic hypertension (Boeve, 2005; 
Caviness et al., 2011). One of the challenges is balancing levodopa levels to minimise dyskinesias 
whilst maintaining alleviation of muscle rigidity and hypokinesia (Rang et al., 2003). 
Prior to the widespread use of dopamine replacement therapies, muscarinic acetycholine 
antagonists (eg. benzatropine) were used. These anticholinergic drugs dampen acetycholine release 
and act to address the imbalance between dopaminergic inhibition and acetycholine excitation of 
striatal neurons (Rang et al., 2003). Anticholinergics can reduce tremor but are not as effective at 
treating rigidity and hypokinesia as dopaminergic agents (Rang et al., 2003); furthermore they are 
associated with a significantly higher rate of adverse neuropsychiatric events (Katzenschlager et al., 
2003).  
Ehrt et al undertook a comprehensive study into the effects of anticholinergics on PD patients and 
reported declines in cognition (assessed by MMSE) up to 6.5 times higher than subjects on placebo 
(Ehrt et al., 2010). The authors suggest this may be due to anticholinergic drugs exacerbating a 
cortical cholinergic deficit already present in PD patients who are borderline PDD. Additionally 
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muscarinic receptor activity has been associated with reductions in the three main pathological 
proteins Aβ, tau (Perry et al., 2003), and α-syn (Leng et al., 2001), all of which are in turn linked to 
deficits in cognition and so it is plausible that blockade of muscarinic receptors by anticholinergics 
may exacerbate these pathologies and their effect on cognition (Ehrt et al., 2010).  
1.1.5.2 Cholinesterase Inhibitors 
The main currently available pharmacological option to treat AD patients are acetylcholinesterase 
inhibitors (AChEIs); aimed at reversing the decline of the cholinergic system and providing 
symptomatic relief of cognitive impairment through increasing local acetycholine levels at synapses 
by inhibiting enzymatic breakdown of acetycholine (Francis et al., 1999). However they do not 
completely reverse or halt cognitive decline, but merely compensate (Simard and van Reekum, 
2004). 
Donepezil, rivastigmine and galantamine are the three AChEIs currently in use for moderate AD. 
Clinical trials have shown all three to confer a moderate cognitive improvement to patients; a mean 
increase of 2.7 on the cognitive section of the Alzheimer’s Disease Assessment Scale (Rodda and 
Carter, 2012). There is argument concerning the clinical relevance of so small a change but the 
counter argument that ‘reduced worsening than would be expected if the patient was untreated’ 
has weight. Currently only donepezil is licensed for use in all stages of AD in the USA but mild to 
moderately severe in the UK (Ballard et al., 2011a). 
It would seem plausible for AChEIs to be efficacious in DLB and PDD given the considerable deficits in 
the cortical cholinergic system in both dementias (Perry et al., 1994). Rolinski et al. (2012) undertook 
an extensive review of clinical trials conducted with AChEIs in PDD and DLB patients using Cochrane 
methodology. They concluded that there was a benefit to patients cognition, that was more 
pronounced in PDD than DLB, and that there was an improvement in behavioural disturbances in 
PDD, detected using NPI, but only when taking rivastigmine (Emre et al., 2004).  However, the 
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likelihood of experiencing an adverse event was increased when taking AChEIs and parkinsonism 
symptoms such as tremor were more frequent in those taking AChEIs (Rolinski et al., 2012).  
In contrast to the rather limited clinical benefits, there is evidence from neuronal cell culture work 
that AChEIs can be neuroprotective. In particular donepezil, at clinically relevant concentrations, has 
been shown to preserve rat cortical neurons from oxygen and glucose deprivation damage. However 
this was probably not mediated by AChE inhibition but possibly through alterations in gene 
expression (Akasofu et al., 2003). Donepezil and galantamine also confer neuroprotection from 
glutamate and Aβ induced cytotoxicity; again this was concentration dependent and at a 
physiological concentration (Francis et al., 2005). It should be noted that these neuroprotective 
actions were the result of pre-treatment of the cells; it remains to be seen whether AChEIs in human 
AD can generate the same protective effect in a cellular milieu already undergoing cytotoxic 
processes modelled in vitro. 
Addressing this question by considering the clinical evidence presents a challenge; the symptomatic 
benefits of AChEIs may mask the detection of neuroprotection, even with a ‘delayed end point’ or 
‘withdrawal’ design of trial. ‘Randomised start’ trials, in which subjects on placebo transfer to active 
drug and it can be seen whether they gain immediate alleviation of symptoms and ‘catch up’ with 
the initial active drug group, may offer the best means to delineate neuroprotection and 
symptomatic treatment (Mori et al., 2006). Randomised start trials of donepezil, rivastigmine and 
galantamine have provided some support for a neuroprotective effect; patients on placebo had 
reductions in cognition that were not regained when transferred to the AChEI, likely due to the 
missed period of neuroprotection (Tanji et al., 2010). 
A further way to assess neuroprotection of AChEIs is using brain imaging of patients participating in 
clinical trials. Donepezil can safeguard regional cerebral blood flow in the anterior cingulate gyrus 
and frontal cortex after a year of treatment (assessed by SPECT) (Nakano et al., 2001). Additionally 
MRI has revealed, in two separate studies, that donepezil maintains hippocampal volumes in AD 
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patients (Krishnan et al., 2003; Mori et al., 2006). These imaging findings further endorse a 
neuroprotective role of AChEIs in addition to their primary function of prolonging the presence of 
acetylcholine at the synapse. 
There are indications that AChEIs may have yet another route to efficacy through interactions with 
Aβ pathology in AD (Francis et al., 2005). Studies conducted on all the main AChEI compounds have 
shown an increase in the production of the soluble N-terminal APP fragment produced by alpha-
secretase cleavage – the first stage of the so called ‘non-amyloidogenic pathway’ (Racchi et al., 
2005). It is likely that this is a post-translational modification as APP RNA levels were unchanged. 
However, the main mechanism of action of AChEIs in AD and other dementias remains the inhibition 
of acetylcholinesterase leading to increased synaptic concentrations of acetylcholine and evidence 







1.1.5.3 NMDA receptor antagonists 
 
Deterioration of glutamatergic systems occurs in AD and as the primary glutamate receptor, the 
NMDA (N-methyl-D-aspartate) receptor formed a natural choice of target for pharmacologic 
intervention in AD. It has been proposed that NMDA mediated excitotoxicity, caused by excessive 
localised glutamate release engendering toxic damage and loss of glutamatergic neurons, maybe 
partially responsible for the observed deficit in glutamatergic pathways and reduction of regional 
and global glutamate levels in AD (Geerts and Grossberg, 2006).  
Memantine is a voltage dependant, moderate affinity, non-competitive antagonist of NMDA 
receptors (Francis et al., 2012). It is considered to partially block the ion channel but is only able to 
do so when the receptor has been activated by glutamate binding and is thus already open. In this 
way the effects of memantine are moderated and it is likely this has avoided many of the side 
effects, like hallucinations, associated with other earlier NMDA antagonists developed to combat 
NMDA mediated excitotoxicity associated with stroke (Geerts and Grossberg, 2006; Rogawski and 
Wenk, 2003). 
Aβ has been shown to have a cytotoxic effect on cultured cells and this may be mediated through a 
disruption to Ca2+ balance which in turn causes increased susceptibility of neurons to glutamate 
induced excitotoxicity (Rogawski and Wenk, 2003). Additionally, studies have revealed Aβ can 
interact directly with NMDA receptors resulting in inappropriate activation and possibly contributing 
to the excitotoxic mediated degeneration of glutamatergic neurons (Cowburn et al., 1997). Rogawski 
and Wenk comment on the interesting possibility that memantine can have additional benefits in AD 
by preventing this interaction of Aβ and NMDA receptors – this is substantiated by cell culture 
experiments that showed pretreatment of memantine to inhibit the toxic properties of Aβ (Tremblay 
et al., 2000). 
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The interactions of memantine with pathological proteins are not limited to Aβ but extend to tau. 
Memantine has been shown to inhibit the hyperphosphorylation of tau (Li et al., 2004). Thus in a 
variety of in vitro and in vivo systems memantine has been established to be neuroprotective 
notably against Aβ induced neurotoxicity (reviewed by Rogawski and Wenk, 2003), and may 
therefore slow the neurodegeneration seen in dementia.  
Human trails of memantine in AD patients have established that memantine can be beneficial to 
patients with moderate to severe AD but not mild AD or in patients who have been administered 
cholinesterase inhibitors (McShane et al., 2006; Rodda and Carter, 2012). The first randomised 
double blind placebo controlled trial (RCT) was conducted by Winblad and Poritis (1999) and there 
have since been two more for moderate to severe AD (Herrmann et al., 2011; Winblad and Poritis, 
1999). In light of this, in the UK, memantine is licensed for use in treating only moderate and severe 
AD. Currently most clinical trials of memantine have not exceeded six months making it tenuous to 
draw conclusions about memantine’s role as a neuroprotective agent in humans. Importantly 
memantine is well tolerated and may also prevent development of agitation and lead to 
improvements in other psychiatric symptoms such as delusions and irritability in AD patients 
(Herrmann et al., 2011; McShane et al., 2006). 
There are conflicting reports regarding memantine and psychiatric symptoms in DLB and PDD. Ridha 
et al (2005) describe three patients who developed delusions and hallucinations after initiating 
memantine treatment, highlighting the possibility of an increased susceptability to NMDA related 
glutamate dyshomeostasis in DLB and PDD patients when compared to AD patients(Herrmann et al., 
2011; Ridha et al., 2005). In contrast to this an RCT found no evidence of psychiatric disturbances in 
a study population of 72 DLB and PDD patients and at the same time demonstrated a moderate 
benefit to patients using clinical global impression of change and an improvement in cognition 
according to MMSE scores (Aarsland et al., 2009). Despite this encouraging outcome the authors 
stress the need for further studies of memantine in DLB and PDD with larger populations. 
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Finally there exists the possibility of using memantine alongside AChEIs in a combination therapy 
due to the differing modes of action and side effects of these classes of drugs, although clinical trials 
have shown benefit of this strategy to cognition and behaviour; the focus was on AD rather than LBD 
(Francis et al., 2012; Howard et al., 2012; Tariot et al., 2004). 
1.1.5.4 Treatment of  neuropsychiatric symptoms 
In addition to therapies aimed at restoring cognition which may have additional benefits there are 
specific treatment options for the neuropsychiatric symptoms of DLB and PDD. It is worth noting 
that prior to commencing pharmacological treatment other options such as psychosocial 
interventions like social interaction, music and pet therapy should be explored. These can be 
particularly beneficial to patients suffering depression (Aarsland et al., 2005b). 
For medication of neuropsychiatric symptoms in AD the atypical antipsychotics risperidone and 
olanzapine have proven the most efficacious; particularly olanzapine with regards to psychosis (De 
Deyn et al., 2004) and risperidone for aggression/agitation (Frank et al., 2004). Nevertheless use of 
these drugs is associated with an increase in the incidence of extrapyramidal symptoms, somnolence 
and stroke, a decrease in cognition and in DLB and PDD a severe reaction termed neuroleptic 
sensitivity or syndrome (Aarsland et al., 2005a; McKeith et al., 2005). 
Neuroleptic sensitivity can occur in up to 80% of DLB patients given neuroleptic medication and is 
severe (presenting as rapid acceleration of parkinsonism and an impairment of consciousness) in 
around 50% of individuals with DLB (McKeith et al., 1992) - a similar frequency of occurrence has 
been reported in PDD (39%) and PD (27%) (Aarsland et al., 2005a) – leading to neuroleptic sensitivity 
to be included as a suggestive feature of Lewy body dementias (McKeith et al., 2005). 
Psychosis and aggression/agitation are not usually permanent symptoms in patients and so 
medication must be continually reviewed and altered. Depression can be managed in some patients 
with serotonergic agents such as setraline and citalopram, which are also well tolerated in patients 
(Sink et al., 2005). Neuroleptic drugs have also been shown to worsen cognitive decline in patients 
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with dementia, particularly with regard to persecution. Importantly this decline was not related to 
the severity of Lewy body pathology (McShane et al., 1997). 
Hence with DLB and PDD there arises a paradoxical need to balance the treatment of motor 
symptoms with treatment of psychiatric symptoms on a case by case basis. DLB and PDD are 
frequently associated with a high sensitivity to antipsychotics, including life threatening neuroleptic 
malignant syndrome (Ballard and Howard, 2006; Sink et al., 2005). It is clear that there is a significant 
need for improved symptomatic pharmacological options as well as a medication that can address 
the underlying cause of the pathology and clinical presentation. 
1.1.5.5 Deep Brain Stimulation 
A more experimental, non-pharmacological approach to the motor and non motor symptoms in PD 
is deep brain stimulation (DBS). It is fairly well established that DBS can be beneficial in ameliorating 
motor symptoms, both as a compliment and alternative to pharmacological dopamine replacement 
therapies. However the picture regarding DBS and non-motor symptoms in PD is less clear. There are 
studies showing that sub-thalamic nucleus DBS can both worsen and improve a variety of symptoms. 
The evidence concerning DBS and hallucinations is amongst the more positive, one study noting an 
improvement in hallucinations in 18 patients up to six months after surgery (Fasano et al., 2012).  
Often DBS studies are clouded by issues such as post-operative micro lesions, which can cause a 
temporary worsening of symptoms; and the transient effect of ceasing a patient’s dopamine 
replacement therapy, which again can briefly cause a worsening of symptoms. However DBS holds 
several important advantages over the various drugs used in PDD and DLB in that it does not 
exasperate any symptoms or have any significant side effects, nor can it interact or interfere with 





1.1.6.1 DLB and PDD 
 
The genetics of Lewy body diseases are complex and overlap with each other and with AD, which is 
unsurprising given the overlap in symptoms and pathologies (Meeus et al., 2012).  Cases of familial 
PD provided the first genetic evidence for a Lewy body disorder in the form of three point mutations 
discovered in the α-syn (SNCA) gene (Polymeropoulos et al., 1997) (reviewed by Hardy and 
colleagues (Hardy et al., 2009)). Although only a minority of PD cases are familial  it served to put the 
focus of research on α-syn; a 140 amino acid ubiquitous protein localised to the pre-synaptic 
terminal (Jakes et al., 1994). 
Kurz and colleagues conducted a systematic review into familial PDD and DLB and found reports of 
24 families with a history of PD and dementia occurring in the same individuals, most had mutations 
in the SNCA gene, some in the gene encoding Bsyn (another member of the synuclein family) (Kurz 
et al., 2006). There were less examples of familiar DLB to be found, and a more varied mix of 
mutations, including APOe3/4 (apolipoprotein E), SNCA and Bsyn. Importantly APOe4 has also been 
identified as a genetic risk factor for sporadic DLB (Pickering-Brown et al., 1994). Fascinatingly, some 
families in the report had a history of both DLB and PDD; that these two dementias can arise from 
the same mutation gives weight to the notion they exist on a disease spectrum (Kurz et al., 2006). 
It has been established that there is a dose-dependent relationship between the number of copies of 
the SNCA gene and disease progression; families with a duplication of SNCA develop idiopathic PD 
with a slow clinical progression. In contrast, in families with a triplication of SNCA the disease 
develops faster and earlier and is more likely to be accompanied by dementia (Chartier-Harlin et al., 
2004; Fuchs et al., 2007). The fact that the age of onset of individuals with a point mutation in SNCA 
is similar to those with a duplication of the gene points to a ‘gain of function’ i.e. an increase in α-
syn’s propensity to aggregate as the mechanism by which these genetic alterations achieve 




Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are known to be a leading risk factor for 
sporadic and familial PD, by some estimates as much as 5% of familial and 3% of sporadic cases (Liu 
et al., 2012). LRRK2 encodes a large protein with multiple GTPase and kinase sites which is expressed 
throughout the brain, interestingly most of the reported mutations affect these enzymatic sites 
rather than other protein interacting domains suggesting that this enzymatic activity of the LRRK2 
protein is the more important with regard to the disease process (Cookson, 2010).  
   There have been few comprehensive studies screening for LRRK2 mutations in DLB or PDD but 
there is a high variability in clinical presentation of patients with LRRK2 mutations and some do have 
dementia (Ross et al., 2006). That the penetrance of LRRK2 mutations are age dependent suggests 
the action of modifying factors to disease development (Toft et al., 2005a). Finally, in a study 
screening 242 individuals with dementia (primarily AD), it was concluded that LRRK2 mutations are 
not common in AD as none of the known LRRK2 mutations were detected (Toft et al., 2005b). 
Gauchers disease, a heritable lysosomal storage disorder characterised by a deficiency of 
glucocerebrosidase due to a mutation in the glucocerebrosidase (GBA) gene, can be accompanied 
pathologically by Lewy bodies and clinically by parkinsonism (Campbell and Choy, 2012). Given this, 
it was not surprising that a relationship was found between mis-sense mutations (which typically 
reduce enzymatic activity) in the GBA gene and both PD and DLB (Bonifati, 2008; Goker-Alpan et al., 
2006). Indeed the occurrence of GBA mutation was far higher in DLB cases (present in 23% of cases) 
than in PD (present in 4% of cases) in the study by Goker-Alpan and colleagues. It is possible that this 





Despite this evidence that genetic factors can play a role in the development and progression of DLB 
and PDD there is clearly a large environmental influence. This was elegantly demonstrated by Wang 
and colleagues who gathered a cohort of 11 pairs of monozygotic twins, in which one of each pair 
had autopsy confirmed DLB. There was a very low rate of concordance between twins; in only 1 pair 
did both develop ‘pure’ DLB with no AD pathology; and only a further 4 pairs of twins both had 
dementia of different types. It is interesting to note that even when both twins developed dementia 
there was generally a prolonged interval of up to 9 years between the onset of dementia in the twins 
suggesting that even if genetics predispose to dementia, environmental factors retain a profound 
influence on disease progression (Wang et al., 2009). 
 
1.1.6.2 Alzheimer’s Disease 
There has been considerably more research undertaken into AD genetics than DLB or PDD; in a 
similar study and in direct contrast to the DLB twin study undertaken by Wang et al (2009) it was 
established that there is a strong concordance of 78% for AD amongst monozygotic twins (Bergem et 
al., 1997). As far back as 1991 mutations in the Aβ precursor protein (APP) were discovered by Goate 
and colleagues on chromosome 21 in familial AD, and Aβ has not left the centre stage in AD research 
since then (Goate et al., 1991; Goate and Hardy, 2012). The mechanisms through which Aβ is 
postulated to cause disease will be covered in the pathology and biochemistry sections. 
Two more  genes responsible for early onset familial AD have been well characterised in the PSEN1 
and PSEN2 genes (encoding presenilin 1 and 2 respectively); taken together with APP these 
mutations only account for between 1 and 5% of AD cases (and presenilin comprises 90% of familial 
AD mutations) yet the estimated contribution of genetics to the risk of AD in the general population 
is thought to be around 70% (Ballard et al., 2011b).  
The majority of PSEN mutations are mis-sense resulting in a loss of function. Studies in mice with a 
lack of presenilin function have shown presenilin to be important for neurotransmitter release, in 
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particular glutamate, and so paucity of presenilin function can impact LTP (Saura et al., 2004). It is 
thought that presenilin 1 is required for correct localisation of NMDA receptors to the synaptic 
membrane (Ho and Shen, 2011; Saura et al., 2004).  Mutations in PSEN genes may affect the 
production of Aβ in humans (Ballard et al., 2011b), a fact which is supported by observations in PSEN 
knockout mice showing a lack of Aβ production (Saura et al., 2005). 
The first genetic risk factor for sporadic late onset AD identified was the APOe4 allele. Individuals 
with increased APOe4 alleles had a sevenfold higher risk of AD and an earlier age of onset (Corder et 
al., 1993), individuals with APOe2/3 alleles had a markedly later age of onset leading to speculation 
that APOe2 is a longevity gene (Roses, 2006). 
Further genetic risk factors for AD have been found through genome wide association studies 
(GWAS), in which thousands of samples can be screened for common single-nucleotide 
polymorphisms (SNPs) but none with the effect size of APOe4 have been found to date (Guerreiro 
and Hardy, 2011; Moraes et al., 2012). Instead 26 SNPs (review in depth by Moraes et al. and 
published online in full by the National Human Genome Research Institute 
http://www.genome.gov/gwastudies; Bethesda, USA) have been found which independently confer 
a minor increase in risk of around 1.5 to 2 fold. Of these SNPs the three most consistently 
reproduced are those for the clusterin, phosphatidylinositol binding clathrin assembly protein 
(PICALM) and complement receptor 1 (CR1) genes (Guerreiro and Hardy, 2011; Moraes et al., 2012). 
These findings have served to highlight three biochemical process in the etiology of AD; 
inflammation, endocytosis and lipid metabolism, discussed further in the biochemistry section 






The pathological hallmark of LBD are Lewy bodies, first described by Friederich H. Lewy 100 years 
ago, and which fall into three categories; brainstem predominant (bLB), limbic or transitional and 
cortical (cLB) – all primarily composed of the protein alpha synuclein (α-syn). Typically bLB appear 
first and have a more defined morphology. There is a progression of LB pathology from the 
brainstem, through the limbic regions culminating in the cortex (Braak et al., 2003). It is unclear 
whether brainstem or limbic LBs correlate to the degree of dementia but a correlation between 
dementia and cLBs has been reported (Duda, 2004; Harding and Halliday, 2001). Alongside LBs there 
are other, related, common pathological features; Lewy neuritis, either axons or dendrites 
containing high amounts of aggregated α-syn and so called ‘pale bodies’, thought of as a pre-lewy 
body.  
LBs and Lewy neurites share a similar neuroanatomical distribution throughout most brain regions 
except the cerebellum, where none have been reported. Why this should be so and what is peculiar 
to cerebellar neurons remains to be elucidated (O'Brien et al., 2006; Wakabayashi and Takahashi, 
1997). This is of interest also in view of recent findings in C9ORF72 mutant amyotrophic lateral 
sclerosis with frontotemporal dementia cases where cerebellar pathology is a defining feature (Al-
Sarraj et al., 2011).  Table 1.1.7 summaries the distribution of LBs throughout the brain in DLB and 








Braak PD Stage Anatomical distribution of LBs 
1 Medullary tegmentum, dorsal motor nucleus of vagus, olfactory bulb 
2 Locus ceruleus, caudal raphe, reiticular nucleus of medullary and pontine 
tegmentum 
3 Substantia nigra and basal forebrain 
4 Medial temporal cortices, amygdale, CA2 in hippocampus 
5 Multimodal association cortices, frontal and temporal lobes 
6 Unimodal association cortices and primary cortices 
 
Lewy neurites are found in the hippocampus, cingulate gyrus, entorhinal cortex, amygdale and basal 
ganglia and are an earlier pathological event than LBs (O'Brien et al., 2006).  
Another interesting anomaly regarding LBs is their appearance in genetically defined (Lantos et al., 
1994) and sporadic AD cases (Hamilton, 2000). That this LB pathology is not a separate coincidence is 
supported by the presence of LB pathology in early onset genetic AD cases and in the brains of those 
with Down’s syndrome; indeed, these findings appear to establish a link between Aβ and α-syn 
pathologies (Ballard et al., 2011b; Simard and van Reekum, 2001). However it should also be 
remarked that α-syn can generate Aβ pathology; as demonstrated by the intensified pathology 
resulting in crossing α-syn over-expressing mice with APP transgenics (Masliah et al., 2001b; O'Brien 
et al., 2006). 
In many cases of DLB or PDD there is also an occurrence of pathology regarded as being distinctive 
to AD, namely amyloid-beta (AB) plaques and neurofibrillary tangles (NFT). This can often lead to 
difficulties in diagnosis and this combination of pathologies has been referred to as Lewy body 
variant of AD in earlier studies, although this terminology is now less commonly used (Hansen et al., 
1990; McKeith et al., 2004).  
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The primary AD type-pathologies are abeta positive plaques and tau positive threads and tangles. 
Abeta pathology is principally located in grey matter and spreads throughout brain regions in a 
topographical manner depending on how advanced the disease is. This topographical spread begins 
in the basal regions of the isocortex, followed by the hippocampus and entorhinal cortex, then the 
striatum, brainstem nuclei, and diencephalic nuclei, culminating in the cerebellum and additional 
brainstem nuclei (Thal et al., 2002).  
Tau pathology likewise spreads in a topographical manner, in the early stages of the disease the 
entorhinal cortex is affected, followed by the hippocampus and finally the isocortex (Duyckaerts et 
al., 2009). The amount of AD pathology in DLB and PDD varies but can be as severe as is found in AD 
(Jellinger and Attems, 2008). 
1.1.7.1 Amyloid-beta 
Alzheimer’s disease, like most neurodegenerative disorders, is defined and diagnosed pathologically 
by aggregated protein deposits in the brain. In the case of AD these are extracellular amyloid 
plaques formed principally of amyloid-beta (Aβ), and intracellular neurofibrillary tangles (NFT) 
composed of tau (Duyckaerts et al., 2009). Aβ has been hypothesised to be central to the 
pathogenesis of AD since it was first purified from leptomeningeal  vasculature extracts (Glenner and 
Wong, 1984). Evidence corroborating this keystone of AD theory has accumulated (Ballard et al., 
2011b); most mutations in familial AD and genetic risk factors for sporadic AD affect Aβ metabolism 
in some way (Tanzi and Bertram, 2005) and cell culture work has shown Aβ aggregation, particularly 
as oligomers, to be toxic (Takashima, 2009; Walsh et al., 2002). 
   Aβ is produced through enzymatic cleavage of a transmembrane glycoprotein amyloid precursor 
protein (APP); beta-secretase cleaves a cytosolic fragment from APP which is truncated again by 
gamma-secretase into Aβ and the APP intracellular domain. In a physiological state however, the 
majority of APP is processed by alpha-secretase in a non-pathological pathway that may even by 
neuroprotective (Lahiri and Maloney, 2010). It should be noted that there is variability in the amino 
48 
 
acid composition of Aβ produced in this way, with the peptide chain terminating anywhere from 
amino acid 39 to 42 (Duyckaerts et al., 2009).  
   A similar multifariousness can be found in the descriptions and types of Aβ deposits or plaques. 
Before the advent of Aβ specific antibodies and immunohistochemical techniques stains such as 
congo red, thioflavin S and Bielschowski’s silver stain were used to visualise plaques and so gave rise 
to different classifications of plaques. Plaques broadly fall into three categories based on 
morphology; diffuse, focal or stellate, and are often accompanied by a corona, coined ‘neuritic’ 
plaques (Duyckaerts et al., 2009).  
   Stellate plaques are believed to be astrocytic in origin but are poorly characterised, diffuse 
plaques, as the name suggests, are variable in morphology across different brain regions (Duyckaerts 
et al., 2009). That they are commonly found in aged but cognitively intact individuals lends credence 
to the theory that diffuse plaques are not the primary drivers of neurotoxicity (Dickson et al., 1992). 
Focal (or neuritic) plaques were considered the cytotoxic culprits – although current evidence points 
towards oligomeric species rather than plaques as initiators of toxicity (Walsh et al., 2002). Such 
plaques are dense, with a core consisting primarily of Aβ-42 (Güntert et al., 2006). It has been 
estimated that the quantity of Aβ protein within a plaque can be in the region of 100 fmole 
(Rüfenacht et al., 2005). Neuritic plaques are frequently associated with microglia and NFTs 
reinforcing the link between Aβ and tau and highlighting the role of inflammation in AD pathology, 
both discussed later (Duyckaerts et al., 2009). 
Aβ can also be found accumulated in the walls of cerebral blood vessels, a phenomenon known as 
cerebral amyloid angiopathy (CAA). It is likely that ischaemia and microhaemorrhages, attributed to 
CAA induced damage to vessel walls, contribute to cognitive decline. CAA can arise sporadically in 
non-demented elderly as well as in association with AD, particularly familial AD (Revesz et al., 2009). 
In a study by Attems and colleagues it was reported that the severity of CAA and AD pathology were 
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significantly related; although around a quarter of AD cases examined did not have CAA and a similar 
fraction of control cases did have CAA (Attems et al., 2005). Recently, BrainNet Europe Consortium 
multicenter study emphasized the need to unify assessment of vacular alterations including amyloid 
angiopathy in post-mortem studies (Alafuzoff et al., 2012). 
Diagnosis of Alzheimer’s disease is based on an assessment of pathology at post mortem. Historically 
an array of staining techniques were used to visualise this pathology; to achieve consistency 
between centres, a landmark comparison of staining techniques and assessment criteria across the 
BrainNet Europe centres was conducted and concluded that use of antibodies against Aβ and 
hyperphosphorylated tau gave the highest reliability (Alafuzoff et al., 2012; Alafuzoff et al., 2006). 
The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) published guidelines 
establishing four stages of diagnosis; normal brain, possible AD, probable AD and definite AD (Mirra 
et al., 1991). The semi-quantitative nature of the immunohistochemical grading recommended by 
the CERAD report avoided previous issues of inter-centre and scorer variability, particularly when 
assessing cases with low plaque counts (Duyckaerts et al., 2009). The BrainNet Europe Consortium 
has introduced a simple and reliable staging protocol to assess tau pathology which is now widely 
used by neuropathologists (Alafuzoff et al., 2008). 
However the CERAD stages do not necessarily relate to the severity of the clinical presentation and 
so the National Institute on Aging and Reagan Institute criteria (NIA Reagan criteria) were developed 
to relate the clinical and pathological aspects and to combine the focus on tangles and threads 
recommended by the Braak staging with the attention given to plaques under the CERAD guidelines  
(The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the 
Neuropathological Assessment of Alzheimer’s Disease (1997)). 
Newell et al. assessed the diagnostic effectiveness of the NIA Reagan criteria and found a high 
concordance between clinical AD and a ‘high probability of AD’ at post-mortem according to the NIA 
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Reagan criteria; additionally the NIA Reagan criteria proved superior than CERAD at distinguishing 
DLB from AD (Newell et al., 1999).     
There are a number of suggested physiological roles for Aβ including an oft proposed participation in 
a kinase signalling pathway involving c-Jun N terminal kinase (JNK) (Lahiri and Maloney, 2010). Lahiri 
and Maloney summarise the many other purported functions of Aβ, ranging from providing anti-
oxidative protection from metal ions to cholesterol trafficking. Aβ may also function as a 
neuromodulator at both nicotinic and NMDA receptors through a pathway revolving around 
phosphorylation of Akt (Abbott et al., 2008). Akt is a serine/threonine kinase B implicated in 
neuronal survival and LTP. Recently Soscia and colleagues (2010) have reported Aβ to have an 
antimicrobial role and suggest Aβ production could be a response to microbial pathogens – an idea 
which is substantiated by the oft described inflammatory processes occurring in neurodegeneration 
(Soscia et al., 2010).  
Aβ has been shown to be released at the synapse into the interstitial fluid following normal synaptic 
activity. APP is internalised into synaptic vesicles via the same mechanism as synaptic proteins such 
as synaptophysin – and this is increased with heightened firing of the synapse – resulting in greater 
production and release of Aβ (Cirrito et al., 2008). This is supported by a brain imaging study 
suggesting the brain regions most active throughout life (posterior cortical regions including the 
cingulated and parietal cortices) are the most susceptible to Aβ pathology (Buckner et al., 2005). 
Despite these many theories Aβ’s precise physiological function(s) remain(s) a mystery.  
There is controversy about detection of intracellular Aβ (Duyckaerts et al., 2009). The antibodies 
used in some studies reporting intracellular Aβ may be detecting epitopes common to APP and Aβ. 
Despite availability of Aβ specific antibodies there is still much variability in results due to differences 
in immunochemical techniques; however Aho et al conclusively demonstrate the presence of 
intracellular Aβ in subjects with AD but not in control subjects (Aho et al., 2010). It has been 
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speculated that Aβ may accumulate intracellularly prior to development of extracellular pathology 
and cell loss (Duyckaerts et al., 2009). 
The amyloid hypothesis, formulated in 1991 by AD researchers, states that aggregated Aβ leads to 
NFT formation which in turn causes neuronal death and this progressive process manifests clinically 
as memory loss and other symptoms associated with dementia (Hardy and Allsop, 1991; Selkoe, 
1991). A number of predictions were made regarding Aβ and AD; firstly that other genetic causes of 
AD would have a connection to Aβ, secondly that Aβ would be toxic to neurons and culminating with 
the pivotal concept that reducing Aβ would assuage the clinical symptoms of AD (Hardy, 2009). 
Implicit to the cascade from Aβ via NFT to cell death is the notion that Aβ initiates NFT formation 
and that NFTs are a closer event to cell death than plaque formation. 
Despite the above prediction regarding Aβ toxicity, after the discovery that Aβ was the principal 
component of the extracellular plaques there was considerable debate as to whether it was inert, 
neuroprotective or neurotoxic (Hardy, 2009; Tabaton and Gambetti, 2006; Walsh et al., 2002).      
A significant hurdle to the toxic plaque theory is that poor correlation of plaques to clinical severity 
and neuronal loss. Whilst it is possible that extracellular Aβ may have a toxic effect on membranes 
that can be exerted from a distance or cause a predisposition to the effects of intracellular tau 
aggregation several factors, such as the lack of any known ‘Aβ only’ neurodegenerative condition 
when there are ‘tau’ only diseases casts doubt on this (Benilova et al., 2012) yet the cases of a 
mutation in APP alone being sufficient to give rise to AD reaffirms that Aβ must have a role in the 
disease.  
Another criticism of the amyloid cascade is the presence of often substantial Aβ pathology in non-
demented controls (Dickson et al., 1992; Jellinger and Attems, 2012; Knopman et al., 2003). Despite 
this generally being an observation in a minority of surveyed control cases, it serves to cast further 
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doubt upon Aβ alone being inherently, substantially and consistently neurotoxic to a degree 
necessary for the emergence of significant cognitive impairment. 
Soluble oligomers of Aβ (sAβ) can be isolated from human post-mortem brain tissue and serve as a 
better correlate to clinical symptoms than plaques (Tomic et al., 2009). Amongst the most 
compelling evidence for this is that provided in a study by Lesné et al. using Tg2576 mice expressing 
human APP. These mice developed worsening memory deficits until six months at which age the 
degree of memory impairment plateaued until 14 months when it began to decline further. A 56kDa 
species of soluble Aβ (termed Aβ*56) was found to parallel this pattern up until the later decrease in 
memory at 14 months but the authors conjecture Aβ plaques (which have accumulated sufficiently 
to take up the mantle of synaptic degeneration from Aβ*56) to be responsible for this later decline 
(Lesné et al., 2006).  
This correlative evidence was elegantly cemented with a causative approach by administering Aβ*56 
to rats. A decline in long-term memory mirroring that in the Tg2576 mice was seen; that this decline 
was transient suggests Aβ*56 was having a physiological rather than pathological effect (Lesné et al., 
2006). However there remains the possibility that sodium dodecyl sulphate (SDS) in the buffer could 
either have artificially caused the formation of Aβ*56 or be responsible for the toxicity behind the 
observed memory effects in rats (Benilova et al., 2012; Lesné et al., 2006). 
Clusterin (APOj) has been shown to promote formation of sAβ and in vitro it has been shown that 
sAβ disturbs neurotransmission and causes cell death. Two of the APP mutations causing familial AD 
may predispose to formation of sAβ (Benilova et al., 2012). Furthermore, clusterin has been found to 
associate specifically with Aβ40 containing plaques in the brains of individuals with AD (Howlett et 
al., 2013). 
Neurons contain a heterogeneous mix of Aβ momomers of different amino acid chain lengths, Aβ 40 
being the most common under physiological conditions; this may switch to Aβ 42 in pathological 
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conditions. Changes in the ratio of Aβ lengths, especially 40/42, may be more important than 
concentrations of Aβ in driving the switch from equilibrium to a pathological cascade. Likewise there 
is a considerable variation in the toxic oligomers, both those found biologically and those used in in 
vitro assays. Some of which may not exist biologically or have been created by the purification steps 
used, in particular SDS-page (Benilova et al., 2012). Benilova et al propose that a dynamic 
equilibrium exists between Aβ monomer, oligomer and aggregate although dimeric and 
dodecameric species have received the most attention (Wilcox et al., 2011). 
The matter of exactly what constitutes a toxic effect is another hurdle for the toxic sAβ theory, and 
one that has not been helped by issues with some assays such as possible interference of sAβ with 
the dye in the mitochondrial MTT toxicity assay (Benilova et al., 2012). However the gathering 
weight of evidence from different assays makes it increasingly probable that sAβ does cause cell 
death.  
In addition to cell death it is generally accepted that sAβ can exert synaptic effects. Antibodies 
specific to sAβ species show a dendritic pattern of binding which is increased in AD brain and it has 
been demonstrated using confocal microscopy that sAβ co-localises with PSD95 (Lacor et al., 2004). 
The authors put forward the hypothesis that sAβ binding to synapses is a substrate for the 
impairment of new memory formation observed in individuals at an early stage of AD. 
This concept is supported by evidence from a number of different modicums that sAβ not only binds 
to synapses but has a functional effect; inhibition of long term potentiation (LTP) and depression 
(LTD) using oligomers derived from human AD brain, APP transgenic mice and cells expressing 
human APP (Shankar et al., 2008; Wilcox et al., 2011). In the mice this was accompanied by a 
behavioural effect on memory. However this data is associated with some controversy as other 
groups have been unable to see a cognitive phenotype when introducing sAβ to mice (Benilova et 
al., 2012). Interestingly this effect of Aβ on LTP forms the functional basis for a recent experimental 
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therapeutic approach utilising antibodies to clear the toxic Aβ oligomers interfering with LTP 
(Klyubin et al., 2005). This is discussed further at the end of the Aβ section. 
The mechanism by which sAβ might mediate toxicity or interfere with function at the synapse is 
unclear although recently it has been suggested that decreased phosphorylation of Akt through a 
NMDA and α7 nicotinic receptor mediated pathway - as a consequence of chronic Aβ exposure - may 
explain Aβ generated synaptotoxicity (Abbott et al., 2008). 
Lacor and colleagues found synaptic binding of sAβ caused an up-regulation of Arc (activity regulated 
cytoskeletal) protein (Lacor et al., 2004), a product of a synaptic immediate-early gene, the 
overexpression of which has been linked to synaptic dysfunction and memory impairment 
(Guzowski, 2002). Arc has been proposed to act detrimentally on a number of pathways and 
processes within the synapse affecting spine morphology and receptor trafficking. It is also 
conceivable that sAβ can affect these processes directly (Lacor et al., 2004). 
Thus the nature, role and mechanism of sAβ in AD remains to be elucidated and criticisms abound, 
particularly as to whether the sometimes subtle synaptic effects can fully account for the severity of 
neuronal loss encountered in late-stage AD (Hardy, 2009). Ultimately it will be necessary to 
thoroughly characterise toxic sAβ before it can become a realistic target for interventions such as 
immuno-clearance (Benilova et al., 2012).  
Given the overwhelming evidence for Aβ playing a key role in AD pathogenesis it was a natural 
assumption, and in concord with the amyloid cascade hypothesis, that reduction or complete 
elimination of Aβ plaques and pathology from the brain would ameliorate the clinical syndrome 
(Hardy, 2009; Marchesi, 2012). However there has been no success in any of the clinical trials aimed 
at reducing Aβ levels. There are two general positions taken as to why this may be; the first is that 
Aβ is the wrong target and possibly another aspect of the disease such as tau or metal ions should 
be investigated, the second is that the design of the trials was flawed in testing new therapies in 
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advanced AD patients in which neuronal loss and synaptic damage may be too great for a cessation 
of the pathological mechanisms of Aβ to have any meaningful or detectable benefit to the patient.  
    Instead there is an argument for patients with MCI (mild cognitive impairment) to be used in 
clinical trials. This would require the use of biomarkers to confirm MCI status and assumes that MCI 
patients will progress to AD, however MCI patients may represent a better hope for halting the 
neurodegeneration at a less advanced stage and circumvent the issue of the early onset of pathology 
prior to development of symptoms (Marchesi, 2012). An additional approach has been the use of 
populations of with a more genetically homogeneous presentation of dementia such as the 
dominantly inherited Alzheimer’s disease network (DIAN) cohort – with the additional benefit of the 
extensive clinical and pathological characterisation undergone by participants (Morris et al., 2012). 
The strategies employed by the therapeutic agents assessed in the clinical trials to date centre 
around either blocking production of Aβ, increasing its metabolism or clearing Aβ from the brain 
using antibodies directed against it (Marchesi, 2012). The most (or possibly the only) success has 
been in immunisation based trials. The concept was successfully demonstrated in transgenic mice 
over-expressing APP, in which it was possible to remove almost all Aβ deposits in aged mice as well 
as prevent development of deposits in young mice (Schenk et al., 1999). Of the few individuals who 
participated in human trials and have had an autopsy Aβ was reduced or absent yet there was no 
clear clinical improvement in the trials . Additionally a number of important questions remain, for 
example, there was a reduction brain volume in immunised individuals, also the mechanism by 
which antibodies clear Aβ remains unclear, the possibilities include stimulating phacocytosis, 
sequestering of Aβ elsewhere in the brain periphery or simply blocking aggregation (Delrieu et al., 
2012). In the Aβ42 immunisation trial published by Holmes and colleagues (Holmes et al., 2008) it is 
suggested immunisation may have increased production of toxic oligomeric and soluble Aβ species 
as a direct consequence of the breakdown of plaques (Boche et al., 2010) or by exacerbating the 
immune response such that further neurodegeneration occurred  – indeed this last point was further 
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suggested by follow-up examination of microglial activity in immunised patients in which it was 
found that Aβ42 immunisation altered microglial activity (Zotova et al., 2011).   
1.1.7.2 Alpha Synuclein 
 
Alpha synuclein (α-syn) is an abundant member of the synuclein family of proteins, of which beta 
and gamma synuclein are other prominent members. It was first identified as a component of LBs by 
Spillantini and colleagues using immunohistochemistry (Spillantini et al., 1997). α-syn’s structure is 
intrinsically disordered (i.e. only a primary peptide structure) unless bound to membranes when it 
takes on an alpha-helical structure and when aggregated in fibrils it assumes a beta-sheet 
conformation (Auluck et al., 2010). α-syn contains 140 amino acids and is located in the presynaptic 
terminal where it is thought to have a role in SNARE (soluble N-ethylmaleimide-sensitive fusion 
protein attachment protein receptors) complex assembly (Burre et al., 2010). Specifically Burre et al 
demonstrated that α-syn drives formation of the SNARE complex through a chaperone-like activity 
involving binding to phospholipids and synaptobrevin-2. The authors suggest α-syn provides a proof-
reading facility to SNARE complex function that is important with increased synaptic activity and age 
dependent, a factor which may go part of the way to explaining the vulnerability of aged neurons to 
a redistribution of α-syn from the synaptic terminal to form LBs. 
This is in contrast to previous work summarised by Goedert (Goedert, 2001) that proposes that it is 
not a loss of function of α-syn that accounts for its role in neurodegeneration, an opinion based on 
studies showing that inactivation of the SNCA gene in mice does not cause an overt 
neurodegenerative phenotype (Abeliovich et al., 2000). Additionally as previously mentioned, 
people with multiple copies of SNCA genes develop PD early and more severely, again suggesting 
that it is a toxic gain of function responsible for α-syn’s pathogenicity (Singleton et al., 2003). 
Ultimately there may well exist a level of redundancy or an ability to compensate for a loss of α-syn 
in its physiological role. Mice lacking the genes for α-syn and gamma synuclein showed a similar 
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pattern of altered gene expression suggesting gamma synuclein to be involved in some of the same 
pathways and functions as α-syn and so may contribute to this compensation (Kuhn et al., 2007). 
However, it remains α-syn’s propensity to aggregate that sets it apart from other synaptic associated 
proteins. It is believed that α-syn oligomerisation, followed by its aggregation, directly precedes the 
formation of Lewy bodies and is in some way cytotoxic. α-syn shares a considerable degree of its 
amino acid sequence with Bsyn which focuses attention on the differences in the sequences to 
answer the question of why Bsyn does not aggregate. α-syn contains a central hydrophobic, non-
amyloid, sequence, made conspicuous by its absence in Bsyn and which when deleted or the 
hydrophobicity is altered, seems to prevent aggregation and the consequential deleterious effect to 
neurons, albeit in a fly model (Auluck et al., 2010; Periquet et al., 2007; Vekrellis et al., 2011).  
Some of the mutations in the SNCA gene known to give rise to α-syn disorders exert their pathogenic 
effect through alterations in the amino acid sequence of α-syn which lead to changes in aggregation 
or oligomerisation. For example the A53T mutation triples the size of the hydrophobic, aggregation 
driving domain of α-syn to 30 amino acids whilst the A30P and E46K mutations decrease α-syn’s 
affinity for phospholipid binding which promotes dimerisation (Auluck et al., 2010). Furthermore 
both of these mutated forms of α-syn can affect membrane curvature – an important property in 
determining the efficiency and frequency of vesicle binding at synapses. Essentially the higher the 
curvature, the greater the structural strain on the membrane and thus the propensity to bind is 
higher. A30P and E46K α-syn reduce membrane curvature and so, by this mechanism, may behave as 
a brake on vesicle binding and neurotransmitter release and cause an accumulation of vesicles in 
synaptic terminal reserve pool (Auluck et al., 2010; Perlmutter et al., 2009). 
The toxicity of α-syn, in sporadic and familial disease, has been proposed to arise in several ways; 
through inhibition of histone acetylation by α-syn, perforation of membranes and the consequent 
disruption of ionic balance and finally neuronal death via the inhibition of a neuronal survival factor 
MEF2D (Beyer et al., 2009a). Beyer et al suggest that in fact there maybe multiple pathways 
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involving α-syn and other proteins linked to LBs that culminate in the same end-stage pathology of 
Lewy bodies and neurites.  
Another interesting anomaly in the evidence for α-syn as a toxic agent is the survival and apparent 
health of some neurons that contain aggregated α-syn and that LBs can be found in non-demented 
individuals at autopsy (Brown, 2010). It was partly in response to this conundrum that different 
species of α-syn were identified and theories emerged that it may be different forms of α-syn to the 
aggregates seen in LBs that are driving the cell death and synaptic degeneration. 
There is a variety of oligomeric α-syn species reported in the literature and considerable debate as 
to how they may form; Brown opines that ‘molecular crowding’ is the most likely although there is 
also evidence for a prion like seeding mechanism, discussed later. Many of the oligomeric species 
identified have a stellate, pore like structure and this has been thought to attribute for the formation 
of pores in cell membranes and increased ion permeability (Brown, 2010). 
 
There is a theory that oligomeric α-syn may assist in forming a link between the reported metal ion 
abnormalities in DLB and PDD and the biochemical pathology and that increases in local copper ion 
availability may facilitate toxicity of oligomers (Wright et al., 2009). This is explored further in the 
section on zinc and other metals in the CNS. 
Many synucleinopthies, in particular PD, are characterised by a topographical spread of pathology, 
which begins in the medulla oblongata and olfactory bulb, spreading to the midbrain/substantia 
nigra and culminating in cortical pathology, which was first described by Braak and colleagues and 
now forms the basis for a formal neuropathological staging (Braak et al., 2003). 
However the Braak Lewy body staging (Braak et al., 2003) has come under increasing criticism, 
initially as a consequence of a number of PD cases in which the topographical spread of Lewy 
pathology did not follow the caudo-rostral pattern used as the basis for the Braak staging. This was 
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observed in a large number of cases in two separate investigations (Attems and Jellinger, 2008; 
Kalaitzakis et al., 2008). Furthermore these studies brought the supposed origin of pathology in the 
medulla – specifically the dorsal motor nucleus of vagus – under question as in a subset of cases 
there was an absence of pathology in this nucleus. Additionally some cases of preclinical PD (or 
incidental Lewy body disease) showed development of pathology simultaneously across multiple 
brain regions which casts further doubt on the applicability of the original Braak staging to all cases 
with Lewy pathology (Dickson et al., 2008). 
In defence of these criticisms Braak and colleagues revised the original 2006 staging criteria in the 
form of a ‘dual hit’ hypothesis in which they propose pathology can arise in the olfactory bulb or 
enteric nerve plexuses of the foregut and that this pathology is initiated by as yet unknown 
pathogens (Hawkes et al., 2009). The BrainNet Europe Consortium, similar to the approach applied 
for tau and Abeta, made recommendations regarding the immunohistochemical protocol and 
assessment criteria (Alafuzoff et al., 2009). 
Another pitfall of the 2003 Braak staging is the relationship between pathology and 
disease/symptom severity. Inherent in the topographic staging is the concept that with increasing 
spread and density of pathology there is a worsening of disease severity and a progression from 
motor symptoms to cognitive symptoms (Jellinger, 2008). This is generally accepted to be the case, 
in particular when dementia is already present there is often a good correlation between pathology 
and disease severity (Jellinger, 2008; Kövari et al., 2003; Mattila et al., 2000; van den Berge et al., 
2012), yet whilst this is found to be true for PDD, this correlation has not been replicated in DLB 
(Marui et al., 2002). Despite this difference in the relationship between cortical Lewy pathology and 
cognitive decline in PDD and DLB, cortical Lewy pathology cannot be used to distinguish PDD from 
DLB (Harding and Halliday, 2001), it is likely that AD pathology may play a significant role in 
determining disease progression in DLB (Aarsland et al., 2004), in fact Weisman and colleagues go as 
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far as to suggest that the presence of AD pathology determines diagnostic success in that when AD 
pathology was high it became much harder to accurately distinguish DLB (Weisman et al., 2007). 
Compounding the difficulties in establishing clarity with regards to pathological and clinical severity 
are reports of cases of cognitively intact individuals with high levels of cortical Lewy pathology and 
vice versa (low/absent pathology in apparently demented patients). Colosimo et al. report multiple 
cases of clinical PD patients without dementia who, upon autopsy, were found to have extensive 
neocortical Lewy pathology consistent with that typically encountered in DLB (Colosimo et al., 2003). 
Furthermore cortical Lewy pathology can be encountered in individuals with no Parkinsonism or 
dementia (Jellinger, 2004; Parkkinen et al., 2005). In contrast Aho and colleagues found 53% of cases 
in a cohort of 178 aged brains from individuals with and without dementia had considerable α-syn 
pathology yet no cognitive decline or dementia (Aho et al., 2008), a finding repeated by other 
studies (Parkkinen et al., 2008). It is interesting to note that unlike tau and Aβ pathology, Lewy 
pathology is not regarded as a normal feature of aged brains and that these reports of cognitively 
intact aged individuals with Lewy pathology are exceptions - albeit relatively frequent exceptions 
(Jellinger, 2008). 
In view of the discrepancies outlined above, it is clear that there are other factors at work in 
determining both the pattern of progression of Lewy pathology and how this affects the 
development of symptoms; probably glial and neuronal loss and other pathologies such as tau and 
Aβ play an important role (Jellinger, 2008; Parkkinen et al., 2008). 
Prion disease is characterised by the spread of a pathologically misfolded prion protein which has 
the unique ability to induce similar misfolding in non-misfolded native prion proteins and thus 
propagates infection across neurons – probably via trans-synaptic transport (Jucker and Walker, 
2011). Prion disease can be spontaneous with no clear cause, genetic in nature or transmissible. 
There are a number of striking similarities between prion disease and several neurodegenerative 
diseases such as AD and the synucleinopathies. Firstly both feature misfolded native protein which 
61 
 
forms beta-sheet rich aggregates within neurons, which appear to be toxic to the neurons. 
Additionally, this pathology spreads in a stepwise manner through the brain rather than arising 
independently in multiple regions (Alberts et al., 2002; Braak et al., 2003; Jucker and Walker, 2011).  
 
 
Figure 1.1; Diagrams showing the progression of pathology through the brain in accordance with the 




Some of the most compelling evidence for neurodegenerative proteins like α-syn acting in a prion 
like manner comes from studies showing transmissibility of aggregated proteins, for example 
introduction of aggregated Aβ to the brains of APP transgenic mice instigated deposition of Aβ in 
these mice (Kane et al., 2000). Furthermore in vitro work on α-syn transmission has clearly shown 
that α-syn can spread from neuron to neuron (and to glial cells) via endocytosis and that this 
transmitted α-syn forms inclusions and initiates apoptosis (Desplats et al., 2009; Jucker and Walker, 
2011). It has also been known for some time that transplanted cells in PD patients develop α-syn 
pathology. This is particularly unusual because the grafted neurons are typically between 11 to 22 
years old by the time the recipient reaches post mortem and so much younger than most non-
grafted neurons with reported α-syn pathology. Additionally grafted neurons in Huntington’s disease 
have not been observed to develop α-syn pathology, casting doubt on this pathology arising as a 
result of the grafting process (Hansen and Li, 2012). Although Jucker and Walker argue that this is 
not such compelling evidence for a prion like mechanism as there remains the possibility this α-syn 
aggregation was independent of the host (Jucker and Walker, 2011). 
    Kramer and Schulz-Schaeffer (Kramer and Schulz-Schaeffer, 2007) reported accumulation of small 
aggregates of α-syn at the synapses of DLB post mortem brains that were proposed to interfere with 
synaptic function (Figure 1). The authors also suggest this is a direct precursor to the development of 
LBs, and possibly represents a final cytoprotective attempt before cell death. Thus it could be 
hypothesised that by the time LB formation begins in a neuron it is likely to be too late for continued 
cell viability and thus focus on the events occurring at the synapse far in advance of LB formation 
would be of greater potential therapeutic benefit.  
Other proteins have been shown to be associated with LBs.  A recent proteomic analysis showed 
there are around 300 different proteins in LBs, of which 34% were intracellular signalling proteins 
and 19% part of the cytoskeletal network (Leverenz et al., 2007). Interestingly few of the 300 
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proteins were involved in neurotransmission or synaptic activity so clearly dysfunction in many 
aspects of cell function and regulation contribute to the pathogenesis and clinical presentation of 







Hyperphosphorylated tau is the major protein constituent of one of the pathological hallmarks of 
AD, neurofibrillary tangles (NFTs), the other main molecular component is ubiquitin (in about 60% of 
NFTs) (Duyckaerts et al., 2009; Kosik et al., 1986; Wolozin et al., 1986). Ubiquitin is a highly abundant 
protein used as a molecular tag for other proteins requiring degradation by the ubiquitin-
proteosome system, this explains ubiquitins presence in such quantities in NFTs as much of the 
aggregated tau will have been targeted to the ubiquitin-proteosome system in an attempt at 
removal (Lee et al., 2013). NFTs are intracellular, fibrillar and correlate with cell death and severity of 
clinical symptoms (Arriagada et al., 1992; Takashima, 2009). Tau is an abundant microtubule 
associated protein found in the soma and axons of all neurons where it is thought to stabilise the 
cytoskeleton (Lee et al., 1989). Neurons are inherently vulnerable to defects in intracellular protein 
trafficking due to the distances of synapses from the cell bodies and the high metabolism and 
turnover of proteins; hence the notion that NFTs may interfere with (or a lack of physiological tau 
may inhibit) this delicate and vital process has been gaining prominence (Santacruz et al., 2005). It is 
delineating the pathways that lead to this compromised axonal transport that is the challenge 
(Ballatore et al., 2007). 
Tau pathology can be subdivided into tangles (aggregation of tau in the cell body), threads 
(aggregation of tau in dendrites) and dystrophic neurites - the tau component within the corona of 
neuritic plaques which is axonal in origin (Duyckaerts et al., 2009). In tauopathies tau pathology is 
commonly encountered throughout the neocortex, in particular layers 3 and 5, the pyramidal cells of 
the hippocampus, the entorhinal cortex and the olfactory system (Duyckaerts et al., 2009). This 
topographical progression of tau pathology was formalised into a scoring system to aid 




Pre-tangles represent an immature form of tangle composed of hyperphosphorylated tau fibrils 
which have yet to form NFTs (Bancher et al., 1989) and on the other side of the spectrum are so 
called ‘ghost tangles’, the remnants of intracellular NFTs where the neuron has disappeared (Ikeda 
et al., 1992). This persistence of tau pathology is in contrast to α-syn pathology which does not 
remain after cell death (see α-syn section for discussion) (Greffard et al., 2010). Consequently tau 
pathology accumulates in the brain throughout the duration of the disease; this is one of the factors 
allowing the correlation between tau pathology and clinical severity to be detected (Arriagada et al., 
1992).  
Duyckaerts et al reported an interesting case of a patient with surgically acquired damage to a 
section of frontal cortex resulting in the severance of this piece of cortex from the surrounding brain 
tissue. Upon autopsy Aβ and tau pathology were found throughout the cortex but in the 
disconnected piece of cortex there was Aβ pathology but an absence of tau pathology. The 
disconnected area of cortex had a slightly higher neuronal count than surrounding areas ruling out 
the possibility that impaired neuronal health, due to the severance, was responsible for the lack of 
tau pathology. The authors hypothesised that the tau pathology spreads through anatomical 
connections between neurons, almost in a prion like manner, and that it has a degree of 
independence from Aβ pathology (Duyckaerts et al., 1997).  
Indeed, the link between Aβ and tau pathologies remains one of the significant outstanding 
questions of AD research. Initially, based on observations that APP mutations causing an increase in 
Aβ production initiated a pathway terminating in production of tau pathology, it was assumed that 
Aβ pathology was an upstream driver of tau pathology (Goate et al., 1991; Goate and Hardy, 2012); 
whereas development of tau pathology through mutations was not sufficient to initiate Aβ 
pathology (as evinced from familial cases of FTD) (Hutton et al., 1998) thus advocating tau pathology 
as downstream of Aβ (Duyckaerts et al., 2009). However, for sporadic disease the situation may be 
different as suggested by analysis by Braak et al of a large group of general autopsy cases (without 
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regard for diagnosis) in which tau pathology was found to be more common than Aβ, and although 
there are limitations in extending this finding to the general population it remains unexpected (Braak 
and Braak, 1997; Duyckaerts and Hauw, 1997).  
Observations from the primary animal model for AD, APP transgenic mice, add to the disconnect 
between Aβ and tau pathologies as these mice, despite expressing high levels of Aβ pathology, do 
not develop tau pathology unless human mutant tau transgene is included (Oddo et al., 2003). Yet 
conversely tau hyperphosphorylation does occur in APP transgenic mice and in tau transgenic mice 
there is no Aβ pathology, so perhaps it is not possible to deduce the relationship between tau and 
Aβ pathology from mouse models (Ittner and Gotz, 2011).  
Recently a tau/APP mouse model has been developed, which develops both tau and abeta 
pathology. It was found that these mice had more severe NFT pathology, hippocampal neuron loss 
and motor deficits than tau-only mice, highlighting the importance of abeta to tau misprocessing 
(Héraud et al., 2013). A final point on this is speculation from Ittner and Gotz (2011) that tau 
deposition may be initiated non-specifically by amyloidogenic proteins, based on insights from 
research into the rare familial British and Danish dementias in which Bri peptide (the pathological 
hallmark of these dementias) when injected into tau transgenic mice, aggravates tau pathology in a 
similar manner to injection of synthetic Aβ. 
The six different isoforms of tau derived from the MAPT gene differ in binding properties to beta-III-
tubulin, the primary cytoskeletal partner of tau (although it should be noted there are other possible 
candidates for tau interactions from as diverse a range as presenilin1 and cell membranes). The 3R 
and 4R isoforms (named for the number of Btub binding site repeats) are the most common and 
exist in a 1 to 1 ratio under physiological conditions (Hong et al., 1998). It is possible alterations in 
this ratio (maybe due to mutations in the MAPT gene) can have pathological implications. 
Significantly mutations in the MAPT gene are known to be sufficient to give rise to 
neurodegeneration without other pathologies such as Aβ or α-syn, this was proven when MAPT 
67 
 
mutations were demonstrated to cause frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP17) (Ballatore et al., 2007; Hong et al., 1998).  
Phosphorylation and dephosphorylation of tau by specific kinases and phosphatases controls a 
dynamic equilibrium of tau binding and detachment from microtubules (MTs) (Drechsel et al., 1992). 
This equilibrium becomes disturbed during neurodegeneration leading to almost total 
phosphorylation of all available sites; leading to a dramatic increase in the propensity of tau to form 
aggregates (Kuret et al., 2005). An important step in the pathway to aggregation are straight and 
paired helical filaments – beta-sheet enriched forms of tau, which, when formed, can further self-
assemble into NFTs (Ballatore et al., 2007). 
The question of gain of function versus loss of function with regards to tau toxicity is clouded. 
Stabilisation of MTs by the compound paclitaxel succinctly demonstrated that pharmacological 
replacement of absent tau could reverse the deficits in axonal transport arising from a lack of tau-
stabilisation of MTs and reduced the motor symptoms observed in the mice (Zhang et al., 2005), 
thus supporting a toxic loss of function. However the fact that NFTs (and incidentally not Aβ plaques) 
correlate to clinical severity in humans would suggest that the NFTs and a toxic gain of function 
cause the neurodegeneration and synaptic dysfunction that results in the clinical symptoms 
(Arriagada et al., 1992; Ballatore et al., 2007). It is of course possible that the absence of tau in its 
role as a stabiliser of MTs and the consequent support to axonal transport combines with the 
physical obstruction to the already impaired axonal transport caused by NFTs thus delivering a dual 
attack on neuronal integrity. 
Whatever the mechanism by which tau exerts its neurotoxicity, it is clear that this toxicity occurs 
well before the presence of NFTs. Some of this knowledge has come through observations in a 
tauopathy mouse model showing that hippocampal synaptic dysfunction and microgliosis precede 
deposition of NFTs (Yoshiyama et al., 2007). There was a marked decrease in synaptophysin positive 
synapses, followed by impairment of synaptic function, months before tau deposition was evident. 
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Furthermore immunosuppression reduced the damage to hippocampal neurons and improved 
survival of the mice, highlighting the role of inflammation and microglial induced damage to 
neurons.  
In addition to tubulin, tau has proven binding and interactions with dynamin, a tyrosine kinase 
protein called FYN and PSD95. Phosphorylation of tau increases its binding to FYN which propels FYN 
to the dendritic spines where FYN plays a crucial role in mediating the interaction of NMDA 
receptors and PSD95 through phosphorylation of NMDA receptors (Ittner and Gotz, 2011). This 
pathway is thought to be instrumental in Aβ induced excitotoxicity based upon studies that have 
demonstrated tau knockout mice to be less susceptible to Aβ and experimentally induced seizures 




1.1.7.4 Mixed Pathologies 
DLB, PDD and AD are often thought of as possessing distinct pathologies instrumental in defining the 
diseases from one another yet the reality is far more complex. Amyloid and tau pathology can occur 
in DLB and PDD and vice versa for α-syn pathology in AD (Jellinger and Attems, 2008). In an 
assessment of the prevalence of typical AD pathology in PDD, DLB and PD, Jellinger and Attems 
found PDD to be associated with higher levels of Aβ pathology than PD (around two-thirds of PDD 
patients had severe Aβ loads). The DLB cases (although less than half the number of PDD at 20) were 
characterised by higher quantities of α-syn and Aβ pathology. AD pathology was a greater 
determinant of cognitive decline than LB pathology in PDD cases and in both PDD and DLB cases 
where AD pathology was severe, cognitive scores were lowest, highlighting the importance of AD 
pathology to the clinical syndrome of DLB/PDD (Jellinger and Attems, 2008). The relationship 
between different pathologies remains intricate but it appears clear that a combination of 
pathologies is a better predictor of severity of the clinical aspects of the disease than severity of any 
one type of pathology (Compta et al., 2011). 
Current guidelines for pathological diagnosis, according to McKeith et al, are that a higher severity of 
DLB pathology and a lower severity of AD pathology increase the probability that the observed 






1.1.8 Mild Cognitive Impairment (MCI) 
The concept of MCI was developed in response to the increase in patients presenting at memory 
clinics that had an impairment of cognition, generally memory, but did not yet meet the 
requirements for a diagnosis of dementia. Despite initial assumptions that MCI was merely 
prodromal dementia it is now accepted that not all MCI cases progress to dementia, often vascular 
insults or depression can be the underlying cause of MCI, however the majority of MCI cases are 
amnestic and progress to AD (Mufson et al., 2012). 
Pathologically MCI is characterised by a roughly intermediate degree of Aβ deposition (in 
comparison to controls and AD) although often levels are not significantly different to controls 
(when assessed at post mortem and by imaging studies) and so it would appear unlikely that Aβ 
pathology is driving the change from MCI to AD (Mufson et al., 2012). However Aβ oligomers may be 
of more relevance in this regard as it has been reported that the ratio of Aβ42 to Aβ40 can 
distinguish AD and MCI from controls. Additionally work in human post mortem tissue found that 
accumulation of Aβ oligomers (particularly dimers and pentamers) in the frontal cortex was inversely 
correlated to MMSE score and levels of synaptic proteins, including the post-synaptic marker PSD95, 
these observations were supported by experiments in APP transgenic mice that showed Aβ 
oligomers and PSD95 co-precipitated at dendritic sites (Pham et al., 2010). This suggests that Aβ 
oligomers are initiating a deleterious chain of events at the synapse leading to synaptic deterioration 
which manifests clinically as an advancing cognitive impairment. Exactly what the sequence of 
events and proteins connecting Aβ oligomers and PSD95 is remains to be elucidated. Possibly Aβ 
oligomers cross the synaptic cleft from pre to post synaptic terminal via exocytosis and endocytosis 





1.2 Biochemistry of dementia 
1.2.1 Beta-III-tubulin 
Beta-tubulin is a key component of the cytoskeleton, with several isoforms, one of which, beta-III-
tubulin, is the solely expressed in neurons (Sullivan, 1988). This has led to widespread use of Btub as 
a marker for neurons in biochemical and cellular studies. 
1.2.2 Synaptic proteins and process 
Synaptic dysfunction has been of interest to dementia research since Davies et al (1987) first showed 
an increased loss of synapses in patients with AD (Davies et al., 1987). Synaptophysin (SPP) has been 
one of the most popular means to assess both the functional state and relative quantity of synapses 
in dementia. A number of studies have shown decreases in SPP in human post-mortem tissue, 
mainly from AD patients (DeKosky et al., 1996; Masliah et al., 1989; Pozueta et al., 2012). The picture 
is less clear in LBD, one study showed no link between lewy bodies and SPP (Clare et al., 2010; 
Revuelta et al., 2008); others have shown decreases in synaptic density in LBD compared to controls 
(Brown et al., 1998) and no significant difference between SPP levels in controls and LBD (Hansen et 
al., 1998). Probably the choice of brain region and type of LBD cases selected have some impact on 




Drebrin is an actin binding protein expressed in two isoforms in humans (A and E) (Shirao et al., 
1988; Shirao et al., 1990). Drebrin A (the adult isoform) is found only in neurons, mainly in dendritic 
spines, where it promotes extension of the spine through its interaction with actin and the 
cytoskeleton (Ivanov et al., 2009). A lack of drebrin in vitro caused a decrease in spine density and 
individual spine length. Drebrin A can also influence glutamatergic transmission, altering the balance 
of excitatory glutamatergic transmission at the expense of inhibitory GABAergic transmission (Han 
and Kim, 2008; Takahashi et al., 2003).  
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Drebrin targets post synaptic density scaffold protein (PSD95) and NMDA receptors to the post 
synaptic membrane (Han and Kim, 2008). Decreases in drebrin have been reported in AD and DLB, 
the decrease in AD correlated with the severity of dementia and in DLB it was suggested that this 
decrease was activity dependent due to reduced synaptic transmission caused by the observed 
presynaptic accumulation of α-syn (Kramer and Schulz-Schaeffer, 2007; Shim and Lubec, 2002). 
These findings, coupled with the importance of spines for long term potentiation (LTP) – the major 
cellular correlate of learning and memory – highlight the significance of drebrin and spines to 






Synaptophysin (SPP) is a 38 kDa protein associated with synaptic vesicle membranes. Since its 
discovery in 1985 (Wiedenmann and Franke, 1985) it has been well established as a biochemical 
marker of synaptic vesicles and following universal acceptance of the so called ‘kiss and run’ theory 
of vesicle endocytosis and recycling of vesicles within synaptic terminals by extension SPP became a 
marker of the presynaptic terminal itself (Valtorta et al., 2004). SPP being the most abundant 
synaptic vesicle protein has greatly helped establishment of this role. 
SPP is purported to be employed in vesicle trafficking and exo/endocytosis, including interactions 
with other vesicle associated proteins such as VAMP2, participation in the formation and fusion of a 
membrane channel to allow rapid neurotransmitter release and a role in clathrin dependent 
endocytosis (Valtorta et al., 2004). 
SPP is encoded by the SYP gene and  several groups have produced knock-out mice (Eshkind and 
Leube, 1995; McMahon et al., 1996), initial studies found no overt phenotype suggesting a degree of 
redundancy in the role of SPP at the synapse or subtlety of the behavioural effect of SPP depletion 
beyond the capacity of animal models to detect. However, Schmitt et al recently showed that in 
mice lacking SPP there were learning and memory deficits such as reduced object recognition and 
Morris water maze performance; thus it would seem SPP is a vital component for normal learning 
and memory (and thus healthy synaptic function) (Schmitt et al., 2009). The reason for the negative 
findings in the earlier studies remains unclear. 
The delivery of vesicles to the appropriate cell membrane docking site is a complex task requiring a 
high degree of precision and with the potentially significant consequences of a failure in this it is no 
surprise that mammalian cells have around 20 different proteins dedicated to this task (Jahn and 
Fasshauer, 2012). They are referred to as SNARE proteins, divided into transmembrane and vesicle 
SNAREs, and with specific SNARE proteins for each intracellular compartment. In neurons SNARE 
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proteins control docking of vesicles to the synaptic membrane immediately prior to release of 
neurotransmitter and the activity of SNARE proteins are in turn controlled by an assortment of other 
mediator proteins such as the Rab protein family and GTPases (Alberts et al., 2002; Sollner et al., 
1993). α-syn has been implicated in assisting SNARE function under physiological conditions and 
altering it under pathological conditions (Burre et al., 2010; Garcia-Reitbock et al., 2010). 
It has recently been demonstrated that in transgenic mice expressing a truncated, more aggregation-
prone, form of α-syn there was a redistribution of SNARE proteins at synapses in the striatum 
(Garcia-Reitbock et al., 2010). This resulted in decreased vesicle release and dopamine signalling and 
suggests a toxic gain of function of aggregated α-syn.           
Synaptophysin has been consistently found to be decreased in the PFC in AD compared to non-
demented control cases (Clare et al., 2010; Davies et al., 1987; Leuba et al., 2008; Minger et al., 
2001; Terry et al., 1991). Additionally SPP has been found to be decreased in the hippocampus of AD 
patients (n=6) and to correlate to cognitive decline and Braak stage, although no significant change 
in SPP levels was reported in the entorhinal and occipital cortices and the caudate nucleus. There 





PSD95 is a 95kDa post synaptic protein involved in the cellular scaffolding and regulation of 
membrane expressed neurotransmitter receptors at the post synaptic terminal. PSD95 is widely 
recognised to have roles in synaptic function including regulation of the localisation of membrane 
proteins and protein trafficking (Han and Kim, 2008). Whilst it is likely that PSD95 is important in 
directing NMDA receptor localisation to the synapse, there is a degree of redundancy in this role as 
PSD95 knockout mice show no alterations in NMDA receptor expression or localisation, nor was 
there any difference in synaptophysin levels between wild type and mutant mice. Taken together 
with the pronounced alteration in the frequency of LTP-inducing synaptic activity in PSD95 
knockouts, the mediation of which is likely undertaken by post synaptic phosphatases and kinases, 
this suggests that PSD95 is crucial for downstream mediation of NMDA related LTP and does not 
have an influence on the pre-synaptic terminal (Migaud et al., 1998). 
PSD95, a member of the MAGUK (membrane associated guanylate kinases) family of proteins, is the 
most abundant protein of the PSD (post-synaptic density) and is one of the most extensively 
characterised proteins of the PDZ domain containing proteins – a protein interaction domain 
allowing multiple binding to other peptides, common in scaffolding proteins (Kim and Sheng, 2004). 
PSD95 can form oligomers within the PSD which may facilitate clustering of its interaction partners. 
AMPA (α-amino-3hydroxy-5-methyl-4-isoxazole propionate) receptors are ionotropic glutamatergic 
receptors (Honoré et al., 1982), which undergo an increase in number at the post-synaptic 
membrane as a focal part of LTP (Shi et al., 1999). Studies from hippocampal slice culture 
overexpressing PSD95 and rats expressing mutant PSD95 in part of the cortex have shown that 
PSD95 is elemental in recruiting AMPA receptors to the post-synaptic membrane (Ehrlich and 
Malinow, 2004). This is in direct conflict with observations made by Migaud et al in the PSD95 
knockout mice, in which the frequency and amplitude of excitatory post-synaptic currents (EPSCs) 
were increased in the absence of wild-type PSD95. Ehrlich and Malinow postulate that this 
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discrepancy is due to the presence of compensatory mechanisms revolving around a truncated form 
of PSD95 in these knockout mice (Ehrlich and Malinow, 2004; Migaud et al., 1998). 
In animal models of AD, PSD95 has been shown to be perturbed by the associated pathology in line 
with current theories that AD and dementia in general are synaptic failures. Using mouse 
amyloidopathy and tauopathy models, Shao et al measured an age-related decrease in synaptic 
PSD95 (which was importantly not explained by neuronal death) in both models and a redistribution 
of PSD95 to the neuronal cell body (Shao et al., 2011). The same mice develop age-related 
impairments in spatial memory which were elegantly demonstrated to be associated not with the 
significant increase in pathology but to the reduction in PSD95 occurring some months after 
pathology peaks (Oakley et al., 2006). 
In the human brain the connection between pathology and PSD95 is markedly less clear. Shao and 
colleagues found the variability in the levels of PSD95 between cases too large for quantification 
(Shao et al., 2011). Other studies have reported decreases in PSD95 in temporal cortex of AD cases 
and in synaptosomes prepared from AD post-mortem tissue (Gylys et al., 2004; Proctor et al., 2010). 
Proctor and colleagues speculate that the observed reductions in scaffolding proteins such as PSD95 
and SAP-102 (synapse-associated protein of 102 kDa – involved in regulation of NMDA receptor 
activity and expression (Müller et al., 1996)) - may explain the decrease in NMDA receptors and 
consequent cognitive decline due to impaired LTP and LTD (the opposing weakening of synaptic 
strength in an activity dependent fashion (Bear et al., 2006)). An alternative explanation is that loss 
of PSD95 is implicated in NMDA excitotoxicity and synapse loss which manifests as cognitive decline 
(Proctor et al., 2010). 
However Leuba et al, using semi-quantitative immunohistochemical and western blot analysis of 
PSD95 levels in the hippocampus and prefrontal cortex from a small cohort of six AD brain, found an 
increase in PSD95 levels compared to non-demented controls. It is unusual for increases to be 
detected in synaptic proteins in post-mortem neurodegenerative tissue; the authors defend their 
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findings with the postulation that ubiquitin-proteosome degradation of PSD95 may have been 
impaired or that aberrant axonal transport, possibly due to tau aggregation, lead to a build up of 
PSD95 (Leuba et al., 2008). In support of this concept, it has been shown that inhibition of the 
proteosome prevents PSD95 mediated, NMDA-induced internalisation of AMPA receptors and the 





1.2.3 Zinc and other metals in the CNS 
Recently the role of metal ions in neurodegeneration has been receiving increased attention, with an 
emphasis on the ions of the three most biologically abundant ‘trace’ elements iron, copper and zinc 
(Roberts et al., 2012) (Note in this section all reference to metals is to the ions of these metals).  
The majority of biological Zn is located bound to a class of proteins called metallothioneins, with 
‘free’ Zn comprising a minority of total biological zinc. Metallothioneins play a crucial role in Zn 
homeostasis by acting as Zn reservoirs and regulating the availability of Zn in its various roles. There 
are four isoforms of metallothionein in humans (MT-1 to 4), with MT1, MT2 and MT3 all expressed 
in the CNS, (principally in astrocytes but also in neurons and microglia). Studies in mice with the 
metallothionein gene deleted have established the importance of this family of proteins for 
protection from heavy metal toxicity, cognition and oxidative stress (Santos et al., 2012). 
Zn, Cu and Fe all cause Aβ to aggregate and Aβ has binding sites for Zn and Cu, and for Fe under 
acidic conditions (Bush et al., 1994). Importantly the affinity of Aβ for these ions is within the 
physiological concentrations of synaptically released Zn and Cu (Roberts et al., 2012). In 1991 a 
clinical trial in which AD patients were orally administered zinc supplements was abandoned after 
only a few days due to an alarming deterioration in cognition in the AD group, unfortunately no 
biochemical investigation was undertaken but reports of zinc aggregating Aβ have been suggested as 
a cause for this cognitive decline (Bush et al., 1994; Kaiser, 1994). 
Zn is required for the successful function of alpha secretase thus it could be speculated that the 
reductions in Zn levels seen in aging and to a greater extent in AD brains may affect activity of alpha 
secretase and possibly drive APP processing towards the amyloidogenic pathway. However it is likely 
that Zn is required at relatively low concentrations and binds with high affinity to alpha secretase 
and so a depletion of local Zn is far more likely to affect other functions first. Likewise Cu is required 
for beta secretase activity and in the case of Cu it has been demonstrated that reductions in Cu push 
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the equilibrium of APP processing to the amyloidogenic route (Edwards et al., 2008; Roberts et al., 
2012). 
Both Zn and Cu are found at high levels within plaques (Lovell et al., 1998), possibly this represents 
an entrapment of these ions and thus a detraction from their physiological roles, alternatively these 
ions may remain from the reported binding and aggregation of soluble Aβ (Bush et al., 1994).          
However, as focus on the toxicity of pathological proteins in neurodegeneration has shifted from the 
gross aggregates to soluble oligomeric species so has research on metalobiology of 
neurodegeneration (Roberts et al., 2012).  
Zn binds to histidine residues within the Aβ peptide and in this way assists formation of bonds 
between the same peptide and between other Aβ peptides, thus precipitating aggregation (again 
this is possible at physiological synaptic concentrations of Zn) (Bush et al., 1994; Curtain et al., 2001). 
Interestingly, mice and rats have a sufficiently different sequence of amino acids at the Zn, Cu and Fe 
binding sites to the human peptide that metal binding does not occur, raising the interesting 
possibility that this explains the unique lack of age related Aβ deposits in these mammals (Roberts et 
al., 2012). 
Cu and Fe have been implicated in oxidative damage; binding of either ion to Aβ can increase 
production of hydrogen peroxide (a mediator of oxidative damage) and a decrease in availability of 
Cu drives the Aβ-Cu interaction to membrane lipid rafts, likely amplifying any toxic effect (Hung et 
al., 2009). It has been speculated that at low concentrations, Zn binding to Aβ may inhibit Cu binding 
and thus provide protection from Cu-mediated Aβ-induced hydrogen peroxide production and 
oxidative damage (Cuajungco et al., 2000). An additional postulated neuroprotective effect of Zn is 
blockage of the membrane pores formed by Aβ – thought to be one of the primary toxic 
mechanisms of synaptic Aβ oligomers (Jomova et al., 2010). Thus it can be seen the exact role of Zn 
in AD pathology remains, to some extent, contradictory. 
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Deductions about the role of Zn and other metals in Lewy body dementias can be made from 
research into Parkinson’s disease metalobiology. Reports that PD can be caused by environmental 
exposure to heavy metals are conflicting, some reports have epidemiologically linked Zn exposure to 
PD (Rybicki et al., 1993; Uversky et al., 2001) whilst others have not replicated this finding (Gorell et 
al., 1999). 
It has been established that Zn and Fe are increased in the substantia nigra in PD (Dexter et al., 1989) 
but the physiological relevance of this remains to be elucidated (Barnham and Bush, 2008). Metal 
chelation in a mouse model of proteosome-inhibition induced nigro-striatal degeneration 
(commonly used to simulate aspects of PD) prevented dopaminergic neuron loss and restored motor 
abilities (Zhu et al., 2007), the authors propose this effect to be caused by removal of excess Fe 
however Barnham and Bush remark that chelation of Zn is equally possible as an explanation. 
Zn has been demonstrated to propagate α-syn aggregation under in vitro conditions by a number of 
groups. Kim et al found Zn to be able to precipitate α-syn and decrease α-syn’s ability to perform a 
chaperone-like activity with damaged proteins (Kim et al., 2000). In another study Zn promoted the 
formation of SDS resistant α-syn dimrs, an activity that was inhibited by magnesium ions (Golts et al., 
2002). Perhaps the most compelling evidence comes from work by Paik and colleagues in which Zn-
induced, self-oligomerisation of α-syn, was dependent on a pH of 6.5, ceasing at a pH of 7.5, and in 
contrast to metal ion induced aggregation of Aβ, which is not pH dependent (Paik et al., 1999). More 
recently these findings have been corroborated by Yamin and colleagues who demonstrated the 
fibrillation of oxidised α-syn by Zn, highlighting the importance of oxidative stress to Zn mediated 
neurotoxicity (Yamin et al., 2003). 
However, in a study by Uversky and colleagues, incubation of Zn and α-syn did not produce fibrils 
after 100 hours (Uversky et al., 2001). Possibly pH, ionic concentration and the species of α-syn 
influence aggregation, and despite fairly convincing in vitro work demonstrating a possible role for 
Zn in α-syn’s pathogenicity, it remains to be shown whether this translates to in vivo models. 
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Zinc is enriched at many glutamatergic synapses, including those in the hippocampus and neocortex, 
and it is now widely accepted that zinc is co-released with glutamate and other neurotransmitters 
and thereby acts as a long term modulator of synaptic plasticity (Sensi et al., 2009). The zinc 
transporter (ZnT) family of proteins remove Zn from the cytoplasm into vesicles or to the 
extracellular space and the ZIP (Zrt-and-Irt-like) proteins govern cytoplasmic uptake of Zn, see figure 
1.2.3 for more details (Gaither and Eide, 2001). 
 One of the predominant and best characterised post-synaptic binding partners of Zn is the NMDA 
receptor. Zn has the remarkable ability to inhibit this receptor in a non-competitive voltage 
independent manner across an extraordinary concentration range (from nanomolar to micromolar) 
depending upon the subunit composition of the receptor. The NR2A subunit possesses a particularly 
high affinity for Zn such that even at resting conditions and ambient Zn levels there is inhibition. 
Thus, it is apparent that Zn acts in a tonic and phasic manner at glutamatergic synapses (Paoletti et 
al., 1997; Paoletti et al., 2009). 
Mutations in the Zn binding site on the murine glycine receptor prevented Zn binding, and resulted 
in a post-synaptic potential of greatly reduced amplitude; this was accompanied by extreme motor 
deficits in the animals. Since no alterations in receptor localisation or expression were detected, the 
observed effect was attributable to the inability of Zn to potentiate the receptor and provided the 
first evidence for Zn acting as a neuromodulator (Hirzel et al., 2006).  
Another recently purported synaptic role for Zn is at the PSD. It is established that a fraction of 
vesicular Zn enters the postsynaptic terminal via Ca2+/Zn2+ ion channels. Baron and colleagues 
demonstrated this Zn binding to a domain on the SHANK3 protein (a major component of the PSD 
instrumental in organisation of PSD structure) (Baron et al., 2006) and proposed that the resultant 
improvement in the ordering and density of the SHANK3 helical fibres condenses the PSD matrix to 
cluster receptors and enhance neurotransmission; part of this enhancement is likely to involve Zn 
recruiting further SHANK3 molecules and a consequent enlargement of the PSD through the 
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increased availability of SHANK3 cytoskeletal and receptor anchoring sites (Gundelfinger et al., 
2006). Yet it remains to be proven that this Zn-SHANK3 ordering of the PSD occurs in a cell model. 
In addition to interactions with Aβ, Zn has been shown to promote phosphorylation and aggregation 
of tau. Under physiological conditions Zn concentrations remain low outside of synaptic vesicles but 
have been reported to rise significantly in the cytosol in AD. Mo and colleagues demonstrated low 
micromolar Zn to promote formation of tau fibrils (Mo et al., 2009); whilst another study showed 
elevated Zn concentrations to propel tau phosphorylation and that this was a bimodal relationship 
as lower Zn concentrations dephosphorylated tau (Boom et al., 2009).  
 
Figure 1.2.3; Pathways and systems regulating Zn2+ homeostasis in neurons.  
Zn2+ enters neurons mainly through activated voltage-gated Ca2+ channels (VGCCs) and Ca2+- and 
Zn2+-permeable GluR2-lacking AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) 
receptors (AMPARCa–Zns). At the plasma membrane level, Zn2+ transporter 1 (ZnT1) controls Zn2+ 
efflux but may also interact with the L-type VGCC that regulates Ca2+ and Zn2+ influx. The Na+–Zn2+ 
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exchanger, a putative member of the Na+–Ca2+ exchanger superfamily, can move Zn2+ in or out of 
neurons depending on the Na+ gradient; in addition, Zn2+ importing proteins (ZIPs) may act as H+ or 
HCO3- Zn2+ co-transporters and facilitate Zn2+ influx. Inside of neurons, vesicular ZnTs act as H+–Zn2+ 
exchangers and are located on the Golgi apparatus and other secretory vesicles. Mitochondria also 
sequester Zn2+ through the activation of both the Ca2+ uniporter and a Ca2+ uniporter-independent 
mechanism that has not yet been molecularly identified. Finally, metallothioneins greatly contribute 
to the maintenance of Zn2+ homeostasis, as these are the major Zn2+ buffering peptides in neurons. 
The structural model of the Zn2+ binding site of a ZnT protein, based on the homology with the 
bacterial transporter YiiP, shows the striking similarity between the coordinating residues for the 
Zn2+ binding site of ZnTs (top) and the bacterial transporter (bottom). ER, endoplasmic reticulum. 
The inset is reproduced from (Ohana et al., 2009) whilst the rest of the figure and caption are from 
(Sensi et al., 2009).Zinc and Depression. 
 
A number of observational studies have linked Zn to depression in humans including several studies 
that have shown serum Zn levels inversely correlate to the severity of depression (McLoughlin and 
Hodge, 1990; Nowak and Schlegel-Zawadzka, 1999; Szewczyk et al., 2011). Furthermore 
administering the anti-depressant therapies citalopram, imipramine, electroconvulsive shock and 
various combinations of these to rats increased serum Zn levels by up to 30% in the hippocampus, 
with smaller increases in other regions including the frontal cortex (Nowak and Schlegel-Zawadzka, 
1999). This is supported by observations that Zn levels remain low in human patients with treatment 
resistant depression (Maes et al., 1997), that anti-depressants in humans may raise Zn levels and 
that Zn administration may have an anti-depressant effect (Levenson, 2006; Szewczyk et al., 2011).  
It is well established that the selective serotonin reuptake inhibitors (SSRIs) class of anti-depressant 
drug exert their anti-depressant effect through blockage of 5-HT (serotonin) reuptake at the synaptic 
cleft, this causes a chronic down regulation of 5-HT receptors and thus reduces 5-HT 
neurotransmission and alleviates some of the symptoms of depression (Levenson, 2006). An 
investigation into the molecular mechanisms by which Zn and SSRIs might interact to achieve the 
reported enhancements of anti-depressant effect ran contrary to the hypothesis that Zn would 
magnify the inhibition of 5-HT reuptake, and instead, showed addition of Zn to cortical slices 
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returned 5-HT reuptake to levels of controls despite presence of one of the three main SSRIs (García-
Colunga et al., 2005). It is possible this unexpected action of Zn may be explained by a report that Zn, 
through allosteric modulation, can act as both an agonist or antagonist at the 5-HT1A receptor  
(depending on concentration) (Barrondo and Sallés, 2009). 
Despite regulation by the blood-brain barrier, Zn levels in the cortex and in particular hippocampus, 
are susceptible to chronic changes in the dietary intake of Zn (Takeda and Tamano, 2009), thus 
observations that animal models of dietary Zn restriction caused anxiety and depression-like 
symptoms suggest a direct role for Zn in mediating the neurochemistry of these conditions (Joshi et 
al., 2012; Tassabehji et al., 2008; Whittle et al., 2009).  
The glutamatergic system has been increasingly implicated in depression, partly as a response to 
shortcomings in the longstanding hypothesis that the monoamine system mediates depression 
(inadequacies in treatment response and an unexplained lag between pharmacological actions and 
emergence of therapeutic benefit), and through observations that NMDA receptor antagonists have 
an anti-depressant effect and that glutamatergic signalling is increased in depression (Sanacora et 
al., 2012).  
Zn release has been shown to down-regulate glutamatergic signalling through a variety of 
mechanisms (comprehensively reviewed by Smart and colleagues) including non-competitive 
antagonism of NMDA receptors in a fashion that is independent from the blocking actions of Mg2+, 
but sensitive to Ca2+ levels, which rise in response to increased glutamatergic activity to form part of 
the glutamatergic excitotoxic pathway; and stimulation of GABA release from inhibitory 
interneurons – which decreases glutamate release (Smart et al., 1994). Indeed Joshi et al suggest 
that Zinc’s antagonistic action at NMDA receptors may explain the alleviation of depressive and 
anxiety like symptoms upon administration of Zn to mice (Joshi et al., 2012). Additionally Zn has 






At the synapse zinc is sequestered into synaptic vesicles by a synapse-specific member of the zinc 
transporter family of proteins, ZnT3 (Palmiter et al., 1996). ZnT3 contains six transmembrane 
domains circling a central pore through which Zn ions are actively pumped in exchange for hydrogen 
ions (Gaither and Eide, 2001). Whilst ZnT3 is the only synaptic vesicle Zn transporter it is not 
exclusive to neuronal synapses, some glial cells express ZnT3 RNA and ZnT3 has also been reported 
in the testis (Palmiter et al., 1996) and more recently a variety of other organs; however ablation of 
the ZnT3 gene in mice only affects Zn levels in the brain thus highlighting the essential role ZnT3 
plays in brain Zn regulation (Cole et al., 1999; Smidt and Rungby, 2012). 
ZnT3 can exist as a functional dimer of 80kDa (monomeric ZnT3 being 40 kDa); the formation of 
which may be driven by the redox status of the cellular milieu (Salazar et al., 2009). In a cellular 
model of oxidative stress Salazar et al found ZnT3 dimerisation to be increased. Additionally, this 
dimerisation was instrumental in targeting ZnT3 to vesicles and in conferring resistance to zinc-
induced toxicity to the cells, as evinced by the decreased vesicle targeting and heightened sensitivity 
to zinc levels when cells expressed mutant ZnT3 protein lacking the amino acid tyrosine at the 
positions required for dityrosine bond formation and subsequent dimerisation (Salazar et al., 2009). 
Salazar and colleagues conclude by proposing that dimeric ZnT3 is necessary for efficient synaptic 
zinc regulation.  
The adaptor protein complex 3 (AP3) assists in stabilising ZnT3 to the vesicle membrane (Kantheti et 
al., 1998). In mice lacking AP3, ZnT3 was found to be reduced at the synapse and instead localised to 
the nuclear membrane (Kantheti et al., 1998; Stoltenberg et al., 2004). Kantheti et al. found reduced 
synaptic Zn yet inexplicably, Stoltenberg and authors – using a more sensitive stain - found Zn was 
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not depleted at the synapse, possibly due to the remaining ZnT3 and so clearly AP3 is not essential 
for proper vesicular function of ZnT3.  
Of particular interest is the recent observation that ablation of the ZnT3 gene in mice (ZnT3 KO) 
caused an age-related impairment in the Morris water maze task (Adlard et al., 2010). It was 
therefore suggested that ZnT3 mediated synaptic zinc homeostasis is important for maintenance of 
cognition and that loss of ZnT3 and the consequent dyshomeostasis of synaptic zinc adversely affects 
memory and cognition.  ZnT3 knock-out mice also showed decreases in PSD95 and dendritic spine 
density only after 6 months (Adlard et al., 2010). Interestingly SPP was increased after 6 months; the 
authors suggest this to represent a compensatory mechanism initiated in response to the deficits at 
the post-synaptic terminal. Together, these results provide mechanistic insights into how changes in 
the level of zinc at the synapse may influence cognitive function, possibly this occurs through an 
effect on the scaffolding of NMDA receptors by PSD95; but as yet there is little literature on any 
interaction between Zn and PSD95 apart from Adlard et al. 
As discussed in the preceding section, Zn can promote aggregation of Aβ, tau and α-syn; thus it 
would seem plausible that failure in the regulatory mechanisms of synaptic zinc (i.e. ZnT3) could be a 
trigger for this aggregation. However there was a reduction in synaptic Aβ oligomers in hippocampal 
slices from mice lacking ZnT3, incubated with Aβ oligomers, compared to wild type (Deshpande et 
al., 2009). The authors attributed this to vesicular Zn playing a crucial role in the synaptic targeting of 
Aβ molecules; a hypothesis consistent with experiments published in the same paper showing Zn 
chelation to reduce synaptic targeting of Aβ oligomers in hippocampal slices. Further evidence for 
this is provided by a recent study on post mortem tissue from individuals with AD pathology in the 
absence of cognitive deficits. Hippocampal tissue from these cases was found to have reductions in 
synaptic Aβ oligomers and total Zn levels, and no reduction in ZnT3 levels, compared to AD cases 
(Bjorklund et al., 2012); emphasising the role of Zn homeostasis in synaptic health and cognition. 
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The findings of Deshpande and colleagues are supported by a study using a double transgenic mouse 
generated from an APP transgenic (Tg2576) and ZnT3 knock-out, in which it was found that APP 
over-expressing mice without ZnT3 had a markedly diminished plaque load and concentration of 
insoluble Aβ than APP mice expressing ZnT3 (Lee et al., 2002). This is even more striking given that 
ordinarily APP transgenic mice have raised ZnT3 levels compared to wild type mice (Zhang et al., 
2010); and raises the possibility that removal of synaptic Zn may protect from plaque formation. 
However the authors (Lee et al., 2002) did not report any investigations into the behaviour of the 
mice used thus preventing comparison to other work on ZnT3 knockout mice showing age related 
cognitive decline caused by a lack of synaptic Zn (Adlard et al., 2010). 
ZnT3 has been shown to be co-localised with cortical A plaques in human post mortem tissue from 
AD cases (Zhang et al., 2008) and in the brains of APP transgenic mice (Zhang et al., 2010). The 
authors conclude this to be evidence that ZnT3 is directly implicit in plaque formation rather than 
acting indirectly through its effect on Zn levels at the synapse or merely trapped in the aggregates as 
cellular debris from degenerating neurons. However, Zhang and colleagues also demonstrated an 
upregulation of ZnT3 in the hippocampus and cortex of the same APP transgenic mice; thus it is 
plausible that overproduction of ZnT3 coupled with synaptic toxicity and degeneration has lead to 
entrapment of ZnT3 within Aβ aggregates. 
Other groups have described reductions both in ZnT3 RNA (Beyer et al., 2009b) and protein 
expression (Adlard et al., 2010) in AD post mortem tissue. Beyer and colleagues examined ZnT3 RNA 
levels in all main cortical areas; the reduction reported was evident in AD cases of Braak stage IV (i.e. 
cases moderately affected by AD pathology) and this result was not attributable to neuronal loss. 
The authors speculate that this reduction could be a protective mechanism to reduce synaptic Zn 
levels in response to a disease related increase in synaptic Zn. In agreement with Beyer and 
colleagues, Adlard et al observed a decrease in ZnT3 quantity in post mortem tissue associated with 
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1.2.4 Neurotransmitter systems 
A characteristic neurochemical feature of both DLB and PDD is a decrease in cholinergic function, 
evidenced by reduced activity of choline acetyltransferase resulting in diminished production of 
acetylcholine, and eventually a loss of cholinergic neurons (Francis, 2009; Perry et al., 1994; 
Tiraboschi et al., 2000). In the neocortex the cholinergic deficit occurs earlier than in AD and is more 
pronounced; additionally there is reduced cholinergic activity in the basal ganglia and the 
pedunculopontine pathway (Tiraboschi et al., 2002). It is thought that the loss of function in the 
cholinergic system could be responsible for some of the psychiatric symptoms of DLB and PDD.  
1.2.5 Mitochondrial Dysfunction 
Mitochondria are organelles that generate cellular energy in the form of adenosine tri-phosphate 
(ATP) and in neurons are found both in the soma but with significant localisation to the synaptic bulb 
– indeed this was how synapses were first located during the earliest electron microscopy studies 
(Hollenbeck, 2005). This stationing of mitochondria is vital in providing a local and immediately 
available energy supply for the high demands created by the intensive endocytosis, exocytosis and 
vesicle recycling at the synapse; additionally mitochondria are essential for sequestering Ca2+ and to 
assist in recovery from synaptic depression following an action potential (Hollenbeck, 2005).  
Consequential to this necessity of synaptic mitochondria (and coupled to the extended morphology 
of neurites, and the inability of neurons to meet their energy needs through glycolysis alone, when 
oxidative phosphorylation is saturated) is a particular synaptic vulnerability to mitochondrial 
dysfunction (Simpson et al., 2007). It is believed that the majority of mitochondria are manufactured 
in the soma and transported to and from synapses in a synaptic-activity dependent fashion 
(primarily in response to calcium ion and glutamate levels) (Chen and Chan, 2009; Sheng and Cai, 
2012).  
   Specialised molecular machinery, unique to neurons, exists to facilitate movement of mitochondria 
via axonal transport. It is worth noting that tau is a key player. In vitro overexpression of tau 
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accentuates tau binding to microtubule associated proteins (MAP) which inhibits anterograde 
mitochondrial transport, resulting in imbalanced retrograde transport and accumulation of 
mitochondria in the soma. This can be rescued by removing tau from MAP through increasing tau 
phosphorylation (Sheng and Cai, 2012). A mechanism evolved by mitochondria to offset the 
challenge of axonal transport is mitochondrial fission and fusion; a dynamic process through which 
mitochondria can replicate at the synapse (via fission) and limit damage (via fusion) (Knott et al., 
2008) 
Mouse models have shown that both Aβ and tau disrupt mitochondrial function, although they 
target different components, tau complex 1 and Aβ complex IV (Ittner and Gotz, 2011). Interestingly 
in the absence of tau the negative impact of Aβ on mitochondrial function was removed (Sheng and 
Cai, 2012).  
The link between α-syn and mitochondrial dysfunction is not clear; an investigation by Reeve et al 
using post-mortem substantia nigra neurons from individuals with DLB and PD, and controls found 
no significant change in mitochondrion numbers in neurons containing α-syn versus those that did 
not; thus, despite the established role of mitochondria in synaptic failure, the connection between 
this role and the synaptic pathologies remains to be elucidated (Reeve et al., 2012). Pharmacological 
interference in oxidative phosphorylation complex 1 (in humans and animal models) produces 
parkinsonism symptoms and it is known that Pink1 and Parkin are important for mitochondrial 
health (Chen and Chan, 2009).  
   Familial PD can be caused by mutations in either of these genes, and sporadic PD is characterised 
by mitochondrial complex 1 dysfunction caused by a significant decline in substantia nigra levels of 
the antioxidant glutathione, partly as a result of the high susceptibility of dopaminergic neurons to 





1.3 Brain regions of interest 
1.3.1 Prefrontal cortex 
 
   The PFC is the association cortex of the frontal lobe and is one of the last cortices to fully mature in 
humans. It has extensive connections to the rest of the brain, in particular to the temporal, parietal 
and occipital cortices, hippocampus, thalamus and the limbic areas. Thus enabling processing of 
sensory and emotive input, vital for the PFC’s control of executive function, which Teffer and 
Semendeferi define as ‘the organization of input from diverse sensory modalities, the maintenance 
of attention, the monitoring of information in working memory, and the coordination of goal-
directed behaviors’ (Teffer and Semendeferi, 2012).  Additionally the different areas of the PFC have 
prominent connections to each other, and indeed there is much overlap in function between the 
different Brodmann areas that make up the PFC. 
    Much of the knowledge linking specific functions to a brain region comes from studies of lesions to 
these areas and any arising behavioural abnormalities in the subject. Lesions of the part of the PFC 
containing BA9 result in a loss of executive function, characterised by the inability to plan; eg. the 
construction or initiation of spoken or written sentences (Fuster, 2001). However other reports and 
insights from lesions to the PFC have suggested behavioural and emotional changes to be the 
primary manifestations, foremost amongst these is the case of Phineas Gage, who retained intellect 
and memory after massive damage to the frontal lobe – but was drastically altered in his emotional 
and behavioural faculties (including disinhibition and impulsiveness) (reviewed by (Cato et al., 
2004)). This historic observation has been substantiated by subsequent reports including injured 
soldiers and patient “K.M.”, who underwent a lesion of the PFC as treatment for seizures (Cato et al., 
2004). Cato and colleagues suggest that the evidence accumulated to date attributes emotional and 
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behavioural control to the ventro-medial PFC and cognitive and executive function to the dorso-
lateral PFC (including BA9). 
The diagnostic criteria for DLB according to McKeith et al state a deficit of executive function as 
essential for the diagnosis of DLB and so BA9 is highly likely to be implicated in the etiology of this 
symptom of DLB (McKeith et al., 2005). 
1.3.2 Cingulate gyrus 
 
Brodmann’s area 24 corresponds to the anterior cingulate gyrus, which is part of the medial cortex 
and a constituent brain region of the limbic system (Zilles and Amunts, 2010). BA24 participates in 
several major anatomical connections to the PFC and specifically BA9, in addition to significant 
outputs to the ventral striatum and a feedback loop via the thalamus (Tekin and Cummings, 2002).  
There is extensive debate over the function of the cingulate gyrus. Studies from patients with 
damage to the cingulate gyrus, or generally the medial cortex, point to attention emotional 
processing as a major function of the gingulate gyrus. Such patients also experience difficulty with 
behavioural and cognitive tasks (Fuster, 2001). This is consistent with a comprehensive review of 
lesions to BA24, which found the most significant presentation of these lesions to be apathy – 
including decreased spontaneity and initiation of movement and speech (Tekin and Cummings, 
2002). 
Raichle reviews a number of imaging studies which have provided further insights into anterior 
cingulate function, including both PET imaging in humans and monkeys that has shown BA24 to be 
key in attention and language generation. fMRI studies have shown increased activation of the BA24 
in humans performing tasks involving sustained concentration (Raichle, 1994). Precise detail of the 
nature of the attention mediated by BA24 is summarised by Fuster, as shifting the focus of attention 
from different locations in the visual field (Fuster, 2001). This is supported by evidence of the 
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reciprocal connections between the cingulate, and the parietal and PFC – as all three regions are 





1.3.3 Parietal cortex 
 
Brodmann’s area 40 (along with area 39) forms part of the inferior parietal lobule (IPL) of the 
parietal cortex – as outlined in a review of Brodmann’s map by Zilles and Amunts (Zilles and Amunts, 
2010). The IPL has long been known to perform important roles in integrating visual, auditory and 
somatosensory input – this is achieved by multiple connections to other cortical regions. In 
particular, the IPL has significant output connections to the visual cortical areas and the prefrontal 
cortex and receives input from the CA1 in the hippocampus, the superior colliculus and the 
cerebellum (Clower et al., 2001). The IPL is heterogeneous – a characteristic reflected in these 
regions innervating the IPL; hippocampal input is thought to relate to spatial perception and 
navigation, that from the superior colliculus to visual processing and whilst input from the 
cerebellum is theorised to correspond to the proprioceptive aspect of motor performance adaption 
(Clower et al., 2001).  
Recently Kenny and colleagues reported increased connectivity to the primary visual cortex in DLB 
patients (compared to controls) using fMRI, and suggested that intact visual cortex is required to 
experience visual hallucinations and that the neural-processing errors responsible for the visual 
processing abnormalities and symptoms in DLB must occur upstream at a ‘higher’ organisational 
level – possibly in the parietal cortex (Kenny et al., 2012). 
1.3.4 Temporal Cortex 
 
The temporal cortex includes the visual association cortex, which comprises BA21 (and BA20 and 37) 
(Catani et al., 2012). Temporal lobe lesions have led to this region being implicated in memory 
related tasks, such as the retention and perception of objects (Milner, 2003). This is supported by 
observations from monkeys where lesion of the temporal or parietal cortex caused either 
impairment of object discrimination or discrimination of spatial relationships respectively (Müller 
and Knight, 2006). Additionally nominal aphasia (impaired naming) and autoscopy (visual 
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hallucinations of one’s own body) have been linked to lesions of BA21 specifically (Catani et al., 
2012). 
The visual association cortex has prominent connections to the occipital cortex (via the inferior 
longitudinal fasciculus) and the frontal and parietal cortices, via the arcuate and uncinate fasciculi 
(Catani et al., 2012). 
1.3.5 Brain Region Summary 
In summary – the prefrontal cortex (PFC) including, the superior frontal cortex, Brodmann area 9 
(BA9) is responsible for executive function (Fuster, 2001); and changes are a core symptom of DLB 
and PDD, whilst BA24 is one of the earliest affected cortical regions in LBD. BA40 was selected as a 
comparison region as this region is much less affected in LBD but exhibits considerable pathology in 
AD (McKeith et al., 2005). The evidence for the functions of these regions support the hypothesis 
that DLB and PDD are executive, visuo-spatial and attentional dementias (Collerton et al., 2003); as 
does the involvement of these regions in the pathology and etiology of DLB and PDD.  
Furthermore, all of these regions described above are included in the standard block-taking protocol 
for the assessment of neuropathology in aged individuals (Alafuzoff et al., 2008; Alafuzoff et al., 




1.4 Hypothesis    
It is not yet clear whether pathology is an independent predictor of clinical symptoms or whether 
synaptic dysfunction is driving synaptic pathology or vice versa. Using the unique and extensive 
cohort and associated biochemical, clinical and pathological data, we wish to investigate 
relationships between pathology, synaptic biochemistry and cognitive and behavioural states in DLB, 
PDD and AD patients. Particular focus was given to the degree of synaptic dysfunction across brain 
regions and diagnostic groups, to synaptic dysfunction’s relationship with pathology and clinical data 
across brain regions, and to the relationships between different pathologies. 
The over-arching hypothesis behind these studies was that changes in synaptic structure and 
function in particular brain regions would underlie the clinical symptoms in the combined 
dementia cohort. ZnT3 was selected as a protein of interest based on evidence that zinc is 
important for cognition and may be involved in the generation of pathology; therefore, it was 
predicted that deficits in ZnT3 would relate to cognitive impairment and increased pathology. The 
other proteins were selected to provide a representation of the two synaptic terminals (SPP and 
PSD95) and a neuronal count (Btub). This was in order to determination the degree of contribution 
made by any loss of these elements to symptoms and what the relationship was between 
synapses and pathology. The anticipated outcomes being an increased knowledge of the synaptic 
biochemistry in LBD and its relationship to pathology and symptoms, with the potential to assist in 
the development of biomarkers and treatment strategies. 
Additionally, it was hoped to identify differences between the three dementias, both in terms of 
distribution and frequency of clinical symptoms, pathology and levels of synaptic proteins, and in 
terms of any relationships between these variables. This could be of assistance in either delineating 






Using the Brains for Dementia Research (BDR) network we have assembled an unrivalled group of 
over 90 autopsy confirmed LBD cases with detailed serial clinical assessments in the majority of 
cases and detailed semi-quantitative neuropathological scores for all regions.   
In order to test these hypotheses the following steps were taken;  
 A description of the clinical and pathological characteristics of the cohort. 
 Analysis of the relationship between behavioural, cognitive and pathological data 
 A description of the synaptic biochemistry according to brain region and clinical diagnosis 






2 Methods and Materials 
2.1 Cohort description. 
2.1.1 Description of the clinical and pathological data 
 
The data available to this project can be classified into three categories; clinical, pathological and 
biochemical. The clinical data can be further subdivided into that of cognitive or behavioural nature. 
The cognitive data comprises MMSE scores – analysed independently and used to provide the basis 
for an additional cognitive variable, the three categories of cognitive impairment to which cases 
were assigned. These were; 
 ‘unimpaired cognition’ – for cases classified by the brain bank as being clinical controls, 
  ‘mildly impaired cognition without dementia’ – for cases with MMSE scores of 25 to 30,  
 ‘mildly impaired cognition with dementia’ – for cases with MMSE scores from 17 to 24, 
 ‘moderately impaired cognition’ – for cases with MMSE scores of 10 to 16, 
 ‘severely impaired cognition’ for cases with MMSE scores of 9 or less.  
These categories were primarily based a division of the cohort into terciles according to MMSE 
score. This created ‘cut off’ MMSE values of 9 and 16. However, it was felt that the two cases with a 
score of 29 and the two cases with a score of 30 could not be included in the same category as cases 
with a score of 17. Therefore, an additional group, ‘mildly impaired cognition without dementia’, 
was created to accommodate these cases and the others above 24. These category definitions are 
supported by published criteria (Boller et al., 2002; Reisberg et al., 1994) and guidelines on the 
Alzheimer’s Association website (http://www.alz.org/alzheimers_disease_steps_to_diagnosis.asp).  
The behavioural data comprises semi-quantitative scores for four symptoms – agitation, depression, 
hallucinations and persecution, for most dementia cases these originated as NPI values, which were 
subsequently converted to the 0-3 scale in order to achieve compatibility with cases given a score on 
this scale based upon either observations made by a clinician or the inclusion of a case as a control. I 
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would like to express my thanks to Professors Clive Ballard and Dag Aarsland and Dr Julie Vallortigara 
for their significant contributions to the compilation and standardisation of this clinical data. 
The pathological data is likewise semi-quantitative (on a scale of 0 – none, 1 – sparse, 2 – moderate, 
3 - severe) and comprises scores for plaques/Aβ pathology, tangle/tau pathology and α-synuclein 
pathology. This score is based upon immunohistochemical staining, some of which was undertaken 
specifically for this project, whilst some was diagnostic, undertaken when the case in question was 
received by the respective brain bank. The semi-quantitative score was primarily introduced to 
standardise between scorers and between methodologies. I was involved in the coordination and 
compilation of this data for the cohort – as well as assisting with scoring and staining. I would like to 
express thanks to Dr Johannes Attems, Dr Tibor Hortobagyi and Dr David Howlett for their significant 
contributions to this pathological data – in particular staining and scoring of sections.  
The biochemical data presented in this project was obtained from homogenised frozen grey matter 
using Western blotting and ELISA – and from paraffin embedded sections using 










2.1.2 Description of post-mortem tissue 
Post-mortem brain tissue from DLB, PDD and AD patients with age and gender matched healthy 
control tissue was the main resource for this project (see table 2.1 for details). These brains have 
come from a variety of sources to which the author is indebted; University Hospital Stavanger, the 
Brains for Dementia project based at the Institute of Psychiatry (KCL), Newcastle University and the 
Thomas Willis Brain Collection at Oxford University.  
From each brain there is a frozen hemisphere and a hemisphere fixed in formaldehyde and extensive 
clinical data (see preceding section). A 500mg sample of frozen tissue was taken from the pre-frontal 
cortex (BA9), the cingulate gyrus (BA24) and the parietal cortex (BA40) and processed for Western 
blot and ELISA analysis whilst paraffin fixed, wax-embedded blocks were available for 
immunohistochemical analysis (see following sections). 
 
Diagnosis Gender (M/F) 
% 




pH (mean) Years in 
storage 
(mean) 
Control (25) 60/40 79.7  ± 7.6 39.1  ± 22.9 6.47  ± 0.28 11.8 ± 5.6 
PDD (34) 53/47 79.9  ± 6.0 33.5  ± 15.6 6.44  ± 034 9.4 ± 1.2 
DLB (55) 58/42 81.7  ± 6.5 41.3  ± 28.0 6.37  ± 0.41 7.8 ± 4.6 
AD (16) 31/69 88.0  ± 7.8 34.9  ± 23.9 6.30  ± 0.33 2.9 ± 0.8 







The fixed tissue was examined using immunohistochemistry (IHC) for selected proteins of interest.   
A standard IHC protocol was used with changes made to antibody concentration and incubation 
length and to the epitope retrieval technique. 7m sections of paraffin embedded tissue were cut 
and de-waxed using xylene and alcohol. Epitope retrieval consisted of heating the sections in citrate 
buffer using a microwave to remove cross-linage of peptides caused by fixation in formaldehyde 
(Yamashita, 2007). The length of time and microwave power was varied to achieve the best staining 
(see table 2.2.1). Methanol with 0.75% hydrogen peroxide was used to quench endogenous 
peroxidase enzynmes present in the tissue thereby preventing a non-specific reaction with DAB (di-
amino-benzidine, from Sigma). Normal serum from the same species as the secondary antibody was 
used to block non-specific binding of the primary antibody. A primary antibody specific to the 
protein of interest and a secondary antibody (from Dako) specific to IgG (immunoglobulin G) from 
the same species the first antibody is raised in was used to achieve specific and sensitive detection. 
Visualisation was achieved through a chemical reaction with DAB and hydrogen peroxide catalysed 
by horseradish peroxidase, which is part of an avidin-biotin complex (Vectastain ABC kit, Vector) that 
binds to the biotinylated secondary antibody. Sections were counter stained with haematoxylin, 
which stains the negatively charged DNA molecules thus showing the nuclei and hence cell bodies of 
the neurons. Following this sections were dehydrated with increasing concentrations of alcohol and 
cover-slipped using DPX mounting medium. Tris-buffered saline (TBS), pH 7.6, was used to wash the 
sections for 3 times for 5 minutes between each reagent. 
Figures 2.2.1 and 2.2.2 show images of sections immuno-labelled for PSD95 and SPP respectively as 









ZnT3 rabbit polyclonal, Synaptic Systems 1:200 overnight extended 
citrate 
synaptophysin mouse monoclonal, Dako, clone SY38 1:500 overnight normal citrate 
PSD95 mouse monoclonal, Thermo Scientific, clone 
6G6-1C9 
1:200 overnight extended 
citrate 
Drebrin mouse monoclonal, MBL, clone M2F6 1:200 overnight extended 
citrate 
Table 2.2.1. Proteins of interest and IHC methods.  
This table shows the final antibody dilution and epitope retrieval after optimisation of staining for 
the proteins of interest. Extended citrate is 6 minutes at high power, 800 watts (W), then 16 minutes 












Figure 2.2.1; Cerebellar PSD95 
immunohistochemistry. 
The top image is a cortical section 
immunolabelled for PSD95. Some 
intensely labelled cells can be seen 
in the molecular layer (bottom left 
region of image). The Purkinje cell 
and granular cell layers also display 
positively labelled cells. The bottom 
image shows a negative control with 
no DAB labelling. Both images are 
cerebellum sections from an elderly 











Figure 2.2.2; Cerebellar 
synaptophysin 
immunohistochemistry. 
The top image shows 
immunopositive labelling of cells and 
their synapses in the molecular layer 
(upper right corner) and extensions 
in the granular layer for 
synaptophysin. In the bottom right 
of the image there is white matter 
without positive staining. The 
bottom image is a negative control 
showing only haematoxylin counter-
stain of nuclei in all layers. Both 
images are cerebellum sections from 
an elderly healthy control case. Scale 




2.3 Tissue preparation 
For each tissue sample, the cortical grey matter was dissected from the white matter and the 
meninges at 0°C. Approximately 300mg of cortical grey matter was homogenised in 6ml of ice-cold 
homogenisation buffer at pH 7.4 using an Ultra-Turrax tissue homogeniser (KIA Werke, Germany), 
resulting in a crude homogenate. The homogenisation buffer contained 50mM Tris-HCl, 5mM EGTA, 
10mM EDTA (for chelation of magnesium and calcium ions respectively), ‘Complete Protease 
Inhibitor Cocktail Tablets’ at the appropriate dilution from Roche Applied Science (which inhibit 
serine, cysteine and metallo-proteases) and 2μg/mL pepstatin A (for inhibition of aspartic proteases, 
something not performed by the Roche tablet). This protocol is based upon that previously 
described in (Kirvell et al., 2006). The crude homogenates were immediately frozen on dry ice and 
stored at -70°C for use in protein assays and Western blotting at a later stage.  
2.4 Protein Assay 
The total protein concentration in the crude homogenate was determined using the Bradford 
protein assay method (Kruger, 1994). Before preparing the tissue samples for protein assay, 
standards were made by using bovine serum albumin (BSA) (Sigma-Aldrich, USA) and PBS buffer 
through a series of dilutions, resulting in the following concentrations; 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 
1.6, 1.8 and 2.0 mg/ml. Each of these standards was then diluted by a factor of 10 whilst the samples 
were diluted by a factor 100 (in both cases using distilled deionised water). After the respective 
dilutions, 10μL of standard or sample was added to a 96-well plate (Nunc A/S, Denmark) in triplicate. 
Then 300μL of Coomassie protein assay reagent (Thermo Scientific, USA) was added to each well 
After ensuring no bubbles were present on the surface of the wells, which would interfere with the 
absorbance reading, the absorbance was read at 595nm using a FlexStation 3 (Molecular Devices 
LTD, UK). A standard curve was calculated from the standards, using GraphPad Prism version 5.0 
(GraphPad Software Inc, USA), allowing the concentration of protein in each sample to be 
determined from the absorbance. 
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2.5 Semi-quantitative Western blotting 
To prepare the crude homogenate for Western blotting; 250μL of 5x Laemmli sample buffer for SDS-
PAGE (GenScript, USA), containing bromophenol blue and SDS, was added to 1ml of homogenate 
and then boiled at 95°C for 5 minutes. After cooling down, samples were stored at -20°C until 
Western blotting was performed. 
Western blots were run in duplicate using a 10% SDS-polyacrylamide gel at approximately 160 volts 
(V). On each gel there were three lanes containing rat cortex, (these were always the first lane, a 
central lane and the last lane) and 1.5µl of full range molecular weight marker (MWM, sigma) in a 
central lane. Each human sample was loaded once on each of the tandem gels, the total protein 
concentration of each sample (obtained from the protein assay) allowed the loading volume of each 
sample to be adjusted such that 20µg of protein was loaded onto the gel for each sample. A similar 
approach was taken for rat cortex; however, when quantifying PSD95 and ZnT3, the volume of rat 
cortex was lowered in order to load 10µg of total protein. This was because the signal of these 
proteins was considerably higher in rat cortex than human cortex and therefore distorted the ratio 
of human cortex to rat cortex, which in turn made it harder to achieve satisfactory repetition 
between duplicates. 
When the MWM had reached the bottom of the gel, the contents of the gel were transferred to 
nitrocellulose membrane (Hydrobond-C, Amersham) using semi-dry electroblotting at 60V for 90 
minutes. Non-specific binding sites were blocked using a 1 hour incubation in phosphate-buffered 
saline (pH7.6) with 0.1% tween20 (PBST) and 5% non-fat powdered milk. Membranes were 
incubated overnight in the appropriate primary antibody in PBST and 5% milk (see table 2.5.1 for 
dilutions). Excess antibody was removed with three 5 minute washes in PBST. Membranes were 
incubated in PBST containing 5% milk and the relevant secondary antibody; either a donkey anti-
rabbit visible under the green channel or a goat anti-mouse visible under the red channel, both 
IRDye from LI-COR. An Odyssey infrared scanner was used to take images of the membranes.  Due to 
sufficient difference in molecular weight of the respective proteins, the lack of cross-reactivity 
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between the primary antibodies and availability of secondary antibodies fluorescent under different 
channels, it was possible to incubate the primary antibodies for PSD95 and ZnT3 on the same 
membrane; thus improving the efficiency and sample analysis times for Western blotting, illustrated 
in figure 2.5.1. Btub and SPP were analysed on the same membrane but antibody incubation and 
scanning of membranes was conducted separately, one after the other, as there was some cross-
reactivity, depicted in figure 2.5.2.  
 
Figure 2.5.1; An example of a Western blot for Btub. 
The samples run on this gel were (from left to right); rat cortex, BA9 DLB (x10), mwm, rat cortex, BA9 




Figure 2.5.2; An example of a Western blot for SPP. 
The samples run on this gel were (from left to right); rat cortex, BA24 AD (x10), mwm, rat cortex, 








Figure 2.5.3; An example of a Western blot for PSD95 and ZnT3. 
PSD95 was visible on the red channel, ZnT3 on the green channel. The samples run on this gel were 
(from left to right); rat cortex, BA9 AD (x3), BA24 AD (x2), BA40 AD (x5), mwm, rat cortex, BA40 AD 
(x1), BA40 PDD (x9) and rat cortex. 
 
 




                                                                                                                                                                      
Protein Primary Antibody Primary Antibody Dilution 
ZnT3 rabbit polyclonal, Synaptic Systems 1:1000  
β-tubulin rabbit polyclonal, Abcam 1:10,000  
synaptophysin mouse monoclonal, SY38, Abcam  1:10,000  
PSD95 mouse monoclonal, Thermo Scientific, clone 6G6-1C9 1:5000 
Table 2.5.1. Western blot antibodies 
Antibodies and dilutions used for Western blot analysis of human samples from BA9 (prefrontal 
cortex) and rat cortex.  
 
 
Odyssey infrared imaging systems application software version 3.0.16 was used to measure the 
intensity of each band on the immunoblot images. The mean intensity of the three rat cortex values 
was calculated, this was used to express the band intensity of the samples as a ratio to the mean rat 
cortex band intensity. To confirm satisfactory agreement between duplicate samples on each of the 
tandem membranes, samples were repeated if the percentage difference (after expression as a ratio 
to rat cortex) between duplicates was greater than 30%.  
Due to the high number of samples analysed, more than one aliquot of rat cortex was required. To 
ensure continuity between aliquots of rat cortex, each antibody was quantified in the old and new 
rat cortex aliquot to produce a correction factor if the mean signal intensity was not the same 




2.6 Enzyme-linked immuno sorbent assay (ELISA). 
Preliminary western blot data indicated drebrin levels to be decreased in PDD cases, however this 
analysis could only be completed on 9 cases from the PDD, DLB and control groups before a new 
batch of anti-body was required, unfortunately this new batch did not detect human drebrin, only 
that in the rat cortex. Beta-III-tubulin was run at the same time to confirm the issue was not with 
loading or running the gel or transfer and other drebrin antibodies did not give suitable band quality 
for quantification, so an alternative method of quantification for drebrin was sought in order to 
pursue this line of enquiry. A sandwich enzyme immunoassay kit was purchased from USCN Life 
Sciences Inc. for drebrin (DBN1, code E92431Hu).  
In line with the recommendation by the ELISA manufacturer; crude homogenate was subjected to 
two freeze/thaw cycles (using liquid nitrogen and a water bath at 35°C), centrifuged at 5000g and 
4°C for 5 minutes, allowing the supernatant to be harvested. Two control and two PDD samples were 
used to optimisation sample dilution for the assay (these were selected as the preliminary Western 
blot data indicated controls to have the highest drebrin levels and PDD the lowest, thus it was hoped 
to cover a representative range of drebrin concentration). Following this it was determined that 
samples should be diluted 1:25.  
A blank, 7 standards (10ng/ml, 5ng/ml, 2.5ng/ml, 1.25ng/ml, 0.625ng/ml, 0.312ng/ml and 
0.156ng/ml) and samples were run in duplicate. Standards and samples were incubated in the pre-
coated wells for 2 hours (all incubations were at 37°C), then incubated with the first detection 
reagent for 1 hour. Next the wells were washed thoroughly, the second detection reagent was 
incubated in the wells for 30 minutes, washed out, then substrate and finally stop solutions were 
added. After completion of the assay, the 96-well plate was read at 450nm on a FlexStation 3 




In order to account for varying protein concentrations between samples, a protein assay was 
performed on the supernatant for each sample (see protein assay section under Western blotting for 
details). This allowed the drebrin concentration calculated from the ELISA to be expressed as ng of 
drebrin per µg of total protein. 
2.7 Paraffin-Embedded Tissue Blotting (PET blot) 
This is a technique designed to reveal the localisation of protein aggregates within paraffin 
embedded tissue (Kramer and Schulz-Schaeffer, 2007). Unfortunately, it was not possible to develop 
the technique beyond an experimental stage. Presented here is a description of the optimisation 
attempts and a brief discussion of some problem solving measures undertaken. 
Sections were cut on a microtome (3μm) from the amygdala of a Lewy body disease case and from 
the cerebellum of a healthy control brain and placed in a water bath. Alcohol (20%) was added to 
the water bath to improve the surface tension, making it easier for the very thin sections to be 
mounted on strips of nitrocellulose membrane (Hyrdobond-C, Amersham). The membranes were 
left to dry at 60°C for at least 24 hours. 
     The sections were de-waxed using xylene and hydrated with decreasing concentrations of 
isopropanol (from 100% down to 25%). Isopropanol was used because ethanol causes permanent 
curling of the membranes. The sections were incubated overnight at 60°C in TBS containing 0.1% 
tween20 (TBST) and different concentrations (5-250μg/ml) of proteinase K (Bioline). Sections were 
denatured in 4M guanidinethiocynate (15 minutes), blocked for non-specific binding in TBST with 
0.2% casein, and then incubated in primary antibody (Invitrogen, mouse monoclonal anti-α-syn, 
clone LB509) at different dilutions (from 1:5000 to 1:1000) for 90 minutes.  
    The secondary antibody (incubation 1:1000 for 60 minutes) was an alkaline-phosphatase 
conjugated goat anti-mouse IgG. Prior to application of the visualisation  reagents, sections were 
washed with NTM solution (100nM Tris HCl, 100mM NaCl, 50mM MgCl2, pH 9.5) to raised the pH. 
The detection system used was the formazan reaction, NBT BCIP (nitro-blue tetrazolium chloride and 
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5-bromo-4-chloro-3`-indoyl-phosphate-p-toluidine salt) in a combined liquid substrate system from 
Sigma. Finally, sections were washed in 0.025M EDTA to strengthen the signal before being left at 
room temperature (in a light proof box) to dry. As the sections are opaque standard light-microscopy 
could not be used and, a high-magnification dissecting microscope being unavailable, a powerful 
dissecting torch had to be shone onto the sections when they were under a standard microscope 
lens. 
The two major issues encountered whilst optimising the PET blot technique were the proteinase K 
digestion and visualising the sections under a microscope. The proteinase K concentration of 
250μg/ml used by Kramer and Schulz-Schaeffer is unusually high, in comparison to other 
applications. This necessitated making the solution from powdered enzyme; however, the high static 
charge of proteinase K made accurate weighing (despite use of a static-gun) difficult. To combat this 
a wide range of concentrations were tried to eliminate the possibility of an erroneously high solution 
causing excessive digestion of the tissue section. The other problem with regards to proteinase K 
was the use of the so called ‘pillow technique’, developed by Kramer and Schulz-Schaeffer. This was 
not adequately described, in the original article or email communication with the authors, to be 
replicated. Nor was its purpose fully explained, as immersion of the sections in the digestion buffer 
should have achieved the same result as sandwiching the sections in paper towel soaked in digestion 
buffer. 
Visualisation of the sections, upon completion of the protocol, was difficult due to their opacity and 
the impossibility of retaining a totally flat membrane surface; this meant the microscope could not 
focus on the entire field of view as there were in effect, troughs and peaks in the membrane surface 
(see figures 2.7.1 and 2.7.2). Whilst optimisation was ongoing, a critique of the technique published 
by Kramer and Schulz-Schaeffer was published suggesting improvements, including use of methanol 












Figure 2.7.1; PET blotting in the 
cerebellum. 
The cerebellum serves as a ‘negative 
control’ (because no ASyn pathology 
has been reported in the cerebellum 
in PDD and DLB). Both images are 
from a healthy control, digested with 
60μg/ml proteinase K, immuno-
labelled with 1:1000 anti-ASyn 
antibody and stained using the 
formazan reaction. The top image 
was counter stained with 
haematoxylin (to better reveal the 
tissue structure) and the bottom 












Figure 2.7.2; PET blotting in the 
amygdala. 
Both images are amygdala sections 
from a case diagnosed with Lewy 
body dementia. The top image is a 
section not treated with proteinase 
K, the bottom image is a section that 
was treated with 30μg/ml 
proteinase K. Both were immuno-
labelled with 1:500 anti-ASyn 
antibody and stained using the 




3 Statistical analysis  
3.1 Demographic variables 
There are a variety of factors – beyond the control of investigators - that can influence protein 
expression in frozen brain tissue, and which can be broadly split into those of a demographic nature 
(age at death and gender) and those connected to the tissue donation process (post-mortem delay 
(PMD), brain tissue pH and years in storage). Gender-specific differences within the brain can arise 
as a result of the interactions of sex-steroids such as estrogen (Kelly et al., 1999) – recently it has 
been demonstrated that such interactions exert an influence on the morphology and function of 
dendritic spines (Rasia-Filho et al., 2012). The potential impact of age on synaptic proteins requires 
less evincing - age being the most prominent risk factor for dementia and commonly associated with 
cognitive decline (Ballard et al., 2011b; DeCarli et al., 2012). 
The rationale behind the creation of ‘years in storage’ as a variable is described under synaptophysin 
in the discussion. The pH in brain tissue is known to be unchanged across all brain regions and is not 
significantly affected by frozen storage duration (Johnston et al., 1997); furthermore, pH is a crucial 
confounding factor to be considered as it provides a measure of agonal state – in particular low pH is 
associated with prolonged death and reductions in RNA and protein quality (Johnston et al., 1997). 
The effect of post-mortem delay on synaptic proteins in frozen human brain tissue was investigated 
by Siew and colleagues, and was found to vary according to protein and brain region (Siew et al., 
2004). This is discussed further under synaptophysin and PSD95 in the discussion, but serves here as 
evidence of the importance of considering – and statistically controlling for – the effect of PMD.  
Thus, the necessity of determining the presence of any relationship between the proteins measured 
in this project and these confounding variables is established. Table 2.1 shows the average values for 
these confounding factors, according to diagnosis. 
There are other potential confounding variables specific to post-mortem studies on 
neurodegenerative conditions. In the case of this study these are the duration of dementia, duration 
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of Parkinsonism and medication. In the case of the first two, it was felt that the nature of the 
diagnosis of DLB and PDD is such that clinical diagnosis has already taken into account the duration 
of dementia or Parkinsonism. This was confirmed when creating residual synaptic protein values 
accounting for these variables merely removed the differences in protein levels between DLB, PDD 
and controls. 
However, certain medication can influence synaptic and neuronal proteins (further detail is given in 
the discussion sections for the relevant synaptic proteins). Unfortunately, data was not available on 
the medication taken by the AD cases and certain DLB and PDD cases, making it impossible to 
reliably elucidate any effect on the proteins of interest by medication. The medication appendix 
table shows what data was available, from which it can be seen that medication was broadly similar 




3.1.1 Statistical preparation of semi-quantitative Western blotting values for β-III-
tubulin, PSD95, synaptophysin and ZnT3, and the ratio of synaptophysin to β-III-
tubulin, PSD95 to β-III-tubulin and ZnT3 to synaptophysin in BA9. 
The normality of the data for each protein or ratio was determined using the Shapiro-Wilk test in 
SPSS, this test is the most appropriate for data sizes up to n=2000 (Coolican, 2009). Then the 
relationships between protein values or ratios and confounding variables was determined using 
Spearman’s rank correlation in SPSS to search for significant correlations between the proteins 
measured by semi-quantitative Western blot in each brain region – and gender, age at death, PMD, 
pH and years in storage. Table 3.1.1 shows the significant correlations that occurred in BA9 between; 
PSD95 values and PMD, SPP values and years in storage, ZnT3 values and gender, the ratio of PSD95 
to Btub and PMD and the ratio of ZnT3 to SPP and gender and pH. For full details of all values refer 
to appendix tables ‘Protein values from semi-quantification of Western blotting’, ‘Residual and 
normalised protein values in BA9’ and ‘Residual and normalised protein ratios in BA9’. For all 
statistical analysis in this project p<0.05 was considered as being statistically significant. 






Btub None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) 
PSD95 None (p>0.05) None (p>0.05) None (p>0.05) p<0.05 None (p>0.05) 
SPP None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) p<0.05 
ZnT3 None (p>0.05) p<0.05 None (p>0.05) None (p>0.05) None (p>0.05) 
Ratio of SPP to 
Btub 
None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) p<0.05 
Ratio of PSD95 
to Btub 
None (p>0.05) None (p>0.05) None (p>0.05) p<0.05 None (p>0.05) 
Ratio of ZnT3 
to SPP 
None (p>0.05) p<0.05 p<0.05 None (p>0.05) None (p>0.05) 
 
Table 3.1.1; Correlations between biochemical and demographic data in BA9 
Spearman’s rank correlation was used to determine the effect of demographic factors (age at death 
and gender) and variables associated with the tissue donation process (pH, PMD and years in 
storage) on the protein values and ratios obtained or calculated from semi-quantitative Western 
blotting. The significance levels of the relationship between these protein values (Btub, PSD95, SPP 
and ZnT3) and ratios (SPP to Btub, PSD95 to Btub and ZnT3 to SPP) in BA9 and the aforementioned 




The confounding variables found to correlate with protein values were entered into a regression 
analysis (using the enter method in SPSS) to determine if they were significant predictors of the 
protein value to which the correlation occurred. If this proved to be the case then unstandardised 
residuals were saved from the regression, if not the case then any non-significant predictors were 
removed and the regression redone. If necessary, the residual variables were normalised using a 
transformation. For the sake of consistency, the different transformation operations were 
attempted in the same order; log10, square root, and quantile. Whenever possible the same 
operation was used for all data sets in a brain region – as these were analysed together, however 
quantile transformation is an exception to this – this is discussed under statistical preparation for 
BA24. As residual variables typically contain negative values it was necessary to shift all values above 
0, usually by adding 1 to all values, before operations such as log10 could be performed. 
In BA9 the final values used for each protein and protein ratio in all subsequent analysis were as 
follows; 
 β-III-tubulin – not a residual but normalised using log10 
 PSD95 – residual for prediction by PMD 
 synaptophysin – residual for prediction by ‘years in storage’ and normalised using log10 
 ZnT3 – residual for prediction by gender 
 Ratio of synaptophysin to β-III-tubulin – residual for prediction by ‘years in storage’ 
 Ratio of PSD95 to β-III-tubulin – residual for prediction by PMD 




3.1.2 Statistical preparation of semi-quantitative Western blotting values for β-III-
tubulin, PSD95, synaptophysin and ZnT3 in BA24. 
The normality of the data for each protein and ratio obtained or calculated from semi-quantitative 
Western blotting in BA24 was determined using the Shapiro-Wilk test in SPSS. It was found that 
none of the protein values or ratios were normally distributed. Transformation using Log10 
normalised the distribution of Btub and ZnT3 data but not SPP or PSD95 data. A square root 
transformation normalised PSD95, SPP was left without a normal distribution at this stage as 
conventional means did not achieve normalisation. The ratio of SPP to Btub and ZnT3 to SPP were 
normalised by taking the log10, the ratio of PSD95 to Btub was normalised by taking the square root. 
Following these normalisations, a number of correlations were found between the protein data or 
ratios and the key demographic variables; gender, age at death, brain tissue pH and post mortem 
delay, shown in table 3.1.2. For full details of all protein values refer to appendix tables ‘Protein 
values from semi-quantification of Western blotting’, ‘Residual and normalised protein values in 
BA24’ and ‘Residual and normalised protein ratios in BA24’. 






Btub None (p>0.05) p<0.05 None (p>0.05) None (p>0.05) None (p>0.05) 
PSD95 None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) 
SPP None (p>0.05) None (p>0.05) None (p>0.05) p<0.05 None (p>0.05) 
ZnT3 p<0.05 p<0.05 p<0.05 None (p>0.05) None (p>0.05) 
Ratio of SPP to 
Btub 
None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) 
Ratio of PSD95 
to Btub 
None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) 
Ratio of ZnT3 
to SPP 
p<0.05 None (p>0.05) p<0.05 p<0.05 None (p>0.05) 
 
Table 3.1.2; Correlations between biochemical and demographic data in BA24. 
Spearman’s rank correlation was used to determine the effect of demographic factors (age at death 
and gender) and variables associated with the tissue donation process (pH, PMD and years in 
storage) on the protein values and ratios obtained or calculated from semi-quantitative Western 
blotting. The significance levels of the relationship between these protein values (Btub, PSD95, SPP 
120 
 
and ZnT3) and ratios (SPP to Btub, PSD95 to Btub and ZnT3 to SPP) in BA24 and the aforementioned 
variables are shown in the table. 
 
Residual variables were created using the approach outlined for BA9. In BA24 the final values used 
for each protein and protein ratio in all subsequent analysis were as follows; 
 β-III-tubulin – residual for prediction by gender 
 PSD95 – not a residual but normalised using the square root 
 synaptophysin – residual for prediction by PMD and normalised using quantiles 
 ZnT3 – residual for prediction by age at death and pH 
 Ratio of synaptophysin to β-III-tubulin – not a residual but normalised using log10 
 Ratio of PSD95 to β-III-tubulin – not a residual but normalised using the square root 
 Ratio of ZnT3 to synaptophysin – a residual for prediction by PMD and pH and normalised 
using quantiles 
A quantile transformation was necessary to normalise the SPP residual variable and the ratio of ZnT3 
to SPP residual, in part due to the bimodal nature of these data. As this is a more advanced 
operation beyond the capabilities of SPSS, it was undertaken by Dr Stephen Newhouse, the 
statistician assisting with this project, using R software facility from Free Software Foundation, Inc. 




3.1.3 Statistical preparation of semi-quantitative Western blotting values for β-III-
tubulin, PSD95, synaptophysin and ZnT3 in BA40. 
Normality tests were undertaken as described in the previous sections, followed by the 
establishment of any correlations to demographic and other confounding factors – the result of this 
is displayed in table 3.1.3. For full details of all protein values refer to appendix tables ‘Protein values 
from semi-quantification of Western blotting’, ‘Residual and normalised protein values in BA40’ and 
‘Residual and normalised protein ratios in BA40’. 






Btub p<0.05 None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) 
PSD95 p<0.05 None (p>0.05) None (p>0.05) p<0.05 None (p>0.05) 
SPP None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) 
ZnT3 p<0.05 p<0.05 p<0.05 p<0.05 None (p>0.05) 
SPP to Btub None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) None (p>0.05) 
PSD95 to Btub None (p>0.05) None (p>0.05) None (p>0.05) p<0.05 None (p>0.05) 
ZnT3 to SPP None (p>0.05) p<0.05 p<0.05 None (p>0.05) None (p>0.05) 
Table 3.1.3; Correlations between biochemical and demographic data in BA40. 
Spearman’s rank correlation was used to determine the effect of demographic factors (age at death 
and gender) and variables associated with the tissue donation process (pH, PMD and years in 
storage) on the protein values and ratios obtained or calculated from semi-quantitative Western 
blotting. The significance levels of the relationship between these protein values (Btub, PSD95, SPP 
and ZnT3) and ratios (SPP to Btub, PSD95 to Btub and ZnT3 to SPP) in BA40 and the aforementioned 
variables are shown in the table. 
Residual variables were created using the approach outlined for BA9. In BA40 the final values used 
for each protein and protein ratio in all subsequent analysis were as follows; 
 β-III-tubulin – residual for prediction by age at death 
 PSD95 – residual for prediction by PMD 
 synaptophysin – no transformation or residual 
 ZnT3 – residual for prediction by PMD 
 Ratio of synaptophysin to β-III-tubulin – not a residual but normalised using log10 
 Ratio of PSD95 to β-III-tubulin – a residual for prediction by PMD 
 Ratio of ZnT3 to synaptophysin – a residual for prediction by gender 
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3.1.4 Statistical analysis outline 
 
Advice on statistical procedure was gratefully received from a statistician – Dr Stephen Newhouse – 
who has been associated with this project. This consisted of guidelines on the creation of residuals 
and the use of multiple regression in SPSS. The approach used for analysis of relationships between 
the variables of interest was the same as that applied to the creation of residuals. Spearman’s 
correlation and/or one-way ANOVAs were used to screen for significant differences. Variables that 







When the antibody signal was quantified on the membrane, the values for each protein were 
expressed as ratios to rat cortex, however, the values used in all analysis and figures have been 
subjected to further analysis including normalisation and the creation of residuals. To avoid 
repetitive complexities in the figure captions these have been comprehensively detailed in the 
methods section, thus all subsequent reference to the values of a protein or protein ratio refers to 
the final output values from these statistical computations and not the initial quantification from 
Western blotting. 
Furthermore, the number of cases analysed and depicted in the graphs varies for each protein and 
brain region. Scatter plots have been used to allow a visual approximation of the n for each figure to 
be arrived at by the viewer, for the complete description the relevant appendix tables should be 
referred to.  
Some of these final residual variables contained negative values, to allow easy visual comparison of 
the data when depicted as scatter plots, the decision was taken to translate any variables that 
contained negative values by an amount sufficient to ensure the largest negative value became 
positive. An advantage of this is that the data points do not risk being obscured by their original 





4.1 Clinical and pathological data 
 
As described under the methods and materials section, the cases used in this study included semi-
quantitative scores (on a scale of 0 - absent, 1 – sparse or mild, 2 - moderate and 3 - frequent or 
severe) for Aβ, tau and α-synuclein pathology in BA9, BA24, BA21 and BA40. Figures 4.1.1 to 4.1.4 
illustrate the distribution of these three pathologies, by severity and according to brain region and 
diagnosis. Figures 4.1.5, 4.1.6 and 4.1.7 show examples of the four categories of staining severity for 
Aβ, tau and α-syn respectively. It can be seen in figure 4.1.1 that control cases had a complete 
absence of α-syn pathology in all brain regions; tau pathology was likewise relatively sparse, whilst 
Aβ pathology was more common, with a few cases in the severe category. PDD cases were similarly 
characterised by a relative scarcity of α-syn, except in BA24, and, across all regions, tau (depicted in 
figure 4.1.2). In DLB cases there was a considerably greater frequency of cases with moderate and 
severe scores for all pathologies (figure 4.1.3); moreover the majority of AD cases had 
frequent/severe scores for Aβ and tau pathology (except in BA24 where cases were spread evenly 







Figure 4.1.1 Frequency of pathology scores in Control cases 
The frequency of each pathology score, by brain region, was calculated for those control cases that 







Figure 4.1.2 Frequency of pathology scores in PDD cases 
The frequency of each pathology score, by brain region, was calculated for those PDD cases that had 








Figure 4.1.3 Frequency of pathology scores in DLB cases 
The frequency of each pathology score, by brain region, was calculated for those DLB cases that had 









Figure 4.1.4 Frequency of pathology scores in AD cases 
The frequency of each pathology score, by brain region, was calculated for those AD cases that had 






Figure 4.1.5; Images of Aβ staining representative of the four categories of semi-quantitative score. 
Immuno-labelling with a 1E8 antibody for Aβ at 1:1000 was used to reveal Aβ pathology. Whilst the 
whole section was viewed to determine the semi-quantitative score, representations of each score 
category are shown here; image A is from a case given a score of absent/0, image B is from a case 
given a score of sparse/1, image C is from a case given a score of moderate/2 and image D is from a 






Figure 4.1.6; Images of tau staining representative of the four categories of semi-quantitative score. 
Immuno-labelling with a AT8 antibody (Innogenetics) at 1:200 was used to reveal tau pathology. 
Whilst the whole section was viewed to determine the semi-quantitative score, representations of 
each score category are shown here; image A is from a case given a score of absent/0, image B is 
from a case given a score of sparse/1, image C is from a case given a score of moderate/2 and image 







Figure 4.1.7; Images of α-synuclein staining representative of the four categories of semi-
quantitative score. 
Immuno-labelling with a NCL-SYN antibody (Novacastra Laboratories) at 1:200 was used to reveal α-
synuclein pathology. Whilst the whole section was viewed to determine the semi-quantitative score, 
representations of each score category are shown here; image A is from a case given a score of 
absent/0, image B is from a case given a score of sparse/1, image C is from a case given a score of 







The clinical data available to this project can be divided into that of a cognitive or behavioural 
nature. The behavioural data comprises semi-quantitative scores (on a similar scale to that of the 
pathology) for agitation/aggression, depression, hallucinations and persecution. These have been 
derived from a combination of NPI scores, case notes from clinicians or inclusion as a clinical control 
by the brain bank. Thus, control cases were assumed to have an absence of all behavioural 
symptoms (illustrated in figure 4.1.5). The same figure shows the frequency of the four symptoms 
across the other diagnostic groups, where it can be seen that AD cases had relatively high agitation 
scores, which was less so for DLB cases, with PDD cases falling between the two. Depression scores 
were particularly low in DLB cases, with a fairly even spread for AD and PDD. However, AD cases had 
considerably lower hallucination scores than DLB or PDD cases. Cases of all three dementias were 
fairly evenly distributed across the categories of persecution scores. Nonetheless, it should be noted 
a considerable percentage of cases of each dementia had a score of absent for each symptom.  
The cognitive data was in the form of MMSE scores, which were not available for control cases. In 
order to included controls in the analysis of cognition, five categories of cognitive impairment were 
created, based upon either the final MMSE score before death, or the inclusion in the brain bank of a 
case as a clinical control (see the relevant methods and materials section for further details). Figure 
4.1.6 shows the distribution of cases, according to clinical diagnosis, amongst these cognitive 
impairment categories. The highest frequency of cases classified as severely impaired were AD, 
furthermore there were no AD cases classified as belonging to the MCI category.  Interestingly, more 
DLB cases had moderate impairment than severe impairment. The percentage of PDD cases in 






Figure 4.1.5. Frequency of behavioural scores in all cases. 
The frequency of each behavioural score was calculated for all cases that had scores and 
represented graphically, according to clinical diagnosis. The y axis represents the percentage of cases 




Figure 4.1.6. Percentage of cases in each cognitive impairment category. 
The frequency cases in each category of cognitive impairment was calculated based upon MMSE 
scores (see section 2.1.1 for details) and represented graphically, according to clinical diagnosis (see 






To determine the relationship of the behavioural symptoms (hallucination, persecution, depression 
and agitation) to cognition – regression analysis was performed using the scores for these 
behaviours as independent predictor variables for the category of cognitive impairment cases were 
classified as falling into (these were ‘cognitively unimpaired’, ‘moderately impaired cognition’ and 
‘severely impaired cognition’ – based upon either the final MMSE score prior to death or the 
selection of a case as a control by the MRC London Neurodegenerative Diseases Brain bank). As a 
result it was found that both depression and agitation scores significantly predicted cognitive 
impairment in an inverse manner – the regression values are detailed in figure 4.1.7, part A, and the 
differences in depression and agitation scores are depicted in the scatter plots in this figure (parts B 
and C respectively). One-way ANOVA analysis showed cases without cognitive impairment to have 
significantly lower depression and agitation scores than cases with either moderate or severe 
cognitive impairment. 
The association between pathology and behavioural scores was investigated in the same manner, 
although Pearson’s correlation was used as a screen enabling only those pathology scores that 
correlated to the behavioural score in question to be entered into the regression analysis as 
independent variables. This strategy was adopted, in line with advice from a statistician (Stephen 
Newhouse), due to the large number of different pathology scores and lack of a clear biological 
rationale behind division of these scores into sub-groups during analysis. 
It was found that hallucination scores were predicted by α-synuclein pathology in BA40 in a positive 
manner (figure 4.1.8). Cases without hallucinations had substantially lower levels of α-synuclein 
pathology in the parietal cortex than cases with mild, moderate or frequent/severe hallucination 




Figure 4.1.7 Depression and agitation scores were significant independent predictors of cognitive 
impairment (based upon MMSE score).  
Multiple regression analysis using the semi-quantitative scores for the four behavioural symptoms of 
interest (hallucination, persecution, depression and agitation - coded into absent, mild, moderate or 
severe and assuming control cases to have a score of absent) as independent predictor variables 
found depression and agitation scores to independently predict the cognitive impairment group that 
cases were classified as belonging to – based upon MMSE scores. The ANOVA for the model was 
significant (p<0.001).  The regression values for depression and agitation were p=0.03, Beta = -0.254 
and p=0.042, Beta = -0.236 respectively. Analysis of the differences in depression and agitation 
scores between the MMSE groups was performed using non-parametric Mann Whitney-U tests as 
the homogeneity of variance was significant. Cases in the ‘cognitively normal’ group were found to 
have significantly lower depression scores than cases in the ‘moderately impaired cognition’ and 
‘severely impaired cognition’ groups (W=879.0, Z= -3.833, p=0.00 and W=780.5, Z= -4.441, p<0.001 
respectively). Agitation scores were likewise significantly lower in cases belonging to the ‘cognitively 
normal’ group than cases in either the ‘moderately impaired cognition’ or ‘severely impaired 
cognition’ (W=873.5, Z= -3.612, p<0.001 and W=762.5, Z= -4.527, p<0.001 respectively). The 






Model R R Square 
Adjusted R 
Square 










Model Sum of Squares df Mean Square F Sig. 
1 Regression 17.485 4 4.371 8.871 .000
a
 
Residual 44.347 90 .493   
Total 61.832 94    









t Sig. B Std. Error Beta 
1 (Constant) 2.468 .104  23.770 .000 
Hallucination score -.068 .074 -.089 -.909 .366 
Persecution score -.081 .085 -.101 -.943 .348 
Depression score -.194 .088 -.254 -2.201 .030 
Agitation score -.178 .086 -.236 -2.063 .042 















































































































Figure 4.1.8. The α-synuclein score in BA40 predicted hallucination scores. 
Regression analysis was utilised to determine if there were significant associations between the 
semi-quantitative pathology and behavioural scores. Pearson’s correlation was used to screen for 
pathologies that had significant associations to the hallucination score, these were the α-synuclein 
score in each region and the plaque score in BA24, and were used as independent variables in the 
regression. It was found that the α-synuclein score in BA40 predicted the hallucination score (image 
A), when control cases were included (regression values were beta=0.361, p=0.019). The ANOVA for 
the model was significant (p=0.001). The difference in values for these two pathologies between 
hallucination score groups was analysed using the Mann-Whitney U test, as the homogeneity of 
variance was significant. The α-synuclein score in BA40 was significantly lower in cases without 
hallucinations than cases with mild, moderate or severe hallucinations (graph B; W=1621, Z= -3.093, 
p=0.002, W=1653.5, Z= -3.449, p=0.001 and W=1474.5, Z= -3.867, p<0.001 respectively). The 
horizontal lines within data points represent the mean value. *=p<0.05, **=p<0.01 and ***=p<0.001 
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Square 









Model Sum of Squares df Mean Square F Sig. 
1 Regression 22.829 5 4.566 4.842 .001
a
 
Residual 70.726 75 .943   









t Sig. B Std. Error Beta 
1 (Constant) .387 .186  2.081 .041 
alpha synuclein score for BA24 .076 .126 .085 .601 .549 
alpha synuclein score for BA21 .078 .192 .067 .408 .684 
alpha synuclein score for BA9 .021 .215 .016 .100 .921 
alpha synuclein score for BA40 .550 .230 .361 2.393 .019 
plaque score for BA24 .066 .107 .065 .617 .539 





















































4.2 Analysis of the neuronal and synaptic biochemistry according to clinical diagnosis 
 
4.2.1 Analysis of β-III-tubulin, PSD95, synaptophysin and ZnT3 values in BA9 according to 
clinical diagnosis 
The levels of the four proteins of interest, Btub, PSD95, SPP and ZnT3, in homogenised grey matter 
from BA9, were determined using semi-quantitative Western blotting. The cases were grouped by 
clinical diagnosis into control, PDD, DLB and AD to reveal differences in the relative levels of proteins 
between diagnostic groups, shown in figure 4.2.1. Btub was not significantly altered across any of 
the diagnostic groups; however, figure 4.2.1 shows PDD cases had significantly lower levels of 
PSD95, SPP and ZnT3 than control cases. This reduction was also significant compared to DLB and AD 
cases for PSD95 and SPP, whereas ZnT3 values in DLB cases were significantly lower than controls 
but not significantly different to PDD. PSD95 values in DLB cases were also significantly lower than 
controls, yet significantly higher than PDD. Interestingly, the levels of all 4 proteins in AD cases were 
not significantly different to the control cases. 
To determine the effect of AD (Aβ and tau) pathology on protein levels in PDD and DLB, a regression 
analysis was carried out to examine the effect of AD pathology, and where necessary, to create 
residual variables for the protein in question that accommodate for any significant predicting of the 
protein value by either the plaque or tangle scores. As AD pathology did not significantly predict 
Btub or ZnT3 values this was not done for these proteins.  
Figure 4.2.2 shows these ‘AD pathology residual’ values for PSD95 and SPP, grouped by clinical 
diagnosis. It can be seen that, despite accounting for the relationship between PSD95 and plaques, 
and SPP and tangles, there remains a significant reduction in the levels of both proteins in PDD 
compared to all other diagnostic groups. Additionally, DLB cases continue to have significantly lower 






Figure 4.2.1 Protein values, from semi-quantitative Western blotting in BA9, by diagnosis. 
Statistical analysis was performed using One-way ANOVA and Bonferroni post-hoc test. The 
ANOVA for Btub values (graph A) was significant but there was no difference between groups 
according to the post hoc test. ZnT3 values (graph B) for the control group were significantly 
higher than the PDD (p<0.001) and DLB (p=0.001) groups. PSD95 values (graph B) for the control 
group were significantly higher than the PDD (p<0.001) and DLB (p=0.001) groups. PSD95 values 
for the PDD group were significantly lower than the AD (p=0.012) and DLB (p=0.036) groups. SPP 
values (graph C) for the PDD group were significantly lower than the control (p=0.003), DLB 
(p<0.001) and AD (p<0.001) groups. The AD group SPP values were significantly higher than the 
control group (p=0.005) and DLB group (p=0.009). The ANOVA values are as follows; Btub, 
F=2.819, df=3,111, PSD95; F=12.809, df=3,108, p<0.001, SPP; F=4.862, df=3,97, p=0.003 and 
ZnT3; F=9.409, df=3,111, p<0.001. The horizontal bars within the data points in the graphs 
represent the mean values. 















Figure 4.2.2 SPP and PSD95 protein values, from semi-quantitative Western blotting in BA9, 
expressed as residuals for tangle and plaque scores respectively, and grouped by diagnosis. 
Statistical analysis was performed using One-way ANOVA and Bonferroni post-hoc test. SPP 
tangles residual values were significantly lower in the PDD group compared to the control 
group (p=0.002), DLB group (p=0.002) and AD group (p=0.001). For the ANOVA; F=9.691, df= 
3,99, p<0.001. PSD95 plaque residual values were significantly lower in the PDD group 
compared to the control group (p<0.001), the DLB group (p=0.02) and AD group (p=0.001). 
Control values were significantly higher than DLB values (p=0.01). For the ANOVA; F=11.870, 
df=3,103, p<0.001. There was no significant difference between AD and DLB or control values 





4.2.2 Analysis of β-III-tubulin, PSD95, synaptophysin and ZnT3 values in BA24 according to 
clinical diagnosis 
The levels of the four proteins of interest, Btub, PSD95, SPP and ZnT3, in homogenised grey matter 
from BA24, were determined using semi-quantitative Western blotting. The cases were grouped by 
clinical diagnosis into control, PDD, DLB and AD to reveal differences in the relative levels of proteins 
between diagnostic groups, shown in figure 4.2.3. The only proteins with significant changes in value 
between any of the diagnostic groups were PSD95 and Btub – the former was significantly higher in 
AD cases compared to control and PDD cases, and the latter significantly lower in PDD versus DLB. 
The distribution of some protein values was characterised by a high variance – in particular SPP 
values. Contrastingly, Btub values were particularly clustered. 
To determine the effect of AD (Aβ and tau) pathology on protein levels in PDD and DLB, a regression 
analysis was carried out to examine the effect of AD pathology, and where necessary, to create 
residual variables for the protein in question that accommodate for any significant predicting of the 
protein value by either the plaque or tangle scores. However, AD pathology (plaques and tangles) 
was only a significant predictor of ZnT3. The ZnT3 ‘AD pathology’ residual is shown in the bottom 
graph in figure 4.2.2 – where it can be seen that there was no significant difference in ZnT3 values 




Figure 4.2.3 – Proteins values, obtained from semi-quantitative Western blotting in BA24, by clinical 
diagnosis 
Statistical analysis (One-way ANOVA and Bonferroni post hoc test) confirmed there was no significant 
difference between diagnostic groups for SPP and ZnT3 values (graphs C and D) but showed PSD95 values 
were significantly higher in AD cases compared to control (p=0.037) and PDD cases (p=0.027) (graph B). For 
the ANOVA (PSD95); F=3.745, df=3,100, p=0.013. Btub values were analysed non-parametrically using Mann 
Whitney-U tests, (as the homogeneity of variance was significant) which revealed DLB values to be 
significantly higher than PDD (W=965.0, Z= -2.43, p=0.015) (graph A). There was no significant difference 
between diagnostic groups for the ZnT3 ‘AD pathology’ residual variable (graph E). The horizontal bars within 
the data points on the graphs represent the mean values. 
 














































4.2.3 Analysis of β-III-tubulin, PSD95, synaptophysin and ZnT3 values in BA40 according to 
clinical diagnosis 
The levels of the four proteins of interest, Btub, PSD95, SPP and ZnT3, in homogenised grey matter 
from BA40, were determined using semi-quantitative Western blotting. The cases were grouped by 
clinical diagnosis into control, PDD, DLB and AD to reveal differences in the relative levels of proteins 
between diagnostic groups, shown in figure 4.2.4. AD cases were characterised by significant 
reductions, compared to all other diagnostic groups, for the synaptic and neuronal marker proteins 
PSD95, SPP and Btub - excepting PSD95, which was unchanged between DLB and AD cases. ZnT3 
values were not significantly different between any diagnostic groups.  
To determine the effect of AD (Aβ and tau) pathology on protein levels in PDD and DLB, a regression 
analysis was carried out to examine the effect of AD pathology, and where necessary, to create 
residual variables for the protein in question that accommodate for any significant predicting of the 
protein value by either the plaque or tangle scores. Tangle scores significantly predicted all four 
proteins of interest in BA40 and so residual variables were created to account for this effect (see 
methods section for details). Figure 4.2.5 shows that there was no significant difference in the levels 





Figure 4.2.4 – Btub, PSD95, SPP and ZnT3 values, obtained from semi-quantitative Western blotting 
in BA40, by clinical diagnosis 
Statistical analysis was performed using One-way ANOVA and Bonferroni post-hoc test. Graph A 
shows AD Btub values were significantly lower than all other groups (PDD and control p<0.001, DLB 
p=0.017); DLB Btub values were significantly lower than PDD (p=0.04). AD PSD95 values (graph B) 
were significantly lower than control (p=0.02) and PDD (p=0.005). AD SPP values (graph C) were 
significantly lower than all other diagnostic groups (control and PDD p=0.001, DLB p=0.049). There 
was no significant difference in ZnT3 values between diagnostic groups (graph D). The ANOVA values 
were; Btub, F=11.395, df=3,98, p<0.001, PSD95, F=5.04, df=3,86, p=0.003, SPP, F=6.891, df=3,95, 















Figure 4.2.5 Btub, PSD95, SPP and ZnT3 values, from semi-quantitative Western blotting in BA40, 
expressed as residuals for tangle scores, and grouped by diagnosis. 
The semi-quantitative score for tangles correlated to the values for all four proteins in BA40 and 
significantly predicted the values of each protein. To counter this effect of tangles on the protein 
values residual variables for each protein were created through linear regression analysis and 
normalised by transformation when necessary. Statistical analysis was performed using One-way 
ANOVA and Bonferroni post-hoc test and found no significant difference between any diagnostic 








Analysis of the ratio of the pre and post-synaptic markers SPP and PSD95 to the neuronal marker 
Btub, and of ZnT3 to the pre-synaptic marker SPP, in BA9, according to clinical diagnosis. 
The values obtained from quantification of the Western blots were used to create ratios to 
determine the relative changes in pre and post-synaptic terminals over and above any change in the 
neuronal marker Btub, and to determine the change in ZnT3 levels over and above any change in the 
levels of pre-synaptic terminals. The differences in these ratios in BA9 between diagnostic groups are 
shown in figure 4.2.6. The ratio of SPP to Btub was similar between diagnostic groups – apart from a 
significant increase in AD cases compared to PDD cases. The ratio of PSD95 to Btub was significantly 
lower in PDD and DLB cases verses controls, and unchanged in AD cases. However, the ratio of ZnT3 
to SPP was characterised by significant reductions in all three dementias compared to controls – 
quite substantial in the case of DLB and AD (p=0.001) – which were also reduced relative to PDD 
cases. 
To determine the effect of AD pathology on these ratios a regression analysis was carried out to 
establish whether plaque or tangle scores significantly predicted any of the ratios, and if so, to 
create residual variables for the ratios in question that accommodate for the significant predicting of 
the ratio value by either the plaque or tangle scores. This was carried out for the ratio of ZnT3 to 
SPP, - with respect to the tangle score, shown in the bottom-right graph in figure 4.2.6. When the 
effect of the tangle score was thus statistically compensated, there was no significant difference in 










Figure 4.2.6 Ratio of SPP to Btub, PSD95 to Btub and ZnT3 to SPP in BA9 grouped by diagnosis. 
Analysis was carried out using one-way ANOVA and Bonferroni post-hoc test. The ratio of SPP to 
Btub (graph A) was significantly higher in AD cases compared to PDD cases (p=0.005). The ANOVA 
values were; F=4.862, df=3,97, p=0.003. The ratio of PSD95 to Btub (graph B) was significantly higher 
in control cases compared to PDD (p=0.004) and DLB (p=0.007) cases. ANOVA values were; F=5.23, 
df=3,101, p=0.002. The homogeneity of variance for the ratio of ZnT3 to SPP was significant and so 
non-parametric analysis (Mann Whitney-U) was used and showed significantly higher values in 
control cases compared to PDD (W=650.0, Z= -2.183, p=0.029), DLB (W820.0, Z= -3.378, =p=0.001) 
and AD cases (W=207.0, Z= -3.226, p=0.001), and in PDD cases compared to DLB (w=972.0, Z= -2.232, 
p=0.026) and AD cases (W=273.0, Z= -2.253, p=0.024) (graph C). There was no significant difference 
between diagnostic groups for the ‘tangle residual’ ZnT3 to SPP ratio (graph D). Horizontal bars 






4.2.4 Analysis of the ratio of the pre and post-synaptic markers SPP and PSD95 to the 
neuronal marker Btub, and of ZnT3 to the pre-synaptic marker SPP, in BA24, according 
to clinical diagnosis. 
The values obtained from quantification of the Western blots were used to create ratios to 
determine the relative changes in pre and post-synaptic terminals over and above any change in the 
neuronal marker Btub, and to determine the change in ZnT3 levels over and above any change in the 
levels of pre-synaptic terminals. The differences in these ratios in BA24 between diagnostic groups 
are shown in figure 4.2.7. The only significant change for any of the ratios was that of PSD95 to Btub 
in AD cases – which were increased in comparison to the other diagnostic groups. There was no 
significant relationship between AD pathology in BA24 and these ratios and so no further 



















































































































Figure 4.2.7 The ratios of SPP to 
Btub, PSD95 to Btub and ZnT3 to SPP 
by diagnostic group in BA24 
Analysis of the difference between 
the protein ratios across diagnostic 
groups was performed using one-
way ANOVA and Bonferroni post-hoc 
tests when the test for homogeneity 
of variance was met – which was the 
case for the ratio of PSD95 to Btub 
and the ratio of ZnT3 to SPP. The 
homogeneity of variance was 
significant for the ratio of SPP to 
Btub and so nonparametric analysis 
was used, which showed no 
significant difference between 
diagnostic groups (graph A). The 
ratio of PSD95 to Btub was 
significantly higher in AD cases 
compared to control (p=0.043), PDD 
(p=0.037) and DLB (p=0.035) cases 
(graph B). The ANOVA values were; 
F=3.437, df=3,89, p=0.02. Whilst the 
ANOVA for the ratio of ZnT3 to SPP 
was significant (F=2.928, df=3,124 
p=0.036) there was no significant 
difference between diagnostic 
groups according to the Bonferroni 







4.2.5 Analysis of the ratio of the pre and post-synaptic markers SPP and PSD95 to the 
neuronal marker Btub, and of ZnT3 to the pre-synaptic marker SPP, in BA40, according 
to clinical diagnosis. 
The values obtained from quantification of the Western blots were used to create ratios to 
determine the relative changes in pre and post-synaptic terminals over and above any change in the 
neuronal marker Btub, and to determine the change in ZnT3 levels over and above any change in the 
levels of pre-synaptic terminals. The differences in these ratios in BA40 between diagnostic groups 
are shown in figure 4.2.8. There was no significant difference in the ratios of SPP or PSD95 to Btub 
between diagnostic groups; however, the ratio of ZnT3 to SPP was significantly lower in DLB cases 
than all other cases. There was no significant relationship between AD pathology in BA40 and the 
ratios described above, and so no further investigation was undertaken into any effect AD pathology 



























































































































Figure 4.2.8 Ratio of SPP to Btub, 
PSD95 to Btub and ZnT3 to SPP 
values, derived from semi-
quantitative western blotting in 
BA40, and grouped by diagnosis. 
Analysis was carried out using one-
way ANOVA and Bonferroni post-hoc 
test for SPP to Btub and PSD95 to 
Btub and revealed no significant 
difference between diagnostic 
groups (graphs A and B respectively), 
although the ANOVA was significant 
for the ratio of SPP to Btub (F=2.854, 
df=3,86, p=0.041). The homogeneity 
of variance was significant for the 
ratio of ZnT3 to SPP and so the non-
parametric Mann-Whitney U test 
was used for analysis, and showed 
the ratio of ZnT3 to SPP (graph C) 
was significantly lower in DLB cases 
compared to controls (W=472.0, Z= -
2.353, p=0.019) and AD (W=397.0, 
Z= -3.016, p=0.002) cases and PDD 
cases (W=521.5, Z= -3.148, p=0.002). 
Horizontal bars within the data 







4.3 Relationships between clinical data and synaptic and neuronal biochemistry 
from semi-quantitative Western blotting 
 
Regression analysis was undertaken to investigate the relationship between the proteins of interest 
and the behavioural symptom scores. Each brain region was analysed separately to avoid contrasting 
patterns of increased or decreased levels for the same protein in different regions masking an effect 
on a symptom, and due to biological rationale linking some symptoms to a brain region (see 
discussion).  
When regression analysis was performed using the values from semi-quantitative Western blotting 
(after statistical processing) for Btub, PSD95, SPP and ZnT3 in BA9 as independent predictor variables 
for the depression score, including control cases under the assumption they did not have 
depression, it was found that ZnT3 values in BA9 significantly predicted the severity of depression. 
This predictive relationship was inverse, indicated by the negative beta value, such that a decrease in 
ZnT3 value related to an increase in incident of depression. The output from the regression analysis 
and a graphic depiction of the relationship between ZnT3 in BA9 and depression score is shown in 
figure 4.3.1. The scatter plot highlights the difference in ZnT3 values between the depression score 
groups, which was significantly higher in cases with no depression than cases with a score of severe. 
Regression analysis using values from semi-quantitative Western blotting (after statistical 
processing) for Btub, PSD95, SPP and ZnT3 in BA40 as independent predictor variables for the 
hallucination score established the SPP value to be a significant predictor, in a direct manner, 
indicated by the positive beta value. Thus, an increase in SPP value related to an increase in the 
incident of hallucinations. Control cases were excluded from this analysis as they were characterised 
by low hallucination scores and high SPP values, relative to dementia cases, and therefore masked 
the relationship between hallucinations and SPP observed in dementia cases. Figure 4.3.2 shows the 
values from the regression analysis and a scatter plot depicting the SPP values by hallucination score 
157 
 




Figure 4.3.1 ZnT3 levels, obtained from semi-quantitative Western blotting in BA9, predict 
depression. 
Depression in dementia (DLB, PDD and AD) cases and control cases was significantly predicted by 
ZnT3 values from semi-quantitative Western blotting in BA9. (Beta= -0.358, p=0.002). Analysis was 
performed using multiple regression with SPP, PSD95, Btub and ZnT3 as independent predictor 
variables, according to the analysis strategy. The ANOVA for the model was significant (p=0.001, 
Rsq= 0.207) suggesting that the proteins have a combined predictive effect on depression scores. 
One-way ANOVA and Bonferroni post-hoc analysis showed ZnT3 levels to be significantly higher in 
cases without depression compared to cases with severe depression (p=0.018). The ANOVA values 
were; F=4.534, df=3,91, p=0.005). The horizontal bars within the data points represent the mean. 
 
Model Summary 
Model R R Square Adjusted R 
Square 










Model Sum of 
Squares 
df Mean Square F Sig. 
1 
Regression 17.474 4 4.368 4.889 .001
b
 
Residual 67.014 75 .894 
  
Total 84.487 79 
   




Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 
(Constant) 2.089 .755 
 
2.766 .007 
Btub (relative units) -1.421 .817 -.185 -1.739 .086 
ZnT3 (relative units) -1.355 .423 -.358 -3.203 .002 
PSD95 (relative units) -.682 .482 -.154 -1.414 .161 
SPP (relative units) .773 .879 .098 .879 .382 



























Figure 4.3.2 SPP levels in BA40, from semi-quantitative Western blotting, predict hallucinations 
within dementia cases. 
Multiple regression analysis (with Btub, PSD95, SPP and ZnT3 values from semi-quantitative Western 
blotting as independent variables/predictors) showed that hallucinations in dementia cases only 
(DLB, PDD and AD) were significantly predicted by SPP values in BA40 (Beta=0.475, p=0.005). 
Analysis was performed using multiple regression with SPP, PSD95, Btub and ZnT3 as independent 
predictor variables, according to the analysis strategy. The ANOVA for the model was significant 
(p=0.031, Rsq=0.191) suggesting that the proteins have a combined predictive effect on 
hallucination scores. One-way ANOVA and Bonferroni post-hoc analysis showed SPP levels to be 
significantly higher in cases with severe hallucinations compared to cases without hallucinations (a 
score of absent) p=0.017; ANOVA: F=3.479, (df=3,68), p=0.021. The horizontal bars within the data 
points represent the mean. 
 
Model Summary 
Model R R Square Adjusted R Square Std. Error of the 
Estimate 




Model Sum of Squares df Mean Square F Sig. 
1 
Regression 12.767 4 3.192 2.894 .031b 
Residual 54.048 49 1.103 
  
Total 66.815 53 
   
a. Dependent Variable: Hallucination (NPI coded; dementia cases only) 
 
Coefficientsa 
Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 
(Constant) -.913 .724 
 
-1.261 .213 
SPP (relative units) 2.489 .841 .475 2.959 .005 
PSD95 (relative units) .295 .884 .056 .334 .740 
Btub (relative units) -.645 .561 -.183 -1.151 .255 
ZnT3 (relative units) .268 .746 .056 .359 .721 



















































Cases were classified into groups according to the degree of cognitive impairment using either the 
final MMSE score prior to death, or acceptance by the MRC London Neurodegenerative Diseases 
Brain bank as a control case.  The groups were; control cases, cognitively normal/MCI (MMSE of 25 
to 30 but diagnoses as dementia), dementia with mild cognitive impairment (as opposed to MCI, 
MMSE of 17 to 24), moderately impaired cognition (MMSE of 10 to 16) and severely impaired 
cognition (MMSE of 9 or less), (see the methods section for details about the creation of these 
groups). It was found, using regression analysis, that PSD95 and ZnT3 values in BA9 significantly 
predicted cognitive impairment, in an inverse manner. This is illustrated in figure 4.3.3. The ratios of 
PSD95 to Btub and of ZnT3 to SPP in BA9 were also significant predictors of cognitive impairment, 
shown in figure 4.3.4. The distribution, between cognitive impairment groups, of all proteins of 
interest and protein ratios, in each brain region, was analysed by one-way ANOVA and Bonferroni 
post-hoc test. Scatter plots for the proteins that had significantly different levels between ‘cognitive 
impairment’ groups are shown in figure 4.3.5. SPP values in BA40 were significantly lower in cases 
classified as having severely impaired cognition compared to cases without cognitive impairment, 
but not significantly different for cases classified as having moderate cognitive impairment to either 
of the other groups. ZnT3 and PSD95 values in BA9 were significantly lower in cases classified as 
having severe cognitive impairment and moderate cognitive impairment compared to cases without 
cognitive impairment. Figure 4.3.3 shows the values from the regression analysis and a scatter plot 
depicting the ZNT3 to SPP ratio by MMSE group – cases with MMSE scores meriting classification as 





Figure 4.3.3. PSD95 and ZnT3 values in BA9 predict disease severity based upon the classification of 
cognitive impairment. 
Regression analysis using the values for Btub, PSD95, SPP and ZnT3 from BA9 as independent 
predictor variables showed PSD95 and ZnT3 values to be significant predictors of the cognitive 
impairment group, which is a marker for disease severity (beta= -0.246, p=0.021 and beta= -0.377, 
p=0.001 respectively). The ANOVA for the model was significant (p<0.001). The cognitive impairment 
groups were; ‘controls’ (assigned a value of 1 and including all designated control cases), 
‘MCI/normal’ (dementia cases assigned a value of 2 and based on a MMSE score of 25 to 30), ‘mild 
dementia’ (assigned a value of 3 and based upon a MMSE score of 17 to 24), ‘moderate dementia’ 
(assigned a value of 4 and based upon a MMSE score of 10 to 16) and ‘severe dementia’ (assigned a 
value of 5 and based upon a MMSE score of 9 or less). The difference in PSD95 and ZnT3 values 
between cognitive impairment groups was analysed by one-way ANOVA and the Bonferroni post-
hoc test, which revealed ZnT3 values to be significantly higher in controls compared to cases with 
severe dementia (p=0.003), moderate dementia (p=0.001), mild dementia (p=0.021) and 
MCI/normal cognition (p=0.044). PSD95 values were calculated to be significantly higher in control 
cases than in cases with moderate dementia (p<0.001) and severe dementia (p=0.003). The ANOVA 
values were; F=6.043, df=4,90, p<0.001 for PSD95 and F=5.731, df=4,95, p<0.001 for ZnT3. The 






Model R R Square 
Adjusted R 
Square 










Model Sum of Squares df Mean Square F Sig. 
1 Regression 51.236 4 12.809 6.994 .000
a
 
Residual 141.020 77 1.831   
Total 192.256 81    









t Sig. B Std. Error Beta 
1 (Constant) 4.063 1.112  3.655 .000 
Btub (relative units) -.914 1.202 -.080 -.760 .450 
ZnT3 (relative units) -2.152 .594 -.377 -3.624 .001 
PSD95 (relative units) -1.621 .685 -.246 -2.366 .021 

































































































Figure 4.3.4 The ratio of ZnT3 to SPP in BA9, from semi-quantitative Western blotting, predicts the 
degree of cognitive impairment. 
Regression analysis using the three protein ratio variables from BA9 (SPP to Btub, PSD95 to Btub and 
ZnT3 to SPP) as independent predictor variables showed the ratio of ZnT3 to SPP to be a significant 
predictor of cognitive impairment (beta= -0.325, p=0.006). The ANOVA for the model was significant 
(p=0.003). The cognitive impairment groups were; ‘controls’ (assigned a value of 1 and including all 
designated control cases), ‘MCI/normal’ (dementia cases assigned a value of 2 and based on a MMSE 
score of 25 to 30), ‘mild dementia’ (assigned a value of 3 and based upon a MMSE score of 17 to 24), 
‘moderate dementia’ (assigned a value of 4 and based upon a MMSE score of 10 to 16) and ‘severe 
dementia’ (assigned a value of 5 and based upon a MMSE score of 9 or less). The difference in the 
distribution of the three protein ratios between cognitive impairment groups was analysed by one-
way ANOVA and the Bonferroni post-hoc test, which revealed the ratio of ZnT3 to SPP to be 
significantly higher in control cases compared to cases with severe cognitive impairment (p=0.003), 
moderate cognitive impairment (p=0.009) and cases classified as MCI/normal (p=0.04). The ANOVA 
values were; F=4.886, df=4,88, p=0.001. The ratio of PSD95 to Btub was significantly higher in control 
cases compared to cases with moderate cognitive impairment (p=0.01). The ANOVA values were; 









Model R R Square 
Adjusted R 
Square 










Model Sum of Squares df Mean Square F Sig. 
1 Regression 31.708 3 10.569 5.135 .003
a
 
Residual 160.548 78 2.058   
Total 192.256 81    









t Sig. B Std. Error Beta 
1 (Constant) 6.779 1.268  5.346 .000 
Ratio of SPP to Btub -.933 1.036 -.106 -.900 .371 
Ratio of PSD94 to Btub -1.064 .689 -.178 -1.544 .127 





















































































































Figure 4.3.5. ZnT3 values in BA40 predict disease severity, based upon the classification of cognitive 
impairment. 
Regression analysis using the values for Btub, PSD95, SPP and ZnT3 from BA40 as independent 
predictor variables showed ZnT3 values to be a significant predictor of the cognitive impairment 
group (beta= -0.415, p=0.003), used as an indicator of disease severity. The ANOVA for the model 
was significant (p=0.004). The cognitive impairment groups were; ‘controls’ (assigned a value of 1 
and including all designated control cases), ‘MCI/normal’ (dementia cases assigned a value of 2 and 
based on a MMSE score of 25 to 30), ‘mild dementia’ (assigned a value of 3 and based upon a MMSE 
score of 17 to 24), ‘moderate dementia’ (assigned a value of 4 and based upon a MMSE score of 10 
to 16) and ‘severe dementia’ (assigned a value of 5 and based upon a MMSE score of 9 or less). The 
difference ZnT3 values between cognitive impairment groups was not found to be significantly 
different according to a Kruskal Wallis test (p=0.093). The scatter plot depicts the relationship 




Model R R Square 
Adjusted R 
Square 










Model Sum of Squares df Mean Square F Sig. 
1 Regression 34.258 4 8.565 4.235 .004
a
 
Residual 125.384 62 2.022   
Total 159.642 66    









t Sig. B Std. Error Beta 
1 (Constant) 3.964 .808  4.907 .000 
SPP (relative units) -.716 .930 -.109 -.770 .444 
PSD95 (relative units) .340 .984 .050 .346 .731 
Btub (relative units) -.605 .666 -.121 -.907 .368 




















































































Figure 4.3.6 The ratio of ZnT3 to SPP in BA40, from semi-quantitative Western blotting, predicts the 
degree of cognitive impairment. 
Regression analysis using the three protein ratio variables from BA40 (SPP to Btub, PSD95 to Btub and 
ZnT3 to SPP) as independent predictor variables showed the ratio of ZnT3 to SPP to be a significant 
predictor of cognitive impairment (beta= -0.311, p=0.021). The ANOVA for the model was significant 
(p=0.032). The cognitive impairment groups were; ‘controls’ (assigned a value of 1 and including all 
designated control cases), ‘MCI/normal’ (dementia cases assigned a value of 2 and based on a MMSE 
score of 25 to 30), ‘mild dementia’ (assigned a value of 3 and based upon a MMSE score of 17 to 24), 
‘moderate dementia’ (assigned a value of 4 and based upon a MMSE score of 10 to 16) and ‘severe 
dementia’ (assigned a value of 5 and based upon a MMSE score of 9 or less). The difference in the 
distribution of the three protein ratios between cognitive impairment groups was not significantly 




Model R R Square 
Adjusted R 
Square 










Model Sum of Squares df Mean Square F Sig. 
1 Regression 20.620 3 6.873 3.115 .032
a
 
Residual 139.021 63 2.207   
Total 159.642 66    








t Sig. B Std. Error Beta 
1 (Constant) 3.287 .184  17.890 .000 
Ratio of SPP to Btub 1.915 1.614 .169 1.187 .240 
Ratio of ZnT3 to SPP -1.638 .693 -.311 -2.365 .021 





















































4.4 Relationships between pathology, and synaptic and neuronal 
biochemistry. 
 
When investigating the relationships between the pathology data; in the form of semi-quantitative 
scores for Aβ staining (plaque pathology), tau staining (tangle pathology) and α-synuclein 
staining/pathology, and the biochemical data, the reciprocal nature of this relationship became 
apparent. Many of the synaptic proteins measured in this study were decreased in cases with more 
severe pathology scores, yet there are biological arguments for neuronal proteins precipitating 
aggregation of pathological proteins, as there are counter arguments for pathological deposits 
causing damage to, and reductions in, synaptic and neuronal proteins. Thus, there is a valid case for 
using pathology scores as predictors of synaptic biochemistry values and vice versa. However, in the 
majority of instances only one combination gave a statistically significant result, and this has been 
reported. The exception was the relationship between tangles and PSD95 and Btub in BA40, in which 
the prediction was reciprocal. Therefore the stronger relationship, both in terms of statistics and 
biological rationale, was reported. 
Regression analysis was performed using the semi-quantitative scores for the three pathology types 
(plaques, tangles and α-synuclein) in BA9 as independent predictor variables for each of the proteins 
of interest (Btub, PSD95, SPP and ZnT3) derived from semi-quantitative Western blotting. This 
established the tangle score to be a significant predictor of SPP values in BA9 – with a direct 
relationship, indicated by the positive beta value, such that a decrease in the tangle score related to 
a decrease in the SPP value. Figure 4.4.1 shows the values from the regression analysis and a scatter 
plot depicting SPP values according to tangle score group, whilst a trend of increasing SPP values 
with increasing tangle score can be detected it was not statistically significant according to post hoc 
test. 
Regression analysis using the values for the proteins of interest as predictors of pathology did not 
reveal any significant relationships. However, similar analysis using the ratios of SPP to Btub, PSD95 
174 
 
to Btub and ZnT3 to SPP as independent predictor variables for each of the types of semi-
quantitative pathology scores found the ratio of ZnT3 to SPP in BA9 to predict both the tangle and 
plaque scores. Figure 4.4.2 shows the inverse relationship between the ratio of ZnT3 to SPP and the 
plaque score in BA9 – evinced by the negative beta value from the regression analysis, and depicted 
graphically by the scatter plot showing a significantly lower ratio of ZnT3 to SPP in cases with severe 
tangle score to cases with a plaque score of moderate or none. Similarly, figure 4.4.3 shows the 
inverse relationship between the ratio of ZnT3 to SPP and tangle score, with a table of output from 
the regression analysis and a scatter plot illustrating the significantly higher ratio of ZnT3 to SPP in 
cases with no tangles compared to cases with moderate of severe tangle scores. None of the 




Figure 4.4.1. The semi-quantitative tangle score predicted SPP values (from semi-quantitative 
Western blotting) in BA9.  
Regression analysis, using the semi-quantitative scores for the three types of pathology assessed in 
each brain region (Aβ, tau and α-synuclein) as independent predictor variables, showed the tangle 
(tau) score to be a significant predictor of SPP values (obtained from semi-quantitative Western 
blotting) in BA9 (beta= 0.319, p=0.011). The ANOVA for the regression model was significant 
(p=0.016). The difference in SPP values between tangle score groups was analysed by one-way 
ANOVA and the Bonferroni post-hoc test, whilst the ANOVA was significant – the post hoc test found 
no differences between specific groups (F=2.956, df=3,99, p=0.036). The horizontal bars within the 
data points in the graph represent the mean values. 
Model Summary 
Model R R Square 
Adjusted R 
Square 










Model Sum of Squares df Mean Square F Sig. 
1 Regression .174 3 .058 3.614 .016
a
 
Residual 1.537 96 .016   
Total 1.711 99    









t Sig. B Std. Error Beta 
1 (Constant) -.051 .022  -2.300 .024 
plaque score for BA9 -.001 .013 -.008 -.069 .945 
tangle score for BA9 .041 .016 .319 2.603 .011 
alpha synuclein score for BA9 -.011 .014 -.080 -.825 .412 



































Figure 4.4.2 The ratio of ZnT3 to SPP (relative units), from semi-quantitative Western blotting, 
predicted the plaque score in BA9 
Regression analysis using the 3 protein ratio variables from BA9 (SPP to Btub, PSD95 to Btub and 
ZnT3 to SPP) as independent predictor variables showed the ratio of ZnT3 to SPP to be a significant 
predictor of the semi-quantitative plaque score in BA9 (beta= -0.323, p=0.006). The ANOVA for the 
model was significant (p=0.002). The difference between plaque score groups was analysed by one-
way ANOVA and the Bonferroni post-hoc test, which revealed the ratio of ZnT3 to SPP to be 
significantly lower in cases with a severe plaque score compared to cases with a plaque score of 
absent and moderate (p=0.001, p=0.027), for the ANOVA; F=5.893, (df=3,94), p=0.001. The 
horizontal bars within the data points in the graph represent the mean values. 
 
Model Summary 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 





Model Sum of Squares df Mean Square F Sig. 
1 Regression 19.900 3 6.633 5.242 .002a 
Residual 102.500 81 1.265   
Total 122.400 84    








t Sig. B Std. Error Beta 
1 (Constant) 1.449 .123  11.807 .000 
Ratio of SPP to Btub (relative units) -.068 .786 -.010 -.087 .931 
Ratio of PSD to BTUB (relative units) -.857 .537 -.183 -1.596 .114 
Ratio of ZnT3 to SPP (relative units) -1.459 .513 -.323 -2.846 .006 






























































Figure 4.4.3 The ratio of ZnT3 to SPP (relative units), from semi-quantitative Western blotting, 
predicted the tangle score in BA9 
Regression analysis using the three protein ratio variables from BA9 (SPP to Btub, PSD95 to Btub and 
ZnT3 to SPP) as independent predictor variables showed the ratio of ZnT3 to SPP to be a significant 
predictor of the semi-quantitative tangle score in BA9 (beta= -0.319, p=0.008). The ANOVA for the 
model was significant (p=0.023). The difference between plaque score groups was analysed by one-
way ANOVA and the Bonferroni post-hoc test, which revealed the ratio of ZnT3 to SPP to be 
significantly lower in cases with a severe plaque score compared to cases with a plaque score of 
absent and moderate (p=0.001, p=0.027), for the ANOVA; F=5.893, (df=3,94), p=0.001. Analysis of 
the differences in ZnT3 to SPP ratio between tangle score groups was carried out using the non-
parametric Mann Whitney U test as the homogeneity of variance was significant. Cases with no 
tangles had a significantly higher ratio of ZnT3 to SPP than cases with moderate or severe tangle 
scores (W=223, Z= -2.303, p=0.021 and W=253, Z= -2.28, p=0.023). The horizontal bars within the 
data points in the graph represent the mean values. 
Model Summary 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .330a .109 .076 1.004 
 
ANOVAb 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 10.101 3 3.367 3.337 .023a 
Residual 82.737 82 1.009   
Total 92.837 85    







t Sig. B Std. Error Beta 
1 (Constant) .904 .109  8.305 .000 
Ratio of SPP to Btub (relative units) .189 .693 .033 .273 .786 
Ratio of PSD to BTUB (relative units) .010 .482 .002 .020 .984 






























































The relationships between the pathology scores and proteins and protein ratios in BA24 were 
investigated in the same manner as in BA9, with the same combinations of variables (likewise for 
BA40). It was found that the values for PSD95 and ZnT3 significantly and independently predicted 
both the plaque score and the tangle score in BA24. Figure 4.4.4 shows the regression output for 
prediction of plaque score. PSD95 had a direct relationship to plaque score whilst ZnT3 had an 
inverse relationship; this was also the case for tangle scores – shown in figure 4.4.5. The scatter plots 
in figure 4.4.4 reflect this; showing that there was no significant difference between PSD95 values 
for the different plaque scores – yet a trend of increasing PSD95 value as plaque score increased. 
Conversely, the scatter plot for ZnT3 shows significantly lower ZnT3 values in cases with a plaque 
score of severe compared to cases with a plaque score of none. 
The relationship between PSD95 and ZnT3 values and tangle score is shown in figure 4.4.5. The 
scatter plots illustrate the non-significant trends present for both proteins which mirror the positive 
and negative beta values for PSD95 and ZnT3 respectively – with PSD95 values increasing as tangle 




Figure 4.4.4 PSD95 and ZnT3 levels, from semi-quantitative Western blotting, predict plaque scores 
in BA24. 
Regression analysis, using the values obtained from semi-quantitative Western blotting for the 
proteins of interest (Btub, PSD95, SPP and ZnT3) as independent predictor variables, showed PSD95 
and ZnT3 to be significant predictors of the semi-quantitative plaque score in BA24 (beta= 0.251, 
p=0.034 and beta= -0.346, p=0.003). The ANOVA for the model was significant (p=0.01). The 
difference  in ZnT3 and PSD95 values between plaque score groups was analysed by one-way ANOVA 
and the Bonferroni post-hoc test, which revealed ZnT3 values to be significantly lower in cases with a 
severe plaque score compared to cases with a plaque score of absent (p=0.029), for the ANOVA; 
F=3.331, (df=3,91), p=0.023. There was no significant difference in PSD95 values between plaque 
score groups. The horizontal bars within the data points in the graphs represent the mean values. 
 
Model Summary 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 




Model Sum of Squares df Mean Square F Sig. 
1 Regression 14.201 4 3.550 3.569 .010a 
Residual 75.602 76 .995   
Total 89.802 80    








t Sig. B Std. Error Beta 
1 (Constant) .259 .393  .657 .513 
PSD95 (relative units) 1.110 .513 .251 2.163 .034 
ZnT3 (relative units) -1.514 .484 -.346 -3.127 .003 
Btub (relative units) .809 .855 .108 .947 .347 
SPP (relative units) -.023 .118 -.022 -.196 .845 



































































Figure 4.4.5 PSD95 and ZnT3 values, from semi-quantitative Western blotting, predicted tangle score 
in BA24. 
Regression analysis, using the values obtained from semi-quantitative Western blotting for the 
proteins of interest (Btub, PSD95, SPP and ZnT3) as independent predictor variables, showed PSD95 
and ZnT3 to be significant predictors of the semi-quantitative tangle score in BA24 (beta= 0.337, 
p=0.003 and beta= -0.303, p=0.006). The ANOVA for the model was significant (p=0.007). The 
difference in ZnT3 and PSD95 values between tangle score groups was analysed by one-way ANOVA 
and the Bonferroni post-hoc test, which revealed no significant difference in the values of either 
protein between tangle score groups. The horizontal bars within the data points in the graphs 
represent the mean values. 
 
Model Summary 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 




Model Sum of Squares df Mean Square F Sig. 
1 Regression 11.750 4 2.938 3.831 .007a 
Residual 60.571 79 .767   
Total 72.321 83    








t Sig. B Std. Error Beta 
1 (Constant) -.143 .337  -.423 .673 
PSD95 (relative units) 1.332 .442 .337 3.016 .003 
ZnT3 (relative units) -1.166 .415 -.303 -2.810 .006 
Btub (relative units) .356 .742 .054 .480 .632 
SPP (relative units) -.032 .101 -.035 -.317 .752 


































































Btub and tangles have an intertwined relationship in BA40 – with the values (or score) for each 
predicting the other. Figure 4.4.6 contains the output from the regression analysis in which Btub 
values significantly predicted tangle score in BA40 in an inverse manner, and a scatter plot depicting 
the significantly lower Btub values found in cases with a tangle score of severe compared to cases 
with a tangle score of none or sparse. Figure 4.4.7 illustrates the reciprocal relationship in which the 
tangle score in BA40 significantly predicted Btub values. In addition, it was found that the tangle 




Figure 4.4.6 The semi-quantitative tangle score predicted PSD95 and Btub values (obtained from 
semi-quantitative Western blotting) in BA40. 
Regression analysis, using the semi-quantitative scores for the three types of pathology assessed in 
each brain region (Aβ, tau and α-synuclein) as independent predictor variables, showed the tangle 
(tau) score to be a significant predictor of PSD95 and Btub values (obtained from semi-quantitative 
Western blotting) in BA40 (beta= -0.400, p=0.003 and beta= -418, p=0.002). The ANOVAs for both 
regression models were significant (p=0.001). The difference in PSD95 values between tangle score 
groups was analysed by one-way ANOVA and the Bonferroni post-hoc test, which showed cases with 
no tangles to have higher PSD95 levels than cases with a tangle score of frequent or moderate 
(p=0.003 and p=0.006); for the ANOVA, F=7.456, (df=3,83), p<0.001. The differences between Btub 
values for tangle scores categories is described statistically and depicted graphically in the preceding 
figure. The horizontal bars within the data points in the graph represent the mean values. 
Model Summary 
Model R R Square Adjusted R Square Std. Error of the 
Estimate 




Model Sum of Squares df Mean Square F Sig. 
1 
Regression .701 3 .234 5.955 .001b 
Residual 3.061 78 .039 
  
Total 3.762 81 
   




Model Unstandardized Coefficients Standardized 
Coefficients 
T Sig. 
B Std. Error Beta 
1 
(Constant) .072 .035 
 
2.055 .043 
plaque score for BA40 -.009 .024 -.051 -.394 .695 
tangle score for BA40 -.082 .027 -.400 -3.105 .003 









Model R R Square Adjusted R Square Std. Error of the 
Estimate 





Model Sum of Squares df Mean Square F Sig. 
1 
Regression 1.186 3 .395 5.690 .001b 
Residual 6.113 88 .069 
  
Total 7.299 91 
   





Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 
(Constant) .047 .045 
 
1.061 .292 
plaque score for BA40 .009 .032 .039 .299 .766 
tangle score for BA40 -.108 .034 -.418 -3.220 .002 
alpha synuclein score for BA40 .043 .036 .119 1.198 .234 
       



























































To determine the relationship between the protein ratios and pathology in BA40 regression analysis 
was performed using the protein ratios as predictor variables for the pathology scores and vice 
versa. It was found that the tangle score was significantly predicted by both the ratio of SPP to Btub 
(in a direct manner) and of PSD95 to Btub (in an inverse manner) – the values for the regression 
analysis are shown in figure 4.4.8, as are scatter plots depicting the distribution of the ratios of SPP 
to Btub and PSD95 to Btub according to tangle score. 
It was also found that the ratio of ZnT3 to SPP significantly predicted the α-synuclein score in BA40 in 
an inverse manner - the values for this regression analysis are shown in figure 4.4.9, as is a scatter 
plot depicting the distribution of the ratio of ZnT2 to SPP according to α-synuclein score. 




Figure 4.4.7 The ratio of SPP to Btub and PSD95 to Btub, obtained from semi-quantitative Western 
blot analysis, predicted the tangle score in BA40 
Regression analysis using the three protein ratio variables from BA40 (SPP to Btub, PSD95 to Btub 
and ZnT3 to SPP) as independent predictor variables showed the ratio of SPP to Btub, and the ratio 
of PSD95 to Btub, to be significant predictors of the semi-quantitative tangle score in BA40 (beta= 
0.467, p=0.002 and beta= -0.361, p=0.023). The ANOVA for the model was significant (p=0.011). The 
differences in the ratio of SPP to Btub, and PSD95 to Btub, between tangle score groups was 
analysed by one-way ANOVA and the Bonferroni post-hoc test, which revealed no significant 
differences. The horizontal bars within the data points in the graphs represent the mean values. 
 
Model Summary 
Model R R Square Adjusted R Square Std. Error of the 
Estimate 
1 .393a .155 .116 .981 
 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 11.621 3 3.874 4.021 .011b 
Residual 63.579 66 .963 
  
Total 75.200 69 
   
a. Dependent Variable: tangle score for BA40 
 
Coefficientsa 
Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 
(Constant) .789 .118 
 
6.671 .000 
Ratio of SPP to Btub (relative units) 3.511 1.065 .467 3.298 .002 
Ratio of ZnT3 to SPP (relative units) .123 .453 .035 .271 .787 
Ratio of PSD95 to Btub (relative units) -1.391 .596 -.361 -2.335 .023 





















































































Figure 4.4.8 The ratio of ZnT3 to SPP, obtained from semi-quantitative Western blotting, predicted 
the α-synuclein score for BA40. 
Regression analysis using the 3 protein ratio variables from BA40 (SPP to Btub, PSD95 to Btub and 
ZnT3 to SPP) as independent predictor variables showed the ratio of ZnT3 to SPP to be a significant 
predictor of the semi-quantitative alpha synuclein score in BA40 (beta= -0.430, p=0.002). The 
ANOVA for the model was significant (p=0.008). The differences in the ratio of ZnT3 to SPP between 
alpha synuclein score groups was analysed by one-way ANOVA and the Bonferroni post-hoc test, 
which revealed no significant differences. The horizontal bars within the data points in the graph 




Model R R Square Adjusted R Square Std. Error of the 
Estimate 
1 .410a .168 .129 .691 
 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 6.172 3 2.057 4.304 .008b 
Residual 30.592 64 .478 
  
Total 36.765 67 
   
a. Dependent Variable: alpha synuclein score for BA40 
 
Coefficientsa 
Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 
(Constant) .574 .084 
 
6.812 .000 
Ratio of SPP to Btub (relative units) .331 .764 .062 .434 .666 
Ratio of ZnT3 to SPP (relative units) -1.084 .327 -.430 -3.313 .002 
Ratio of PSD95 to Btub (relative units) .304 .425 .112 .715 .477 




























































4.5 Measurement of drebrin in BA9 by ELISA and its relationship to alpha 
synuclein pathology. 
 
The relationship between drebrin concentration, quantified by ELISA in BA9, and pathology was 
determined by regression analysis. It was found that the semi-quantitative α-synuclein score in BA9 
significantly predicted drebrin concentration (expressed as the log10 of the ng per µg of total 
protein) in a direct manner – evinced by the positive beta coefficient shown in the table of 
regression values in figure 4.5.1. The scatter plot in figure 4.5.1 shows the trend of drebrin 
concentration increasing with α-synculein score. 
Drebrin concentration was not significantly different between control, DLB, PDD and AD cases 
despite higher mean values for DLB and PDD than control and AD. However, when PDD and DLB 
cases were combined into a Lewy body dementia (LBD) group, the drebrin concentration was 




Figure 4.5.1. In BA9 the semi-quantitative α-synuclein score significantly predicted drebrin values 
obtained from ELISA. 
The relationship between the three pathologies (α-synuclein, plaques and tangles) and drebrin 
concentration in BA9 was analysed by multiple regression (image A). The ANOVA for the model was 
significant (p=0.002). The α-synuclein score significantly predicted drebrin concentration 
(beta=0.449, p<0.001). The scatter plot (image B) shows the distribution of drebrin values according 
to α-synuclein score, with a linear regression line. Note that there were only two cases with drebrin 
values in the ‘severe α-synuclein pathology’ group and so these were combined with the moderate 
α-synuclein pathology group. 
 
Model Summary 
Model R R Square 
Adjusted R 
Square 










Model Sum of Squares df Mean Square F Sig. 
1 Regression 33266.602 3 11088.867 5.581 .002
a
 
Residual 127163.424 64 1986.929   
Total 160430.026 67    










t Sig. B Std. Error Beta 
1 (Constant) 90.697 9.449  9.599 .000 
plaque score for BA9 .825 5.986 .020 .138 .891 
tangle score for BA9 -2.898 6.605 -.064 -.439 .662 




























































Figure 4.5.2. Drebrin concentration in BA9 according to clinical diagnosis. 
The difference in drebrin concentration (measured by ELISA and expressed as the log10 of the ng per 
µg of total protein per case) between diagnostic groups was analysed by one-way ANOVA and 
Bonferroni post-hoc test. There was no significant difference between standard diagnostic groups 
(shown in the top graph) – despite a trend of higher concentrations in PDD and DLB cases compared 
to control and AD cases. However, when values for PDD and DLB cases were combined into a Lewy 
body dementia (LBD) group, drebrin concentration was significantly higher in cases in this group 
compared to AD cases (see bottom graph) p=0.045 (ANOVA values; F=3.901, df=2,70, p=0.025). The 


























































































4.6 Immunohistochemical investigation of the expression of ZnT3 
Immunohistochemistry was used to investigate the expression of ZnT3 in paraffin embedded 
sections of post-mortem tissue from various cortical regions (see figures 3.6.1 and 3.6.2 for details) 
from individuals with one of the three dementias of interest and healthy controls. Whilst the Znt3 
antibody was undergoing optimisation to confirm the presence of specific staining and establish a 
protocol an unexpected pattern of staining was observed. This is illustrated in figure 4.6.1, where it 
can be seen that in the cortex of the Lewy body disease there was a perinuclear pattern of ZnT3 
staining, something not seen in the control cases. ZnT3 expression has not been reported in human 
cortex, but an image from the only other study reporting a perinuclear expression of ZnT3 (in the 
MOCHA mouse, a model for lysosomal storage disorders) has been included for the purposes of 
comparison (Stoltenberg et al., 2004).  
Further staining was performed for ZnT3 in sections taken from BA9 from the four diagnostic groups 
(PDD, DLB, AD and control) with the intention of further investigating the perinuclear staining and of 
corroborating the Western blotting data showing decreased ZnT3 levels in BA9. Unfortunately, the 
perinuclear pattern of ZnT3 staining was not duplicated in other cases and brain regions but a 









Figure 4.6.1. Altered ZnT3 expression in LBD cortex.  
ZnT3 expression was investigated using DAB immuno-staining. Image A shows perinuclear 
expression of ZnT3 in the temporal cortex of a Lewy Body disease cases. Image B (adapted from 
Stoltenberg et al.) shows abnormal perinuclear ZnT3 expression from a mice model of a 
lysosomal storage pool deficiency syndrome (MOCHA mice) (Stoltenberg et al., 2004). The 






Figure 4.6.2: Examples of ZnT3 immuno-labelling in prefrontal cortex according to diagnosis 
Coronal sections of BA9 were labelled for ZnT3 (images A-E, A=control, B=AD, C=PDD, D=DLB, E=no 
primary antibody). It can be seen that PDD sections had very low levels of neuropil staining, almost 
comparable to no primary antibody, and that DLB cases had slightly lower staining than control and 




In order to test the hypotheses, first the behavioural, cognitive and pathological characteristics of 
the cohort were examined to determine what underlying trends and differences between diagnostic 
groups were present. Furthermore, as has been stated in the hypothesis; it is not yet clear whether 
pathology is an independent predictor of clinical symptoms or whether synaptic dysfunction is 
driving synaptic pathology or vice versa, thus the predictive relationship between pathology and 
cognitive and behavioural symptoms was investigated. 
5.1 The clinical and pathological characteristics of the cohort, according to 
diagnostic group. 
 
Agitation and depression predicted cognitive impairment in a negative manner, and both were 
significantly lower in cases without cognitive impairment. As cases in the ‘moderately impaired 
cognition’ group can be interpreted as individuals who died at an earlier stage during the 
progression of cognitive impairment, this latter point provides evidence that depression and 
agitation are prevalent at an intermediate stage of dementia when cognition is not severely 
impaired and, whilst the difference between these scores in moderate and severely impaired 
cognition is not significant – the regression analysis supports the idea that depression and agitation 
worsen as does cognitive impairment. 
That depression and agitation scores are so similar in their relationship to cognition can be explained 
to a large extent by their inter-correlation, something which is to be expected given the frequent co-
morbidity of these symptoms. Indeed it has been suggested that agitation is a manifestation of 
depression in individuals with cognitive impairment of a magnitude that prevents expression of their 




5.1.1 Pathological characteristics of the study cohort 
Several key observations can be made regarding the pathology scores across the brain regions and 
diagnostic. Firstly, control cases had low levels of pathology, as would be expected, with the 
exception of Aβ pathology, for which some cases were categorised as severe. Upon a cursory 
examination, this may appear to contradict selection of these cases as controls. However, as detailed 
under the Aβ section of the introduction, Aβ pathology is frequently found in substantial quantities 
in otherwise normal and non-demented controls (Dickson et al., 1992; Jellinger and Attems, 2012; 
Knopman et al., 2003). One of the cornerstones of criticisms of the amyloid cascade hypothesis is the 
theory that Aβ is a damage response protein (Hardy, 2009). This is supported by its accumulation at 
the site of haemorrhages (Atwood et al., 2002; Cullen et al., 2006), and in the brains of boxers 
(dementia puglistica) and in the brains of individuals (generally soldiers) who have suffered blast 
injuries (Blennow et al., 2012). 
Secondly, PDD cases had surprisingly little α-synuclein and tau pathology. Previous reports have 
found PDD cases to have a similar degree of cortical α-synuclein pathology to DLB cases (Harding and 
Halliday, 2001). Harding and Halliday examined LB pathology in the same cortical regions as this 
study but the number of cases for each diagnostic group was considerably lower. Indeed, cortical tau 
pathology has been reported in PDD with great regularity (Jellinger, 2011; Jellinger and Attems, 
2008). Furthermore, tau and Α-syn have been implicated on a molecular level by a study showing α-
syn to induce phosphorylation of tau (Jensen et al., 1999).  
However, the low cortical tau pathology observed in the PDD cohort is consistent with a report by 
Wills and colleagues, in which tau pathology was only encountered in the striatum of PDD cases, and 
not the inferior frontal gyrus (IFG) (Wills et al., 2010). The authors attribute this to difference to the 
higher oxidative stress, inherent in the striatal dopaminergic neurons, causing increased 
concentrations of phosphorylated GSK-3β (a kinase responsible for pathological phosphorylation of 
tau); an occurrence spared to the IFG, due to the lack of dopaminergic neurons and consequently 
lower oxidative stress. 
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Thirdly, DLB cases were characterised by universally high scores of all three types of pathology. This 
finding is in concordance with most reports of DLB pathology (McKeith et al., 2005), and in 
particular, with a recent comprehensive comparison of AD pathology in DLB and PDD which found 
DLB cases to have significantly more AD pathology than PDD (Jellinger and Attems, 2008). Indeed, 
tau pathology has been reported to provide a better correlate of dementia/cognitive impairment 
than α-syn pathology (Oinas et al., 2009). 
Finally, AD cases were likewise characterised by high scores for Aβ and tau and relatively absent α-
synuclein. The latter point is probably due to the selection criteria stipulated by this project for the 
AD cases, which required AD cases with little α-synuclein pathology in order that they might better 
serve to distinguish α-syn dementias from AD. Thus, it is not surprising that the AD cases in this 
study have α-syn pathology levels at variance with reports of an association between, and high 
prevalence of, α-syn and tau in AD (Arai et al., 2001; Hamilton, 2000). Indeed, it has been suggested 
that α-syn can seed tau precipitation through promotion of tau phosphorylation (Duka et al., 2006).  
The validity of the semi-quantitative immunohistochemical staining and scoring of these pathologies 
is  sound due to the multi-centre nature, inter-scorer reliability and simplicity of the scoring system. 
Indeed, semi-quantitative scales have been shown to be superior to more formal pathology scoring 
systems due to the ease of comparison between pathology types and different studies (Compta et 
al., 2011). Ultimately, the discrepancies revealed between the PDD pathology in this study and that 
of previous investigations serve to highlight the inherent variance of human studies and the need for 
ever larger cohort sizes to combat this variance. Indeed, such variance in the levels of α-synuclein 





5.1.2 Cognitive and behavioural characteristics of the study cohort 
The distribution and frequencies of the behavioural data present less controversy than the 
pathology data. Hallucinations are typically associated with the Lewy body dementias and not AD 
(Bjoerke-Bertheussen et al., 2012; McKeith et al., 2005). Perhaps the most note-worthy observation 
is the low prevalence of depression in the DLB cases.   Depression is a supportive diagnostic feature 
of DLB (McKeith et al., 2005), and a number of studies have found DLB to be associated with higher 
incidence of depression than AD (Ballard et al., 1999; Fritze et al., 2011a; Klatka et al., 1996; Yamane 
et al., 2011). Fritze and colleagues combined DLB and PDD into a single group when making their 
comparison to AD, the PDD group in this study had relatively high depression scores, so had the 
same approach been taken a similar finding may have been encountered. Furthermore, not all 
studies have found DLB to be associated with a higher incident of depression than AD (Rockwell et 
al., 2000; Samuels et al., 2004). Clearly there is considerable variance in the prevalence of depression 
in dementia, even without accounting for the difficulty of diagnosis and under-reporting of this 
symptom. 
The profile of cognitive impairment across diagnostic groups was not unusual apart from the lack of 
AD cases categorised as having MCI, but again this is probably a reflection of the selection criteria for 
AD cases specifying those with ‘pure’ AD, and a facet of the autopsy cohort, as few individuals die at 
an MCI stage and even less come to autopsy.  
Rockwell and colleagues found a higher incident of depression in DLB cases with a greater severity of 
cognitive impairment (Rockwell et al., 2000), that this was not replicated in this cohort is perhaps 
indicative of the relatively lower percentage of DLB cases in the severely impaired cognition category 




5.2 Characteristics of the synaptic biology, according to clinical diagnosis 
and brain region. 
Another key aspect of the hypotheses was the determination of any differences in synaptic biology 
between diagnostic groups; something of particular importance with regards to delineating DLB and 
PDD, an outcome which is of relevance to clinicians in addressing neuroleptic sensitivity, and in 
general to provide assistance in establishing the degree of commonality shared by DLB and PDD. 
5.2.1 Changes in β-III-tubulin, PSD95, synaptophysin and ZnT3 are diagnosis and brain 
region specific 
In BA9 there was a reduction of PSD95, SPP and ZNT3 in PDD cases compared to controls – and of 
PSD95 and ZnT3 in DLB cases; something that was not observed in AD cases. This would suggest 
there to be a deficit of pre and post-synaptic terminals in the PFC of PDD accompanied by 
dyshomeostasis of Zn at the synapse, with a similar picture in DLB – excepting the loss of pre-
synaptic terminals. In the case of ZnT3, this was corroborated by IHC. It is interesting to note the lack 
of a deficit in these cellular features in the AD cases. Furthermore, the lack of significant change in 
Btub values across the diagnostic results suggests the dementia cases are not characterised by any 
substantial neuronal loss from the PFC. 
The creation of residual variables for those proteins that were significantly predicted by either Aβ or 
tau pathology (in the case of BA9 these were PSD95 and SPP) allowed the effect of this pathology to 
be statistically negated. That this resulted in no alteration to the aforementioned diagnostic 
differences in PSD95 or SPP levels, would suggest that AD pathology that is not a dominating 
mediator of the synaptic dysfunction observed in PDD and DLB prefrontal cortex.  
In BA24 there were few significant alterations in the levels of the proteins of interest between 
diagnostic groups. However, there was a marked increase in PSD95 values in AD cases – something 
that has been found previously (albeit using immunohistochemistry and on fewer AD cases) (Leuba 
et al., 2008). In neurodegenerative conditions it is relatively unusually to find an increase in synaptic 
proteins; however, this may be a compensatory mechanism to alleviate effects of factors not 
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measured by this study such as synaptic soluble oligomers of the pathologic proteins such as Aβ. 
Upregulation of PSD95 has been reported in post mortem thalamic tissue from schizophrenic 
patients (Clinton et al., 2006), which the authors propose to be a compensatory response to NMDA 
receptor dysfunction. 
It is interesting to note that residual values for ZnT3 in BA24 that accounted for the predictive effect 
of Aβ and tau scores produced no difference in terms of the pattern of changes between diagnostic 
groups. This would appear to suggest that, whilst AD pathology correlated to ZnT3 values, it is not 
driving any significant alterations in these values. 
AD cases had significantly lower levels of Btub, PSD95 and SPP in BA40. This suggests that there is a 
substantial loss of neurons and synaptic terminals in BA40 of AD cases compared to control cases – 
and also to PDD cases, which appear highly similar to controls. DLB cases appeared to follow this 
trend – although not to a degree that was statistically distinguishable. Strikingly, the creation of 
residual variables for the tangle score – which had a significant relationship to the values of all 
proteins in BA40 – completely abolished the substantial reductions in Btub, PSD95 and SPP in AD 
cases, and the lesser reductions in DLB cases. Thus, a compelling link between tau pathology and 
synaptic and neuronal loss is established. 
5.2.2 Changes in pre and post-synaptic terminal markers relative to changes in the 
neuronal population, are brain region and diagnosis specific. 
Creation of ratios of the pre and post-synaptic markers SPP and PSD95 to Btub allowed changes in 
these proteins relative to neuronal loss to be approximated, thus allowing changes at the synaptic 
terminals to be dissected from changes due to neuronal loss. The importance – but not necessity - of 
both SPP and PSD95 to synaptic function (best demonstrated by knockout mice that survive yet 
develop cognitive phenotypes (Han and Kim, 2008; Migaud et al., 1998; Schmitt et al., 2009)) allows 
two deductions to be made about a loss of either protein; that synaptic terminals exist with a 
reduction in quantity of the protein – and the consequent dysfunction, or that neurons exist with a 
complete loss of some synaptic terminals – with the remaining terminals containing relatively 
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normal quantities of the protein in question. In other words, a reduction in SPP to 50% of control 
levels could correspond to 100% of synapses with 50% SPP levels, or a loss of 50% of synapses – with 
the remaining 50% containing control levels of SPP. In reality it is likely that a combination of both 
scenarios occurs plus, as it is not possible to actually quantify synapses by western blotting,  this 
report will relate deficits in SPP or PSD95 to synaptic dysfunction without attempting to elucidate 
whether this dysfunction is due to synapses with significant reductions in key proteins or neurons 
with significant reductions in synapses. 
In BA9 PDD cases were found to have significant pre-synaptic dysfunction compared to AD cases – 
and a non-significant trend showing a loss of pre-synaptic marker relative to control and DLB cases. 
A similar observation can be made with respect to PSD95 – there is a loss of post-synaptic marker in 
DLB and PDD compared to control and AD cases. This follows the pattern of change in protein values 
in BA9 and serves to confirm that neuronal loss is not the cause of the reductions seen in the 
synaptic proteins measured. 
There was a lack of any significant differences in pre-synaptic marker (relative to neuronal loss) in 
BA24 between diagnostic groups, and thus suggesting no significant pre-synaptic dysfunction in 
dementia cases, confirming what was found for SPP values. However, BA24 in AD cases was 
characterised by an increased ratio of PSD95 to Btub, suggesting either the control cases (in addition 
to DLB and PDD) had deficits at the post-synaptic terminal or that AD cases had compensatory 
upregulation of PSD95 (as described in the preceding section). 
The ratios of SPP to Btub and PSD95 to Btub were not significantly different between diagnostic 
groups. This finding is in contrast to the decreases seen in these proteins in AD cases (see preceding 
section), but is easily explained by observing that Btub is decreased to a similar extent as SPP and 
PSD95. Thus it would appear that the synaptic deficits detected in BA40 in AD cases are the result of 
neuronal loss – evinced by reduced Btub – and not a specific deficit to pre or post-synaptic terminals 
– demonstrated by the restoration of AD cases to control levels when ratios are used. 
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5.2.3 Changes in the levels of ZnT3, relative to the synaptic marker synaptophysin, are 
brain region and diagnosis specific.  
In a similar manner to SPP and PSD95 (as discussed in the previous section), changes in ZnT3 levels 
could be a consequence of a loss of synaptic vesicles - this being the physiological location for ZnT3 
(Palmiter et al., 1996), or be independent of any loss of synaptic vesicles. Thus the ratio of ZnT3 to 
SPP was calculated for the three brain regions where ZnT3 and SPP were quantified to allow the 
nature of the changes in ZnT3 levels with respect to synaptic vesicles to be determined.  
There was a significant decrease in the ratio of ZnT3 to SPP across the three dementias, and which is 
the most substantial in AD cases. These observations should be compared to those discussed in 
section 4.1.1, concerning the changes in protein values in BA9 according to diagnosis. Whilst no 
statistically significant change was found between control and AD cases for either ZnT3 or SPP levels, 
it is clear that SPP levels are generally higher in AD cases than controls, with the opposite being the 
case for ZnT3. Thus, in consideration, it is not so surprising that upon combining the values for these 
two proteins into a ratio a significant reduction is detected in AD cases compared to controls, 
additionally, there was a significant increase in the ratio of SPP to Btub in AD cases compared to 
controls in BA9. Thus it can be suggested that the observed deficit of ZnT3 is not an artefact of 
synaptic vesicle, synapse of neuronal loss, but has occurred independently. The same argument 
applies – to a lesser extent – to the reduction in ZnT3 levels seen in DLB and PDD cases. 
Furthermore, due to the prediction of the ratio of ZnT3 to SPP by the tangle score in BA9 – a residual 
variable for the ratio was created to statistically remove this predictive effect of tangles. As a 
consequence of the above steps, there was no longer any significant difference in the ratio of ZnT3 
to SPP between diagnostic groups. Thus it would appear that tangle pathology is a significant 
contributor to the observed deficits in ZnT3 in BA9. 
In BA24 there were no significant differences between diagnostic groups in terms of the ratio of 
ZnT3 to SPP; suggesting that there was no loss of ZnT3, with respect to synaptic vesicles, in the 
dementia cases.  
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Contrastingly, in BA40 there were marked reductions in the ratio of ZnT3 to SPP for all dementias 
compared to controls – with the largest reduction in DLB cases. Again this serves to highlight the 
different insight offered by expressing the proteins of interest as ratios, as the greatest deficit for the 
proteins in BA40 was found in AD cases, yet the ratio of ZnT3 to SPP in BA40 is lowest in DLB cases. 
This suggests DLB cases are characterised by a loss of ZnT3 from synaptic vesicles in BA40, whereas 
some of the loss of ZnT3 in BA40 seen in AD cases, whilst not statistically significant as an 
independent measure, is due to reductions in synaptic vesicles. It should be remarked that this loss 
of ZnT3 in AD cases is unlikely to be a consequence of neuronal loss – as there was no significant 




5.3 The relationships of synaptic biology to behavioural and cognitive 
data. 
 
It was hypothesised that synaptic dysfunction – measured by deficits in the synaptic proteins 
featured in this study – would underlie cognitive impairment and increased behavioural symptoms in 
dementia cases.  
5.3.1 Associations between ZnT3, depression and cognition in BA9. 
ZnT3 values in BA9 predicted the semi-quantitative depression score in an inverse manner, such that 
cases with higher depression scores had lower ZnT3 levels in BA9. It must be noted that this analysis 
included control cases under the assumption that they did not have clinical depression, an 
assumption substantiated by the MRC London Neurodegenerative Diseases Brain bank’s criteria for 
accepting cases as a control – which includes assessment of G.P. notes. Substantial evidence has 
been accumulated linking Zn in the brain to depression; so whilst the association between Zn 
dyshomeostasis in the prefrontal cortex and depression reported in this study is in accordance with 
the literature, care must be taken with the interpretation of the relationship between ZnT3 and 
depression, in light of the strong relationship between cognitive impairment (disease severity) and 
depression. The data available to this project did not have sufficient statistical power to distinguish 
between the relationships cognitive impairment and depression to ZnT3 in BA9. 
Multiple links were observed between ZnT3 and cognition in BA9 and BA40, both ZnT3 values and 
the ratio of ZnT3 to SPP predicted cognitive impairment in BA9 and were significantly reduced even 
in dementia cases with high MMSE scores (the MCI group – scores of 24 to 30) compared to control 
cases. Control cases had significantly higher ZnT3 values and ratio of ZnT3 to SPP than all the other 
cognitive impairment categories yet there were no significant reductions between cases classified as 
having some degree of cognitive impairment. Thus, it appears from the data that Znt3 is reduced 
from an early stage of cognitive impairment, or dementia progression. Furthermore, this reduction is 
not attributable to a loss of synaptic vesicles (evinced by the ratio of ZnT3 to SPP maintaining the 
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same association to cognitive impairment as ZnT3 values). The comparison of groups by one-way 
ANOVA would suggest that after an initial decline with very early and/or slight cognitive impairment 
there are no further significant reductions in Znt3, however the one-way ANOVA test is biased 
towards large differences between groups and less sensitive to a slight but consistent trend across a 
range of groups (Coolican, 2009). However, regression analysis posses the opposite bias and so has 
shown Znt3 values and more importantly, the ratio of ZnT3 to SPP, in BA9, to predict cognitive 
impairment. This is indicative of a trend of decreasing ZnT3 with increasing cognitive impairment.  
A similar, albeit weaker, relationship between ZnT3 and cognition was observed in BA40; where both 
ZnT3 values and the ratio of ZnT3 to SPP predicted cognitive impairment. That there were no 
significant differences between the cognitive impairment groups, in spite of the highly significant 
regression coefficient, reinforces the earlier point about the relative bias of one-way ANOVA and 
regression analysis.  
Thus, it can be concluded that dyshomeostasis of synaptic Zn in BA9 and BA40 contributes to 
cognitive impairment; and that in BA9 this is from the outset and continues until impairment is 
severe. These findings are consistent with the reports of cognitive impairment in mice lacking ZnT3 
protein (Adlard et al., 2010) which prompted the part of the hypothesis of this study concerning Zn 
and cognition.  
Despite the accumulation of evidence connecting reductions in cortical zinc to depression, there has 
been no reported investigation into ZnT3 and depression. Adlard and colleagues did not test for 
behavioural symptoms such as depression in their ZnT3 knockout mice. This is not surprising given 
the difficulty and controversy of modelling depression in mice, due to a host of factors such as 
anthropomorphism, lack of biomarkers, universal treatment and heterogeneity of symptoms (Berton 
et al., 2012). Animal models of depression have demonstrated the importance of zinc in modulating 
this behaviour. Zinc deprivation has been shown to induce depressive-like behaviour in the forced 
swim test (Młyniec et al., 2012). However, there may well be significant differences in the etiology of 
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depression in dementia compared to depression in non-demented individuals, thus it remains a 
challenge to model this facet of dementia. 
In addition to ZnT3; PSD95 values and ratio to Btub were shown to predict cognitive impairment in 
BA9 but not BA40. However, there were no significant differences between groups, highlighting the 
more gradual nature of reduction of PSD95. Therefore, the data suggest that a gradual loss of PSD95, 
in excess of any neuronal loss, contributes to cognitive impairment. In other words, post-synaptic 
dysfunction, rather than pre-synaptic dysfunction or neuronal loss, is the greater contributor to 





5.3.2 Post-synaptic alterations in the study cohort 
Reductions in PSD95 have been reported in the hippocampus of individuals with MCI (Sultana et al., 
2010); the authors suggested that, amongst the myriad roles of PSD95 at the synapse, it is the 
clustering of NMDA receptors and the consequent impact on LTP that may provide the mechanism 
for a reduction in PSD95 to impact cognition. Observations in animals support a connection between 
PSD95 reduction and cognitive impairment, in particular the original study in which the PSD95 gene 
was knocked-out in mice, leading to impaired learning and memory (Migaud et al., 1998). Mice 
overexpressing human APP develop cognitive deficits (according to the Morris water maze) and 
were characterised by synaptic dysfunction, including reduced PSD95, in the hippocampus (Simón et 
al., 2009). A similar finding, reductions in a number of pre and post-synaptic markers including 
PSD95, was made by Majdi and colleagues in aged cognitively impaired rats (Majdi et al., 2007).  
In this study, it was found that PSD95 was significantly reduced (relative to controls) in BA9 from DLB 
and PDD cases, but not in AD cases. Whereas, in BA24, PSD95 values were increased in AD (relative 
to controls) and not changed in PDD or DLB; and in BA40 PSD95 values were decreased in AD and 
unchanged in DLB and PDD. These patterns of change are independent of neuronal loss, apart from 
the decrease in AD BA40, which appears to be related to neuronal loss and therefore may not 
represent overt synaptic dysfunction. 
PSD95 levels are relatively well characterised in post-mortem AD cortex, due to its predominance as 
the primary post-synaptic marker; several groups have found reductions in PSD95 in AD cases (Gylys 
et al., 2004; Love et al., 2006). However, Love et al. only measured PSD95 in the temporal cortex, 
whilst Gylys and colleagues measured PSD95 in the prefrontal cortex, neither group examined BA24 
or BA40 and so these reports are not directly comparable. Additionally it should be remarked that an 
increase has been reported for PSD95 in AD post-mortem tissue (mentioned in the discussion of SPP) 
(Leuba et al., 2008). 
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5.3.3 Alterations in zinc regulation in the study cohort 
Loss of ZnT3 reduces the pool of so called ‘free’ Zn (Zn that is not bound to metalloproteins and is 
thus available for synaptic release) (Cole et al., 1999) and so it is reasonable to assume some of the 
described anti-depressant and cognitive effects of Zn will be reduced as a consequence. The more 
important question is how this reduction in ZnT3 could have arisen.  
Lee and colleagues used APOe knockout mice to establish the first link between APOe and ZnT3; the 
mice exhibited reductions in ZnT3, an associated modulator of ZnT3 – AP3δ – and synaptic Zn (Lee et 
al., 2010). Whilst it is accepted that APOe binds Zn along with Aβ in plaques, the different isoforms 
of APOe have widely different affinities for Zn binding; APOe2 has the highest and APOe4 the lowest 
– which the authors speculate in may leave greater quantities of Zn free to bind Aβ and precipitate 
aggregation and plaque formation (Lee et al., 2010).  
Consistent with this hypothesis is the observation that Zn is preferentially elevated in the brains of 
individuals with AD who carry the APOe4 allele, to the extent that the authors state raised Zn levels 
to be an independent risk factor for AD (González et al., 1999). Lee et al. did not propose a 
mechanism through which APOe might reduce ZnT3 expression, although they confirmed the 
synaptic health of the mice through SPP quantification and state the need to address the question of 
how the different Zn binding affinities of the APOe isoforms affects synaptic Zn. AP3 targets ZnT3 to 
the vesicle membrane (Salazar et al., 2004) and so the reduction in the delta subunit of AP3 found by 
Lee et al (Lee et al., 2010) suggests APOe may impair the correct targeting and localisation of ZnT3 to 
the vesicle membrane. 
The possible behavioural manifestations of a reduction in synaptic Zn have the potential to be 
diverse and complicated. Ablation of the ZnT3 protein (and by extension synaptic Zn (Cole et al., 
1999)) in mice causes cognitive deficits (Adlard et al., 2010) yet removal of synaptic Zn may also 
prevent synaptic accumulation of Aβ oligomers; as evinced by studies in Tg2576 APP transgenic mice 
crossed with ZnT3 knockouts (Lee et al., 2002) and hippocampal slices (either from ZnT3 knockout 
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mice or with Zn chelators) incubated in soluble Aβ oligomers (Deshpande et al., 2009). Thus these 
studies appear to suggest synaptic Aβ mediated by Zn is not linked to cognitive impairment. Perhaps 
these studies could be taken as evidence against the amyloid hypothesis. However Adlard et al offer 
the theory that synaptic Aβ aggregates deny synaptic Zn to its physiological roles and so this could 
explain how reductions in synaptic Zn can be consistent with reduced cognition and increased 
depression, in the presence of Aβ aggregation driven by dyshomeostasis of synaptic Zn. 
Additionally, given that Zn can aggregate tau and α-syn (Boom et al., 2009; Mo et al., 2009; Paik et 
al., 1999; Yamin et al., 2003), it would be interesting to see the effect of Zn removal in a model of 
either of these pathologies.  Compounding the picture are the data suggesting reductions in Zn to be 
instrumental in depressive and anxiety like behaviours (Szewczyk et al., 2011).  
The data presented here supports a link between reduced ZnT3 (and thus reduced synaptic Zn) to 
both cognitive impairment, and depression, which are consistent with the literature. However, 
reductions of ZnT3 in the prefrontal cortex in cases with higher Aβ pathology should not be expected 
if synaptic Zn is precipitating Aβ pathology. Although clearly tau pathology and other factors not 
measured in this study play a significant role. 
Activity-dependent regulation of ZnT3 levels – if Zn is depleted then cellular response is to reduce 
ZnT3? A compensatory increase in ZnT3 could make more sense. However if AP3 is reduced or 
dimerisation of ZnT3 affected then an explanation for reduced ZnT3 would have been offered. 
 It should be remarked that there was no significant link between ZnT3 (and any other of the 
proteins measured) in BA24 and cognition. 
5.3.4 Alterations in the localisation of ZnT3 
The ZnT3 immunohistochemistry has revealed two interesting findings; firstly a reduction in synaptic 
staining in PDD cases, a finding supportive of Western blot data and discussed in the preceding 
section, and secondly immunolabelling in the nuclear membrane. This latter observation was of 
interest because ZnT3 has not previously been reported in this location in human cortex. ZnT3 is 
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expressed predominantly in synaptic vesicles and would thus be expected to be localised to the 
presynaptic terminal (Palmiter et al., 1996; Salazar et al., 2004); indeed a synaptic pattern of staining 
was obtained with the subsequent IHC comparing diagnostic groups. 
Znt3 has been reported in a perinuclear localisation in human retinal pigment epithelium (RPE) cells 
(Leung et al., 2008) and in cortical neurons in a mouse model of lysosomal storage disorder (Kantheti 
et al., 1998; Stoltenberg et al., 2004). Leung and colleagues do not offer comment upon their finding 
and the relevance of ZnT3 expression in RPE cells to expression in cortical neurons remains to be 
determined. However, the perinuclear ZnT3 expression in MOCHA mice is suggestive of erroneous 
ZnT3 trafficking and targeting to vesicles as a consequence of the loss of function of AP3 in these 
mice, supported by evidence that AP3 directs ZnT3 to vesicles (Salazar et al., 2004). Thus, it is 
conceivable that a similar outcome (reduced synaptic and increased perinuclear ZnT3) arises in DLB 
and PDD as a consequence of altered cellular transport and trafficking of ZnT3. AP-3 reductions have 
been reported in AD human neocortex (Yao and Coleman, 1998) but no investigation has been 
undertaken in DLB or PDD. It would therefore be interesting to investigate AP3 levels in these 
dementias to determine if alterations in AP3 underlie any defects in cellular trafficking. 
There remain other explanations for this perinuclear ZnT3 staining. Clearly, the ZnT3 protein is 
manufactured within the cytoplasm, and so it could be that the staining reflects ZnT3 awaiting 
transport to vesicles and the synapse. It is also possible that the antibody is detecting another 
member or members of the ZnT family, due to the high level of similarity in the sequence between 
ZnT proteins. ZnT3 and ZnT9 have been reported to be associated with the nuclear membrane under 
certain conditions, including high Zn concentrations and hormone exposure (Huang and 
Tepaamorndech, 2013). However the specificity of ZnT3 Western blotting casts doubt on this as an 
explanation. Ultimately, the failure to replicate the perinuclear Znt3 staining, (stemming from the 
lack of time available for a comprehensive investigation of ZnT3 staining in multiple brain regions 
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from a large number of cases), combined with the conflicting and sparse literature on ZnT3 
localisation, makes it difficult to fully attribute an explanation. 
5.3.5 Alterations in the pre-synaptic density in the study cohort 
 
Since the first investigations into synaptic density, and the consequent verification of the hypothesis 
that a decrease in synaptic density and synapse loss correlates to the severity of cognitive deficit, 
synaptophysin has been consistently found to be decreased in the PFC in AD compared to non-
demented control cases (Clare et al., 2010; Davies et al., 1987; Leuba et al., 2008; Minger et al., 
2001; Terry et al., 1991). That this study found no significant difference in SPP levels between AD 
and controls in BA9 is unexpected and clearly not congruent with the majority of the literature. 
However SPP levels in BA40 were significantly decreased in AD, which was expected given the 
severity of AD pathology in this region. 
In light of this the first recourse was to the validity of the experiments conducted for this study. The 
loading of the correct volume per sample (and hence protein concentration) appears consistent as 
beta-II-tubulin was immunoblotted and quantified on the same membranes – and in tandem with 
SPP – and was not increased relative to controls in BA9. Furthermore, BA9 was not analysed in 
isolation but alongside (on the same gels as) BA24 and BA40, and so errors in protein transfer or 
treatment of membranes cannot explain the specificity of the unexpected results to one brain region 
- BA9. 
In examining the literature on SPP and other synaptic proteins some inconsistencies have been 
found. Leuba et al. reported an increase in PSD95 in post-mortem AD versus control tissue (from 
BA9), which was accompanied by a decrease in SPP, and offered compensatory upregulation of 
PSD95 as a response to decreased pre-synaptic activity as an explanation (Leuba et al., 2008). 
Interestingly the opposite was observed in the ZnT3 knockout mice; SPP was increased whilst PSD95 
was decreased after 6 months – the time point at which cognitive deficits were observed (Adlard et 
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al., 2010). The authors also suggest this to be a compensatory mechanism involving reductions in 
ZnT3 affecting Zn homeostasis – which has a knock on effect at the post-synaptic terminal. Thus it is 
plausible that the pre and post-synaptic terminals are involved in a reciprocal feedback mechanism 
governing upregulation of key proteins as a response to deficits in other proteins. 
Additional evidence of relevance here, comes from a study on post mortem tissue from patients 
with progressive supranuclear palsy, in which SPP levels in the frontal cortex were reported to be 
elevated in demented subjects compared to non-demented (Bigio et al., 2001). Despite the 
extremely low number of cases (n=8), this study – along with the other observations outlined above 
- serves to highlight the complexities inherent in linking any single element of the vast synaptic 
machinery too closely to cognition.  
With respect to the number of cases – it should be noted that this study reported SPP values for BA9 
from 16 AD cases, a similar number to many of the referenced studies on SPP. There are other case 
specific differences between this study and literature reports, for example in the severity of 
cognitive deficit in the AD cases. When Minger et al. grouped their AD cases by severity of cognitive 
deficit based upon MMSE score – only cases with a score of 2 or less had significantly reduced PFC 
SPP levels (Minger et al., 2001). In contrast, 7 of the 16 AD cases in this study had MMSE scores of 13 
or higher, making it perhaps less surprising that SPP levels were relatively preserved. However SPP 
has also been reported to be lost as an early event with respect to the time course of cognitive 
decline, a contradiction that likely reflects differences in the method and sensitivity of cognitive 
assessment (Masliah et al., 2001a).  
A final explanation for the inexplicable brain region specificity seen in the preservation of SPP levels 
was arrived at through analysis of the length of time samples spent in storage at -80°C. A strong 
correlation and predictive effect was detected for time in storage solely for SPP in BA9. This was 
expected for the AD cases as this group were all recent additions to the brain bank (within the last 4 
years), whereas the other 3 diagnostic groups included cases dating from the late 1980s. What was 
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striking was that only BA9 SPP values, and no other brain region or protein, was affected by the time 
in storage.  
Increased duration of frozen storage undergone by brain tissue has been shown to relate to 
reductions in muscarinc receptors in several brain regions, although the authors do not speculate on 
the mechanism(s) for this observation, but merely caution researchers to consider frozen storage 
time as a confounding variable (Rodŕiguez-Puertas et al., 1996).  
A similar finding concerns brain region specific differences in the effect of PMD on synaptic protein 
levels. Siew and colleagues found PSD95 and syntaxin to be affected (decreased) by an increase in 
PMD in BA9 but not BA21, and suggested that the lower synaptic density found naturally in BA9 may 
somehow cause greater exposure of synaptic proteins to degradative processes than occurs in other 
brain regions (Siew et al., 2004). Whilst Siew and colleagues did not detect changes in SPP related to 
PMD of up to 72 hours, due to the stability of SPP arising from its secure embedding into the vesicle 
membrane, it is conceivable that great lengths of time in storage at -80°C could disrupt the lipid 
environment of the vesicle membrane and that this would be compounded by the reduced synaptic 
density of BA9. Certainly disruption to the lipid membrane of vesicles during freezing has been 
reported (Strauss and Hauser, 1986), albeit without investigation into the effect of this on 
membrane embedded proteins – so any resultant change to SPP levels remains conjecture. 
It is perhaps noteworthy that BA9 is in greater demand from brain banks for research samples than 
the other regions, thus it could be speculated that the coronal slices containing BA9 had been 
subjected to more thawing and re-freezing over the years as samples were taken. That this could 
compound any damaging effect of ice crystals to membranes is not beyond possibility – see the 
methods section for the drebrin ELSIA. 
Interestingly, the solubility of SPP has been reported to be altered by Aβ42 peptides in APP double 
transgenic mice (hAPPsw/hPS2m). These mice had higher concentrations of Aβ42 than the other 
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transgenics examined, and a reduction in soluble SPP but not total SPP. The authors pursued this 
investigation as a response to conflicting accounts of SPP levels both increased and decreased in 
mouse models of AD, and thus propose this alteration of SPP solubility as an explanation for the 
apparent changes in SPP levels (Hwang et al., 2011). This would appear to be supported by 
observations that SPP is scarce at sites where Aβ oligomers have accumulated (Ishibashi et al., 2006), 
however this observation was based upon IHC, which was the same method used by Hwang et al. to 
determine total SPP. It is therefore more likely that this is due to oligomer and/or human specific 
effects on SPP rather than that of Aβ42. 
Additionally, mediation, in particular anti-psychotics and anti-depressants, have been reported to 
induce changes in synaptic proteins when administered to rats, including an increase in SPP (Varea 
et al., 2007) (Eastwood et al., 1997). However this is not consistent with findings by Gabriel and 
colleagues that SPP levels in post-mortem tissue were not different between schizophrenia patients 
that had or had not taken anti-psychotics (Gabriel et al., 1997). Unfortunately, due to a lack of 
medication data, it was not possible to determine if there was any effect of medication on SPP levels 
in this study. 
5.3.6 Associations between synaptic biology in BA40 and hallucinations 
 
It was found that both α-synuclein pathology and SPP levels, in the parietal cortex, predicted 
hallucinations. The parietal cortex has an established role in visual processing (see introduction 
section on parietal cortex for details). Furthermore, it has been suggested that the neural basis for 
hallucinations resides in ‘higher’ cortical regions, such as the parietal cortex, as opposed to the visual 
cortex; a theory based upon observations from fMRI studies showing intact visual cortex in DLB 
patients (Kenny et al., 2012).  
α-syn pathology has previously been linked to hallucinations (Harding et al., 2002), although this 
pathology was in the inferior temporal cortex. Harding and colleagues did not find a relationship 
between parietal α-syn pathology and hallucinations; but remark upon the ability of subtle 
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differences in the precise brain region(s) selected, in addition to the inherent cohort differences, to 
affect findings of this nature, in defence of a study previous to theirs that found no relationship 
between pathology and hallucinations in DLB whatsoever (Gómez-Isla et al., 1999). It is therefore 
relevant to remark that Harding and colleagues scored α-syn pathology in BA39 and not BA40 and 
compiled staining from ubiquitin and α-syn antibodies to give a LB count rather than a semi-
quantitative score encompassing all types of α-syn pathology (an approach established to be better 
at comparisons between staining techniques and laboratories (Compta et al., 2011), as was done in 
this study). Additionally, a striking cohort-specific difference between Harding et al. and this study is 
the paucity of tau pathology in the DLB cases utilised by Harding, an observation in direct contrast to 
the DLB cases in this study. 
Harding and colleagues highlight the link between their findings and the reported association 
between deficits in cholinergic neurotransmission in the temporal cortex and visual hallucinations 
(Ballard et al., 2000; Marra et al., 2012; Perry et al., 1990), and suggest a need for further work to 
establish the sequence of these events with an aim of establishing whether the α-syn pathology 
propagates synaptic dysfunction and loss of cholinergic neurotransmission, or if it is caused by this 
cholinergic deficit. 
A study by Papapetropoulos and colleagues was the only report of a connection between α-syn 
pathology in the parietal cortex and hallucinations found in a literature search using pubmed.com 
(Papapetropoulos et al., 2006). The authors used BA39 to represent the parietal cortex and made 
the comparison between PD cases with and without a history of hallucinations, the consequence of 
which was a significant association between LBs in several brain regions (including the amygdale, 
temporal cortex and parietal cortex) and visual hallucinations. This corroborated an earlier study 
that found decreased metabolic activity (according to FDG-PET) in the parietal cortex (including 
BA40) of PD patients with visual hallucinations, despite the exclusion of individuals meeting criteria 
for dementia (Nagano-Saito et al., 2004). 
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To the author’s knowledge, there are no publications reporting a direct connection between SPP and 
hallucinations. However, schizophrenia research has long focussed on reported links between 
synaptic plasticity and hallucinations, albeit generally of an auditory nature (Stephan et al., 2009). 
Port and Seybold suggest that potentiated LTP in the hippocampus forms the biological basis for 
psychosis and hallucinations in schizophrenia (Port and Seybold, 1995), and that blockade of NMDA 
receptors may alleviate this. It is plausible that such an increase in LTP could involve changes to 
synaptophysin levels as SPP is an established regulator of synaptic plasticity (Alder et al., 1995). 
There is considerable evidence for SPP playing a role in schizophrenia and hallucinations, the 
majority of studies have found SPP expression to be reduced in schizophrenia (summarised by Shen 
et al.) (Shen et al., 2012); however, elevated levels of SPP have been reported in the cingulate gyrus 
of schizophrenia patients (Gabriel et al., 1997), as has increased synaptic density (Aganova and 
Uranova, 1992; Selemon et al., 1995).  
As discussed in the preceding SPP section, a number of confounding factors could cause an artificial 
increase in synaptic proteins such as synaptophysin, amongst which, the reports of anti-psychotics 
and anti-depressants producing elevated SPP concentrations are the most relevant for consideration 
here. Nevertheless, hallucinations can be thought of as a gain of function as opposed to a loss of 
function, thus it is not altogether surprising that they may be accompanied by abnormal increases in 
neuronal connectivity and synaptic activity. 
In summary, this study has established a link between the parietal cortex and hallucinations; the 
proposed mechanism of which being synaptic dysfunction, primarily mediated by increased Ayn 
pathology. That elevated SPP was associated with hallucinations is harder to reconcile, despite the 
precedence for this in schizophrenia, but could be related to medication, or represent a 
compensatory increase, perhaps in an attempt to correct an imbalance in vesicle dynamics caused 
by the α-syn pathology. A similar argument stands as to that given by Harding et al. with regards to 
cause verses consequence of these two events (α-syn and SPP), one which post-mortem studies are 
severely limited in answering due to the end-stage nature of any observations made. It would have 
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been interesting to have data on cholinergic neurotransmission in the cortical regions studied in this 
project to determine if the connection between cholinergic deficits and hallucinations was 
replicated. 
As a final remark, it should be clarified that SPP did not predict hallucinations when including 
controls because SPP was elevated in control cases, this was coupled with no hallucinations; thus the 







5.3.7 Rationale for use of cognitive impairment categories based upon MMSE score 
 
The ‘cut off’ score below which an individual is regarded as having dementia was originally 
recommend as 24 by the creators of the MMSE, Folstein and colleagues (Folstein et al., 1975). 
However, there have since been a number of proposed revisions to this guideline based upon 
observations that in populations with higher educational levels or in the very old (90 years and 
older) this cut off score of 24 is not adequate. A score of 25 as a cut off point for dementia has been 
suggested (Ganguli et al., 1990), as has a score of 26 (Monsch et al., 1995) and 27 (Kukull et al., 
1994). This latter recommendation was specific to cohorts with a higher than average educational 
background, something which cannot be ascertained for the cohort presented in this project, and so 
is of less relevance, but serves to highlight the ongoing debate concerning the interpretation of 
MMSE scores. A cut off score of 25 was chosen as the upper boundary for this study, based not only 
upon that suggested by Ganguli et al. but on guidelines published on the Alzheimer’s Association 
website (http://www.alz.org/alzheimers_disease_steps_to_diagnosis.asp). The cut off point of 10 or 






5.4 Associations between biochemistry and pathology in the study cohort. 
Given evidence of interactions between pathological and synaptic proteins, a key aspect of this 
project was to determine what relationships existed between the synaptic proteins of interest and 
the three principle pathologies of the dementias studied, and whether synaptic deficits were 
underlying pathological deposition or vice versa.  
5.4.1 Associations between tau pathology and neuronal biochemistry. 
In BA9, tangle score predicted SPP values and that in BA40 the tangle score predicted PSD95 and 
Btub values, additionally, PSD95 values in BA24 predicted tangle scores. It is interesting to note that 
PSD95 values were increased with higher tangle scores in both instances mentioned above (the 
prediction was of a direct nature), whereas SPP values in BA9 and Btub values in BA40 had an 
inverse relationship to tangle score.  
Synapses depend upon axonal transport, a process mediated by the cytoskeleton, for the correct 
delivery and localisation of synaptic proteins (Alberts et al., 2002). Tau plays an important role in 
stabilising the cytoskeleton, in part through binding to Btub, and is therefore instrumental (albeit 
indirectly) in the appropriate transport of proteins along the dendrites (Ballatore et al., 2007; Lee et 
al., 1989; Santacruz et al., 2005). Furthermore, tau pathology has been suggested to be more 
neurotoxic than Aβ pathology, based upon evidence that it is a better correlate of neuronal death 
and cognitive decline (Arriagada et al., 1992; Takashima, 2009).  
Decreases in pre-and post-synaptic terminal density have recently been reported in a mouse model 
of tau pathology (Tg-FDD-Tau, a transgenic combination of human mutant tau and human mutant 
BRI – the gene responsible for familial Danish dementia) (Garringer et al., 2013). In this study it was 
found that SPP decreased in an age-dependent manner, prior to overt tau pathology, which, 
according to the authors, was suggestive of an effect of oligomeric ‘pre-tangle’ tau; and served to 
corroborate other studies suggesting abnormalities in tau function to be causative of synaptic 
deficits via an impact on axonal transport (Lasagna-Reeves et al., 2011; Yoshiyama et al., 2007). 
Thus, the finding in this study that increased tau pathology was associated with, and predicted 
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reduced SPP and Btub levels is not surprising. That increased PSD95 levels are associated with higher 
tau scores is unexpected and is due to the elevated PSD95 detected in AD cases, this is discussed 
under PSD95.  
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5.4.2 Associations between synaptic biochemistry and Aβ pathology. 
Synaptic activity has been implicated in the production of Aβ pathology and the conference of 
susceptibility to Aβ pathology to specific brain regions (Bero et al., 2011). In a search for molecular 
markers of this synaptic activity mediated regional vulnerability to Aβ deposition, Shinohara and 
colleagues found a positive correlation between both PSD95 and SPP and soluble Aβ40 and Aβ42 
(Shinohara et al., 2013). The authors propose this relationship to be indicative of a causative link 
between synaptic activity and generation of Aβ. Thus, there are two potentially conflicting theories 
with regards to synapses and pathology; one being that synaptic dysfunction and loss occurs in 
dementia as a result of pathological damage from Aβ (Lesné et al., 2006; Shankar et al., 2008; Walsh 
et al., 2002; Walsh and Selkoe, 2004) and the second that synaptic activity promotes pathological 
deposition of Aβ (Bero et al., 2011; Cirrito et al., 2005). Possibly these theories can be reconciled 
with the notion that synaptic activity generates the initial stages of pathological deposition, which 
eventually reaches toxic levels and damages synapses. 
This concept is consistent with the data in this project, where both positive and negative 
relationships have been found between synapses and pathology. In BA24, PSD95 was elevated, and 
ZnT3 decreased, in cases with higher Aβ pathology; whereas in BA40, SPP and PSD95 were 
decreased in cases with higher levels of tau pathology. 
 
5.4.3 Associations between ZnT3 and pathology. 
It was found that a loss of ZnT3 from synaptic vesicles predicted plaque and tangle scores in BA9 and 
α-synuclein scores in BA40. Additionally, in BA24, ZnT3 values (but not the ratio to SPP) predicted 
plaque and tangle pathology. This latter point is probably due to the higher variation in SPP values in 
BA24 removing any significance in the ratio of ZnT3 to SPP. The association between ZnT3 and AD 
pathology, and not to α-synuclein pathology, in BA9, is probably a consequence of the relative 
absence of BA9 α-synuclein pathology in the PDD cases, coupled with relatively higher AD pathology 
and reduced ZnT3 levels. Likewise, the lack of association between ZnT3 and AD pathology in BA40 is 
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a result of the relatively unchanged ZnT3 levels between the cases with the highest AD pathology 
(AD cases) and the lowest (controls). 
As mentioned in the introduction section on ZnT3, a reduction in ZnT3 can be directly equated to a 
loss of regulation of synaptic Zn as it is the sole vesicular Zn transporter, thus Zn is unable to be 
released from vesicles as a co-transmitter in the absence of ZnT3; indeed, this is well established in 
ZnT3 knockout mice (Adlard et al., 2010; Cole et al., 1999; Linkous et al., 2008). The initial reports on 
the cognitive phenotype of ZnT3 knockout mice (Cole et al., 1999) were confounded by the 
unexpected preservation of learning and memory in these mice; an unexpected finding in the light of 
the essential nature of Zn as a modulator of neurotransmission. However, Adlard and colleagues 
reported the hypothesised cognitive phenotype did occur, but later in life, and proposed an 
interaction with AD pathology to explain this delayed onset of cognitive impairment in the absence 
of ZnT3. The mechanism of which, they suggest to be an entrapment of Zn by the lifetime 
accumulation of plaques producing a similar effect to the ablation of ZnT3.  
In vitro studies have implicated Zn in the aggregation of Aβ (Bush et al., 1994; Curtain et al., 2001), 
tau (Boom et al., 2009; Mo et al., 2009) and α-synuclein (Paik et al., 1999; Yamin et al., 2003). 
Therefore, the finding of associations between dyshomeostasis of synaptic Zn and these pathological 
proteins in this study is in accordance with the reported in vitro evidence, and the theory proposed 
by Adlard et al. may offer a connection between this association of Zn and pathology to that 
observed between Zn and cognitive decline. In summary, it can be hypothesised that loss of 
regulation of synaptic Zn denies Zn as a modulator of neurotransmission and cognition, and may 
increase availability of Zn to promote aggregation of Aβ, tau and α-synuclein at the synapse; an 





5.5 Modulation of synaptic zinc as an approach to disease modification 
 
The published evidence (as discussed in the preceding sections, and supported by the findings of this 
project) suggest there to be a two-fold story to zinc in dementia; excess Zn can increase pathological 
proteins whilst its absence is detrimental to cognition and depression. This evidence for an 
interaction between Zn ions and Aβ pathology that was deleterious to cognition led to investigations 
into pharmacological modulation of Zn as a potential avenue of disease treatment; with the 
important caveat that reducing Zn concentrations could worsen cognition even if it reduced the 
propagation of pathology (especially given the doubt concerning the direct impact of Aβ pathology 
on cognition) and that increasing Zn concentration could have the reverse effect (Relkin, 2008).  
A quinoline derivative, PBT2, has indeed been demonstrated to reduce the interaction between Zn 
and Aβ whilst increasing the availability of Zn to the synapse for physiological functions (Adlard et 
al., 2008). PBT2 is classed as an ionophore, a compound able to promote the movement of an ion (in 
this case Zn) across a cell membrane (Adlard et al., 2008). In vitro studies by Adlard et al. have 
established PBT2 to reduce Zn binding to (and precipitation of) Aβ, and in doing so to mitigate Aβ 
mediated synaptotoxicity (a finding corroborated by increased SPP levels in APP transgenic mice 
treated with PBT2). Additionally the authors demonstrated PBT2 to lower concentrations of soluble 
and insoluble Aβ and plaque scores in Tg2576 APP transgenic mice without affecting overall Zn levels 
in the brain. Strikingly, these mice displayed improved learning and memory after PBT2 
administration that was superior to wild type mice, even wild type that had also been given PBT2. 
PBT2 treated APP/PS1 transgenic mice were found to have reduced phospho-tau concentrations, 
and the Tg2576 mice reduced total tau concentrations (Adlard et al., 2008), although the authors did 
not speculate on whether this was related to the reductions in Aβ or direct interference of Zn 
mediated tau aggregation (Boom et al., 2009; Mo et al., 2009). Adlard and colleagues propose PBT2 
to elucidate these effects by promoting Zn transport into the pre-synaptic terminals of neurons, thus 
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denying Zn any role in Aβ aggregation and increasing Zn availability for release with 
neurotransmitter in its physiological role. 
PBT2 has been demonstrated to be well tolerated in a phase IIa clinical trial in patients with mild AD 
(Lannfelt et al., 2008). Reductions in CSF Aβ42 concentrations were reported in this trial, in addition 
to hints at an efficacious impact on cognition, despite the trial not being designed to detect this. 
Subsequent analysis attributed greater statistical significance to the improvement in cognition 
caused by PBT2 (Faux et al., 2010), leading the authors to conclude that PBT2 was likely to have a 
rapid beneficial effect on cognition in patients with AD through a disease modifying mechanism, and 
that further large scale trials were justified. 
Despite reports of Zn promoting aggregation of α-syn (Golts et al., 2002; Paik et al., 1999), little 
investigation has been undertaken with regards to modifying this phenomenon. There has been 
recent criticism of this theory by Valiente-Gabioud and colleagues (Valiente-Gabioud et al., 2012), 
who (in light of the fact that Zn is mainly shown to promote α-syn aggregation at mM 
concentrations, combined with their findings that the Zn-α-syn interaction is low affinity) suggest 
doubt as to the physiological relevance of Zn-α-syn interactions given that the average brain 
concentration of Zn falls in the µM range (Takeda, 2000). However, Zn concentrations have been 
reported in excess of 1mM in synaptic vesicles (Frederickson et al., 2000); so given that synapses are 
proposed to be the site of α-syn aggregation mediated toxicity and ZnT3 mediated dyshomeostasis 
(and therefore the location where any Zn-α-syn interaction would have the greatest relevance) it is 
plausible that Zn can reach concentrations at the synapse that are more than sufficient for 
promotion of aggregation of α-syn. It would be of interest to explore the potential for modifying the 




5.6 Unexpected findings 
It could have been expected that some relationships would be detected between synaptic 
dysfunction and persecution and agitation. However, the relatively low number of cases with scores 
for these symptoms, and in particular high scores will have impaired the ability to detect any 
relationship to the biochemistry.   
Additionally, it is interesting that there were so few links between α-synuclein pathology and 
synaptic biochemistry. Only ZnT3 in BA40 and drebrin in BA9 were altered in cases with higher α-syn 
scores. Several factors could explain this, PDD cases had low levels of α-syn pathology, whilst they 
did have the higher deficits in synaptic proteins in BA9; this was not sufficiently different to DLB to 
cause a positive correlation.  
It may be that soluble α-syn oligomers are the synapto-toxic species of α-syn and thus have greater 
responsibility for synaptic deficits. A growing body of evidence supports the synaptic presence and 
toxicity of such species (Kramer and Schulz-Schaeffer, 2007; Nakata et al., 2012; Tanji et al., 2010). 
Although the Novacastra antibody used for the majority of α-syn IHC and semi-quantification in this 
study reveals some extent of these synaptic aggregates, it does not detect soluble species of α-syn. 
Additionally, as the PET blot developed by Kramer and Schulz-Schaeffer (Kramer and Schulz-
Schaeffer, 2007) could not be replicated in our lab (see method section on PET blotting), the extent 




5.7 Concluding Remarks 
The principal findings of this study were; the association between reduced ZnT3 in the prefrontal 
cortex and both cognitive decline and depression, the associations between ZnT3 and alpha-
synuclein pathology in the parietal cortex and Aβ and tau pathology in the prefrontal cortex and the 
differences in synaptic biochemistry between DLB and PDD cases. 
Once differences between diagnostic groups were detected it was perhaps inevitable that 
associations between the proteins of interest and both clinical and pathological data would also be 
detected because it is this clinical and pathological data that forms the essence of the diagnosis. 
However it could not be assumed to be guaranteed as the quality and quantity of clinical and 
pathological data, with particular concern to the control cases, would determine the ability of the 
statistical methods employed to detect any associations between the biochemistry and the clinical 
and pathological data. If the control cases had either poor data in terms of missing data, or were 
poorly selected as controls (i.e. had high pathology) then it would have been immensely harder to 
detect any possible association between the biochemistry and pathology. This point is especially 
valid for the behavioural and cognitive data as this data relies upon the selection criteria for control 
cases due to the assumptions made that control cases fall into the ‘absent’ or ‘none’ categories. 
It is encouraging to have discovered potential correlates of cognitive decline that are of a synaptic 
and functional nature as this is consistent with current opinion. Klucken and colleagues have 
proposed the lack of overt neuronal loss in DLB (compared to AD and controls) (Buldyrev et al., 2000; 
Lippa et al., 1994) in combination with poor correlation between α-syn pathology and cognitive 
decline (Colosimo et al., 2003) to support evidence that functional synaptic  deficits underlie 
cognitive impairment in DLB (Klucken et al., 2006; Klucken et al., 2003). 
Determining whether biochemical differences exist between PDD and DLB could be of assistance in 
diagnosis and management of these dementias, particularly in light of neuroleptic sensitivity in DLB 
patients (Aarsland et al., 2005a; McKeith et al., 1992). CSF is the most likely medium for any 
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biomarker based upon synaptic proteins. It has been reported that SPP is not sufficiently stable in 
CSF (due to its high hydrophobicity) to allow accurate or reliable detection, but other synaptic 
proteins such as SNPA25 and synaptotagmin are (Davidsson et al., 1999), and so if synaptic 
dysfunction is a point of distinction between DLB and PDD it could be useful to investigate other 
synaptic markers in CSF to establish the viability of this approach as a biomarker. There are no 
reports of the viability of detection of PSD95 or ZnT3 in CSF, thus development of an assay to detect 
these proteins could provide an avenue for a biomarker. However, the differences in synaptic 
proteins between dementias shown in this project are brain region specific and thus may not be 
reflected in CSF; this would need to be determined. 
The sample size of this study was limited by the availability of DLB and PDD cases with detailed 
clinical data, and whilst the numbers of these cases was large relative to similar studies on DLB and 
PDD, they are low in comparison to post-mortem studies of AD and other types of studies. This 
creates common problems encountered throughout biomedical research when sample sizes are 
limited, and is a specific problem to post-mortem studies. Button and colleagues recently discussed 
some of the issues faced by studies with small sample sizes (Button et al., 2013). Amongst these was 
a bias towards reporting false negatives and an exaggeration of any true effect that is detected. 
Whilst there was little that could have been done to counter these limitations in this study, the 
authors also comment that large sample numbers have drawbacks such as the inclusion of poorer 
quality cases/data in order to improve the n number, something that was addressed by this study. 
Finally, it should be remarked that high variance is expected in human studies of this nature, due to 
the large genetic and environmental heterogeneity inherent in cohorts sourced from such a wide 
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Demographic and confounding variables 













A011/06 Control F 82 43.0 6.4 - - 0 frequent - - - 
6 
A047/02 Control F 87 21.5 6.0 0 0 0 none - - - 
10 
A048/09 Control M 81 42.0 6.7 1 1 - - - - - 
3 
A049/03 Control M 79 34.0 6.3 - - - - - - - 
9 
A063/10 Control F 90 74.0 6.6 - 1 - - - - - 
2 
A133/95 Control M 85 48.0 7.0 - - - - - - - 
17 
A134/00 Control M 86 6.0 6.8 2 1 0 none 0 - - 
12 
A136/10 Control F 89 65.0 6.4 2 1 0 none - - - 
2 
A153/01 Control M 71 5.0 6.4 0 0 0 none 0 - - 
11 
A170/00 Control F 68 9.0 6.6 0 0 0 none 0 - - 
12 
A185/04 Control M 80 48.0 6.6 4 2 1 sparse 0 - - 
8 
A219/97 Control F 76 63.0 6.0 0 0 0 none 0 - - 
15 
A223/96 Control M 80 11.0 6.7 0 0 0 none 0 - - 
16 
A239/95 Control F 79 38.0 6.5 3 2 1 sparse 0 - - 
17 
A283/96 Control M 77 29.0 6.5 1 1 0 none 0 - - 
16 

















A31/96 Control M 70 45.0 6.8 0 0 0 none 0 - - 
16 
A316/95 Control M 80 35.0 6.4 1 1 0 none 0 - - 
17 
A320/94 Control M 77 96.0 6.6 - - 9 - - - - 
18 
A33/96 Control F 96 72.0 6.1 2 1 0 none 0 - - 
16 
A346/95 Control M 85 16.0 6.2 4 2 1 sparse 0 - - 
17 
A359/08 Control F 80 22.0 6.5 - - - - - - - 
4 
A401/97 Control M 85 42.0 6.1 3 2 0 none 0 - - 
15 
A61/96 Control M 65 29.0 6.8 0 0 0 none 0 - - 
16 
A94/95 Control F 80 31.0 6.2 1 1 0 none 0 - - 
17 
A143/00 PDD F 89 54.0 6.1 2 1 0 none 0 - - 
10 
20020080 PDD M 70 17.0 6.2 2 1 0 none 6 5 12 
9 
20030004 PDD F 69 46.0 6.6 2 1 0 none 11 10 10 
9 
20030103 PDD F 73 30.0 5.8 4 2 1 sparse 16 4 10 
9 
20030111 PDD M 81 40.0 5.9 2 1 0 none 11 8 9 
9 
20030134 PDD M 75 40.0 6.5 3 2 1 sparse 19 2 4 
8 
20040022 PDD M 79 30.0 6.8 3 2 1 sparse 15 9 14 
8 

















20040105 PDD M 68 11.0 6.2 5 3 3 frequent 18 6 8 
7 
20050096 PDD M 73 31.0 5.8 0 0 0 none 8 5 23 
7 
20050099 PDD M 89 64.0 6.0 3 2 1 sparse 9 3 16 
12 
ST01/01 PDD F 83 24.0 6.6 - 1 2 moderate 11 4 19 
11 
ST02/01 PDD M 83 37.0 6.5 - 1 0 none 6 1 15 
11 
ST03/01 PDD M 75 36.0 6.3 - 1 1 sparse 14 1 13 
11 
ST04/01 PDD F 85 - 6.8 - 2 3 frequent 18 4 8 
11 
ST09/02 PDD M 79 72.0 6.8 - 3 3 frequent 3 1 9 
10 
ST10/02 PDD M 82 24.0 6.4 - 1 1 sparse 12 1 3.5 
10 
ST11/02 PDD F 73 60.0 6.7 2 1 1 sparse - - - 
10 
ST12/02 PDD F 80 28.0 6.3 - 1 0 none 3 1 6 
10 
ST13/02 PDD F 81 28.0 6.9 2.0 1 1 sparse - - - 
10 
ST14/02 PDD M 78 24.0 6.5 3.0 2 2 moderate - - - 
10 
ST15/02 PDD F 88 72.0 5.9 2.0 1 0 none - - - 
10 
ST16/02 PDD M 80 26.0 6.6 2.0 1 0 none - - - 
10 
ST17/02 PDD M 72 9.0 6.9 1.0 1 0 none - - - 
10 

















ST19/02 PDD F 84 27.0 6.2 - 1 0 none 6 - 6 
10 
ST20/02 PDD F 85 36.0 6.4 - 1 2 moderate 20 2 16 
10 
ST21/03 PDD F 83 24.0 6.5 - 1 3 frequent 15 2 26 
9 
ST22/02 PDD F 75 24.0 7.2 - 1 3 frequent 6 2 7 
9 
ST23/03 PDD F 82 33.0 6.7 - 1 2 moderate 14 2 14 
9 
ST24/03 PDD M 88 24.0 6.5 - 2 1 sparse - 6 15 
9 
ST25/04 PDD F 86 24.0 6.3 2 1 1 sparse - 7 21 
8 
ST29/04 PDD F 88 32.0 6.2 - 2 1 sparse - - - 
8 
ST30/04 PDD M 86 32.0 6.7 - 0 0 - - - - 
8 
A014/07 DLB M 74 20.0 6.9 - 3 0 frequent 18 - - 
19 
A028/10 DLB M 81 85.0 6.6 - 2 0 moderate 14 - - 
19 
A035/08 DLB F 83 14.0 6.2 - 2 0 sparse 18 - - 
21 
A040/10 DLB F 87 33.0 6.1 - 1 0 none 12 - - 
18 
A046/07 DLB M 76 53.0 6.5 - 2 0 moderate 9 - - 
14 
A053/09 DLB M 91 45.0 6.2 5 3 3 frequent 10 - - 
13 
A055/09 DLB F 87 30.0 6.3 5 3 3 frequent 13 - - 
9 

















A084/09 DLB F 85 31.0 5.9 5 3 3 frequent - - - 
8 
A092/07 DLB M 88 17.5 6.5 6 3 3 frequent 18 - - 
8 
A109/01 DLB M 65 5.0 6.6 3 2 1 sparse 19 9 7 
7 
A148/08 DLB F 84 13.5 6.1 4 2 2 moderate 11 - - 
7 
A162/07 DLB M 80 25.0 7.3 3 2 1 sparse 7 - - 
6 
A190/03 DLB M 83 38.0 6.2 3 2 1 sparse 16 - - 
5 
A196/09 DLB F 80 28.0 6.6 4 2 1 sparse 20 - - 
5 
A204/07 DLB M 74 18.0 6.7 2 1 0 none 9 - - 
4 
A229/05 DLB M 79 4.0 6.9 3 2 1 sparse 15 - - 
2 
A231/06 DLB F 70 22.5 6.9 3 2 2 moderate 9 - - 
4 
A249/06 DLB M 83 4.0 6.7 4 2 2 moderate 14 3 - 
4 
A273/05 DLB M 86 8.0 5.9 2 1 1 sparse 11 4 - 
13 
A304/06 DLB F 92 55.0 6.6 3 2 1 sparse 15 9 - 
9 
A335/08 DLB M 79 12.3 6.8 1 1 0 none 0 - - 
12 
A336/99 DLB M 69 21.0 7.3 3 2 1 sparse 14 3 - 
11 
20030007 DLB F 88 16.0 5.9 3 2 2 moderate 11 8 4 
12 

















20040034 DLB F 75 64.0 5.7 6 3 3 frequent 20 3 2 
10 
20040085 DLB M 77 29.0 5.7 2 1 2 moderate 18 2.5 2 
4 
20050030 DLB F 91 84.0 5.8 5 3 3 frequent 6 7 3 
5 
20050040 DLB F 75 78.0 6.0 6 3 3 frequent 16 5 3 
2 
20060025 DLB M 76 13.0 6.0 2 1 1 sparse 14 8 7 
4 
20070009 DLB M 74 42.0 5.6 4 2 1 sparse 10 8 3 
2 
20070105 DLB M 71 8.0 5.7 2 1 1 sparse 19 7 7 
5 
20080083 DLB F 80 17.0 5.7 5 3 3 frequent 19 8 6 
3 
20100575 DLB M 77 46.0 5.9 3 2 0 none 10 11 7 
3 
027 93/1089 DLB F 87 13.0 6.4 5/6 3 3 frequent - 6 0 
3 
036 93/1075 DLB M 85 19.0 6.2 5/6 3 3 frequent - 10 4 
3 
051 91/1249 DLB M 82 80.0 6.4 5/6 3 3 frequent - 3 0 
5 
052 94/1224 DLB M 82 29.0 6.2 3/4 2 2 moderate - 7 1 
11 
055 98/1226 DLB M 81 38.0 6.7 3/4 2 1 sparse - 9 24 
4 
106 99/1109 DLB F 88 34.0 6.8 3/4 2 2 moderate - 0 0 
5 
333 08/064 DLB F 87 24.0 6.2 5/6 3 3 frequent - 99 99 
9 

















383 99/1147 DLB F 92 60.0 6.0 1/2 1 1 sparse - 3 0 
5 
436 03/148 DLB M 76 70.0 6.2 1/2 1 3 frequent - 7 5 
7 
439 00/1140 DLB M 75 76.0 6.9 3/4 2 2 moderate - 4 3 
6 
470 01/156 DLB M 84 74.0 6.5 3/4 2 3 frequent - 4 2 
6 
475 00/1108 DLB F 85 38.0 6.3 3/4 2 3 frequent - 2 1 
7 
495 01/172 DLB M 86 115.0 6.7 3/4 2 2 moderate - 6 3 
6 
550 02/021 DLB M 77 57.0 6.9 5/6 3 0 none - 1 1 
4 
745 08/126 DLB F 76 96.0 6.5 1/2 1 3 frequent - 10 10 
13 
C1007 
01/176 DLB M 82 55.0 6.8 1/2 1 0 none - 6 9 
11 
ST26/04 DLB M 90 48.0 6.5 5 3 3 frequent - 4 - 
8 
ST27/04 DLB M 80 84.0 6.5 5 3 3 frequent - 7 - 
8 
ST28/04 DLB F 88 - 6.6 3 2 2 moderate - 8 - 
8 
ST32/05 DLB F 88 24.0 6.1 6 3 2 moderate - 10 - 
7 
A071/09 AD M 80 10.0 6.3 6 3 - - - 9 0 
3 
A108/09 AD F 84 24.5 6.7 4 2 - - - 8 0 
3 
A120/09 AD F 85 79.0 6.3 6 3 - - - 16 0 
3 

















A216/09 AD F 88 44.0 6.0 5 3 - - - 7 0 
4 
A267/09 AD F 90 74.0 6.0 5 3 - - - 8 0 
3 
A349/08 AD F 86 14.0 6.6 6 3 - - - 8 0 
4 
A350/09 AD F 98 24.0 6.4 4 2 2 moderate - 11 0 
3 
A37/09 AD M 88 29.0 6.5 6 3 - - - 12 0 
3 
A371/08 AD M 82 70.0 7.1 4 2 - - - 9 0 
4 
A38/11 AD F 72 67.0 6.0 6 3 - - - 9 0 
1 
A61/09 AD F 103 12.3 6.4 5 3 - - - 13 0 
3 
A7/10 AD F 84 30.0 6.1 6 3 - - - 8 0 
2 
A76/09 AD M 97 18.0 6.2 5 3 3 frequent - 12 0 
3 
A8/10 AD F 98 25.0 6.1 6 3 - - - 11 0 
2 






































































































































A011/06 Control - - - - - - - - - - - - - - - - 3 - - - - 
A047/02 Control - - - - - - - - - - - - - - - - 3 - - - - 
A048/09 Control - - - - - - - - - - - - - - - - 3 - - - - 
A049/03 Control - - - - - - - - - - - - - - - - 3 - - - - 
A063/10 Control - - - - - - - - - - - - - - - - 3 - - - - 
A133/95 Control - - - - - - - - - - - - - - - - 3 - - - - 
A134/00 Control - - - - - - - - - - - - - - - - 3 - - - - 
A136/10 Control - - - - - - - - - - - - - - - - 3 - - - - 
A153/01 Control - - - - - - - - - - - - - - - - 3 - - - - 
A170/00 Control - - - - - - - - - - - - - - - - 3 - - - - 
A185/04 Control - - - - - - - - - - - - - - - - 3 - - - - 
A219/97 Control - - - - - - - - - - - - - - - - 3 - - - - 
A223/96 Control - - - - - - - - - - - - - - - - 3 - - - - 
A239/95 Control - - - - - - - - - - - - - - - - 3 - - - - 
A283/96 Control - - - - - - - - - - - - - - - - 3 - - - - 
A308/09 Control - - - - - - - - - - - - - - - - 3 - - - - 
A31/96 Control - - - - - - - - - - - - - - - - 3 - - - - 
A316/95 Control - - - - - - - - - - - - - - - - 3 - - - - 
A320/94 Control - - - - - - - - - - - - - - - - 3 - - - - 
A33/96 Control - - - - - - - - - - - - - - - - 3 - - - - 
A346/95 Control - - - - - - - - - - - - - - - - 3 - - - - 


































































































































A401/97 Control - - - - - - - - - - - - - - - - 3 - - - - 
A61/96 Control - - - - - - - - - - - - - - - - 3 - - - - 
A94/95 Control - - - - - - - - - - - - - - - - 3 - - - - 
A143/00 PDD - - - - - - - - - - - - - - - - - - - - - 
20020080 PDD 3 1 - 1 - - - - - - - 8 13 25 16 9 2 1 2 1 0 
20030004 PDD - 3 - - - - - - - 3 4 - 10 19 19 0 2 2 1 0 0 
20030103 PDD - - - 3 3 - 8 - 3 - - - 17 27 5 11 1 1 0 3 0 
20030111 PDD - 1 - - - - 4 - - - - 6 11 21 6 7.5 1 1 0 0 0 
20030134 PDD - - - - - - - - - - - - 0 27 17 3.3 2 2 0 0 2 
20040022 PDD - - - - - - - - - - - - 0 20 0 6.6 1 2 0 1 0 
20040076 PDD - 4 1 - 1 - 12 - - 4 4 4 30 16 0 8 1 2 1 0 1 
20040105 PDD - - - - - - - - - - - - - 22 9 6.5 1 3 2 3 3 
20050096 PDD - 8 1 4 3 - - - - - - - 16 17 19 0 2 3 1 2 1 
20050099 PDD 6 - 6 4 - - 1 - 3 1 8 - 29 23 4 4.8 1 0 2 3 3 
ST01/01 PDD - - - - - - - - - - - - - - 12 88 2 1 0 1 0 
ST02/01 PDD - - - - - - - - - - - - - - 16 88 2 1 2 2 0 
ST03/01 PDD - - - - - - - - - - - - - - 16 88 2 2 2 0 2 
ST04/01 PDD - - - - - - - - - - - - - - 2 88 1 0 0 0 3 
ST09/02 PDD - - - - - - - - - - - - - - 9 88 1 2 0 2 1 
ST10/02 PDD - - - - - - - - - - - - - - 20 88 2 0 1 2 3 
ST11/02 PDD - - - - - - - - - - - - - - 25 88 3 3 2 1 2 
ST12/02 PDD - - - - - - - - - - - - - - 29 88 3 0 0 0 0 
ST13/02 PDD - - - - - - - - - - - - - - 26 88 3 1 1 1 1 


































































































































ST15/02 PDD - - - - - - - - - - - - - - 13 88 2 2 0 3 2 
ST16/02 PDD - - - - - - - - - - - - - - 20 88 2 0 2 0 0 
ST17/02 PDD - - - - - - - - - - - - - - 27 88 3 1 1 2 1 
ST18/02 PDD - - - - - - - - - - - - - - 10 88 1 3 3 3 2 
ST19/02 PDD - - - - - - - - - - - - - - - 88 - - - - - 
ST20/02 PDD - - - - - - - - - - - - - - 3 88 1 0 0 3 1 
ST21/03 PDD - - - - - - - - - - - - - - 14 88 2 2 2 0 1 
ST22/02 PDD - - - - - - - - - - - - - - 12 88 2 2 2 2 0 
ST23/03 PDD - - - - - - - - - - - - - - 6 88 1 0 0 1 0 
ST24/03 PDD - - - - - - - - - - - - - - 15 88 2 2 0 1 2 
ST25/04 PDD - - - - - - - - - - - - - - 11 88 2 1 0 1 1 
ST29/04 PDD - - - - - - - - - - - - - - 3 88 1 0 0 3 3 
ST30/04 PDD - - - - - - - - - - - - - - 16 88 2 1 0 1 0 
A014/07 DLB - - - - - - - - - - - - - 25 24 0.5 2 - - - - 
A028/10 DLB - - - - - - - - - - - - - 30 10 6.67 1 - - - - 
A035/08 DLB - - - - - - - - - - - - - 29 - - - - - - - 
A040/10 DLB - - - - - - - - - - - - - - - - - - - - - 
A046/07 DLB - - - - - - - - - - - - - 21 18 0.75 2 - - - - 
A053/09 DLB - - - - - - - - - - - - - - - - - - - - - 
A055/09 DLB - - - - - - - - - - - - - 25 0 8.33 1 - - - - 
A072/09 DLB - - - - - - - - - - - - - - - - - - - - - 
A084/09 DLB - - - - - - - - - - - - - - - - - - - - - 
A092/07 DLB - - - - - - - - - - - - - - - - - - - - - 


































































































































A148/08 DLB - - - - - - - - - - - - - 24 18 3 2 - - - - 
A162/07 DLB - - - - - - - - - - - - - 30 30 0 3 - - - - 
A190/03 DLB - - - - - - - - - - - - - - - - - - - - - 
A196/09 DLB - - - - - - - - - - - - - - - - - - - - - 
A204/07 DLB - - - - - - - - - - - - - 29 0 2.64 1 - - - - 
A229/05 DLB - - - - - - - - - - - - - 18 11 7 2 - - - - 
A231/06 DLB - - - - - - - - - - - - - - - - - - - - - 
A249/06 DLB - - - - - - - - - - - - - - 7 88 1 - - - - 
A273/05 DLB - - - - - - - - - - - - - 29 29 0 3 - - - - 
A304/06 DLB - - - - - - - - - - - - - 26 - - - - - - - 
A335/08 DLB - - - - - - - - - - - - - - - - - - - - - 
A336/99 DLB - - - - - - - - - - - - - 28 20 88 2 - - - - 
20030007 DLB 1 4 1 1 - 1 8 2 2 - - 8 28 21 18 1.5 2 3 1 1 2 
20030113 DLB - - 2 - - - 8 1 - - - 6 17 20 12 4 2 1 1 1 1 
20040034 DLB 6 12 4 2 4 - 4 - - 6 - - 38 14 6 4 1 3 3 1 2 
20040085 DLB - 1 4 - - - - - - - - 3 8 10 88 6 1 2 1 1 2 
20050030 DLB - - - - - - 8 - - - - - 8 25 88 1 3 2 2 1 0 
20050040 DLB - - - - - - - - - - - - 0 19 15 4 2 0 0 1 0 
20060025 DLB - - - - 1 - - - - - - 8 9 17 88 5 1 3 1 1 2 
20070009 DLB 6 4 - - - - 6 - - - - 4 20 26 12 3.5 2 3 2 2 0 
20070105 DLB - 4 4 - 4 - 12 - - 8 - 12 44 23 1 
3.666
667 1 3 3 1 2 
20080083 DLB - - 6 - - - 12 - - - - - 18 11 88 88 9 2 2 0 3 


































































































































027 93/1089 DLB - - - - - - - - - - - - - 24 11 3.7 2 1 - 0 - 
036 93/1075 DLB - - - - - - - - - - - - - 3 0 1 1 0 0 0 0 
051 91/1249 DLB - - - - - - - - - - - - - 12 6 4 1 0 0 0 0 
052 94/1224 DLB - - - - - - - - - - - - - 21 9 2.7 1 2 - 0 - 
055 98/1226 DLB - - - - - - - - - - - - - 28 27 0 3 0 0 1 1 
106 99/1109 DLB - - - - - - - - - - - - - 29 30 0 3 0 0 0 0 
333 08/064 DLB - - - - - - - - - - - - - 21 17 0.42 2 0 - 0 - 
367 08/134 DLB - - - - - - - - - - - - - 27 10 1.8 1 1 - 0 - 
383 99/1147 DLB - - - - - - - - - - - - - 14 14 -1 2 2 - - - 
436 03/148 DLB - - - - - - - - - - - - - 22 16 2.2 2 0 1 0 0 
439 00/1140 DLB - - - - - - - - - - - - - 23 15 5.3 2 2 0 0 0 
470 01/156 DLB - - - - - - - - - - - - - 23 18 3.3 2 1 0 0 0 
475 00/1108 DLB - - - - - - - - - - - - - 22 7 15 1 0 2 0 0 
495 01/172 DLB - - - - - - - - - - - - - 5 7 0 1 0 1 1 1 
550 02/021 DLB - - - - - - - - - - - - - 23 16 7 2 0 0 0 0 
745 08/126 DLB - - - - - - - - - - - - - 14 14 14 2 2 - 0 - 
C1007 01/176 DLB - - - - - - - - - - - - - 30 25 2.5 3 0 2 0 0 
ST26/04 DLB - - - - - - - - - - - - - 17 - 88 1 - - - - 
ST27/04 DLB - - - - - - - - - - - - - 22 18 88 2 3 0 0 0 
ST28/04 DLB - - - - - - - - - - - - - 27 20 88 2 0 3 3 3 
ST32/05 DLB - - - - - - - - - - - - - 99 - 88 - - - - - 
A071/09 AD 1 - - - - - 4 1 - - - - - 23 8 15 1 0 2 1 0 
A108/09 AD - - - - - - 12 - - 8 - - - 22 0 5.5 1 0 0 0 0 


































































































































A147/10 AD - - 12 12 12 - 12 12 12 12 - 12 - 21 0 5.25 1 0 0 2 2 
A216/09 AD 1 1 1 3 4 - 4 - - 4 - 12 - 25 16 3 2 1 2 3 0 
A267/09 AD - - 1 - 2 8 6 3 4 12 - 4 - 11 13 88 2 0 0 3 2 
A349/08 AD - - 12 8 - - 4 - 6 - 8 6 - 21 3 4.5 1 0 0 2 3 
A350/09 AD 8 - 8 4 - - 3 - 9 - 3 - - 20 15 2.5 2 2 3 3 3 
A37/09 AD - 3 1 - - - 4 - - 1 - 3 - 22 17 1 2 2 0 0 1 
A371/08 AD 4 2 9 6 - - 12 6 6 - 6 8 - 21 17 1.33 2 1 2 2 3 
A38/11 AD 3 - 12 3 6 - 9 4 4 12 12 8 - 10 0 5 1 0 3 2 3 
A61/09 AD - - - - - - - - - - - - - - - 88 9 - - - - 
A7/10 AD - - - - - - 12 - - - - - - 12 6 1 1 0 2 0 1 
A76/09 AD - - - - - - - - - - - - - 16 15 0.25 2 0 0 1 0 
A8/10 AD - - 2 2 - - 12 - 3 3 - 8 - 10 0 2.5 1 0 2 2 2 









































































































































A011/06 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
A047/02 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
A048/09 Control 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 
A049/03 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
A063/10 Control 0 2 2 0 1 1 1 0 0 0 - 0 1 3 0 - 
A133/95 Control - - - - - - - - - - - - - - - - 
A134/00 Control 0 0 0 0 0 0 3 0 0 0 - 0 0 0 0 - 
A136/10 Control 2 0 3 3 0 0 1 0 0 0 - - 2 0 - - 
A153/01 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
A170/00 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
A185/04 Control 1 - 1 2 0 - 0 0 0 - 0 0 1 - 2 1 
A219/97 Control 0 0 0 0 0 0 0 0 0 0 - - 0 0 - - 
A223/96 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
A239/95 Control 1 3 1 1 1 1 1 1 0 0 0 0 2 4 2 2 
A283/96 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
A308/09 Control 1 0 1 1 0 0 0 0 0 0 - 0 1 0 1 - 
A31/96 Control 0 - 0 0 0 - 0 0 0 - 0 0 0 - 0 0 
A316/95 Control 2 0 2 1 1 0 0 0 0 0 0 0 3 0 1 2 
A320/94 Control - - - - - - - - - - - - - - - - 
A33/96 Control 0 0 0 0 0 0 0 0 0 0 - - 0 0 - - 
A346/95 Control 1 1 1 1 0 0 0 0 0 0 0 0 1 1 1 1 
A359/08 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 






































































































































A61/96 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
A94/95 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
A143/00 PDD 1 1 1 1 1 0 1 1 0 1 0 0 2 2 2 2 
20020080 PDD 0 0 1 0 - 0 0 - 1 0 1 1 - 0 - 2 
20030004 PDD 1 0 0 0 0 1 1 0 1 3 1 1 2 4 1 2 
20030103 PDD 3 2 2 - 1 1 0 0 2 3 1 1 6 6 - 3 
20030111 PDD 2 1 1 1 0 1 0 0 1 3 2 0 3 5 1 3 
20030134 PDD 2 2 1 1 1 2 1 1 2 3 1 1 5 7 3 3 
20040022 PDD 3 1 - - 1 1 2 1 1 3 1 1 5 5 - - 
20040076 PDD 2 1 1 2 0 1 1 1 1 1 2 2 3 3 5 4 
20040105 PDD 2 3 2 2 2 2 2 2 1 2 2 3 5 7 7 6 
20050096 PDD 1 3 1 1 1 2 0 0 1 2 2 1 3 7 2 3 
20050099 PDD 0 1 1 2 1 1 1 1 2 2 1 1 3 4 4 3 
ST01/01 PDD 3 0 1 2 1 0 1 1 1 1 2 1 5 1 4 4 
ST02/01 PDD 0 0 0 0 1 0 0 0 0 2 1 1 1 2 1 1 
ST03/01 PDD 1 0 0 1 0 0 0 0 1 3 2 0 2 3 1 2 
ST04/01 PDD 3 3 1 3 1 1 1 0 2 3 2 0 6 7 3 4 
ST09/02 PDD 1 2 - 2 0 0 0 0 0 1 1 0 1 3 2 - 
ST10/02 PDD 1 1 0 0 0 0 0 1 1 3 1 0 2 4 1 1 
ST11/02 PDD 0 0 1 1 0 0 0 1 0 2 1 0 0 2 2 2 
ST12/02 PDD 0 0 - 0 1 0 0 0 0 1 1 0 1 1 0 - 
ST13/02 PDD 1 1 1 1 0 0 1 0 1 2 1 0 2 3 1 3 
ST14/02 PDD 0 1 1 1 1 1 1 1 1 3 0 0 2 5 2 2 
ST15/02 PDD 0 0 0 0 0 0 0 0 0 2 1 1 0 2 1 1 






































































































































ST17/02 PDD 2 3 1 3 0 0 0 1 0 1 0 0 2 4 4 1 
ST18/02 PDD 3 2 1 0 0 1 0 0 0 0 0 0 3 3 0 1 
ST19/02 PDD 1 1 0 1 0 0 0 0 0 0 0 0 1 1 1 0 
ST20/02 PDD 2 1 1 3 1 1 0 1 2 2 2 1 5 4 5 3 
ST21/03 PDD 3 1 1 3 0 0 0 0 0 2 0 0 3 3 3 1 
ST22/02 PDD 3 0 1 3 1 0 0 0 0 1 0 0 4 1 3 1 
ST23/03 PDD 3 1 1 2 0 0 1 1 1 1 0 1 4 2 4 2 
ST24/03 PDD 2 1 1 1 1 0 1 1 3 3 3 2 6 4 4 5 
ST25/04 PDD - 0 0 - - 1 0 0 0 0 0 0 - 1 - 0 
ST29/04 PDD 0 0 0 0 0 0 0 0 1 3 0 0 1 3 0 0 
ST30/04 PDD 0 0 0 1 1 1 0 1 0 2 0 1 1 3 3 0 
A014/07 DLB 3 3 3 3 3 3 3 3 3 3 3 3 9 9 9 9 
A028/10 DLB 1 0 3 0 1 1 1 1 2 3 2 2 4 4 3 6 
A035/08 DLB 3 3 1 3 1 1 1 2 3 3 3 3 7 7 8 5 
A040/10 DLB 2 2 2 3 1 1 1 1 3 2 2 2 6 5 6 5 
A046/07 DLB 2 0 2 0 0 0 1 0 2 2 2 2 4 2 2 5 
A053/09 DLB 3 2 3 2 1 3 3 2 0 0 0 0 4 5 4 6 
A055/09 DLB 3 3 3 3 2 3 3 2 3 3 2 3 8 9 8 8 
A072/09 DLB 1 1 3 1 1 2 2 1 1 3 2 2 3 6 4 7 
A084/09 DLB 2 3 3 2 1 3 2 3 2 3 2 1 5 9 6 7 
A092/07 DLB 3 1 3 3 1 2 3 1 3 2 3 3 7 5 7 9 
A109/01 DLB 2 0 1 1 1 0 1 0 3 3 3 3 6 3 4 5 
A148/08 DLB 3 1 2 1 1 1 1 1 1 3 1 1 5 5 3 4 
A162/07 DLB 3 0 1 2 0 1 3 0 1 1 0 0 4 2 2 4 






































































































































A196/09 DLB 1 1 3 1 1 2 3 1 3 3 3 3 5 6 5 9 
A204/07 DLB 0 0 0 0 0 0 0 0 2 2 1 2 2 2 2 1 
A229/05 DLB 0 1 2 0 1 0 1 1 3 2 3 3 4 3 4 6 
A231/06 DLB 2 2 2 2 1 1 1 1 - 1 1 1 - 4 4 4 
A249/06 DLB 1 1 1 1 0 1 1 0 2 3 3 1 3 5 2 5 
A273/05 DLB 3 2 3 3 0 0 0 0 2 3 0 1 5 5 4 3 
A304/06 DLB 1 1 1 1 1 0 1 1 3 3 3 1 5 4 3 5 
A335/08 DLB 1 0 1 0 0 0 1 0 0 0 0 0 1 0 0 2 
A336/99 DLB 1 0 1 1 1 0 1 1 3 3 3 2 5 3 4 5 
20030007 DLB - 2 1 2 0 1 1 0 3 3 1 1 - 6 3 3 
20030113 DLB 3 3 1 1 0 1 0 1 2 - 2 2 5 - 4 3 
20040034 DLB - 1 1 3 3 3 2 3 - 3 2 3 - 7 9 5 
20040085 DLB 2 2 2 1 1 1 2 2 2 2 2 1 5 5 4 6 
20050030 DLB 2 3 2 3 2 3 1 2 1 1 0 1 5 7 6 3 
20050040 DLB 0 0 0 0 2 1 2 1 2 2 - 2 4 3 3 - 
20060025 DLB 2 2 2 1 1 1 1 1 1 3 1 1 4 6 3 4 
20070009 DLB 2 1 1 1 1 1 1 1 1 2 1 1 4 4 3 3 
20070105 DLB 2 2 3 3 1 2 1 1 2 3 2 2 5 7 6 6 
20080083 DLB 2 - 1 1 2 2 3 2 2 3 3 1 6 - 4 7 
20100575 DLB 0 0 0 0 0 1 0 1 1 2 1 1 1 3 2 1 
027 93/1089 DLB 2 - 3 3 1 - 2 1 0 3 3 2 3 - 6 8 
036 93/1075 DLB 3 - 3 2 1 - 2 1 2 3 3 2 6 - 5 8 
051 91/1249 DLB 3 - 3 3 3 - 3 3 1 3 3 0 7 - 6 9 
052 94/1224 DLB 1 0 2 2 0 0 0 0 2 2 3 2 3 2 4 5 






































































































































106 99/1109 DLB 2 3 2 1 1 3 1 0 0 2 0 0 3 8 1 3 
333 08/064 DLB 3 1 3 3 2 2 1 1 0 2 0 0 5 5 4 4 
367 08/134 DLB 1 2 2 1 0 2 1 0 0 2 1 1 1 6 2 4 
383 99/1147 DLB 1 0 0 0 0 0 0 0 0 2 1 0 1 2 0 1 
436 03/148 DLB 0 0 0 0 0 0 0 0 1 2 1 0 1 2 0 1 
439 00/1140 DLB 1 2 2 2 1 2 1 0 3 3 3 3 5 7 5 6 
470 01/156 DLB 3 0 3 3 1 0 1 1 1 3 2 1 5 3 5 6 
475 00/1108 DLB 1 2 3 1 0 1 1 1 0 2 3 1 1 5 3 7 
495 01/172 DLB 2 1 2 2 1 1 1 1 1 3 2 1 4 5 4 5 
550 02/021 DLB 3 3 3 2 1 3 2 1 1 3 2 1 5 9 4 7 
745 08/126 DLB 0 - 0 0 0 0 0 0 2 3 2 1 2 - 1 2 
C1007 01/176 DLB 0 0 0 0 0 1 0 0 1 3 1 1 1 4 1 1 
ST26/04 DLB 1 1 1 2 1 1 2 0 - 0 - - - 2 - - 
ST27/04 DLB 2 2 1 1 1 1 2 1 2 2 3 1 5 5 3 6 
ST28/04 DLB 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1 1 
ST32/05 DLB 3 1 1 2 3 2 3 3 1 1 0 1 7 4 6 4 
A071/09 AD 3 1 3 3 3 0 3 3 0 0 0 0 6 1 6 6 
A108/09 AD 3 1 3 3 2 1 3 3 0 0 0 0 5 2 6 6 
A120/09 AD 3 3 3 3 3 3 3 3 0 0 1 0 6 6 6 7 
A147/10 AD 3 2 3 3 3 1 3 3 1 0 - 0 7 3 6 - 
A216/09 AD 3 2 3 3 3 3 3 3 0 0 0 0 6 5 6 6 
A267/09 AD 3 - 3 3 3 1 3 3 0 0 0 0 6 - 6 6 
A349/08 AD 3 1 3 3 2 1 1 2 0 0 0 0 5 2 5 4 
A350/09 AD 1 0 1 1 2 0 2 2 0 0 0 0 3 0 3 3 






































































































































A371/08 AD 3 1 3 2 2 0 3 3 0 0 0 0 5 1 5 6 
A38/11 AD 3 3 3 3 3 3 3 3 0 2 0 0 6 8 6 6 
A61/09 AD 3 3 3 3 2 2 3 3 0 0 0 0 5 5 6 6 
A7/10 AD 3 1 2 3 3 3 3 3 0 1 1 1 6 5 7 6 
A76/09 AD 3 2 3 2 3 2 3 3 1 2 1 1 7 6 6 7 
A8/10 AD 3 2 3 1 2 3 3 2 0 0 0 0 5 5 3 6 



























according to BNF 
coding (4th etc) 
Medication 
classification 
according to BNF 
coding (5th etc) 
N Valid 0 0 0 0 0 
























according to BNF 
coding (4th etc) 
Medication 
classification 
according to BNF 
coding (5th etc) 
N Valid 31 21 13 5 2 








Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid donezepil 8 23.5 25.8 25.8 
anti-parkinsonism 23 67.6 74.2 100.0 
Total 31 91.2 100.0  
Missing System 3 8.8   











Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid donezepil 1 2.9 4.8 4.8 
anti-muscarinic for PD 1 2.9 4.8 9.5 
anti-parkinsonism 8 23.5 38.1 47.6 
anti-depressant 9 26.5 42.9 90.5 
anti-psychotic drugs 2 5.9 9.5 100.0 
Total 21 61.8 100.0  
Missing System 13 38.2   
Total 34 100.0   
Diagnosis = PDD 
 
 




Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid anti-depressant 6 17.6 46.2 46.2 
anti-psychotic drugs 3 8.8 23.1 69.2 
anxiolytic 2 5.9 15.4 84.6 
hypnotic 2 5.9 15.4 100.0 
Total 13 38.2 100.0  
Missing System 21 61.8   








Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid anti-psychotic drugs 3 8.8 60.0 60.0 
hypnotic 2 5.9 40.0 100.0 
Total 5 14.7 100.0  
Missing System 29 85.3   
Total 34 100.0   










Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid hypnotic 2 5.9 100.0 100.0 
Missing System 32 94.1   
Total 34 100.0   























according to BNF 
coding (4th etc) 
Medication 
classification 
according to BNF 
coding (5th etc) 
N Valid 38 27 11 3 1 
Missing 17 28 44 52 54 
Diagnosis = DLB 
 
 




Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 9.00 1 1.8 2.6 2.6 
Tacrine 4 7.3 10.5 13.2 
donezepil 11 20.0 28.9 42.1 
anti-muscarinic for PD 2 3.6 5.3 47.4 
anti-parkinsonism 7 12.7 18.4 65.8 
anti-depressant 3 5.5 7.9 73.7 
anti-psychotic drugs 6 10.9 15.8 89.5 
anxiolytic 2 3.6 5.3 94.7 
hypnotic 2 3.6 5.3 100.0 
Total 38 69.1 100.0  
Missing System 17 30.9   
Total 55 100.0   










Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 60.00 1 1.8 3.7 3.7 
Tacrine 4 7.3 14.8 18.5 
anti-parkinsonism 5 9.1 18.5 37.0 
anti-depressant 8 14.5 29.6 66.7 
anti-psychotic drugs 3 5.5 11.1 77.8 
anxiolytic 2 3.6 7.4 85.2 
hypnotic 4 7.3 14.8 100.0 
Total 27 49.1 100.0  
Missing System 28 50.9   
Total 55 100.0   








Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 59.00 1 1.8 9.1 9.1 
Tacrine 1 1.8 9.1 18.2 
Ginkgo 1 1.8 9.1 27.3 
anti-parkinsonism 1 1.8 9.1 36.4 
anti-depressant 2 3.6 18.2 54.5 
82.00 1 1.8 9.1 63.6 
anxiolytic 3 5.5 27.3 90.9 
hypnotic 1 1.8 9.1 100.0 
Total 11 20.0 100.0  
Missing System 44 80.0   
Total 55 100.0   











Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid memantine 1 1.8 33.3 33.3 
anti-depressant 1 1.8 33.3 66.7 
hypnotic 1 1.8 33.3 100.0 
Total 3 5.5 100.0  
Missing System 52 94.5   
Total 55 100.0   








Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid anti-muscarinic for PD 1 1.8 100.0 100.0 
Missing System 54 98.2   
Total 55 100.0   


























according to BNF 
coding (4th etc) 
Medication 
classification 
according to BNF 
coding (5th etc) 
N Valid 38 27 11 3 1 
Missing 17 28 44 52 54 











Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 9.00 1 1.8 2.6 2.6 
Tacrine 4 7.3 10.5 13.2 
donezepil 11 20.0 28.9 42.1 
anti-muscarinic for PD 2 3.6 5.3 47.4 
anti-parkinsonism 7 12.7 18.4 65.8 
anti-depressant 3 5.5 7.9 73.7 
anti-psychotic drugs 6 10.9 15.8 89.5 
anxiolytic 2 3.6 5.3 94.7 
hypnotic 2 3.6 5.3 100.0 
Total 38 69.1 100.0  
Missing System 17 30.9   
Total 55 100.0   








Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 60.00 1 1.8 3.7 3.7 
Tacrine 4 7.3 14.8 18.5 
anti-parkinsonism 5 9.1 18.5 37.0 
anti-depressant 8 14.5 29.6 66.7 
anti-psychotic drugs 3 5.5 11.1 77.8 
anxiolytic 2 3.6 7.4 85.2 
hypnotic 4 7.3 14.8 100.0 
Total 27 49.1 100.0  
Missing System 28 50.9   
Total 55 100.0   












Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 59.00 1 1.8 9.1 9.1 
Tacrine 1 1.8 9.1 18.2 
Ginkgo 1 1.8 9.1 27.3 
anti-parkinsonism 1 1.8 9.1 36.4 
anti-depressant 2 3.6 18.2 54.5 
82.00 1 1.8 9.1 63.6 
anxiolytic 3 5.5 27.3 90.9 
hypnotic 1 1.8 9.1 100.0 
Total 11 20.0 100.0  
Missing System 44 80.0   
Total 55 100.0   
Diagnosis = DLB 
 
 




Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid memantine 1 1.8 33.3 33.3 
anti-depressant 1 1.8 33.3 66.7 
hypnotic 1 1.8 33.3 100.0 
Total 3 5.5 100.0  
Missing System 52 94.5   
Total 55 100.0   
Diagnosis = DLB 
 
 




Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid anti-muscarinic for PD 1 1.8 100.0 100.0 
Missing System 54 98.2   
Total 55 100.0   






























A011/06 208.01 0.70 0.92 0.61 0.63 1.46 0.42 0.96 0.79 1.02 - 1.00 0.09 
A047/02 64.34 1.21 0.99 0.61 0.90 - - - - 1.07 - 1.14 0.17 
A048/09 90.32 0.48 0.33 0.67 1.26 1.08 - 0.98 1.43 0.91 0.40 0.71 0.12 
A049/03 68.99 1.46 0.84 0.67 1.30 0.60 0.98 1.95 1.09 1.34 0.53 1.25 0.23 
A063/10 147.24 0.54 0.28 0.75 0.95 0.86 0.53 0.96 0.38 - 0.23 0.66 0.05 
A133/95 - 0.93 0.38 0.61 0.55 - 0.44 0.76 0.38 0.86 0.04 0.80 0.30 
A134/00 - 1.49 2.19 0.57 0.65 0.61 0.26 0.77 0.51 0.85 0.98 0.89 - 
A136/10 109.30 0.68 0.65 0.92 1.73 1.06 0.40 0.99 1.34 1.14 1.01 1.09 0.71 
A153/01 - 0.87 1.02 0.95 0.38 2.04 0.71 0.90 0.47 0.82 2.01 1.13 0.49 
A170/00 - 0.59 2.25 0.60 0.29 0.48 0.24 0.77 0.28 0.85 0.98 0.76 0.23 
A185/04 85.70 0.79 1.31 0.60 0.25 1.50 - 0.80 0.37 0.80 0.82 1.15 1.12 
A219/97 - - 0.06 0.26 0.08 - - - - 1.05 0.85 0.66 0.61 
A223/96 83.59 1.08 0.79 - 0.51 1.37 - 0.87 0.31 1.22 2.00 1.66 0.53 
A239/95 50.16 - 0.74 0.75 0.36 1.86 0.23 0.84 0.33 0.86 0.87 0.80 1.30 
A283/96 54.17 1.28 0.69 0.75 0.31 0.95 0.44 0.54 0.48 1.38 0.82 0.92 0.43 
A308/09 90.68 0.47 0.71 0.66 1.24 0.63 - 0.99 0.86 0.87 0.25 - 0.16 
A31/96 - 0.75 1.81 0.63 0.77 0.43 0.53 0.62 0.39 0.80 0.83 0.63 0.41 
A316/95 55.85 0.77 0.42 1.24 0.74 0.50 0.72 0.53 0.24 0.90 1.28 0.96 3.68 
A320/94 95.48 1.11 0.41 0.86 0.59 - - 0.88 0.42 0.84 0.64 1.40 - 
A33/96 - 1.02 0.24 0.62 0.26 0.77 0.43 0.48 0.27 1.01 0.37 0.96 0.46 
A346/95 60.84 0.98 0.60 0.83 0.59 0.58 0.17 0.45 0.31 1.18 0.83 0.61 0.48 
A359/08 85.92 1.41 0.70 0.97 1.44 0.68 - 0.73 - 0.90 0.56 - 0.10 
A401/97 94.77 0.76 1.60 0.64 0.73 0.98 0.22 0.37 0.12 0.99 0.69 0.77 0.47 
A61/96 - - - - - 0.62 0.24 0.70 - 0.80 0.90 0.78 1.30 




























A143/00 - 0.75 0.36 0.86 0.20 - - - - - - - - 
20020080 253.18 0.75 0.44 0.70 0.45 1.02 0.65 0.73 0.35 1.69 1.24 1.33 0.71 
20030004 161.53 0.53 0.32 0.48 0.51 0.89 0.51 0.76 0.47 1.22 0.78 0.94 0.53 
20030103 - 0.83 0.19 0.91 0.24 1.20 0.78 0.75 0.50 0.82 0.71 0.85 - 
20030111 - - - - - 0.82 0.27 0.67 0.33 0.79 0.27 0.65 0.16 
20030134 271.98 1.60 0.34 0.30 0.22 0.65 0.38 0.57 0.35 0.57 1.11 0.51 0.40 
20040022 248.23 1.04 0.33 0.75 0.37 0.90 0.47 0.57 0.34 0.75 - 0.74 0.75 
20040076 32.88 0.64 0.85 0.78 0.44 1.06 1.60 0.49 0.57 1.42 - 0.75 0.48 
20040105 97.47 0.49 0.51 0.36 0.25 1.40 1.50 0.52 0.59 1.56 - 0.86 0.29 
20050096 79.11 1.05 0.47 - 0.22 0.93 0.87 0.44 0.37 1.02 1.02 1.02 0.99 
20050099 137.81 1.03 0.27 0.88 0.50 0.83 0.66 0.58 0.26 0.70 0.50 0.73 0.19 
ST01/01 - 0.72 0.61 0.51 0.29 0.47 0.18 0.73 0.54 1.20 0.41 0.99 0.18 
ST02/01 106.76 0.74 0.36 0.44 0.29 0.79 0.59 0.78 0.48 1.04 0.95 0.82 0.27 
ST03/01 136.37 0.54 0.25 0.45 0.57 0.91 0.16 1.68 0.17 0.70 0.59 1.00 0.45 
ST04/01 92.59 0.61 0.47 0.60 0.34 0.93 0.45 1.79 0.35 1.09 - 0.73 0.22 
ST09/02 91.36 0.57 0.41 0.37 0.33 0.81 0.04 2.60 0.21 1.06 0.30 0.70 0.34 
ST10/02 118.79 0.67 0.49 0.30 0.29 0.84 0.14 0.69 0.21 0.92 1.08 1.16 0.79 
ST11/02 58.24 0.61 0.51 0.33 0.31 0.91 0.36 0.68 0.20 1.14 0.93 1.20 0.37 
ST12/02 80.49 0.83 0.35 0.32 - 0.99 0.63 - 0.52 1.06 1.22 0.93 0.18 
ST13/02 111.90 0.69 0.18 0.29 0.41 0.50 0.34 0.61 0.42 0.89 0.61 0.83 0.45 
ST14/02 78.99 0.62 0.39 0.32 0.09 0.92 0.72 1.14 0.14 0.63 - 1.07 0.09 
ST15/02 134.36 0.53 0.40 0.30 0.09 0.63 0.10 0.44 0.10 1.10 0.48 1.38 0.06 
ST16/02 118.24 0.49 0.52 0.60 0.52 0.76 0.54 0.85 0.40 0.60 0.45 0.84 0.31 
ST17/02 92.20 0.68 0.74 0.62 0.31 0.77 0.57 0.64 0.27 - 1.06 0.91 0.36 
ST18/02 96.13 0.71 0.42 0.52 0.17 1.16 0.42 0.88 0.72 0.97 1.50 0.96 0.87 
ST19/02 - 0.75 0.28 0.22 0.13 0.36 0.31 0.59 0.29 0.50 1.40 0.94 0.49 




























ST21/03 - 0.53 0.15 0.29 0.12 0.96 0.53 0.88 0.22 1.32 1.15 0.80 0.17 
ST22/02 - 1.78 - 0.55 0.41 0.44 0.21 0.54 0.48 0.98 1.21 0.94 0.43 
ST23/03 - 0.54 0.25 0.54 0.59 0.58 0.25 0.55 0.44 1.03 0.43 0.93 0.33 
ST24/03 163.76 0.68 0.40 0.55 - 0.90 1.24 0.75 0.30 0.79 - 0.68 0.24 
ST25/04 - 0.62 0.42 0.45 0.20 0.41 0.49 0.61 0.35 1.12 0.86 1.39 - 
ST29/04 - 0.53 0.32 0.35 0.14 0.37 0.52 0.38 0.65 1.43 1.09 0.92 0.55 
ST30/04 - 0.60 0.16 - 0.17 1.11 0.07 - 0.21 0.44 0.81 0.88 0.40 
A014/07 - 0.75 0.62 0.85 0.55 - - - - - - - - 
A028/10 - 1.09 - - - - - - - - - - - 
A035/08 - 0.70 0.75 - 0.49 - 0.62 - - - - - - 
A040/10 - - - - - - - - - - - - - 
A046/07 - 0.85 0.47 0.68 - - - - - - 1.36 - 0.39 
A053/09 - 0.98 0.24 0.70 - 0.69 - 0.88 - - - - - 
A055/09 - 0.93 0.33 - 0.92 0.59 - 0.59 - - - - - 
A072/09 - 0.53 - - - - - - - - - - - 
A084/09 - - 0.71 0.56 1.06 - - - - - - - - 
A092/07 - 1.13 0.57 - 0.47 - 0.52 - - - - - - 
A109/01 - 0.76 0.81 - 0.56 1.50 1.06 0.40 - - - - - 
A148/08 - - - - - 0.96 - 0.48 0.27 - - - 0.26 
A162/07 - - - - - 0.99 - 0.46 - - - - 0.33 
A190/03 - 0.59 0.51 0.78 0.48 - 0.87 - - - - - - 
A196/09 - - 0.67 - - - - - - - - - - 
A204/07 - 1.41 0.73 - 0.45 1.35 1.22 0.76 0.86 - - - - 
A229/05 - 0.55 0.67 0.57 0.49 - 0.63 - - - - - - 
A231/06 - 0.34 0.20 - 0.17 1.49 0.35 0.78 - - - - - 
A249/06 - - - - - 1.68 - 0.64 1.02 - - - 0.41 




























A304/06 - - 0.62 - 0.54 1.04 0.62 0.60 - - - - - 
A335/08 - 0.65 0.62 - 0.35 1.05 0.52 0.63 0.35 - - - 0.30 
A336/99 - 0.68 0.35 0.55 0.40 - - - - - 0.54 - 0.32 
20030007 73.53 0.79 0.72 1.19 0.26 0.83 0.45 0.85 0.35 0.82 0.55 1.07 0.37 
20030113 129.80 2.18 0.16 0.68 0.33 0.86 0.55 0.93 0.25 0.84 0.63 0.80 0.18 
20040034 77.68 1.49 0.42 0.71 0.21 - 0.31 0.72 0.10 0.83 0.33 1.07 0.14 
20040085 257.26 - 0.36 1.18 0.37 0.66 0.30 0.60 0.20 0.74 0.26 0.92 0.20 
20050030 76.20 0.73 0.46 1.29 0.25 - 0.43 1.08 0.13 0.89 0.27 0.75 0.08 
20050040 106.23 - 0.31 0.67 0.23 - 0.57 1.03 0.26 1.00 0.24 1.04 0.13 
20060025 - - - - - - 0.70 - - 0.90 0.81 0.81 0.35 
20070009 167.98 1.08 0.42 0.72 0.37 0.87 1.01 0.94 0.29 0.57 0.40 0.96 0.17 
20070105 166.73 0.83 0.87 1.18 0.34 0.83 0.52 0.81 0.23 0.90 0.95 1.01 0.32 
20080083 177.46 1.08 0.53 0.89 0.48 0.70 0.39 0.67 0.28 1.04 0.47 0.88 0.29 
20100575 122.08 1.01 0.25 1.34 0.55 0.95 0.29 0.81 0.43 0.88 0.36 0.79 0.26 
027 93/1089 129.68 0.78 0.38 0.46 0.19 1.03 0.38 0.73 0.15 0.73 0.68 - 0.48 
036 93/1075 - - - - - 1.61 1.05 1.13 0.19 0.85 - 0.89 - 
051 91/1249 88.86 0.94 0.18 0.70 0.17 1.33 0.59 1.02 0.54 0.58 0.44 0.56 0.19 
052 94/1224 65.20 0.86 0.69 0.54 0.32 0.84 0.50 0.90 0.33 0.44 0.83 0.82 0.26 
055 98/1226 - 0.97 0.32 0.57 0.19 1.07 1.07 0.96 0.54 - - - - 
106 99/1109 100.64 1.31 0.89 1.29 0.36 1.09 2.19 - 0.51 0.86 0.10 0.60 0.13 
333 08/064 111.29 0.88 0.69 0.81 0.20 1.07 0.49 0.70 0.15 0.84 0.27 0.58 0.19 
367 08/134 - 1.03 0.28 1.05 0.20 0.94 0.32 0.54 0.12 0.71 0.72 - 0.15 
383 99/1147 - 1.21 0.78 0.62 0.34 - 0.78 - 0.25 1.43 0.53 0.91 0.31 
436 03/148 - 0.81 0.72 0.79 0.47 - 0.81 0.94 0.39 0.75 0.73 - 0.50 
439 00/1140 - 0.95 - 1.02 0.51 0.78 0.26 0.89 0.30 0.81 0.36 0.65 0.15 
470 01/156 - 0.98 0.28 0.72 0.18 0.73 - 0.81 0.33 0.49 0.57 0.74 0.31 




























495 01/172 - 0.82 0.32 0.82 0.57 0.73 0.38 0.71 0.18 1.23 0.69 0.82 0.18 
550 02/021 54.34 1.11 0.33 0.71 0.37 1.09 0.50 1.14 0.23 0.87 0.43 0.70 0.24 
745 08/126 - 0.69 0.38 0.74 0.50 1.24 0.30 1.41 0.32 0.31 0.69 0.66 0.31 
C1007 
01/176 77.14 0.91 0.33 0.63 0.12 1.41 0.54 1.11 0.39 0.59 1.21 0.86 0.29 
ST26/04 109.91 0.68 0.91 0.72 0.52 0.86 0.42 0.86 0.18 0.81 - 0.96 0.35 
ST27/04 - 0.66 0.37 0.78 0.39 0.84 0.99 0.94 0.85 0.94 0.20 - 0.42 
ST28/04 - 0.53 0.36 0.64 0.27 0.44 0.39 0.70 0.60 0.77 0.26 0.95 - 
ST32/05 - 0.57 0.40 0.35 0.17 0.46 0.22 0.60 0.21 - 0.37 0.91 0.11 
A071/09 53.15 1.04 0.48 1.21 0.69 0.99 0.58 0.82 0.67 0.53 0.22 0.57 0.08 
A108/09 - 0.78 0.53 0.71 0.48 0.63 0.34 0.74 0.52 0.74 0.55 1.01 0.38 
A120/09 114.46 0.84 - 0.77 0.34 0.63 0.43 0.84 0.09 0.58 0.38 0.79 0.17 
A147/10 84.42 0.74 0.68 1.57 0.16 0.85 0.90 0.79 0.06 0.22 0.28 0.31 0.23 
A216/09 64.90 0.34 - 1.53 0.22 0.73 0.45 0.65 0.32 0.47 - 0.52 0.07 
A267/09 117.32 0.78 0.32 1.37 0.13 0.71 0.70 0.51 0.08 0.57 0.37 0.50 - 
A349/08 53.41 - 0.32 1.66 0.23 0.99 0.81 - 0.21 0.39 0.32 0.59 0.28 
A350/09 68.75 0.94 0.40 1.46 0.45 1.21 - 1.17 0.52 0.40 - 0.60 0.38 
A37/09 66.23 0.85 1.07 0.53 0.50 0.96 1.92 1.06 0.45 0.43 - 0.71 - 
A371/08 90.02 0.71 0.32 1.44 0.52 0.69 0.44 0.68 0.48 0.49 0.29 0.58 0.33 
A38/11 132.53 0.77 0.68 1.47 0.18 0.72 1.08 0.71 0.17 0.32 0.32 0.44 0.29 
A61/09 74.92 0.95 0.66 0.84 0.44 0.91 0.82 0.88 0.07 0.69 - 1.37 0.47 
A7/10 32.64 0.86 0.93 0.57 0.51 0.85 1.17 1.03 0.25 1.12 - 0.33 0.17 
A76/09 112.82 0.88 1.10 1.28 0.77 0.66 0.68 0.87 0.29 0.41 0.90 0.60 0.56 
A8/10 77.41 0.74 - 1.36 0.29 0.70 - 0.84 0.25 0.43 0.50 0.51 0.19 





Residual and normalised protein values in BA9 








A011/06 Control 0.7 0.92 0.61 0.63 0.85 0.29 -0.03 0.29 
A047/02 Control 1.21 0.99 0.61 0.9 1.08 0.24 -0.20 0.45 
A048/09 Control 0.48 0.33 0.67 1.26 0.68 -0.16 0.12 0.48 
A049/03 Control 1.46 0.84 0.67 1.3 1.16 0.21 -0.26 0.5 
A063/10 Control 0.54 0.28 0.75 0.95 0.73 -0.11 0.10 0.47 
A133/95 Control 0.93 0.38 0.61 0.55 0.97 -0.08 0.03 0.12 
A134/00 Control 1.49 2.19 0.57 0.65 1.17 0.53 -0.29 0.2 
A136/10 Control 0.68 0.65 0.92 1.73 0.83 0.22 0.09 0.73 
A153/01 Control 0.87 1.02 0.95 0.38 0.94 0.19 0.15 -0.04 
A170/00 Control 0.59 2.25 0.6 0.29 0.77 0.55 0.13 -0.04 
A185/04 Control 0.79 1.31 0.6 0.25 0.9 0.46 -0.06 -0.22 
A219/97 Control - - 0.26 0.08 - - -  -0.6 
A223/96 Control 1.08 0.79 - 0.51 1.03 0.1 -  0.09 
A239/95 Control - 0.74 0.75 0.36 - 0.17 -  0.05 
A283/96 Control 1.28 0.69 0.75 0.31 1.11 0.11 -0.04 -0.12 
A308/09 Control 0.47 0.71 0.66 1.24 0.67 0.21 0.13 0.48 
A31/96 Control 0.75 1.81 0.63 0.77 0.88 0.59 0.12 0.27 
A316/95 Control 0.77 0.42 1.24 0.74 0.89 -0.08 0.42 0.25 
A320/94 Control 1.11 0.41 0.86 0.59 1.05 0.13 0.12 0.15 
A33/96 Control 1.02 0.24 0.62 0.26 1.01 -0.19 -0.02 -0.09 
A346/95 Control 0.98 0.6 0.83 0.59 0.99 0 0.14 0.15 
A359/08 Control 1.41 0.7 0.97 1.44 1.15 0.09 -0.17 0.65 
A401/97 Control 0.76 1.6 0.64 0.73 0.88 0.52 0.10 0.25 
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A61/96 Control - - - - - - -  - 
A94/95 Control 0.7 0.93 0.77 0.8 0.85 0.25 0.25 0.4 
20020080 PDD 0.75 0.44 0.7 0.45 0.88 -0.13 0.06 0.04 
20030004 PDD 0.53 0.32 0.48 0.51 0.72 -0.16 0.03 0.2 
20030103 PDD 0.83 0.19 0.91 0.24 0.92 -0.45 0.12 -0.13 
20030111 PDD - - - - - - -  - 
20030134 PDD 1.6 0.34 0.3 0.22 1.2 -0.16 -0.65 -0.27 
20040022 PDD 1.04 0.33 0.75 0.37 1.02 -0.21 -0.08 -0.05 
20040076 PDD 0.64 0.85 0.78 0.44 0.81 0.16 0.15 0.03 
20040105 PDD 0.49 0.51 0.36 0.25 0.69 -0.09 -0.07 -0.22 
20050096 PDD 1.05 0.47 - 0.22 1.02 -0.05 -  -0.27 
20050099 PDD 1.03 0.27 0.88 0.5 1.01 -0.17 -0.02 0.08 
A143/00 PDD 0.75 0.36 0.86 0.2 0.88 -0.08 0.19 -0.21 
ST01/01 PDD 0.72 0.61 0.51 0.29 0.86 0.04 -0.04 -0.04 
ST02/01 PDD 0.74 0.36 0.44 0.29 0.87 -0.14 -0.11 -0.15 
ST03/01 PDD 0.54 0.25 0.45 0.57 0.73 -0.3 0.03 0.14 
ST04/01 PDD 0.61 0.47 0.6 0.34 0.79 - 0.10 0.02 
ST09/02 PDD 0.57 0.41 0.37 0.33 0.76 0.04 -0.09 -0.1 
ST10/02 PDD 0.67 0.49 0.3 0.29 0.83 -0.06 -0.25 -0.15 
ST11/02 PDD 0.61 0.51 0.33 0.31 0.79 0.09 -0.17 -0.02 
ST12/02 PDD 0.83 0.35 0.32 - 0.92 -0.19 -0.32 - 
ST13/02 PDD 0.69 0.18 0.29 0.41 0.84 -0.48 -0.28 0.11 
ST14/02 PDD 0.62 0.39 0.32 0.09 0.79 -0.16 -0.19 -0.66 
ST15/02 PDD 0.53 0.4 0.3 0.09 0.72 0.03 -0.15 -0.55 
ST16/02 PDD 0.49 0.52 0.6 0.52 0.69 -0.02 0.18 0.1 
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ST17/02 PDD 0.68 0.74 0.62 0.31 0.83 0.07 0.05 -0.12 
ST18/02 PDD 0.71 0.42 0.52 0.17 0.85 -0.1 -0.04 -0.39 
ST19/02 PDD 0.75 0.28 0.22 0.13 0.88 -0.29 -0.44 -0.39 
ST20/02 PDD 0.7 0.96 0.34 0.29 0.85 0.28 -0.22 -0.04 
ST21/03 PDD 0.53 0.15 0.29 0.12 0.72 -0.57 -0.18 -0.43 
ST22/02 PDD 1.78 - 0.55 0.41 1.25 - -0.43 0.11 
ST23/03 PDD 0.54 0.25 0.54 0.59 0.73 -0.32 0.08 0.26 
ST24/03 PDD 0.68 0.4 0.55 - 0.83 -0.15 -0.01 - 
ST25/04 PDD 0.62 0.42 0.45 0.2 0.79 -0.12 -0.08 -0.21 
ST29/04 PDD 0.53 0.32 0.35 0.14 0.72 -0.21 -0.12 -0.36 
ST30/04 PDD 0.6 0.16 - 0.17 0.78 -0.51 -  -0.39 
027 
93/1089 DLB 0.78 0.38 0.46 0.19 0.89 -0.21 0.01 -0.23 
036 
93/1075 DLB - - - - - - -  - 
051 
91/1249 DLB 0.94 0.18 0.7 0.17 0.97 -0.28 0.15 -0.39 
052 
94/1224 DLB 0.86 0.69 0.54 0.32 0.93 0.11 0.03 -0.11 
055 
98/1226 DLB 0.97 0.32 0.57 0.19 0.99 -0.19 -0.07 -0.34 
106 
99/1109 DLB 1.31 0.89 1.29 0.36 1.12 0.24 0.14 0.05 
20030007 DLB 0.79 0.72 1.19 0.26 0.9 0.08 0.26 -0.09 
20030113 DLB 2.18 0.16 0.68 0.33 1.34 -0.39 -0.43 -0.1 
20040034 DLB 1.49 0.42 0.71 0.21 1.17 0.02 -0.26 -0.18 
20040085 DLB - 0.36 1.18 0.37 - -0.17 -  -0.05 
20050030 DLB 0.73 0.46 1.29 0.25 0.86 0.14 0.29 -0.11 
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20050040 DLB - 0.31 0.67 0.23 - -0.06 -  -0.15 
20060025 DLB - - - - - - -  - 
20070009 DLB 1.08 0.42 0.72 0.37 1.03 -0.06 -0.17 -0.05 
20070105 DLB 0.83 0.87 1.18 0.34 0.92 0.13 0.16 -0.08 
20080083 DLB 1.08 0.53 0.89 0.48 1.03 -0.05 -0.09 0.17 
20100575 DLB 1.01 0.25 1.34 0.55 1 -0.27 0.08 0.12 
333 08/064 DLB 0.88 0.69 0.81 0.2 0.94 0.09 -0.04 -0.21 
367 08/134 DLB 1.03 0.28 1.05 0.2 1.01 -0.03 0.00 -0.21 
383 
99/1147 DLB 1.21 0.78 0.62 0.34 1.08 0.28 -0.15 0.02 
436 03/148 DLB 0.81 0.72 0.79 0.47 0.91 0.28 0.07 0.06 
439 
00/1140 DLB 0.95 - 1.02 0.51 0.98 - 0.16 0.09 
470 01/156 DLB 0.98 0.28 0.72 0.18 0.99 -0.11 -0.02 -0.36 
475 
00/1108 DLB 0.74 0.42 0.84 0.3 0.87 -0.07 0.18 -0.03 
495 01/172 DLB 0.82 0.32 0.82 0.57 0.91 0.1 0.11 0.14 
550 02/021 DLB 1.11 0.33 0.71 0.37 1.05 -0.11 -0.10 -0.05 
745 08/126 DLB 0.69 0.38 0.74 0.5 0.84 0.1 0.02 0.19 
A014/07 DLB 0.75 0.62 0.85 0.55 0.88 0.03 0.07 0.12 
A028/10 DLB 1.09 - - - 1.04 - -  - 
A035/08 DLB 0.7 0.75 - 0.49 0.85 0.09 -  0.18 
A040/10 DLB - - - - - - -  - 
A046/07 DLB 0.85 0.47 0.68 - 0.93 0.03 -0.09 - 
A053/09 DLB 0.98 0.24 0.7 - 0.99 -0.29 -0.17 - 
A055/09 DLB 0.93 0.33 - 0.92 0.97 -0.21 -  0.46 
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A072/09 DLB 0.53 - - - 0.72 - -  - 
A084/09 DLB - 0.71 0.56 1.06 - 0.13 -  0.52 
A092/07 DLB 1.13 0.57 - 0.47 1.05 -0.02 -  0.06 
A109/01 DLB 0.76 0.81 - 0.56 0.88 0.09 -  0.13 
A148/08 DLB - - - - - - -  - 
A162/07 DLB - - - - - - -  - 
A190/03 DLB 0.59 0.51 0.78 0.48 0.77 0.01 0.20 0.07 
A196/09 DLB - 0.67 - - - 0.09 -  - 
A204/07 DLB 1.41 0.73 - 0.45 1.15 0.09 -  0.04 
A229/05 DLB 0.55 0.67 0.57 0.49 0.74 0 0.06 0.07 
A231/06 DLB 0.34 0.2 - 0.17 0.53 -0.45 -  -0.28 
A249/06 DLB - - - - - - -  - 
A273/05 DLB 0.87 0.88 - 0.61 0.94 0.14 -  0.17 
A304/06 DLB - 0.62 - 0.54 - 0.16 -  0.23 
A335/08 DLB 0.65 0.62 - 0.35 0.81 0 -  -0.07 
A336/99 DLB 0.68 0.35 0.55 0.4 0.83 -0.21 0.05 -0.01 
C1007 
01/176 DLB 0.91 0.33 0.63 0.12 0.96 -0.11 -0.05 -0.54 
ST26/04 DLB 0.68 0.91 0.72 0.52 0.83 0.3 0.09 0.1 
ST27/04 DLB 0.66 0.37 0.78 0.39 0.82 0.04 0.13 -0.03 
ST28/04 DLB 0.53 0.36 0.64 0.27 0.72 - 0.14 -0.08 
ST32/05 DLB 0.57 0.4 0.35 0.17 0.76 -0.15 -0.17 -0.28 
A071/09 AD 1.04 0.48 1.21 0.69 1.02 -0.12 0.04 0.22 
A108/09 AD 0.78 0.53 0.71 0.48 0.89 -0.02 -0.06 0.17 
A120/09 AD 0.84 - 0.77 0.34 0.92 - -0.06 0.02 
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A147/10 AD 0.74 0.68 1.57 0.16 0.87 0.07 0.29 -0.3 
A216/09 AD 0.34 - 1.53 0.22 0.53 - 0.65 -0.16 
A267/09 AD 0.78 0.32 1.37 0.13 0.89 -0.06 0.22 -0.39 
A349/08 AD - 0.32 1.66 0.23 - -0.28 -  -0.15 
A350/09 AD 0.94 0.4 1.46 0.45 0.97 -0.15 0.17 0.15 
A37/09 AD 0.85 1.07 0.53 0.5 0.93 0.3 -0.23 0.08 
A371/08 AD 0.71 0.32 1.44 0.52 0.85 -0.07 0.30 0.1 
A38/11 AD 0.77 0.68 1.47 0.18 0.89 0.24 0.23 -0.25 
A61/09 AD 0.95 0.66 0.84 0.44 0.98 0.03 -0.08 0.14 
A7/10 AD 0.86 0.93 0.57 0.51 0.93 0.24 -0.22 0.2 
A76/09 AD 0.88 1.1 1.28 0.77 0.94 0.27 0.14 0.27 
A8/10 AD 0.74 - 1.36 0.29 0.87 - 0.23 -0.04 




Residual and normalised protein ratios in BA9 















0.87 1.31 1.03 -0.06 0.35 0.29 
A047/02 Control 
0.50 0.82 1.48 -0.30 0.06 0.54 
A048/09 Control 
1.40 0.69 1.88 0.14 0.07 0.47 
A049/03 Control 
0.46 0.58 1.94 -0.34 -0.04 0.59 
A063/10 Control 
1.39 0.52 1.27 0.14 0.07 0.33 
A133/95 Control 
0.66 0.41 0.90 -0.18 -0.14 0.07 
A134/00 Control 
0.38 1.47 1.14 -0.42 0.25 0.23 
A136/10 Control 
1.35 0.96 1.88 0.13 0.30 0.54 
A153/01 Control 
1.09 1.17 0.40 0.04 0.15 -0.13 
A170/00 Control 
1.02 3.81 0.48 0.01 0.67 -0.09 
A185/04 Control 
0.76 1.66 0.42 -0.12 0.47 -0.15 
A219/97 Control 
- - 0.31 - - -0.15 
A223/96 Control 
- 0.73 - - -0.03 - 
A239/95 Control 
- - 0.48 - - -0.07 
A283/96 Control 
0.59 0.54 0.41 -0.23 -0.09 -0.14 
A308/09 Control 
1.40 1.51 1.88 0.15 0.45 0.48 
A31/96 Control 
0.84 2.41 1.22 -0.08 0.62 0.26 
A316/95 Control 
1.61 0.55 0.60 0.21 -0.06 0.04 
A320/94 Control 
0.77 0.37 0.69 -0.11 0.02 0.06 
A33/96 Control 
0.61 0.24 0.42 -0.22 -0.28 -0.03 
A346/95 Control 
0.85 0.61 0.71 -0.07 -0.09 0.19 
A359/08 Control 
0.69 0.50 1.48 -0.16 -0.16 0.42 
A401/97 Control 
0.84 2.11 1.14 -0.07 0.55 0.42 
A61/96 Control 
- - - - - - 
A94/95 Control 
1.10 1.33 1.04 0.04 0.31 0.35 
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0.93 0.59 0.64 -0.03 -0.11 0.13 
20030004 PDD 
0.91 0.60 1.06 -0.04 0.03 0.24 
20030103 PDD 
1.10 0.23 0.26 0.04 -0.46 -0.16 
20030111 PDD 
- - - - - - 
20030134 PDD 
0.19 0.21 0.73 -0.73 -0.45 0.12 
20040022 PDD 
0.72 0.32 0.49 -0.14 -0.32 -0.13 
20040076 PDD 
1.22 1.33 0.56 0.09 0.25 0.01 
20040105 PDD 
0.73 1.04 0.69 -0.13 0.12 0.18 
20050096 PDD 
- 0.45 - - -0.17 - 
20050099 PDD 
0.85 0.26 0.57 -0.07 -0.26 0.13 
A143/00 PDD 
1.15 0.48 0.23 0.06 -0.04 -0.28 
ST01/01 PDD 
0.71 0.85 0.57 -0.15 0.08 -0.03 
ST02/01 PDD 
0.59 0.49 0.66 -0.23 -0.11 0.08 
ST03/01 PDD 
0.83 0.46 1.27 -0.08 -0.13 0.40 
ST04/01 PDD 
0.98 0.77 0.57 -0.01 - -0.08 
ST09/02 PDD 
0.65 0.72 0.89 -0.19 0.21 0.12 
ST10/02 PDD 
0.45 0.73 0.97 -0.35 0.02 0.25 
ST11/02 PDD 
0.54 0.84 0.94 -0.27 0.22 0.18 
ST12/02 PDD 
0.39 0.42 - -0.41 -0.20 - 
ST13/02 PDD 
0.42 0.26 1.41 -0.38 -0.41 0.31 
ST14/02 PDD 
0.52 0.63 0.28 -0.29 -0.05 -0.30 
ST15/02 PDD 
0.57 0.75 0.30 -0.25 0.23 -0.12 
ST16/02 PDD 
1.22 1.06 0.87 0.09 0.19 0.17 
ST17/02 PDD 
0.91 1.09 0.50 -0.04 0.13 -0.15 
ST18/02 PDD 
0.73 0.59 0.33 -0.14 -0.05 -0.31 
ST19/02 PDD 
0.29 0.37 0.59 -0.53 -0.26 0.10 
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0.49 1.37 0.85 -0.31 0.34 0.21 
ST21/03 PDD 
0.55 0.28 0.41 -0.26 -0.39 -0.12 
ST22/02 PDD 
0.31 - 0.75 -0.51 - -0.05 
ST23/03 PDD 
1.00 0.46 1.09 0.00 -0.14 0.23 
ST24/03 PDD 
0.81 0.59 - -0.09 -0.08 - 
ST25/04 PDD 
0.73 0.68 0.44 -0.14 -0.01 -0.05 
ST29/04 PDD 
0.66 0.60 0.40 -0.18 -0.03 -0.06 
ST30/04 PDD 
- 0.27 - - -0.39 - 
027 
93/1089 DLB 
0.59 0.49 0.41 -0.23 -0.20 -0.10 
036 
93/1075 DLB 
- - - - - - 
051 
91/1249 DLB 
0.74 0.19 0.24 -0.13 -0.33 -0.35 
052 
94/1224 DLB 
0.63 0.80 0.59 -0.20 0.08 0.09 
055 
98/1226 DLB 
0.59 0.33 0.33 -0.23 -0.27 -0.28 
106 
99/1109 DLB 
0.98 0.68 0.28 -0.01 0.03 -0.38 
20030007 DLB 
1.51 0.91 0.22 0.18 0.08 -0.27 
20030113 DLB 
0.31 0.07 0.49 -0.51 -0.81 0.06 
20040034 DLB 
0.48 0.28 0.30 -0.32 -0.23 -0.07 
20040085 DLB 
- - 0.31 - - -0.06 
20050030 DLB 
1.77 0.63 0.19 0.25 0.20 -0.28 
20050040 DLB 
- - 0.34 - - -0.08 
20060025 DLB 
- - - - - - 
20070009 DLB 
0.67 0.39 0.51 -0.18 -0.18 0.18 
20070105 DLB 
1.42 1.05 0.29 0.15 0.11 -0.10 
20080083 DLB 
0.82 0.49 0.54 -0.08 -0.18 0.18 
20100575 DLB 
1.33 0.25 0.41 0.12 -0.36 0.00 
333 
08/064 DLB 
0.92 0.78 0.25 -0.04 0.05 -0.27 
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1.02 0.27 0.19 0.01 -0.12 -0.46 
383 
99/1147 DLB 
0.51 0.64 0.55 -0.29 0.11 0.12 
436 
03/148 DLB 
0.98 0.89 0.59 -0.01 0.29 0.09 
439 
00/1140 DLB 
1.07 - 0.50 0.03 - -0.15 
470 
01/156 DLB 
0.73 0.29 0.25 -0.13 -0.19 -0.35 
475 
00/1108 DLB 
1.14 0.57 0.36 0.06 -0.03 -0.16 
495 
01/172 DLB 
1.00 0.39 0.70 0.00 0.12 0.03 
550 
02/021 DLB 
0.64 0.30 0.52 -0.19 -0.24 -0.12 
745 
08/126 DLB 
1.07 0.55 0.68 0.03 0.19 0.07 
A014/07 DLB 
1.13 0.83 0.65 0.05 0.06 -0.03 
A028/10 DLB 
- - - - - - 
A035/08 DLB 
- 1.07 - - 0.14 - 
A040/10 DLB 
- - - - - - 
A046/07 DLB 
0.80 0.55 - -0.10 0.02 - 
A053/09 DLB 
0.71 0.24 - -0.15 -0.37 - 
A055/09 DLB 
- 0.35 - - -0.27 - 
A072/09 DLB 
- - - - - - 
A084/09 DLB 
- - 1.89 - - 0.67 
A092/07 DLB 
- 0.50 - - -0.17 - 
A109/01 DLB 
- 1.07 - - 0.10 - 
A148/08 DLB 
- - - - - - 
A162/07 DLB 
- - - - - - 
A190/03 DLB 
1.32 0.86 0.62 0.12 0.15 0.10 
A196/09 DLB 
- - - - - - 
A204/07 DLB 
- 0.52 - - -0.16 - 
A229/05 DLB 
1.04 1.22 0.86 0.02 0.16 0.08 
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- 0.59 - - -0.08 - 
A249/06 DLB 
- - - - - - 
A273/05 DLB 
- 1.01 - - 0.09 - 
A304/06 DLB 
- - - - - - 
A335/08 DLB 
- 0.95 - - 0.09 - 
A336/99 DLB 
0.81 0.51 0.73 -0.09 -0.15 -0.09 
C1007 
01/176 DLB 
0.69 0.36 0.19 -0.16 -0.16 -0.53 
ST26/04 DLB 
1.06 1.34 0.72 0.02 0.38 0.12 
ST27/04 DLB 
1.18 0.56 0.50 0.07 0.15 -0.06 
ST28/04 DLB 
1.21 0.68 0.42 0.08 - -0.14 
ST32/05 DLB 
0.61 0.70 0.49 -0.21 0.00 0.04 
A071/09 AD 
1.16 0.46 0.57 0.07 -0.24 0.05 
A108/09 AD 
0.91 0.68 0.68 -0.04 -0.01 0.02 
A120/09 AD 
0.92 - 0.44 -0.04 - -0.06 
A147/10 AD 
2.12 0.92 0.10 0.33 0.10 -0.60 
A216/09 AD 
4.50 - 0.14 0.65 - -0.46 
A267/09 AD 
1.76 0.41 0.09 0.24 -0.03 -0.64 
A349/08 AD 
- - 0.14 - - -0.62 
A350/09 AD 
1.55 0.43 0.31 0.19 -0.22 -0.23 
A37/09 AD 
0.62 1.26 0.94 -0.21 0.27 0.22 
A371/08 AD 
2.03 0.45 0.36 0.31 0.00 -0.35 
A38/11 AD 
1.91 0.88 0.12 0.28 0.28 -0.53 
A61/09 AD 
0.88 0.69 0.52 -0.05 -0.05 0.00 
A7/10 AD 
0.66 1.08 0.89 -0.18 0.21 0.31 
A76/09 AD 
1.45 1.25 0.60 0.16 0.23 0.11 
A8/10 AD 
1.84 - 0.21 0.26 - -0.31 
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Residual and normalised protein values in BA24 
Case ID Diagnosis Betatubulin PSD95 SPP ZnT3 Residual Btub Normalised PSD95 Residual SPP Residual ZnT3 
A011/06 Control 1.46 0.42 0.96 0.79 0.27 0.65 0.94 0.39 
A047/02 Control - - - - - - - - 
A048/09 Control 1.08 - 0.98 1.43 0.07 - 1.14 0.55 
A049/03 Control 0.60 0.98 1.95 1.09 -0.18 0.99 2.20 0.54 
A063/10 Control 0.86 0.53 0.96 0.38 0.04 0.73 0.49 0.09 
A133/95 Control - 0.44 0.76 0.38 - 0.66 -0.14 -0.07 
A134/00 Control 0.61 0.26 0.77 0.51 -0.18 0.51 0.38 0.13 
A136/10 Control 1.06 0.40 0.99 1.34 0.14 0.63 0.74 0.66 
A153/01 Control 2.04 0.71 0.90 0.47 0.35 0.84 1.19 0.07 
A170/00 Control 0.48 0.24 0.77 0.28 -0.21 0.49 0.36 -0.23 
A185/04 Control 1.50 - 0.80 0.37 0.21 - 0.02 0.00 
A219/97 Control - - - - - - 0.00 - 
A223/96 Control 1.37 - 0.87 0.31 0.18 - 0.91 -0.12 
A239/95 Control 1.86 0.23 0.84 0.33 0.38 0.48 0.33 -0.04 
A283/96 Control 0.95 0.44 0.54 0.48 0.02 0.66 -0.98 0.10 
A308/09 Control 0.63 - 0.99 0.86 -0.16 - 1.02 0.23 
A31/96 Control 0.43 0.53 0.62 0.39 -0.33 0.73 -0.77 -0.12 
A316/95 Control 0.50 0.72 0.53 0.24 -0.26 0.85 -1.19 -0.16 
A320/94 Control - - 0.88 0.42 - - -0.21 0.02 
A33/96 Control 0.77 0.43 0.48 0.27 0.00 0.66 -1.84 0.11 
A346/95 Control 0.58 0.17 0.45 0.31 -0.20 0.41 -1.35 0.07 
A359/08 Control 0.68 - 0.73 - -0.06 - - - 
A401/97 Control 0.98 0.22 0.37 0.12 0.03 0.47 -2.20 -0.31 
A61/96 Control 0.62 0.24 0.70 - -0.17 0.49 -0.33 - 
A94/95 Control 0.90 0.85 0.71 0.41 0.06 0.92 -0.26 0.15 
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Case ID Diagnosis Betatubulin PSD95 SPP ZnT3 Residual Btub Normalised PSD95 Residual SPP Residual ZnT3 
20020080 PDD 1.02 0.65 0.73 0.35 0.05 0.81 0.09 0.00 
20030004 PDD 0.89 0.51 0.76 0.47 0.06 0.71 -0.09 0.00 
20030103 PDD 1.20 0.78 0.75 0.50 0.19 0.88 -0.02 0.27 
20030111 PDD 0.82 0.27 0.67 0.33 -0.05 0.52 -0.44 0.12 
20030134 PDD 0.65 0.38 0.57 0.35 -0.15 0.62 -0.94 -0.04 
20040022 PDD 0.90 0.47 0.57 0.34 -0.01 0.69 -0.84 -0.10 
20040076 PDD 1.06 1.60 0.49 0.57 0.06 1.26 -1.10 0.19 
20040105 PDD 1.40 1.50 0.52 0.59 0.18 1.22 -0.87 0.22 
20050096 PDD 0.93 0.87 0.44 0.37 0.01 0.93 -1.55 0.14 
20050099 PDD 0.83 0.66 0.58 0.26 -0.04 0.81 -1.24 0.07 
A143/00 PDD - - - - - - - - 
ST01/01 PDD 0.47 0.18 0.73 0.54 -0.22 0.42 -0.05 0.17 
ST02/01 PDD 0.79 0.59 0.78 0.48 -0.06 0.77 0.07 0.16 
ST03/01 PDD 0.91 0.16 1.68 0.17 0.00 0.40 1.99 -0.31 
ST04/01 PDD 0.93 0.45 1.79 0.35 0.08 0.67 - -0.05 
ST09/02 PDD 0.81 0.04 2.60 0.21 -0.05 0.20 2.60 -0.32 
ST10/02 PDD 0.84 0.14 0.69 0.21 -0.04 0.37 -0.28 -0.20 
ST11/02 PDD 0.91 0.36 0.68 0.20 0.07 0.60 -0.65 -0.36 
ST12/02 PDD 0.99 0.63 - 0.52 0.11 0.79 - 0.21 
ST13/02 PDD 0.50 0.34 0.61 0.42 -0.19 0.58 -0.54 -0.02 
ST14/02 PDD 0.92 0.72 1.14 0.14 0.00 0.85 1.55 -0.42 
ST15/02 PDD 0.63 0.10 0.44 0.10 -0.09 0.32 -2.60 -0.33 
ST16/02 PDD 0.76 0.54 0.85 0.40 -0.08 0.73 0.54 0.03 
ST17/02 PDD 0.77 0.57 0.64 0.27 -0.07 0.75 -0.38 -0.29 
ST18/02 PDD 1.16 0.42 0.88 0.72 0.10 0.65 0.62 0.22 
ST19/02 PDD 0.36 0.31 0.59 0.29 -0.33 0.56 -0.68 0.03 
ST20/02 PDD 0.45 0.44 0.75 0.36 -0.24 0.66 -0.07 0.08 
305 
 
Case ID Diagnosis Betatubulin PSD95 SPP ZnT3 Residual Btub Normalised PSD95 Residual SPP Residual ZnT3 
ST21/03 PDD 0.96 0.53 0.88 0.22 0.09 0.73 0.71 -0.17 
ST22/02 PDD 0.44 0.21 0.54 0.48 -0.25 0.46 -0.91 -0.09 
ST23/03 PDD 0.58 0.25 0.55 0.44 -0.13 0.50 -1.02 0.04 
ST24/03 PDD 0.90 1.24 0.75 0.30 -0.01 1.11 0.12 -0.01 
ST25/04 PDD 0.41 0.49 0.61 0.35 -0.28 0.70 -0.49 0.09 
ST29/04 PDD 0.37 0.52 0.38 0.65 -0.32 0.72 -1.73 0.42 
ST30/04 PDD 1.11 0.07 - 0.21 0.08 0.26 - -0.24 
027 93/1089 DLB 1.03 0.38 0.73 0.15 0.12 0.62 0.19 -0.29 
036 93/1075 DLB 1.61 1.05 1.13 0.19 0.25 1.02 1.63 -0.15 
051 91/1249 DLB 1.33 0.59 1.02 0.54 0.16 0.77 0.68 0.21 
052 94/1224 DLB 0.84 0.50 0.90 0.33 -0.04 0.71 0.81 0.06 
055 98/1226 DLB 1.07 1.07 0.96 0.54 0.07 1.03 1.10 0.13 
106 99/1109 DLB 1.09 2.19 - 0.51 0.15 1.48 - 0.13 
20030007 DLB 0.83 0.45 0.85 0.35 0.03 0.67 0.65 0.21 
20030113 DLB 0.86 0.55 0.93 0.25 -0.03 0.74 0.44 -0.04 
20040034 DLB - 0.31 0.72 0.10 - 0.56 -0.46 -0.37 
20040085 DLB 0.66 0.30 0.60 0.20 -0.14 0.55 -0.62 -0.07 
20050030 DLB - 0.43 1.08 0.13 - 0.66 1.06 -0.15 
20050040 DLB - 0.57 1.03 0.26 - 0.75 0.84 -0.03 
20060025 DLB - 0.70 - - - 0.84 - - 
20070009 DLB 0.87 1.01 0.94 0.29 -0.02 1.00 0.87 0.10 
20070105 DLB 0.83 0.52 0.81 0.23 -0.04 0.72 0.57 -0.06 
20080083 DLB 0.70 0.39 0.67 0.28 -0.04 0.62 -0.31 0.11 
20100575 DLB 0.95 0.29 0.81 0.43 0.02 0.54 0.14 0.21 
333 08/064 DLB 1.07 0.49 0.70 0.15 0.14 0.70 -0.12 -0.23 
367 08/134 DLB 0.94 0.32 0.54 0.12 0.08 0.57 -1.99 -0.37 
383 99/1147 DLB - 0.78 - 0.25 - 0.88 - 0.08 
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Case ID Diagnosis Betatubulin PSD95 SPP ZnT3 Residual Btub Normalised PSD95 Residual SPP Residual ZnT3 
436 03/148 DLB - 0.81 0.94 0.39 - 0.90 0.41 0.08 
439 00/1140 DLB 0.78 0.26 0.89 0.30 -0.07 0.51 0.16 -0.22 
470 01/156 DLB 0.73 - 0.81 0.33 -0.10 - -0.36 0.00 
475 00/1108 DLB 0.98 - 0.61 0.12 0.10 - -0.74 -0.39 
495 01/172 DLB 0.73 0.38 0.71 0.18 -0.10 0.62 -1.29 -0.31 
550 02/021 DLB 1.09 0.50 1.14 0.23 0.08 0.71 1.41 -0.31 
745 08/126 DLB 1.24 0.30 1.41 0.32 0.20 0.55 1.84 -0.09 
A014/07 DLB - - - - - - - - 
A028/10 DLB - - - - - - - - 
A035/08 DLB - 0.62 - - - 0.79 - - 
A040/10 DLB - - - - - - - - 
A046/07 DLB - - - - - - - - 
A053/09 DLB 0.69 - 0.88 - -0.12 - 0.46 - 
A055/09 DLB 0.59 - 0.59 - -0.12 - -0.71 - 
A072/09 DLB - - - - - - - - 
A084/09 DLB - - - - - - - - 
A092/07 DLB - 0.52 - - - 0.72 - - 
A109/01 DLB 1.50 1.06 0.40 - 0.21 1.03 -1.48 - 
A148/08 DLB 0.96 - 0.48 0.27 0.09 - -1.14 0.02 
A162/07 DLB 0.99 - 0.46 - 0.03 - -1.41 - 
A190/03 DLB - 0.87 - - - 0.93 - - 
A196/09 DLB - - - - - - - - 
A204/07 DLB 1.35 1.22 0.76 0.86 0.17 1.10 0.21 0.28 
A229/05 DLB - 0.63 - - - 0.79 - - 
A231/06 DLB 1.49 0.35 0.78 - 0.28 0.59 0.26 - 
A249/06 DLB 1.68 - 0.64 1.02 0.26 - -0.19 0.41 
A273/05 DLB 1.16 0.58 0.65 - 0.10 0.76 -0.24 - 
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Case ID Diagnosis Betatubulin PSD95 SPP ZnT3 Residual Btub Normalised PSD95 Residual SPP Residual ZnT3 
A304/06 DLB 1.04 0.62 0.60 - 0.13 0.79 -1.06 - 
A335/08 DLB 1.05 0.52 0.63 0.35 0.06 0.72 -0.41 -0.09 
A336/99 DLB - - - - - - - - 
C1007 01/176 DLB 1.41 0.54 1.11 0.39 0.19 0.73 1.29 -0.01 
ST26/04 DLB 0.86 0.42 0.86 0.18 -0.03 0.65 0.28 -0.21 
ST27/04 DLB 0.84 0.99 0.94 0.85 -0.04 0.99 0.24 0.37 
ST28/04 DLB 0.44 0.39 0.70 0.60 -0.25 0.62 - 0.27 
ST32/05 DLB 0.46 0.22 0.60 0.21 -0.23 0.47 -0.51 -0.05 
A071/09 AD 0.99 0.58 0.82 0.67 0.03 0.76 0.60 0.32 
A108/09 AD 0.63 0.34 0.74 0.52 -0.09 0.58 0.05 0.13 
A120/09 AD 0.63 0.43 0.84 0.09 -0.09 0.66 -0.16 -0.51 
A147/10 AD 0.85 0.90 0.79 0.06 0.04 0.95 0.31 -0.58 
A216/09 AD 0.73 0.45 0.65 0.32 -0.03 0.67 -0.57 0.16 
A267/09 AD 0.71 0.70 0.51 0.08 -0.04 0.84 -1.63 -0.43 
A349/08 AD 0.99 0.81 - 0.21 0.11 0.90 - -0.20 
A350/09 AD 1.21 - 1.17 0.52 0.19 - 1.73 0.34 
A37/09 AD 0.96 1.92 1.06 0.45 0.02 1.39 1.35 0.16 
A371/08 AD 0.69 0.44 0.68 0.48 -0.12 0.66 -0.81 -0.03 
A38/11 AD 0.72 1.08 0.71 0.17 -0.03 1.04 -0.60 -0.24 
A61/09 AD 0.91 0.82 0.88 0.07 0.07 0.91 0.98 -0.49 
A7/10 AD 0.85 1.17 1.03 0.25 0.04 1.08 1.24 0.00 
A76/09 AD 0.66 0.68 0.87 0.29 -0.14 0.82 0.77 0.13 
A8/10 AD 0.70 - 0.84 0.25 -0.04 - 0.51 0.11 





Residual and normalised protein ratios in BA24 
Case ID Diagnosis SPP to Btub PSD95 to Btub ZnT3 to SPP Normalised SPP to Btub Normalised PSD95 to Btub Residual ZnT3 to SPP 
A011/06 Control 0.66 0.29 0.82 -0.18 0.54 1.30 
A047/02 Control - - - - - 0.00 
A048/09 Control 0.91 - 1.46 -0.04 - 1.95 
A049/03 Control 3.25 1.63 0.56 0.51 1.28 0.52 
A063/10 Control 1.12 0.62 0.40 0.05 0.79 0.04 
A133/95 Control - - 0.50 - - -0.33 
A134/00 Control 1.26 0.43 0.66 0.10 0.65 -0.09 
A136/10 Control 0.93 0.38 1.35 -0.03 0.61 2.16 
A153/01 Control 0.44 0.35 0.52 -0.36 0.59 -0.14 
A170/00 Control 1.60 0.50 0.36 0.21 0.71 -0.88 
A185/04 Control 0.53 - 0.46 -0.27 - -0.04 
A219/97 Control - - - - - 0.00 
A223/96 Control 0.64 - 0.36 -0.20 - -1.00 
A239/95 Control 0.45 0.12 0.39 -0.35 0.35 -0.44 
A283/96 Control 0.57 0.46 0.89 -0.25 0.68 1.09 
A308/09 Control 1.57 - 0.87 0.20 - 1.14 
A31/96 Control 1.44 1.23 0.63 0.16 1.11 0.30 
A316/95 Control 1.06 1.44 0.45 0.03 1.20 -0.06 
A320/94 Control - - 0.48 - - 0.74 
A33/96 Control 0.62 0.56 0.56 -0.21 0.75 1.24 
A346/95 Control 0.78 0.29 0.69 -0.11 0.54 0.92 
A359/08 Control 1.07 - - 0.03 - 0.00 
A401/97 Control 0.38 0.22 0.32 -0.42 0.47 -0.19 
A61/96 Control 1.13 0.39 - 0.05 0.62 0.00 
A94/95 Control 0.79 0.94 0.58 -0.10 0.97 0.71 
20020080 PDD 0.72 0.64 0.48 -0.15 0.80 0.09 
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Case ID Diagnosis SPP to Btub PSD95 to Btub ZnT3 to SPP Normalised SPP to Btub Normalised PSD95 to Btub Residual ZnT3 to SPP 
20030004 PDD 0.85 0.57 0.62 -0.07 0.76 0.49 
20030103 PDD 0.63 0.65 0.67 -0.20 0.81 1.36 
20030111 PDD 0.82 0.33 0.49 -0.09 0.57 0.81 
20030134 PDD 0.88 0.58 0.61 -0.06 0.76 0.64 
20040022 PDD 0.63 0.52 0.60 -0.20 0.72 0.01 
20040076 PDD 0.46 1.51 1.16 -0.34 1.23 1.43 
20040105 PDD 0.37 1.07 1.13 -0.43 1.04 1.59 
20050096 PDD 0.47 0.94 0.84 -0.33 0.97 1.69 
20050099 PDD 0.70 0.80 0.45 -0.16 0.89 0.88 
A143/00 PDD - - - - - 0.00 
ST01/01 PDD 1.55 0.38 0.74 0.19 0.62 0.58 
ST02/01 PDD 0.99 0.75 0.62 -0.01 0.86 0.61 
ST03/01 PDD 1.85 0.18 0.10 0.27 0.42 -1.80 
ST04/01 PDD 1.92 0.48 0.20 0.28 0.70 0.00 
ST09/02 PDD 3.21 0.05 0.08 0.51 0.22 -2.16 
ST10/02 PDD 0.82 0.17 0.30 -0.09 0.41 -0.85 
ST11/02 PDD 0.75 0.40 0.29 -0.13 0.63 -0.77 
ST12/02 PDD - 0.64 - - 0.80 0.00 
ST13/02 PDD 1.22 0.68 0.69 0.09 0.82 0.22 
ST14/02 PDD 1.24 0.78 0.12 0.09 0.88 -1.69 
ST15/02 PDD 0.70 0.16 0.23 -0.16 0.40 -0.41 
ST16/02 PDD 1.12 0.71 0.47 0.05 0.84 -0.25 
ST17/02 PDD 0.83 0.74 0.42 -0.08 0.86 -0.92 
ST18/02 PDD 0.76 0.36 0.82 -0.12 0.60 0.67 
ST19/02 PDD 1.64 0.86 0.49 0.21 0.93 0.25 
ST20/02 PDD 1.67 0.98 0.48 0.22 0.99 0.14 
ST21/03 PDD 0.92 0.55 0.25 -0.04 0.74 -1.19 
ST22/02 PDD 1.23 0.48 0.89 0.09 0.69 0.27 
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Case ID Diagnosis SPP to Btub PSD95 to Btub ZnT3 to SPP Normalised SPP to Btub Normalised PSD95 to Btub Residual ZnT3 to SPP 
ST23/03 PDD 0.95 0.43 0.80 -0.02 0.66 0.77 
ST24/03 PDD 0.83 1.38 0.40 -0.08 1.17 -0.52 
ST25/04 PDD 1.49 1.20 0.57 0.17 1.09 0.41 
ST29/04 PDD 1.03 1.41 1.71 0.01 1.19 - 
ST30/04 PDD - 0.06 - - 0.25 0.00 
027 93/1089 DLB 0.71 0.37 0.21 -0.15 0.61 -1.43 
036 93/1075 DLB 0.70 0.65 0.17 -0.15 0.81 -1.50 
051 91/1249 DLB 0.77 0.44 0.53 -0.12 0.67 0.96 
052 94/1224 DLB 1.07 0.60 0.37 0.03 0.77 -0.27 
055 98/1226 DLB 0.90 1.00 0.56 -0.05 1.00 0.12 
106 99/1109 DLB - 2.01 - - 1.42 0.00 
20030007 DLB 1.02 0.54 0.41 0.01 0.74 0.06 
20030113 DLB 1.08 0.64 0.27 0.03 0.80 -0.22 
20040034 DLB - - 0.14 - - -1.05 
20040085 DLB 0.91 0.45 0.33 -0.04 0.67 -0.01 
20050030 DLB - - 0.12 - - -1.09 
20050040 DLB - - 0.25 - - -0.12 
20060025 DLB - - - - - 0.00 
20070009 DLB 1.08 1.16 0.31 0.03 1.08 0.17 
20070105 DLB 0.98 0.63 0.28 -0.01 0.79 -0.55 
20080083 DLB 0.96 0.56 0.42 -0.02 0.75 0.33 
20100575 DLB 0.85 0.31 0.53 -0.07 0.55 1.05 
333 08/064 DLB 0.65 0.46 0.21 -0.18 0.68 -1.14 
367 08/134 DLB 0.57 0.34 0.22 -0.24 0.58 -0.71 
383 99/1147 DLB - - - - - 0.00 
436 03/148 DLB - - 0.41 - - 0.46 
439 00/1140 DLB 1.14 0.33 0.34 0.06 0.58 -0.61 
470 01/156 DLB 1.11 - 0.41 0.05 - 0.19 
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Case ID Diagnosis SPP to Btub PSD95 to Btub ZnT3 to SPP Normalised SPP to Btub Normalised PSD95 to Btub Residual ZnT3 to SPP 
475 00/1108 DLB 0.62 - 0.20 -0.21 - -1.30 
495 01/172 DLB 0.97 0.52 0.25 -0.01 0.72 -0.49 
550 02/021 DLB 1.05 0.46 0.20 0.02 0.68 -1.36 
745 08/126 DLB 1.14 0.24 0.23 0.06 0.49 -0.74 
A014/07 DLB - - - - - 0.00 
A028/10 DLB - - - - - 0.00 
A035/08 DLB - - - - - 0.00 
A040/10 DLB - - - - - 0.00 
A046/07 DLB - - - - - 0.00 
A053/09 DLB 1.28 - - 0.11 - 0.00 
A055/09 DLB 1.00 - - 0.00 - 0.00 
A072/09 DLB - - - - - 0.00 
A084/09 DLB - - - - - 0.00 
A092/07 DLB - - - - - 0.00 
A109/01 DLB 0.27 0.71 - -0.57 0.84 0.00 
A148/08 DLB 0.50 - 0.56 -0.30 - 0.44 
A162/07 DLB 0.46 - - -0.33 - 0.00 
A190/03 DLB - - - - - 0.00 
A196/09 DLB - - - - - 0.00 
A204/07 DLB 0.56 0.90 1.13 -0.25 0.95 1.19 
A229/05 DLB - - - - - 0.00 
A231/06 DLB 0.52 0.23 - -0.28 0.48 0.00 
A249/06 DLB 0.38 - 1.59 -0.42 - 1.50 
A273/05 DLB 0.56 0.50 - -0.25 0.71 0.00 
A304/06 DLB 0.58 0.60 - -0.24 0.77 0.00 
A335/08 DLB 0.60 0.50 0.56 -0.22 0.70 -0.35 
A336/99 DLB - - - - - 0.00 
C1007 01/176 DLB 0.79 0.38 0.35 -0.10 0.62 -0.67 
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Case ID Diagnosis SPP to Btub PSD95 to Btub ZnT3 to SPP Normalised SPP to Btub Normalised PSD95 to Btub Residual ZnT3 to SPP 
ST26/04 DLB 1.00 0.49 0.21 0.00 0.70 -1.24 
ST27/04 DLB 1.12 1.18 0.90 0.05 1.09 1.80 
ST28/04 DLB 1.59 0.89 0.86 0.20 0.94 0.00 
ST32/05 DLB 1.30 0.48 0.35 0.12 0.69 -0.30 
A071/09 AD 0.83 0.59 0.82 -0.08 0.77 1.00 
A108/09 AD 1.17 0.54 0.70 0.07 0.73 0.35 
A120/09 AD 1.33 0.68 0.11 0.12 0.83 -1.59 
A147/10 AD 0.93 1.06 0.08 -0.03 1.03 -1.95 
A216/09 AD 0.89 0.62 0.49 -0.05 0.79 0.85 
A267/09 AD 0.72 0.99 0.16 -0.14 0.99 -0.96 
A349/08 AD - 0.82 - - 0.90 0.00 
A350/09 AD 0.97 - 0.44 -0.01 - -0.17 
A37/09 AD 1.10 2.00 0.42 0.04 1.41 -0.38 
A371/08 AD 0.99 0.64 0.71 -0.01 0.80 0.55 
A38/11 AD 0.99 1.50 0.24 -0.01 1.22 -0.46 
A61/09 AD 0.97 0.90 0.08 -0.01 0.95 - 
A7/10 AD 1.21 1.38 0.24 0.08 1.17 -0.81 
A76/09 AD 1.32 1.03 0.33 0.12 1.02 -0.64 
A8/10 AD 1.20 - 0.30 0.08 - -0.58 




Residual and normalised protein values in BA40 







A011/06 Control 1.02 - 1.00 0.09 0.16 - -0.50 
A047/02 Control 1.07 - 1.14 0.17 0.26 - -0.28 
A048/09 Control 0.91 0.40 0.71 0.12 0.04 -0.18 -0.37 
A049/03 Control 1.34 0.53 1.25 0.23 0.46 -0.11 -0.11 
A063/10 Control - 0.23 0.66 0.05 - -0.22 -0.67 
A133/95 Control 0.86 0.04 0.80 0.30 0.03 -0.59 0.04 
A134/00 Control 0.85 0.98 0.89 - 0.03 0.06 - 
A136/10 Control 1.14 1.01 1.09 0.71 0.34 0.27 0.46 
A153/01 Control 0.82 2.01 1.13 0.49 -0.13 0.49 0.14 
A170/00 Control 0.85 0.98 0.76 0.23 -0.13 0.07 -0.18 
A185/04 Control 0.80 0.82 1.15 1.12 -0.07 0.12 0.61 
A219/97 Control 1.05 0.85 0.66 0.61 0.14 0.18 0.39 
A223/96 Control 1.22 2.00 1.66 0.53 0.35 0.50 0.19 
A239/95 Control 0.86 0.87 0.80 1.30 -0.02 0.11 0.65 
A283/96 Control 1.38 0.82 0.92 0.43 0.48 0.05 0.14 
A308/09 Control 0.87 0.25 - 0.16 -0.12 -0.28 -0.22 
A31/96 Control 0.80 0.83 0.63 0.41 -0.16 0.11 0.17 
A316/95 Control 0.90 1.28 0.96 3.68 0.03 0.30 1.09 
A320/94 Control 0.84 0.64 1.40 - -0.06 0.17 - 
A33/96 Control 1.01 0.37 0.96 0.46 0.27 -0.10 0.29 
A346/95 Control 1.18 0.83 0.61 0.48 0.35 0.02 0.16 
A359/08 Control 0.90 0.56 - 0.10 0.03 -0.13 -0.51 
A401/97 Control 0.99 0.69 0.77 0.47 0.15 0.02 0.22 
A61/96 Control 0.80 0.90 0.78 1.30 -0.20 0.10 0.62 
A94/95 Control 0.94 1.05 0.84 - 0.07 0.18 - 
A143/00 PDD - - - - - - - 
20020080 PDD 1.69 1.24 1.33 0.71 0.73 0.22 0.33 
20030004 PDD 1.22 0.78 0.94 0.53 0.25 0.09 0.28 
20030103 PDD 0.82 0.71 0.85 - -0.11 0.00 - 
20030111 PDD 0.79 0.27 0.65 0.16 -0.08 -0.29 -0.26 
20030134 PDD 0.57 1.11 0.51 0.40 -0.35 0.24 0.14 
20040022 PDD 0.75 - 0.74 0.75 -0.13 - 0.39 
20040076 PDD 1.42 - 0.75 0.48 0.51 - 0.16 
20040105 PDD 1.56 - 0.86 0.29 0.58 - -0.08 
20050096 PDD 1.02 1.02 1.02 0.99 0.09 0.17 0.51 
20050099 PDD 0.70 0.50 0.73 0.19 -0.10 -0.03 -0.12 
ST01/01 PDD 1.20 0.41 0.99 0.18 0.35 -0.23 -0.25 
ST02/01 PDD 1.04 0.95 0.82 0.27 0.19 0.15 -0.04 
ST03/01 PDD 0.70 0.59 1.00 0.45 -0.22 -0.06 0.18 
ST04/01 PDD 1.09 - 0.73 0.22 0.26 - - 
ST09/02 PDD 1.06 0.30 0.70 0.34 0.18 -0.16 0.16 
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ST10/02 PDD 0.92 1.08 1.16 0.79 0.06 0.17 0.40 
ST11/02 PDD 1.14 0.93 1.20 0.37 0.21 0.22 0.16 
ST12/02 PDD 1.06 1.22 0.93 0.18 0.19 0.25 -0.24 
ST13/02 PDD 0.89 0.61 0.83 0.45 0.02 -0.07 0.16 
ST14/02 PDD 0.63 - 1.07 0.09 -0.26 - -0.55 
ST15/02 PDD 1.10 0.48 1.38 0.06 0.29 -0.02 -0.60 
ST16/02 PDD 0.60 0.45 0.84 0.31 -0.27 -0.19 -0.01 
ST17/02 PDD - 1.06 0.91 0.36 - 0.11 0.01 
ST18/02 PDD 0.97 1.50 0.96 0.87 0.09 0.38 0.45 
ST19/02 PDD 0.50 1.40 0.94 0.49 -0.34 0.33 0.20 
ST20/02 PDD 1.40 1.27 0.82 0.29 0.57 0.30 -0.01 
ST21/03 PDD 1.32 1.15 0.80 0.17 0.47 0.21 -0.27 
ST22/02 PDD 0.98 1.21 0.94 0.43 0.06 0.23 0.13 
ST23/03 PDD 1.03 0.43 0.93 0.33 0.17 -0.18 0.04 
ST24/03 PDD 0.79 - 0.68 0.24 -0.02 - -0.12 
ST25/04 PDD 1.12 0.86 1.39 - 0.30 0.06 - 
ST29/04 PDD 1.43 1.09 0.92 0.55 0.62 0.20 0.26 
ST30/04 PDD 0.44 0.81 0.88 0.40 -0.38 0.06 0.12 
A014/07 DLB - - - - - - - 
A028/10 DLB - - - - - - - 
A035/08 DLB - - - - - - - 
A040/10 DLB - - - - - - - 
A046/07 DLB - 1.36 - 0.39 - 0.39 0.17 
A053/09 DLB - - - - - - - 
A055/09 DLB - - - - - - - 
A072/09 DLB - - - - - - - 
A084/09 DLB - - - - - - - 
A092/07 DLB - - - - - - - 
A109/01 DLB - - - - - - - 
A148/08 DLB - - - 0.26 - - -0.12 
A162/07 DLB - - - 0.33 - - 0.02 
A190/03 DLB - - - - - - - 
A196/09 DLB - - - - - - - 
A204/07 DLB - - - - - - - 
A229/05 DLB - - - - - - - 
A231/06 DLB - - - - - - - 
A249/06 DLB - - - 0.41 - - 0.06 
A273/05 DLB - 1.12 - 0.18 - 0.14 -0.29 
A304/06 DLB - - - - - - - 
A335/08 DLB - - - 0.30 - - -0.06 
A336/99 DLB - 0.54 - 0.32 - -0.14 -0.01 
20030007 DLB 0.82 0.55 1.07 0.37 0.01 -0.15 0.04 
20030113 DLB 0.84 0.63 0.80 0.18 -0.06 0.06 -0.14 
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20040034 DLB 0.83 0.33 1.07 0.14 -0.09 -0.16 -0.25 
20040085 DLB 0.74 0.26 0.92 0.20 -0.16 -0.34 -0.19 
20050030 DLB 0.89 0.27 0.75 0.08 0.11 -0.15 -0.44 
20050040 DLB 1.00 0.24 1.04 0.13 0.08 -0.20 -0.24 
20060025 DLB 0.90 0.81 0.81 0.35 -0.01 0.00 0.01 
20070009 DLB 0.57 0.40 0.96 0.17 -0.36 -0.18 -0.22 
20070105 DLB 0.90 0.95 1.01 0.32 -0.05 0.05 -0.04 
20080083 DLB 1.04 0.47 0.88 0.29 0.17 -0.20 -0.06 
20100575 DLB 0.88 0.36 0.79 0.26 -0.02 -0.19 -0.03 
027 93/1089 DLB 0.73 0.68 - 0.48 -0.08 -0.08 0.15 
036 93/1075 DLB 0.85 - 0.89 - 0.02 - - 
051 91/1249 DLB 0.58 0.44 0.56 0.19 -0.28 -0.02 -0.07 
052 94/1224 DLB 0.44 0.83 0.82 0.26 -0.42 0.06 -0.07 
055 98/1226 DLB - - - - - - - 
106 99/1109 DLB 0.86 0.10 0.60 0.13 0.05 -0.52 -0.36 
333 08/064 DLB 0.84 0.27 0.58 0.19 0.03 -0.35 -0.22 
367 08/134 DLB 0.71 0.72 - 0.15 -0.06 0.22 -0.13 
383 99/1147 DLB 1.43 0.53 0.91 0.31 0.66 -0.02 0.09 
436 03/148 DLB 0.75 0.73 - 0.50 -0.16 0.14 0.32 
439 00/1140 DLB 0.81 0.36 0.65 0.15 -0.11 -0.10 -0.19 
470 01/156 DLB 0.49 0.57 0.74 0.31 -0.35 0.05 0.12 
475 00/1108 DLB 0.78 - 0.78 0.09 -0.05 - -0.51 
495 01/172 DLB 1.23 0.69 0.82 0.18 0.41 0.26 0.00 
550 02/021 DLB 0.87 0.43 0.70 0.24 -0.04 -0.10 -0.03 
745 08/126 DLB 0.31 0.69 0.66 0.31 -0.60 0.20 0.18 
C1007 
01/176 DLB 0.59 1.21 0.86 0.29 -0.27 0.33 0.04 
ST26/04 DLB 0.81 - 0.96 0.35 0.02 - 0.11 
ST27/04 DLB 0.94 0.20 - 0.42 0.07 -0.22 0.28 
ST28/04 DLB 0.77 0.26 0.95 - -0.04 - - 
ST32/05 DLB - 0.37 0.91 0.11 - -0.26 -0.46 
A071/09 AD 0.53 0.22 0.57 0.08 -0.34 -0.44 -0.64 
A108/09 AD 0.74 0.55 1.01 0.38 -0.10 -0.12 0.08 
A120/09 AD 0.58 0.38 0.79 0.17 -0.25 -0.07 -0.12 
A147/10 AD 0.22 0.28 0.31 0.23 -0.61 -0.35 -0.15 
A216/09 AD 0.47 - 0.52 0.07 -0.34 - -0.60 
A267/09 AD 0.57 0.37 0.50 - -0.22 -0.09 - 
A349/08 AD 0.39 0.32 0.59 0.28 -0.43 -0.33 -0.08 
A350/09 AD 0.40 - 0.60 0.38 -0.32 - 0.08 
A37/09 AD 0.43 - 0.71 - -0.38 - - 
A371/08 AD 0.49 0.29 0.58 0.33 -0.37 -0.18 0.14 
A38/11 AD 0.32 0.32 0.44 0.29 -0.62 -0.16 0.08 
A61/09 AD 0.69 - 1.37 0.47 0.01 - 0.14 
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A7/10 AD 1.12 - 0.33 0.17 0.28 - -0.26 
A76/09 AD 0.41 0.90 0.60 0.56 -0.32 0.06 0.23 
A8/10 AD 0.43 0.50 0.51 0.19 -0.29 -0.16 -0.22 





Residual and normalised protein ratios in BA40 















A011/06 Control 0.98 - 0.09 -0.01 - -0.52 
A047/02 Control 1.07 - 0.15 0.03 - -0.30 
A048/09 Control 0.78 0.44 0.17 -0.11 -0.24 -0.39 
A049/03 Control 0.93 0.40 0.18 -0.03 -0.29 -0.36 
A063/10 Control - - 0.08 - - -0.59 
A133/95 Control 0.93 0.05 0.38 -0.03 -0.67 -0.05 
A134/00 Control 1.05 1.15 - 0.02 0.07 - 
A136/10 Control 0.96 0.89 0.65 -0.02 0.11 0.34 
A153/01 Control 1.38 2.45 0.43 0.14 0.56 0.01 
A170/00 Control 0.89 1.15 0.30 -0.05 0.08 0.01 
A185/04 Control 1.44 1.03 0.97 0.16 0.13 0.37 
A219/97 Control 0.63 0.81 0.92 -0.20 0.06 0.49 
A223/96 Control 1.36 1.64 0.32 0.13 0.29 -0.12 
A239/95 Control 0.93 1.01 1.63 -0.03 0.10 0.74 
A283/96 Control 0.67 0.59 0.47 -0.18 -0.16 0.05 
A308/09 Control - 0.29 - - -0.33 - 
A31/96 Control 0.79 1.04 0.65 -0.10 0.13 0.19 
A316/95 Control 1.07 1.42 3.83 0.03 0.27 0.96 
A320/94 Control 1.67 0.76 - 0.22 0.13 - 
A33/96 Control 0.95 0.37 0.48 -0.02 -0.21 0.21 
A346/95 Control 0.52 0.70 0.79 -0.29 -0.13 0.27 
A359/08 Control - 0.62 - - -0.17 - 
A401/97 Control 0.78 0.70 0.61 -0.11 -0.06 0.16 
A61/96 Control 0.98 1.13 1.67 -0.01 0.13 0.60 
A94/95 Control 0.89 1.12 - -0.05 0.13 - 
A143/00 PDD - - - - - - 
20020080 PDD 0.79 0.73 0.53 -0.10 -0.11 0.11 
20030004 PDD 0.77 0.64 0.56 -0.11 -0.09 0.28 
20030103 PDD 1.04 0.87 - 0.02 0.00 - 
20030111 PDD 0.82 0.34 0.25 -0.08 -0.32 -0.23 
20030134 PDD 0.89 1.95 0.78 -0.05 0.49 0.27 
20040022 PDD 0.99 - 1.01 -0.01 - 0.38 
20040076 PDD 0.52 - 0.64 -0.28 - 0.19 
20040105 PDD 0.55 - 0.34 -0.26 - -0.09 
20050096 PDD 1.00 1.00 0.98 0.00 0.07 0.37 
20050099 PDD 1.04 0.71 0.26 0.02 0.01 -0.21 
ST01/01 PDD 0.83 0.34 0.18 -0.08 -0.37 -0.21 
ST02/01 PDD 0.79 0.91 0.33 -0.10 0.04 -0.10 
ST03/01 PDD 1.43 0.84 0.45 0.15 0.00 0.03 
ST04/01 PDD 0.67 - 0.30 -0.17 - 0.01 
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ST09/02 PDD 0.66 0.28 0.49 -0.18 -0.28 0.06 
ST10/02 PDD 1.26 1.17 0.68 0.10 0.13 0.21 
ST11/02 PDD 1.05 0.82 0.31 0.02 0.06 0.02 
ST12/02 PDD 0.88 1.15 0.19 -0.06 0.13 -0.19 
ST13/02 PDD 0.93 0.69 0.54 -0.03 -0.11 0.26 
ST14/02 PDD 1.70 - 0.08 0.23 - -0.70 
ST15/02 PDD 1.25 0.44 0.04 0.10 -0.15 -0.84 
ST16/02 PDD 1.40 0.75 0.37 0.15 -0.08 -0.06 
ST17/02 PDD - - 0.40 - - -0.02 
ST18/02 PDD 0.99 1.55 0.91 0.00 0.31 0.34 
ST19/02 PDD 1.88 2.80 0.52 0.27 0.73 0.24 
ST20/02 PDD 0.59 0.91 0.35 -0.23 0.04 0.07 
ST21/03 PDD 0.61 0.87 0.21 -0.22 -0.02 -0.15 
ST22/02 PDD 0.96 1.23 0.46 -0.02 0.16 0.19 
ST23/03 PDD 0.90 0.42 0.35 -0.04 -0.28 0.08 
ST24/03 PDD 0.86 - 0.35 -0.07 - -0.07 
ST25/04 PDD 1.24 0.77 - 0.09 -0.07 - 
ST29/04 PDD 0.64 0.76 0.60 -0.19 -0.05 0.30 
ST30/04 PDD 2.00 1.84 0.45 0.30 0.43 0.04 
A014/07 DLB - - - - - - 
A028/10 DLB - - - - - - 
A035/08 DLB - - - - - - 
A040/10 DLB - - - - - - 
A046/07 DLB - - - - - - 
A053/09 DLB - - - - - - 
A055/09 DLB - - - - - - 
A072/09 DLB - - - - - - 
A084/09 DLB - - - - - - 
A092/07 DLB - - - - - - 
A109/01 DLB - - - - - - 
A148/08 DLB - - - - - - 
A162/07 DLB - - - - - - 
A190/03 DLB - - - - - - 
A196/09 DLB - - - - - - 
A204/07 DLB - - - - - - 
A229/05 DLB - - - - - - 
A231/06 DLB - - - - - - 
A249/06 DLB - - - - - - 
A273/05 DLB - - - - - - 
A304/06 DLB - - - - - - 
A335/08 DLB - - - - - - 
A336/99 DLB - - - - - - 
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20030007 DLB 1.30 0.67 0.35 0.12 -0.15 0.07 
20030113 DLB 0.95 0.75 0.23 -0.02 0.03 -0.27 
20040034 DLB 1.29 0.40 0.13 0.11 -0.21 -0.36 
20040085 DLB 1.24 0.35 0.22 0.09 -0.34 -0.28 
20050030 DLB 0.84 0.30 0.11 -0.07 -0.23 -0.45 
20050040 DLB 1.04 0.24 0.13 0.02 -0.31 -0.38 
20060025 DLB 0.90 0.90 0.43 -0.05 -0.03 0.01 
20070009 DLB 1.68 0.70 0.18 0.23 -0.06 -0.37 
20070105 DLB 1.12 1.06 0.32 0.05 0.03 -0.12 
20080083 DLB 0.85 0.45 0.33 -0.07 -0.30 0.04 
20100575 DLB 0.90 0.41 0.33 -0.05 -0.25 -0.10 
027 93/1089 DLB - 0.93 - - -0.02 - 
036 93/1075 DLB 1.05 - - 0.02 - - 
051 91/1249 DLB 0.97 0.76 0.34 -0.02 0.08 -0.09 
052 94/1224 DLB 1.86 1.89 0.32 0.27 0.44 -0.12 
055 98/1226 DLB - - - - - - 
106 99/1109 DLB 0.70 0.12 0.22 -0.16 -0.58 -0.14 
333 08/064 DLB 0.69 0.32 0.33 -0.16 -0.38 0.04 
367 08/134 DLB - 1.01 - - 0.26 - 
383 99/1147 DLB 0.64 0.37 0.34 -0.20 -0.24 0.06 
436 03/148 DLB - 0.97 - - 0.17 - 
439 00/1140 DLB 0.81 0.45 0.23 -0.09 -0.13 -0.26 
470 01/156 DLB 1.51 1.16 0.42 0.18 0.27 0.00 
475 00/1108 DLB 1.00 - 0.12 0.00 - -0.41 
495 01/172 DLB 0.67 0.56 0.22 -0.18 0.06 -0.28 
550 02/021 DLB 0.81 0.50 0.34 -0.09 -0.15 -0.09 
745 08/126 DLB 2.13 2.23 0.47 0.33 0.75 0.20 
C1007 01/176 DLB 1.47 2.07 0.34 0.17 0.58 -0.09 
ST26/04 DLB 1.19 - 0.36 0.07 - -0.06 
ST27/04 DLB - 0.21 - - -0.32 - 
ST28/04 DLB 1.23 0.34 - 0.09 - - 
ST32/05 DLB - - 0.12 - - -0.39 
A071/09 AD 1.08 0.42 0.14 0.03 -0.35 -0.47 
A108/09 AD 1.36 0.74 0.38 0.14 -0.09 0.10 
A120/09 AD 1.36 0.66 0.22 0.13 0.02 -0.14 
A147/10 AD 1.41 1.27 0.74 0.15 0.17 0.40 
A216/09 AD 1.11 - 0.13 0.04 - -0.34 
A267/09 AD 0.88 0.65 - -0.06 0.00 - 
A349/08 AD 1.51 0.82 0.47 0.18 -0.07 0.20 
A350/09 AD 1.50 - 0.63 0.18 - 0.33 
A37/09 AD 1.65 - - 0.22 - - 
A371/08 AD 1.18 0.59 0.57 0.07 -0.05 0.13 
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A38/11 AD 1.38 1.00 0.66 0.14 0.17 0.35 
A61/09 AD 1.99 - 0.34 0.30 - 0.06 
A7/10 AD 0.29 - 0.52 -0.53 - 0.24 
A76/09 AD 1.46 2.20 0.93 0.17 0.51 0.35 
A8/10 AD 1.19 1.16 0.37 0.07 0.13 0.10 
A92/09 AD 1.98 - 0.35 0.30 - -0.07 
 
 
